Clara D. Bloomfield, M.D. NAME: ADDRESS: EDUCATION:...

Clara D. Bloomfield, M.D. 6/12/2018

1

CURRICULUM VITAE

Clara D. Bloomfield, M.D. NAME: Clara Derber Bloomfield ADDRESS: The Ohio State University

C933 James Cancer Hospital 460 West 10th Avenue Columbus, OH 43210 Phone: 614-293-7518 E-mail: [email protected] BORN: May 15, 1942, Flushing Long Island, New York EDUCATION: 1959-1962 University of Wisconsin, Madison 1962-1963 San Diego State College, San Diego, California B.A., Summa cum laude – 1963 1964-1968 University of Chicago, Chicago, Illinois M.D. – 1968 ACADEMIC APPOINTMENTS: 2010-Present Professor, Division of Hematology, Department of Internal Medicine, The OSU College of

Medicine 2010-Present Professor, Division of Oncology, Department of Internal Medicine, The OSU College of

Medicine 2006-Present Distinguished University Professor, The Ohio State University 2003-Present Cancer Scholar and Senior Advisor to The OSU Comprehensive Cancer Center and Arthur

G. James Cancer Hospital and Richard J. Solove Research Institute 1997-Present William G. Pace III Endowed Chair in Cancer Research and Professor, The OSU College of

Medicine 1997-2010 Professor, Division of Hematology and Oncology, Department of Internal Medicine, The OSU

College of Medicine 1997-2003 Director, Comprehensive Cancer Center and Deputy Director, James Cancer Hospital and

Solove Research Institute, The Ohio State University, Columbus, Ohio 1997-2001 Director, Division of Hematology and Oncology, Department of Internal Medicine, The Ohio

State University College of Medicine 1989-1997 Chair, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 1989-1997 Professor of Medicine and Chief, Division of Oncology, State University of New York at

Buffalo, Buffalo, New York 1980-1989 Professor of Medicine, Division of Oncology, University of Minnesota, Minneapolis,

Minnesota 1976-1980 Associate Professor of Medicine, University of Minnesota, Minneapolis, Minnesota 1973-1976 Assistant Professor of Medicine, University of Minnesota, Minneapolis, Minnesota 1972-1973 Instructor in Medicine, University of Minnesota, Minneapolis, Minnesota 1972 Chief Resident in Medicine, University of Minnesota, Minneapolis, Minnesota (Jan. – June) 1971-1973 Medical Oncology Fellow, University of Minnesota, Minneapolis, Minnesota 1970-1971 Second Year Resident, Internal Medicine, University of Minnesota, Minneapolis, Minnesota 1969-1970 First Year Resident, Internal Medicine, University of Chicago, Chicago, Illinois 1968-1969 Intern in Medicine, University of Chicago Hospitals and Clinics, Chicago, Illinois CERTIFICATIONS: Diplomate of National Board of Medical Examiners, 1969 Licensed to practice medicine, State of Minnesota, 1970-present (#19319) Diplomate in Internal Medicine, American Board of Internal Medicine, 1972 (#37829) Licensed to practice medicine, State of New York, 1989 (#177879) Licensed to practice medicine, State of Ohio, 1997-present (#072617)


2

FELLOWSHIPS: American Cancer Society Clinical Fellow, 1971-72 American Cancer Society Junior Faculty Clinical Fellowship, 1972-75 MAJOR AWARDS AND HONORS: 1962 Phi Beta Kappa, University of Wisconsin 1967 Alpha Omega Alpha, University of Chicago 1981 The Marion Spencer Fay Award, The National Board for Women in Medicine, The Medical

College of Pennsylvania 1987 Past State President's Business and Professional Women's Award, University of Texas, M.D.

Anderson Hospital 1989 Elected External Member, Medical Society of Finland 1995 Elected Fellow, American Association for the Advancement of Science, Cytogenetic Research 1998 Distinguished Service Award, University of Chicago Medical & Biological Sciences Alumni

Association 1998 Third Human Cancer Genetics Program Medal, The Ohio State University Human Cancer

Genetics Program 2000 Expression of Appreciation, The Ohio State University Board of Trustees 2000 The James Champion Award, Board of Trustees of The Ohio State University James Cancer

Hospital & Solove Research Institute 2000 Elected Member, National Academy of Medicine (formerly Institute of Medicine of the National

Academy of Sciences) 2003 The John Peter Minton, MD, Hero of Hope Research Champion Medal of Honor Award, American Cancer Society 2004 Local Legend –Ohio, The National Library of Medicine and The American Medical Women’s

Association 2004 9th AACR – Joseph H. Burchenal Clinical Research Award, American Association for Cancer

Research 2004 Elected Member, The Association of American Physicians 2004 Distinguished Service Award, The OSU Comprehensive Cancer Center 2005 7th Charlotte Friend Memorial Lecture, International Association for Comparative Research on

Leukemia and Related Diseases, IACRLRD 2006 ASCO Distinguished Service Award for Scientific Achievement, American Society of Clinical Oncology 2006 Cancer and Leukemia Group B (CALGB) 50th Anniversary Leadership Award 2007 1st Annual Dr. Emil Frei III Pioneer Award, The Leukemia & Lymphoma Society 2007 Phi Kappa Phi, The Ohio State University – Faculty/Staff Member


3

MAJOR AWARDS AND HONORS (cont.): 2007 ASCO Statesman Award, American Society of Clinical Oncology (award name changed to “Fellow of the American Society of Clinical Oncology” (FASCO) in

2012) 2008 Henry M. Stratton Medal, American Society of Hematology 2009 David A. Karnofsky Memorial Award, American Society of Clinical Oncology 2011 Elected Member, American Academy of Arts & Sciences 2012 Richard L. Schilsky Cancer and Leukemia Group B (CALGB) Achievement Award 2014 Oncology Luminary, American Society of Clinical Oncology 2014 Thomson Reuters Highly-Cited Researcher 2015 Giants of Cancer Care Award, OncLive 2015 Thomson Reuters Highly-Cited Researcher 2016 8th Annual Margaret L. Kripke Award, MD Anderson Cancer Center 2016 Elected Fellow, AACR Academy 2016 Thomson Reuters Highly-Cited Researcher, Clinical Medicine 2017 Robert A. Kyle Award for Outstanding Clinician Scientist, Mayo Clinic Division of Hematology 2017 Frank Rauscher Memorial Lecture, International Association for Comparative Research on

Leukemia and Related Diseases, IACRLRD NATIONAL/INTERNATIONAL SOCIETY PRESIDENCIES: 2006 Association for Patient-Oriented Research (APOR) 2007-2009 International Association for Comparative Research on Leukemia and Related Diseases

(IACRLRD) BEST DOCTOR LISTS-NATIONAL: 1984-June Town & Country Magazine. The Best Medical Specialists in the U.S. Adult Hematologists &

Oncologists (1 of 61 listed) 1992-Oct. Good Housekeeping Magazine. The Best Cancer Specialists in the U.S. Leukemia-Medical

Oncologists and Hematologists. (1 of 24 listed) 1992-1993 The Best Doctors in America. Naifeh S and Smith GW. Woodward/White Aiken, South

Carolina. First Edition. Medical Oncology-Leukemia (1 of 16 listed), Medical Oncology-Lymphoma (1 of 4 listed)

1994-1995 The Best Doctors in America. Naifeh S and Smith GW. Woodward/White Aiken, South Carolina. Second Edition. Medical Oncology-Leukemia (1 of 28 listed), Medical Oncology-Lymphoma (1 of 34 listed)

1996-1997 The Best Doctors in America: Northeast Region. Naifeh S and Smith GW. Woodward/White Aiken, South Carolina. First Edition. Medical Oncology & Hematology


4

AWARDS ESTABLISHED IN MY HONOR: 2009- Clara D. Bloomfield Excellence in Hematology & Oncology Research Award

Established by The Ohio State University Division of Hematology/Oncology, Department of Medicine to recognize annually the most outstanding research by an Internal Medicine Resident in Hematology/Oncology

PATENTS: Marcucci G, Bloomfield CD, Caligiuri MA, Yan P, Maharry K, Bundschuh, R. 2014. Methods of Diagnosing Acute Myeloid Leukemia. U.S. Patent Application 61/923,008, filed January, 2014. Patent Pending. Garzon R, Bloomfield CD. 2014. Using Long Non Coding RNAs (lncRNAs) to Discover Novel Therapeutic Targets and Predict Treatment Response and Outcome in Acute Myeloid Leukemia. Patent Pending. SOCIETIES: 1974- American Association for Cancer Research 1974- American College of Physicians (Fellow) 1974- American Association for the Advancement of Science 1975- American Society of Hematology 1975- American Society of Clinical Oncology 1976- Sigma Delta Epsilon 1978- American Federation for Medical Research (formerly American Federation for Clinical

Research) 1978- Central Society for Clinical Research 1980-1998 New York Academy of Sciences 1986- International Association for Comparative Research on Leukemia and Related Diseases 1988- Women in Cancer Research 1990- European Society for Medical Oncology 1991-1997 New York State Cancer Programs Association, Inc. 1996-2006 International Society for Cellular Therapy (formerly International Society for Hematotherapy &

GraftEngineering) 1997- American Medical Women’s Association 1998-2013 Association for Patient-Oriented Research 2005- American Society of Human Genetics 2007- Phi Kappa Phi 2007- European Hematology Association 2013- Association for Clinical and Translational Science


5

ADVISORY BOARDS: CANCER CENTERS, FOREIGN GOVERNMENTS, FOUNDATIONS AND UNIVERSITIES: Cancer Centers 1. Don and Sybil Harrington Cancer Center, Scientific Advisory Board, Amarillo, Texas, 1979-85 2. Vanderbilt Cancer Center, Nashville, TN, External Scientific Advisory Board, 1994-2000 3. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA External Scientific Advisory Committee, 1994-2004, Chair 1998-2004 4. Dana-Farber Cancer Institute, External Advisory Board, Pediatric Leukemia PPG, 2000 5. The University of Texas M. D. Anderson Cancer Center (MDACC), Division of Cancer Medicine, External

Review Committee, 2001 6. University of Missouri,-Columbia, Comprehensive Cancer Center External Advisory Council, 2001-2002 7. The University of Texas MDACC, External Scientific Advisory Board, Leukemia SPORE 2002-09 8. The University of Texas MDACC, External Scientific Advisory Board, Myelodysplastic Syndrome PPG,

2003-2009 Chair 2006-2009 9. University of California at San Diego Comprehensive Cancer Center, External Scientific Advisory Board

Committee, 2004-2007 10. Herbert Irving Comprehensive Cancer Center, College of Physicians & Surgeons, Columbia University,

New York, NY, Scientific Advisory Board, 2005-2008 11. Comprehensive Cancer Center of Wake Forest University, External Advisory Board Committee, 2014- Foreign Governments/Organizations 1. German Federal Ministry for Education and Research. German Medical Competence Network of Acute

and Chronic Leukemias, International Advisory Board, 2000- 2. Dutch Cancer Society, External Reviewer, 2002- 3. Member, Scientific Committee for Acute Leukemias Symposiums, 2004 4. Alberta (Canada) Cancer Board. Advisory Committee on Research (ACOR), 2004-2006 5. University of Marburg, Germany, Advisory Board Comprehensive Cancer Center, 2004- 6. Scientific Advisory Board of the National Center for Tumor Diseases (NCT) Heidelberg/ Germany, 2009 – 7. University of Ulm, Germany, Advisory Board Comprehensive Cancer Center, 2009- 8. EU-MDS Registry External Advisory Board, 2014- Foundations 1. Leukemia Clinical Research Foundation, Board of Directors, 1988- 2. Cancer Education Consortium (formerly Berlex Oncology Foundation), Board of Trustees, 1992-2007 3. CALGB Foundation, Board of Trustees, 1993-2011 4. CALGB Foundation Long Range Planning & Development Committee, 1995 5. Hematology-Oncology Research Foundation Board of Directors, Columbus, OH, 1997-2003 6. Alliance for Clinical Trials in Oncology Foundation Board of Trustees, 2011-

Universities/ US State Governments 1. Medical College of Pennsylvania, Honorary National Board Member, Philadelphia, Pennsylvania, 1988- 2. University of California, San Diego, Specialized Center of Research (SCOR), External Advisory

Committee in Leukemia & Lymphoma, 2001 3. University of Arkansas for Medical Sciences, External Advisory Committee, NCI P01 Growth Control of

Multiple Myeloma, 2004-2009 4. Univ. of Michigan Medical School, Div. of Hematology/Oncology External Advisory Committee, 2003-2004 5. Cancer Prevention & Research Institute of Texas (CPRIT), Chair Translational/Clinical Research Review

Group 1 and Member Scientific Review Council 2009-2012


6

ADVISORY BOARDS: CANCER CENTERS, FOREIGN GOVERNMENTS, FOUNDATIONS AND UNIVERSITIES (cont.): Advisory Boards: For Profit 1. Current Drugs Ltd., Contributor, Panel of Evaluators, 1998 2. CancerEducation.com, Inc., Member, Medical Advisory Board, 1999 3. CancerSource.com, Contributing Editor, 2000 4. Sanofi-Synthelabo, Inc., Member, Physician Advisory Board, 2000 Advisory Boards: Non-Profit 1. Practical Medical Education & Science ® www.mededscience.com, 2016- CONTRIBUTIONS TO NATIONAL / INTERNATIONAL PROFESSIONAL ORGANIZATIONS: Accreditation Council for Graduate Medical Education 1. Pre-reviewer, Internal Medicine Subspecialty Training Programs: Medical Oncology, 1982-1995 2. Member, Standing Panel for Accreditation Appeals in Internal Medicine/Oncology, 1994- American Academy of Arts and Sciences 1. Membership Panel (Class II, Section 5) 2016- American Cancer Society 1. Scientific Advisory Committee on Clinical Investigations I - Epidemiology, Diagnosis and Therapy, 1990-92 2. Professional Education Committee, New York State Division, 1991-92 American Association for Cancer Research 1. Membership Committee, 1981-82 2. Program Committee, 1981-82, 1986, 1995, Co-Chair 1997 3. Women in Cancer Research, 1988-

a. Nominating Committee, 1997 b. Twelfth Annual Leila Diamond Memorial Networking Breakfast, Discussion Leader, 2004

4. Special Membership Committee, 1991-92 5. AACR New York State Legislative Committee, 1992-1995 6. Richard & Hinda Rosenthal Foundation Award Committee, 1993-1995, Chairperson 1994-1995 7. Sustaining Membership Committee, Chairperson 1994-1995 8. Education Committee, 1994-1996 9. Ad Hoc Committee on Research Ethics & Integrity, 1995-1999 10. Board of Directors, 1995-1998 11. Research Fellowship Committee, 2001-2002 12. Nominating Committee for Clinical Research and Experimental Therapeutic Awards, Chairperson 2004-

2005 13. Clinical Research and Experimental Therapeutics Awards Selection Committee, 2005-2007 14. Organizing Committee for AACR Centennial Conference: The Future of Cancer Research-Science and

Patient Impact, 2008 15. Clinical Research and Experimental Therapeutics Awards Selection Committee (Burchenal and

Rosenthal Awards), Chairperson 2009-2010 16. Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research Selection

Committee, 2011-2012 17. AACR Award for Lifetime Achievement in Cancer Research Selection Committee, 2016-2018


7

CONTRIBUTIONS TO NATIONAL / INTERNATIONAL PROFESSIONAL ORGANIZATIONS (cont.): American College of Physicians 1. Medical Knowledge Self-Assessment Program, Medical Oncology Committee for MKSAP VI, 1980-1982 2. Publication Committee 2005-06 American Federation for Medical Research (formerly American Federation for Clinical Research) 1. Program Committee (Oncology), 1982 American Red Cross, Central Ohio Region 1. Richard M. Ross Cord Blood Bank, Advisory Committee, 1998 American Society of Clinical Oncology 1. Program Committee, 1976, 1985, 1987, Chairperson 1988 2. Coordinator, Evaluation of Education Sessions, 1977, 1978 3. Cancer Education and Training Committee, 1977-79, 1983-84 4. Organizer, Educational Workshop/Symposium: Acute Leukemia, 1978, 1993, 1998 5. Organizer, Educational Workshop: Nutrition and Cancer, 1979 6. Scientific and Publications Committee, 1987-1992, Chairperson 1989-92 7. Nominating Committee, 1989-90 8. Board of Directors, 1991-94 9. Ad Hoc Committee on Oncology Manpower, 1993-1996 10. Oncology Training Programs Committee, 1994-95 11. Chair, Tumor Biology subcommittee of the Program Committee, 1995-96 12. ASCO Online, Classic Oncology References, Acute Leukemia, 2001 http://www.asco.org/prof/tfg/html/syllabus/m_syllabus.htm 13. Hematology Oncology Retreat, August 5-7, 2004 14. ASCO's Roster of Cancer Experts, Member, October 1, 2005 – September 30, 2008 15. ASCO Representative, EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer Scientific

Committee, 2008 – 2011.

American Society of Hematology 1. Subcommittee on Neoplasia, 1976-79 (Chairperson 1977-78), 1986-89 2. Program Committee (Abstract reviewer for Hematologic Malignancies), 1977, 1978, 1981, 1989,1990,

1992, 1996, 1997, 2001, 2011 3. Organizer, Education Program on Acute Leukemia, 1978, 1979, 1981, 1990, 1991, 1992 4. Coordinating Reviewer, Scientific Program for Leukemias-Cytogenetics, Molecular Markers in Diagnosis

and Prognosis, 1996 Association for Patient-Oriented Research 1. Founding Member, 1998 – 2012 (merged with the Society for Clinical and Translational Science and the

Association for Clinical Research Training to form the Association for Clinical and Translational Science) 2. Board of Directors, 2002 – 2007 3. Member, Clinical Research Alliance Committee, 2002- 2007 4. President-elect, 2005 5. President, 2006 6. Past President, 2007


8

CONTRIBUTIONS TO NATIONAL / INTERNATIONAL PROFESSIONAL ORGANIZATIONS (cont.): Chronic Lymphocytic Leukemia Research Consortium (CRC) 1. External Advisory Committee, 2004-2007 College of American Pathologists 1. Member, CAP/ASH Guideline Advisory Panel for the Acute Leukemia Work-Up Guideline, 2011- Congress of the United States 1. Consultant, Office of Technology Assessment, 1988-90 European LeukemiaNet 1. External Reviewer 2006, External Advisory Board, 2007- 2. European LeukemiaNet-Foundation Circle, Ambassador, 2014- 3. MDS-Right, 2014- a. Member, Scientific, Clinical &Ethical Advisory Board, 2015- 4. AML Global Portal Steering Committee, 2015- a. Committee co-chair, 2015- 5. Work Package 5 (WP5), AML co-chair, 2017- Food and Drug Adminastration (FDA) 1. Co-Chair, FDA-ASCO Workshop: Minimal Residual Disease as a Surrogate Endpoint in Acute Myeloid

Leukemia, March 4, 2013 General Motors Cancer Research Foundation 1. Kettering Selection Committee 1986-87 2. Awards Assembly 2004-2005 Institute of Medicine of the National Academies 1. Report Review: Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through

Research 2008 International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD) 1. Member, World Committee, 2005-2009, 2013- 2. Scientific Program Committee, 2005- (Chair 2009- 3. President, 2007-2009 4. Secretary General, 2009-2013 International Human Gene Mapping Workshops 1. HGM8 Helsinki, Finland. August 4-10, 1985. Vice Chairperson, Committee on Chromosome

Rearrangements in Neoplasia and on Fragile Sites 2. HGM9 Paris, France. September 6-11, 1987. Chairperson, Committee on Chromosome

Rearrangements in Neoplasia International Society of Hematology 1. Organizer, Education Program on Acute Leukemia, 1980 2. Organizer, Education Program on Acute Leukemia, 1990


9

CONTRIBUTIONS TO NATIONAL / INTERNATIONAL PROFESSIONAL ORGANIZATIONS (cont.): International Workshops on Chromosomes in Leukemia 1. Third Workshop. Lund, Sweden. Chairperson of the Writing Committee on Clinical Significance of

Chromosome Abnormalities in ALL July 21-25, 1980 2. Fourth Workshop. Chicago, Illinois. Chairperson of the Writing Committee on Clinical Significance of

Chromosome Abnormalities in ALL September 3-7, 1982 3. Fifth Workshop. Saitama-Ken and Tokyo, Japan. October 11-15, 1984 4. Sixth Workshop. London, England. May 10-15, 1987 5. International Workshop on Balanced Chromosome Rearrangements in Treatment Related Leukemia and

Myelodysplastic Syndromes Chicago, Illinois. Chairperson 11q23 Subgroup. June 17-20, 2000 Leukemia Society of America, Inc. 1. Medical and Scientific Advisory Committee of the National Board of Trustees, 1981-85 2. Scientific Program Planning Committee, Second National Symposium, Wesley Chapel, Florida, 1986 MD Anderson Cancer Center 1. Member, Kripke Legend Award Selection Committee, 2017 National Breast Cancer Coalition 1. Participant, Third Aspen Project Meeting, The Aspen Institute, Aspen Colorado, June 24-26, 1998 National Comprehensive Cancer Network 1. Board of Directors, 1997-2010 2. Myelodysplastic Syndromes Guideline Panel, 1998- 3. Hodgkin's Disease Guidelines Panel, 1998-2008 4. Guidelines Steering Committee, 2000-2010 5. Genomics Task Force, 2001-2003 Preleukemia Study Group 1. Subcommittee on Data Processing, 1977 United States National Institutes of Health. Major Review or Advisory Boards 1. Subgroup on Hodgkin's Disease, Non-Hodgkin's Lymphomas, and Plasma Cell Myeloma, Advisory to the

Ad Hoc White Cell Working Group, the Division of Blood Diseases and Resources, the National Heart, Lung and Blood Institute, 1977

2. Cancer Clinical Investigation Review Committee, National Cancer Institute, 1978-82 3. Clinical Oncology Review Committee, Ad Hoc member, 1980 4. National Cancer Institute, Cell Marker Executive Committee, 1980 5. Organizer, National Cancer Institute International Hodgkin's Disease Symposium, 1981 6. Chair, Special Review Committee. DCT Small Grants to Stimulate Correlative Laboratory Studies and

Innovative Clinical Trials, May 31-June 1, 1990 7. Board of Scientific Counselors, Division of Cancer Treatment, October 1, 1991 - June 30, 1995. Chair,

July 1, 1993 - June 30, 1995 8. Chair, Board of Scientific Counselors (DCT) Subcommittee on Breast Cancer, 1993-95 9. Board of Scientific Counselors, Division of Clinical Sciences, March 1, 1996 - June 30, 1998 10. Member, NCI Working Group reviewing NCI activities in the area of cancer prevention, control and early

diagnosis, 1995-1997 11. Member, NCI Working Group to review the NCI's Clinical Trials Program, 1995-1997

Chair subcommittee on Retaining and Recruiting Clinical Scientists 12. Member, NCI Developmental Diagnostics Committee, 1996-1998


10

CONTRIBUTIONS TO NATIONAL / INTERNATIONAL PROFESSIONAL ORGANIZATIONS (cont.): United States National Institutes of Health. Major Review or Advisory Boards (cont.): 13. Member, Special Emphasis Panel, National Cancer Institute, RFA 98-027. The Director’s Challenge –

Molecular Classification of Tumors – Application of Comprehensive Molecular Analyses, August 16, 1999 14. National Cancer Institute State of the Science Workshops: Leukemia. Rockville MD, Feb. 1-2,2000 15. National Cancer Institute State of the Science Workshops: Myelodysplastic syndromes. Rockville MD,

Oct. 30-31, 2000 16. Co-chair, NCI Progress Review Group; Leukemia, Lymphoma and Myeloma, 2000-2001 17. NCI Cancer Translational Research Allied Consortium (C-TRAC), 2002 18. NCI-LIVESTRONG Young Adult Alliance Adolescent and Young Adult Oncology Progress Review

Roundtable participant, April 24-26, 2006 19. Member, NCI AML Working Group of the Leukemia Steering Committee, 2010- 20. Member, NCI ALL Working Group of the Leukemia Steering Committee, 2011- U.S.A. National Cancer Institute Sponsored Clinical Trials Groups Alliance for Clinical Trials in Oncology, 2011- 1. Member, Alliance for Clinical Trials in Oncology Transition Board, 7/2011-11/2013 2. Member, Nominating Committee for Alliance for Clinical Trials in Oncology, 2011 3. Member, Alliance for Clinical Trials in Oncology Board of Directors, 2011-2014, 2017 4. Member, Alliance for Clinical Trials in Oncology Executive Committee, 2011-2014 Cancer and Leukemia Group B, 1973-2011 1. Chairperson, Correlative Sciences Committee, 1982-1999; Member 1982- 2. Board of Directors, 1982-2011 3. Principal Investigator, RPCI, 1989-93 4. Chair, Nominating Committee for CALGB Group Chairman, 1993-95 5. Lymphoma Core Committee, 1982-99 6. Vice-Chairperson, Lymphoma Committee, 1977-82 7. Immunology Core Committee, 1978-82 8. Leukemia Core Committee, 1978- 9. Ad Hoc Committee on ranking CALGB Institutions for Type 5 Redistribution, 1994 10. Ad Hoc Committee on assigning credit for participation in CALGB studies, 1995 11. Principal Investigator, OSU, 1999-2014 12. Ad Hoc Committee on Institutional Probation, 2004-05 13. Chair, Nominating Committee for CALGB Group Statistician, 2005-06 Children’s Oncology Group 1. Leukemia/Lymphoma Data Safety Monitoring Committee, 2002-2006 National Surgical Adjuvant Breast and Bowel Project 1. Oversight Committee 1994 Southwest Oncology Group Consultant 1. Cytogenetics 1986-88 2. Leukemia Committee 1982, 1986 World Health Organization 1. Co-Chair, Clinical Advisory Committee: WHO 2001 Classification for Neoplastic Diseases of the

Hematopoietic and Lymphoid Systems, 1996-2001 2. Chair, Myeloid Advisory Committee: WHO 2008 Classification for Neoplastic Diseases of the

Hematopoietic and Lymphoid Systems, 2006-2008 3. Chair, Myeloid Advisory Committee: WHO 2017 Classification for Neoplastic Diseases of the

Hematopoietic and Lymphoid Systems, 2013-2017


11

CONTRIBUTIONS TO NATIONAL/INTERNATIONAL PROFESSIONAL ORGANIZATIONS (cont.): Editorial Activities 1. Consulting Editor, Leukemia and Lymphoma. Yearbook of Cancer. Year Book Medical Publishers, 1980 2. Associate Editor, Cancer Research, 1981-1988, 1991, 1994-2000 3. Associate Editor, Leukemia Research 1984-87 4. Associate Editor, Leukemia, 1987-89 5. Editorial Board, Journal of Clinical Oncology, 1983-88 6. Editorial Board, Cancer Genetics and Cytogenetics, 1983-87 7. Editorial Board, Directions in Oncology, 1984-86 8. Editorial Board, Cancer Research Bulletin, 1984-85 9. Editorial Board, American Journal of Hematology, 1985-91 10. Associate Editor, 1988-91 11. Guest Editor, Seminars in Oncology. Acute Myelogenous Leukemia, December, 1987 12. Editorial Board, Medical and Pediatric Oncology, 1987-2000 13. Editorial Board, Blood, 1988-92 14. Editorial Advisory Board, Journal of the National Cancer Institute, 1988-98 15. Editorial Board, Annals of Medicine, 1989-1999 16. Editorial Board, Seminars in Oncology, 1989-2010 17. Guest Editorial Board, Japanese Journal of Clinical Oncology, 1991- 18. Guest Editor, Hematology/Oncology Clinics of North America, 1992 19. Editorial Board, Hematopathology and Molecular Hematology, 1993- 20. Associate Editor, Clinical Cancer Research, 1994-1997 21. Editorial Academy, International Journal of Oncology, 1994- 22. Guest Editor, Seminars in Oncology. Acute Leukemias: Recent Advances, February 1997 23. Associate Editor, European Journal of Haematology, 1999-2007 24. Editorial Board, Oncology Economics, 1999-2000 25. Editorial Board, Oncology Spectrums, 2001- 26. Editorial Board, CancerSource, 2001- 27. Editorial Board, Cancer Cell, 2001- 28. Guest Editor, The Oncologist, Novel Approaches to the Treatment of Advanced Hematologic

Malignancies, April 2002 29. Section Editor, Clinical Advances in Hematology & Oncology, 2002-2007 30. Editorial Board, Annals of Internal Medicine, 2003-2006 31. Editorial Board, Clinical Leukemia, 2006- 32. Guest Editor, Seminars in Oncology. Acute Myeloid Leukemia, August 2008 33. Editorial Board, Genes, Chromosomes & Cancer, 2009- 34. Advisory Editorial Board, EMBO Molecular Medicine, 2009-


12

CONTRIBUTIONS TO NATIONAL/INTERNATIONAL PROFESSIONAL ORGANIZATIONS (cont.): Reviewer 1. Cancer Chemotherapy Reports, 1972- 2. Cancer, 1974- 3. Annals of Internal Medicine, 1974- 4. Blood, 1976- 5. Archives of Internal Medicine, 1976- 6. Cancer Research, 1977- 7. New England Journal of Medicine, 1978- 8. Acta Haematologica, 1979- 9. Medical and Pediatric Oncology, 1980- 10. Cancer Genetics and Cytogenetics, 1980- 11. Journal of The National Cancer Institute, 1980- 12. Journal of Clinical Oncology, 1982- 13. Science, 1983- 14. Journal of The American Medical Association, 1983- 15. Pediatrics, 1983- 16. British Journal of Haematology, 1984- 17. Mayo Clinic Proceedings, 1984- 18. American Journal of Haematology, 1984- 19. Leukemia Research, 1984- 20. International Journal of Cancer, 1985- 21. Journal of Clinical Investigation, 1986- 22. Leukemia, 1986- 23. Pediatric Hematology and Oncology, 1986- 24. Annals of Oncology, 1990- 25. Bone Marrow Transplantation, 1991- 26. Clinical Cancer Research, 1994- 27. European Journal of Haematology, 1999- 28. Proceedings of The National Academy of Sciences, USA, 1999- 29. Nature Reviews Cancer, 2002- 30. Cancer Cell, 2003- 31. Nature Medicine, 2005- 32. PLoS ONE, 2011- 33. Human Molecular Genetics, 2011- 34. Nature, 2016-


13

THE OHIO STATE UNIVERSITY ARTHUR G. JAMES CANCER HOSPITAL AND RICHARD J. SOLOVE RESEARCH INSTITUTE University Boards and Committees: Active 1. Member, Discovery Editorial Advisory Board, 2003- 2. Member, Steering committee, Project Cancer, 2003- 3. Member, President’s and Provost’s Advisory Committee (PPAC), 2006- 4. Member, Phase II Advisory Committee, 2006- 5. Senior Advisor, The Ohio State University (OSU) Center for Clinical and Translational Science, 2007- 6. Member, CCC-James Strategic Planning Executive Committee, 2008 – 7. Member, CCC-James Executive Team, 2009- 8. Member, Steering Committee for K12 Training Grant-Experimental Therapeutics in Cancer, 2009- 9. Chair, Advisory Committee for T32 Oncology Training Grant (PI: Caligiuri), 2009- 10. Member, Committee for Academic Advancement of Women Faculty, 2011- 11. Member, CCC Genomics Shared Resources User Oversight Committee, 2012- 12. Member, Internal Advisory Board for P01 Grant (PI: Baiocchi) - Targeting PRMT5 in diffuse large B cell

and mantle cell lymphoma, 2013- 13. Member, CCC Leukemia Research Program, 2014- 14. Member, Scientific Advisory Committee for UM1 Grant (PI: Grever) - Experimental Therapeutics of Anti-

Cancer Agents with Phase I Emphasis, 2014- 15. Senior Faculty Advisor, CCC Leukemia Tissue Bank Shared Resource, 2014- 16. Executive Women Group, Women in Medicine and Science (WIMS), 2016-

University Boards and Committees: Past 1. Member, DMF of Ohio Board of Trustees, 1997-2001 2. Member, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Board, 1997-2009

a. Administration/Operations Committee, 1997-2001 b. Executive Operations Committee, 1997-2002 c. Medical Staff Administrative Committee, 1997-2003 d. Professional Affairs Committee, 1997-2005

3. Co-Chair, CCC-JCH/RJS Coordinating Committee, 1997-2002 4. Member, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Foundation Board, 1997-

2011 5. Member, Search Committee for Chair, Department of Internal Medicine, 1998-1999 6. Member, Medical Advisory Board, OSU Managed Health Care Systems, 1998-1999 7. Member, Leadership Council for Clinical Value Enhancement, Office of Health Sciences, 1998-2000 8. Member, College of Medicine and Public Health Academic Awards Commission, 1998-2000 9. Member, Clinical Research Curriculum Advisory Committee, 1999 10. Member, Advanced Biomedical Imaging Institute Governance Committee, 1999-2000 11. Member, Search Committee for Vice President for Research, 1999-2000 12. Member, Search Committee for Senior Vice President for Health Sciences and Dean of the College of Medicine and Public Health, 1999-2000 13. Member, College of Medicine and Public Health, Policy Advisory Council, 2000 14. Member, College of Medicine and Public Health, Strategic Finance Committee, 2000 15. Member, Medical Advisory Committee, College of Medicine and Public Health, 2000-2001 16. Chair, Task Force for Development of Human Resources Infrastructure, OSU College of Medicine and Public Health, 2000-2001 17. Member, Task Force on Academic and Leadership Progress for Women Faculty, 2000-2001 18. Member, Search Committee for Associate Vice President for Health Sciences Research and Vice Dean

for Research of the College of Medicine and Public Health, 2001 19. Member, The Ohio State University Biomedical Research Planning Group (Informatics Node), College of

Medicine and Public Health, 2001-2002 20. Member, The Ohio State University Medical Center Internal Strategic Planning Group (ISPG), College of

Medicine and Public Health, 2001-2003 21. Member, The Ohio State University Medical Center Strategic Planning Group (SPG), College of

Medicine and Public Health, 2001-2003 22. Member, Division of Hematology-Oncology Finance Committee, 2001-2010


14

THE OHIO STATE UNIVERSITY ARTHUR G. JAMES CANCER HOSPITAL AND Richard J. Solove Research Institute (cont.) University Boards and Committees: Past (cont.) 23. Member, Center-Department Task Force, COMPH 2002-2003 24. Member, Medical Advisory Committee and Resource Review Group (RRG), College of Medicine and

Public Health 2002-2003 25. Member, OSU Tissue Bank Steering Committee, 2003 26. Member, Steering committee, Cancer Program Expansion Feasibility, 2003 27. Internal Group, The Ohio State University Medical Center National Reputation Building Efforts, 2003 28. Member, Search Committee for Vice President for Health Services and Chief Executive Officer of The

Ohio State University Health System, 2003-05 29. Member, CCC Molecular Biology and Cancer Genetics Research Program, 2003-2014 30. Member, Information Enterprise Advisory Board Committee, 2004-2006 31. Steering committee, Project Proton-Particle Therapy, 2004-2006 32. The Ohio State University Research Foundation Board of Directors, 2005-2009 33. Member, Search Committee for Dean, College of Medicine, 2006 34. Co-Chair, Clinical and Translational Science Award (CTSA) Steering Committee, 2006 35. Member, Selection Committee for the 2007 Distinguished University Professors Program, 2007 36. Member, Search Committee for Director, Division of Medical Oncology & Hematology, 2007-2010 37. Member, Department of Internal Medicine Appointments, Promotion and Tenure Committee 2007-2010 38. Member, Recruiting Women into Leadership Positions Task Force, 2010 39. Member, Medical Oncology Finance Committee, 2010-2011 40. Member, James Cancer Hospital Physician in Chief Search Committee, 2010-2011 41. Member, Selection Committee for the Program Leader for the Academic Advancement of Women

Faculty in the College of Medicine, 2011


15

ROSWELL PARK CANCER INSTITUTE CONTRIBUTIONS TO THE INSTITUTE, THE STATE UNIVERSITY OF NEW YORK AT BUFFALO AND AREA HOSPITALS Institute Committees 1. Appointments and Promotions Committee, 1989-91 2. Clinical Review Subcommittee, RPCI Major Modernization, 1989-97 3. Chair, Search Committee for Directors of Cytogenetics and Molecular Diagnostics, 1990-1993; Member,

1993-97 4. Search Committee for Chief of Surgery, 1990-91 5. Tissue Procurement Advisory Committee, 1990-91 6. Aspergillus Task Force, 1992-97 7. Practice Plan Board, Elected Representative, 1993-96 8. Patient Strategies Working Group, 1995-97 9. Ad Hoc CME Committee, 1996-97 10. Staff Seminar Committee, 1996-97 11. Accessibility for Patients and Referring Physicians Committee, 1996-97 12. Medical Staff Executive Committee. Medical Specialty Elected Representative, 1996-97 University Committees 1. Cancer Task Force of the Western New York Health Sciences Consortium, 1989 2. Continuing Medical Education Committee, 1989 3. Steering Committee of the Medical Scientist Training Program (MSTP) of the School of Medicine and

Biomedical Sciences, 1990, 1994 4. University Faculty Senate, Elected Member, 1993-97 5. MD-Ph.D. Committee for the School of Medicine and Biomedical Sciences, 1994-97 6. University Governance Group, Committee on Stresses in Research and Education (National Science

Board and Government-University-Industry Research Roundtable Study), 1996 Hospital Committees 1. Troup Fund Committee of the Board of Trustees of The Buffalo General Hospital, 1990-92 2. Search Committee for Head of Hematology at the Buffalo General Hospital, 1990-92


16

UNIVERSITY OF MINNESOTA Teaching Responsibilities 1. Director, Fellowship Program Medical Oncology, 1987-89 Courses 1. Interdisciplinary course in Oncology - Medicine 5-583 2. Clerkship in Oncology - Phase D - Medicine 5-501 3. 2-4 lectures per month to various courses given in the medical school and university Clinical Teaching 1. Attending on Medical Oncology Ward - 2 months/year 2. Attending on Oncology Consults - 1 month/year CONTRIBUTIONS TO THE HOSPITAL, DEPARTMENT, MEDICAL SCHOOL AND UNIVERSITY Major Medical School Committees 1. Scholastic Standing Committee, 1974-77 2. Cancer Coordinating Committee, 1978-82 3. Steering Committee for Radiation Oncology and Clinical Center, 1978-89 4. Faculty Academic Promotions and Tenure Committee of Medical School, 1981, 1983, 1988-89 5. Clinical Oncology Task Force, 1985-89 Department of Medicine 1. Search Committee for Head of the Section of Infectious Disease 2. Search Committee for Head of the Section of Cardiology 3. Research Conference Committee member 4. Grievance Committee of the Department of Internal Medicine, 1981-89

Hospital Committees 1. Subcommittee Hospital Infection Committee on Antibiotic Usage, 1975-78 2. Thanatology Committee, 1976-1977 3. Tissue and Procedure Review Committee, 1978-1984. Chairperson, 1982-84 4. Bone Marrow Transplant Coordinating Committee, 1979-85 5. Quality Assurance Committee, 1979-80 6. Quality Assurance Steering Committee, 1982-84 University 1. University Senate

a. Alternate 1981-83, 1985-86; b. Member 1986-89

2. Senate Judicial Committee, 1985-88 3. Committee on Equal Employment Opportunity for Women

a. Alternate 1987 b. Member 1988-89

4. All University Commission on Women, 1988-89


17

PUBLICATIONS - Excluding Letters, Abstracts and Edited Books

1. Bloomfield CD, Brunning RD, Kennedy BJ. Daunorubicin therapy in adult acute lymphatic leukemia. Cancer. 1972 Jul;30(1):47-55. PMID: 5067989.

2. Bloomfield CD, Brunning RD, Theologides A, Kennedy BJ. Daunorubicin-prednisone remission induction with hydroxyurea maintenance in acute non-lymphocytic leukemia. Cancer. 1973 April;31(4):931-938. PMID: 4513295.

3. Kennedy BJ, Theologides A, Fortuny I, Bloomfield CD, Kelly RT. Advanced cancer: New concepts of medical therapy. Geriatrics. 1973 Nov;28:51-72. PMID: 4796352.

4. Gajl-Peczalska KJ, Hansen JA, Bloomfield CD, Good RA. B-lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease. J Clin Invest. 1973 Dec;52(12):3064-3073. PMID: 4201499. PMCID: 302581.

5. Bloomfield CD, Theologides A. Acute granulocytic leukemia in elderly patients. JAMA. 1973 Dec 3;226(10):1190-1193. PMID: 4518517.

6. Hansen JA, Bloomfield CD, Dupont B, Gajl-Peczalska K, Kiszkiss D, Good RA. Lymphocyte subpopulations and immunodeficiency in lymphoproliferative malignancies. In Leucocyte Culture Conference: Proceedings: 8th, (Lindahl-Kiessling K, ed), New York, Academic Press; 1974:119-125.

7. Bloomfield CD, Goldman A, Dick F, Brunning RD, Kennedy BJ. Multivariate analysis of prognostic factors in the non-Hodgkin's malignant lymphomas. Cancer. 1974 Mar;33(3):870-879. PMID: 4592906.

8. Dick F, Bloomfield CD, Brunning RD. Incidence, cytology and histopathology of non-Hodgkin's lymphomas in the bone marrow. Cancer.1974 May;33:1382-1398. PMID: 4595977.

9. Bloomfield CD. Acute Leukemia. Modern Management. Minn Med. 1974 Jul;57:532-537. PMID: 4602924.

10. Bloomfield CD, Kennedy BJ. Cephalothin, carbenicillin and gentamicin combination therapy for febrile patients with acute non-lymphocytic leukemia. Cancer. 1974 Aug;34:431-437. PMID: 4850936.

11. Gajl-Peczalska KJ, Bloomfield CD, Nesbit ME, Kersey JH. B-cell markers on lymphoblasts in acute lymphoblastic leukaemia. Clin Exp Immunol. 1974 Aug;17(4):561-569. PMID: 4219600. PMCID: 1554089.

12. Bloomfield CD, Brunning RD. Prognostic implications of cytology in acute leukemia in the adult. The case for subacute leukemia. Hum Pathol.1974 Nov;5:641-659. PMID: 4529350.

13. Bloomfield CD, Brunning RD, Kennedy BJ. Daunorubicin-prednisone treatment of erythroleukemia. Ann Intern Med. 1974 Dec;81:746-750. PMID: 4530645.

14. Brunning RD, Bloomfield CD, McKenna RW, Peterson L. Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med. 1975 Mar;82(3):365-366. PMID: 1172924.

15. McKenna RW, Bloomfield CD, Brunning RD. Nodular lymphoma: Bone marrow and blood manifestations. Cancer. 1975 Aug;36(2):428-440. PMID: 50871.

16. Peterson LC, Bloomfield CD, Sundberg RD, Gajl-Peczalska KJ, Brunning RD. Morphology of chronic lymphocytic leukemia and its relationship to survival. Am J Med. 1975 Sep;59:316-324. PMID: 1080632.


18

PUBLICATIONS - Excluding Letters, Abstracts and Edited Books (cont.)

17. Bloomfield CD. Recognizing and evaluating non-Hodgkin's lymphomas. Geriatrics.1975 Oct;30:56-62. PMID: 1158112.

18. Bloomfield CD, Theologides A, Kennedy BJ. Effectiveness of chemotherapy for non-Hodgkin's lymphomas. Geriatrics.1975 Oct;30:105-109. PMID: 1158108.

19. McKenna RW, Bloomfield CD, Dick F, Nesbit ME, Brunning RD. Acute monoblastic leukemia: Diagnosis and treatment of ten cases. Blood. 1975 Oct;46(4):481-494. PMID: 169929.

20. Gajl-Peczalska KJ, Bloomfield CD, Coccia PF, Sosin H, Brunning RD, Kersey JH. B and T cell lymphomas: Analysis of blood and lymph nodes in 87 patients. Am J Med. 1975 Nov;59:674-685. PMID: 1106193.

21. Fortuny IE, Bloomfield CD, Hadlock DC, Goldman A, Kennedy BJ, McCullough JJ. Granulocyte transfusion: A controlled study in patients with acute nonlymphocytic leukemia. Transfusion. 1975 Nov/ Dec;15(6):548-558. PMID: 1198683.

22. Bloomfield CD. Non-Hodgkin's lymphoma: A review for the surgeon. In Advances in Cancer Surgery (Najarian JS, Delaney JP, eds), New York, Intercontinental Medical Book Corporation; 1976:171-181. ISBN: 0883720396.

23. Bloomfield CD, Kennedy BJ. The malignant lymphomas. In Management of the Patient With Cancer, 2nd edition (Nealon TF, ed), Philadelphia, WB Saunders; 1976:917-963. ASIN: B001RYLFAM.

24. Bloomfield CD, McKenna RW, Brunning RD. Significance of haematological parameters in the non-Hodgkin's malignant lymphomas. Br J Haematol. 1976 Jan;32(1):41-46. PMID: 1259924.

25. Gajl-Peczalska KJ, Bloomfield CD, Sosin H, Kersey JH. B and T lymphocytes in Hodgkin's disease: Analysis at diagnosis and following therapy. Clin Exp Immunol. 1976 Jan;23:47-55. PMID: 1083318. PMCID: 1538370.

26. Levitt SH, Bloomfield CD, Lee CK, Nesbit ME, McKenna RW. Extended field radiotherapy in non-Hodgkin's lymphoma. Radiology. 1976 Feb;118(2):457-459. PMID: 943123.

27. Peterson LC, Bloomfield CD, Brunning RD. Blast crisis as an initial or terminal manifestation of chronic myeloid leukemia: A study of 28 patients. Am J Med. 1976 Feb;60:209-220. PMID: 1062162.

28. Bloomfield CD, Weiss RB, Fortuny I, Vosika G, Kennedy BJ. Combined chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to "MOPP." Cancer. 1976 Jul;38(7):42-48. PMID: 947533.

29. Bloomfield CD, Brunning RD. Acute leukemia as a terminal event in nonleukemic hematopoietic disorders. Semin Oncol. 1976 Sep;3(3):297-317. PMID: 790581.

30. Ramsay NKC, Coccia PF, Krivit W, Bloomfield CD, Nesbit ME. Vinblastine, procarbazine and cytosine arabinoside in combination for reinduction of childhood acute myelocytic leukemia. Cancer Treat Rep. 1976 Nov;60(11):1683-1685. PMID: 1071427.

31. Bloomfield CD, Kersey JH, Brunning RD, Gajl-Peczalska KJ. Prognostic significance of lymphocyte surface markers in adult non-Hodgkin's malignant lymphoma. Lancet. 1976 Dec 18;2(7999):1330-1333. PMID: 63805.

32. Bowers TK, Moldow CF, Bloomfield CD, Yunis EJ. Familial Hodgkin's disease and the major histocompatibility complex. Vox Sang. 1977;33(5):273-277. PMID: 144365.


19


33. Kersey JH, Coccia P, Bloomfield CD, Nesbit M, McKenna R, Brunning R, Hallgren H, Gajl-Peczalska KJ. Surface markers define human lymphoid malignancies with differing prognoses. Haematol Blood Transfus. 1977;20:17-24. PMID: 305392.

34. Bloomfield CD. Treatment of acute leukemia 1970-1976. (Editorial) Minn Med. 1977 Jun;60:49,497.

35. Bloomfield CD, Peterson LC, Yunis JJ, Brunning RD. The Philadelphia chromosome (Ph1) in adults presenting with acute leukaemia: A comparison of Ph1+ and Ph1- patients. Br J Haematol. 1977 Jul;36(3):347-358. PMID: 268208.

36. Peterson BA, Bloomfield CD. Prolonged maintained remissions of adult acute non-lymphocytic leukaemia. Lancet. 1977 Jul 23;2(8030):158-160. PMID: 69780.

37. Cotman HE, Bloomfield CD, Amplatz K, Sosin H, Kuisk H, Levitt S. Lymphography as a guide during laparotomy in Hodgkin's and non-Hodgkin's lymphomas. Acta Radiol Ther Phys Biol. 1977 Aug;16(4):295-304. PMID: 930635.

38. Peterson BA, Bloomfield CD. Treatment of acute nonlymphocytic leukemia in elderly patients. A prospective study of intensive chemotherapy. Cancer. 1977 Aug;40(2):647-652. PMID: 890652.

39. Bloomfield CD, Kersey JH, Brunning RD, Gajl-Peczalska KJ. Prognostic significance of lymphocytic surface markers and histology in adult non-Hodgkin's lymphoma. Cancer Treat Rep. 1977 Sep;61:963-970.

40. Gajl-Peczalska KJ, Chartrand S, Bloomfield CD, Corte J, Coccia PF, Nesbit ME, Kersey JH. Lymphocytes bearing receptors for both sheep erythrocytes and complement in patients with neoplastic and non-neoplastic disease. Clin Immunol Immunopathol. 1977 Sep;8(2):292-299. PMID: 332359.

41. Brunning RD, McKenna RW, Bloomfield CD, Coccia P, Gajl-Peczalska KJ. Bone marrow involvement in Burkitt's lymphoma. Cancer.1977 Oct;40(4):1771-1779. PMID: 907982.

42. Collins AJ, Bloomfield CD, Peterson BA, McKenna RW. Acute nonlymphocytic leukemia in patients with nodular lymphoma. Cancer. 1977 Oct;40(4):1748-1754. PMID: 578490.

43. Peterson BA, Bloomfield CD. High dose methotrexate for the remission induction of refractory adult acute lymphocytic leukemia. Med Pediatr Oncol. 1978;5(1):79-84. PMID: 370537.

44. Kennedy BJ, Bloomfield CD, Kiang DT, Vosika G, Peterson BA, Theologides A. Combination versus successive single agent chemotherapy in lymphocytic lymphoma. Cancer. 1978 Jan;41(1):23-28. PMID: 580070.

45. Kurvink K, Bloomfield CD, Cervenka J. Sister Chromatid exchange in patients with viral disease. Exp Cell Res. 1978 May;113(2):450-453. PMID: 233771.

46. Moldow CF, Bloomfield CD. Haemochromatosis and anthracyclines: free-radical-mediated tissue injury? Lancet. 1978 Jul 15;2(8081):154-5. PMID: 78352.

47. Bloomfield CD. Treatment of adult acute non-lymphocytic leukemia-1978 (Editorial). Arch Intern Med. 1978 Sep;138(9):1333-1334. PMID: 686921.

48. Bloomfield CD, DeCosse JJ. Staging laparotomy (Editorial). Arch Surg. 1978 Oct;113:1135. PMID: 708231.

49. Kurvink K, Bloomfield CD, Keenan KM, Levitt S, Cervenka J. Sister Chromatid exchange in lymphocytes from patients with malignant lymphoma. Hum Genet. 1978 Oct 31;44(2):137-144. PMID: 83281.

http://www.ncbi.nlm.nih.gov/pubmed?term=Moldow%20CF%5BAuthor%5D&cauthor=true&cauthor_uid=78352

http://www.ncbi.nlm.nih.gov/pubmed?term=Bloomfield%20CD%5BAuthor%5D&cauthor=true&cauthor_uid=78352


20


50. Collins AJ, Bloomfield CD, Peterson BA, McKenna RW, Edson JR. Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction. Arch Intern Med. 1978 Nov;138(11):1677-1680. PMID: 281191.

51. Bloomfield CD, Lindquist LL, Brunning RD, Yunis JJ, Coccia PF. The Philadelphia chromosome in acute leukemia. Virchows Arch B Cell Pathol. 1978 Nov 17;29(1-2):81-91. PMID: 103315.

52. Foucar K, McKenna RW, Bloomfield CD, Bowers TK, Brunning RD. Therapy-related leukemia: A panmyelosis. Cancer. 1979 Apr;43(4):1285-1296. PMID: 445330.

53. Frizzera G, Gajl-Peczalska KJ, Bloomfield CD, Kersey J. Predictability of immunologic phenotype of malignant lymphomas by conventional morphology. A study of 60 cases. Cancer. 1979 Apr;43(4):1216-1224. PMID: 376087.

54. Bloomfield CD. Acute non-lymphocytic leukemia. Minn Med. 1979 Jul;62(7):529-531. PMID: 492102.

55. Bloomfield CD. B and T markers in leukemia and lymphoma. Minn Med. 1979 Jul;62(7):499-501. PMID: 315029.

56. Bloomfield CD. Non-Hodgkin's malignant lymphoma. Minn Med 1979 Jul;62(7):533-535.

57. McCormack RT, Nelson RD, Bloomfield CD, Quie PG, Brunning RD. Neutrophil function in lymphoreticular malignancy. Cancer. 1979 Sep;44(3):920-926. PMID: 492104.

58. Bloomfield CD, Gajl-Peczalska KJ, Frizzera G, Kersey JH, Goldman AI. Clinical utility of lymphocytic surface markers combined with the Lukes-Collins histologic classification in adult lymphoma. N Engl J Med. 1979 Sep 6;301(10):512-518. PMID: 313510.

59. McKenna RW, Brynes RK, Nesbit ME, Bloomfield CD, Kersey JH, Spanjers E, Brunning RD. Cytochemical profiles in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol. 1979 Fall;1(3):263-275. PMID: 396800.

60. Bloomfield CD, Gajl-Peczalska KJ. The clinical relevance of lymphocyte surface markers in leukemia and lymphoma. Curr Top Hematol.1980;3:175-240. PMID: 6276102.

61. Bloomfield CD, Smith KA, Hildebrandt L, Zaleskas J, Gajl-Peczalska K, Frizzera G, Peterson BA, Kersey J, Crabtree GR, Munck AU. The therapeutic utility of glucocorticoid receptor studies in non-Hodgkin's malignant lymphoma. In Hormones and Cancer (Progress in Cancer Research and Therapy, Vol. 14) (Lacobelli S, King RJB, Lindner HR, Lippman ME, eds), New York, Raven Press; 1980:345-359.

62. Yasmineh WG, Smith BM, Bloomfield CD. DNA nucleotidylexotransferase (TdT) of normal persons and leukemic patients. Clin Chem. 1980;26(7):891-895. PMID: 6929745.

63. Levitt SH, Bloomfield CD, Frizzera G, Lee CKK. Curative radiotherapy for localized diffuse histiocytic lymphoma. Cancer Treat Rep. 1980 Jan;64(1):175-177. PMID: 6991104.

64. Nissen NI, Pajak TK, Leone LA, Bloomfield CD, Kennedy BJ, Ellison RR, Silver RT, Jones B, Holland JF, Falkson G, Kung F, Lee S. Clinical trial of VP 16-213 (NSC 14150) i.v. twice weekly in advanced neoplastic disease, a study by Cancer and Leukemia Group B. Cancer. 1980 Jan 15;45(2):232-235. PMID: 6985831.

65. Bloomfield CD, Brunning RD, Smith KA, Nesbit ME. Prognostic significance of the Philadelphia chromosome in acute lymphocytic leukemia. Cancer Genet Cytogenet. 1980 Mar;1(3):229-238.


21


66. Peterson LC, Bloomfield CD, Brunning RD. Relationship of clinical staging and lymphocyte morphology to survival in chronic lymphocytic leukaemia. Br J Haematol. 1980 Apr;45(4):563-567. PMID: 7378316.

67. Bloomfield CD, Smith KA, Peterson BA, Hildebrandt L, Zaleskas J, Gajl-Peczalska KJ, Frizzera G, Munck A. In-vitro glucocorticoid studies for predicting response to glucocorticoid therapy in adults with malignant lymphoma. Lancet. 1980 May 3;315(8175):952-956. PMID: 6103302.

68. Bloomfield CD. Adjuvant Therapy of Cancer. In The Science and Practice of Clinical Medicine, Vol 6, Hematology and Oncology (Lichtman M, ed), New York, Grune and Stratton, Inc.; 1980 Jul:279-281. ISBN: 0808912313.

69. Bloomfield CD. Remote Effects of Cancer. In The Science and Practice of Clinical Medicine, Vol 6, Hematology and Oncology (Lichtman M, ed), New York, Grune and Stratton, Inc.; 1980 Jul:254-257. ISBN: 0808912313.

70. Bloomfield CD. Treatment of adult acute non-lymphocytic leukemia - 1980 (Editorial). Ann Intern Med. 1980 Jul;93(1 Pt1):133-135. PMID: 7396289.

71. Peterson BA, Bloomfield CD, Bosl GJ, Gibbs G, Malloy M. Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia. Cancer. 1980 Aug 15;46:663-668. PMID: 7397631.

72. Hansen MM, Bloomfield CD, Jorgensen J, Ersboll J, Pedersen-Bjergaard J, Blom J, Nissen NI. VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas. Cancer Treat Rep. 1980 Oct/ Nov;64(10-11):1135-1137. PMID: 7459900.

73. Bloomfield CD, Hurd DD. Management of acute myeloid leukemia in adults. Curr Concepts Oncol.1980 Winter;2:17-23.

74. Hasegawa DK, Bloomfield CD. Thrombotic and hemorrhagic manifestations of malignancy. In Oncologic Emergencies (Yarbro J, Bornstein R, eds), New York, Grune & Stratton; 1980 Dec:141-196. ISBN: 0808913174.

75. Lee CKK, Bloomfield CD, Goldman AI, Levitt SH. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer. 1980 Dec 1;46(11):2403-2409. PMID: 7438015.

76. Bloomfield CD. Classification and prognosis of acute lymphoblastic leukemia. Prog Clin Biol Res. 1981;58:167-183. PMID: 7022480.

77. Gottlieb AJ, Bloomfield CD, Glicksman AS, Nissen NI, Cooper MR, Pajak TF, Holland JF. Nitrosoureas in the therapy of Hodgkin's disease: A summary of the Cancer and Leukemia Group B experience. In Nitrosoureas: Current Status and New Developments (Presteyko AW, ed), New York, Academic Press; 1981:81-197. ISBN: 0125650604.

78. Hasbrouck DJ, Peterson BA, Hurd DD, Bloomfield CD. Management of patients with acute non-lymphocytic leukemia who fail first cycle of induction therapy. Leuk Res. 1981;5(4-5):357-361. PMID: 7289645.

79. Hurd DD, Peterson BA, McKenna RW, Bloomfield CD. VP 16-213 and cyclophosphamide in the treatment of refractory acute nonlymphocytic leukemia with monocytic features. Med Pediatr Oncol. 1981;9(3):251-255. PMID: 7017368.


22


80. Peterson BA, Bloomfield CD. Re-induction of complete remissions in adults with acute non-lymphocytic leukemia. Leuk Res. 1981;5(1):81-88. PMID: 6939952.

81. Peterson BA, Bloomfield CD, Theologides A, Kennedy BJ. Daunorubicin-prednisone in the treatment of acute nonlymphocytic leukemia. Cancer Treat Rep. 1981;65 (suppl 4):29-33. PMID: 6955011.

82. Peterson BA, Collins AJ, Vogelzang NJ, Bloomfield CD. 5-Azacytidine and renal tubular dysfunction. Blood. 1981 Jan;57(1):182-185. PMID: 6160887.

83. Lee CKK, Bloomfield CD, Goldman AI, Nesbit ME, Levitt SH. The therapeutic utility of lung irradiation for Hodgkin's disease patients with large mediastinal masses. Int J Radiat Oncol Biol Phys. 1981 Feb;7(2):151-154. PMID: 7216852.

84. Gibbs GE, Peterson BA, Kennedy BJ, Vosika G, Bloomfield CD. Long-term survival of patients with Hodgkin's disease. Treatment with cyclophosphamide, vinblastine, procarbazine and prednisone. Arch Intern Med. 1981 Jun;141:897-900. PMID: 7235809.

85. Peterson BA, Bloomfield CD. Long-term disease-free survival in acute non-lymphocytic leukemia. Blood. 1981 Jun;57(6):1144-1147. PMID: 6784795.

86. Kostraba NC, Peterson BA, Kennedy BJ, Grage TB, Bloomfield CD. Laparotomy in the re-evaluation of patients with advanced Hodgkin's disease. Cancer Treat Rep. 1981 Jul/ Aug;65(7-8):685-687. PMID: 7248986.

87. Yunis JJ, Bloomfield CD, Ensrud K. All patients with acute nonlymphocytic leukemia may have a chromosomal defect. N Engl J Med. 1981 Jul 16;305(3):135-139. PMID: 6941081.

88. Strauss RG, Connett JE, Gale RP, Bloomfield CD, Herzig GP, McCullough J, Maguire LC, Winston DJ, Ho W, Stump DC, Miller WV, Koepke JA. A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukemia. N Engl J Med. 1981 Sep 10;305(11):597-603. PMID: 6790985.

89. Bloomfield CD, Goldman AI. Chromosomal abnormalities in acute lymphoblastic leukemia: structural and numerical changes in 234 cases. Third International Workshop on Chromosomes in Leukemia, 1980. Cancer Genet Cytogenet. 1981 Oct;4(2):111-137. PMID: 6949628.

90. Bloomfield CD, Lindquist LL, Arthur D, McKenna RW, LeBien TW, Peterson BA, Nesbit ME. Chromosomal abnormalities in acute lymphoblastic leukemia. Cancer Res. 1981 Nov;41:4838-4843. PMID: 7028252.

91. Bloomfield CD, Smith KA, Peterson BA, Munck A. Glucocorticoid receptors in adult acute lymphoblastic leukemia. Cancer Res. 1981 Nov;41(11 Pt 2):4857-4860. PMID: 6945909.

92. Crabtree GR, Bloomfield CD, Smith KA, McKenna RW, Peterson BA, Hildebrandt L, Munck A. Glucocorticoid receptors and in vitro responses to glucocorticoid in acute non-lymphocytic leukemia. Cancer Res.1981 Nov;41:4853-4856. PMID: 7296546.

93. LeBien T, McKenna R, Abramson C, Gajl-Peczalska K, Nesbit M, Coccia P, Bloomfield C, Brunning R, Kersey J. Use of monoclonal antibodies, morphology, and cytochemistry to probe the cellular heterogeneity of acute leukemia and lymphoma. Cancer Res. 1981 Nov;41(11 Pt 2):4776-4780. PMID: 6945905.

94. Bloomfield CD, Smith KA, Peterson BA, Gajl Peczalska KJ, Munck AU. In vitro glucocorticoid studies in human lymphoma: Clinical and biologic significance. J Steroid Biochem. 1981 Dec;15:275-284. PMID: 7339253.


23


95. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK. Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B. Blood. 1981 Dec;58(6):1203-1212. PMID: 6946847.

96. Shipman GF, Bloomfield CD, Smith KA, Gajl-Peczalska KJ, Munck A. The effects of glucocorticoid therapy on glucocorticoid receptors in leukemia and lymphoma. Blood. 1981 Dec;58(6):1198-1202. PMID: 6946846.

97. Bloomfield CD. Are single-institution studies more innovative than group studies? In Controversies in Oncology (Wiernik PH, ed), New York, John Wiley & Sons; 1982:389-407. ASIN: B000OUS24M.

98. Bloomfield CD, Arthur DC. Evaluation of leukemic cell chromosomes as a guide to therapy. Blood Cells. 1982;8(3):501-518. PMID: 7159762.

99. Peterson BA, Bloomfield CD. Acute leukemia in the adult. In Hematologic Malignancies in the Adult (Newcom SR and Kadin ME, eds), Menlo Park, CA, Addison-Wesley Publishing Co.;1982: 8-62.

100. Arthur DC, Bloomfield CD, Lindquist LL, Nesbit ME, Jr. Translocation 4;11 in acute lymphoblastic leukemia: Clinical characteristics and prognostic significance. Blood. 1982 Jan;59(1):96-99. PMID: 6947832.

101. Bloomfield CD. The clinical relevance of lymphocyte surface markers in adult acute lymphoblastic leukemia. Chapter 9. In: Bloomfield CD, ed. Adult Leukemias 1. Boston, MA: Martinus Nijhoff Publishers; 1982 Jan 1:265-308. ISBN: 9024724783.

102. Peterson BA, Bloomfield CD. Non-Hodgkin's malignant lymphomas. Chapter 22. In: Greenspan EM, ed. Clinical Interpretation and Practice of Cancer Chemotherapy. New York, Raven Press; 1982 Jan 1:519-546. ASIN: B0027CBMQA.

103. Bloomfield CD. Acute leukemia in adults. In Current Therapy (Conn HF, ed), Philadelphia, W. B. Saunders, Co.; 1982 Feb:299-304. ISBN: 0721627102.

104. McKenna RW, Parkin J, Bloomfield CD, Sundberg RD, Brunning RD. Acute promyelocytic leukaemia : A study of 39 cases with identification of hyperbasophilic microgranular variant. Br J Haematol. 1982 Feb;50(2):201-214. PMID: 6949609.

105. Howe RB, Bloomfield CD, McKenna RW. Hypocellular acute leukemia. Am J Med. 1982 Mar;72(3):391-395. PMID: 6949478.

106. Peterson BA, Bloomfield CD, Gottlieb AJ, Coleman M, Greenberg MS. 5-Azacytidine and Zorubicin for patients with previously treated acute nonlymphocytic leukemia: A Cancer and Leukemia Group B Pilot Study. Cancer Treat Rep. 1982 Mar;66(3):563-566. PMID: 6174230.

107. Bloomfield CD, Pajak TF, Glicksman AS, Gottlieb AJ, Coleman M, Nissen NI, Rafla S, Stutzman L, Vinciguerra V, Glidewell OJ, Holland JF. Chemotherapy and combined modality therapy for Hodgkin's disease: A progress report on Cancer and Leukemia Group B studies. Cancer Treat Rep. 1982 Apr;66(4):835-846. PMID: 6176320.

108. Lee CKK, Bloomfield CD, Levitt SH. Results of lung irradiation for Hodgkin's disease patients with large mediastinal masses and/or hilar disease. Cancer Treat Rep. 1982 Apr;66(4):819-825. PMID: 7074653.


24


109. Peterson BA, Pajak TF, Cooper MR, Nissen NI, Glidewell OJ, Holland JF, Bloomfield CD, Gottlieb AJ. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep. 1982 Apr;66(4):889-898. PMID: 7042088.

110. Ginsberg SJ, Crooke ST, Bloomfield CD, Peterson B, Kennedy BJ, Blom J, Ellison RR, Pajak TF, Gottlieb AJ. Cyclophosphamide, doxorubicin, vincristine, and low dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study #7804. Cancer. 1982 Apr 1;49(7):1346-1352. PMID: 6174203.

111. Gajl-Peczalska KJ, Chartrand SL, Bloomfield CD. Abnormal immunoregulation in patients with non-Hodgkin's malignant lymphomas. I. Increased helper function of peripheral blood T lymphocytes. Clin Immunol Immunopathol. 1982 May;23(2):366-378. PMID: 6213342.

112. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma: Summary and description of a working formulation for clinical usage. Cancer. 1982 May 15;49(10):2112-2135. PMID: 6896167.

113. Hurd DD, Vukelich M, Arthur DC, Lindquist LL, McKenna RW, Peterson BA, Bloomfield CD. 15;17 translocation in acute promyelocytic leukemia. Cancer Genet Cytogenet. 1982 Aug;6(4):331-337. PMID: 6956437.

114. Bloomfield CD, Peterson BA, Hurd DD. Are there adults with acute myelogenous leukemia for whom bone marrow transplantation in first complete remission is optimal treatment? In: Recent Advances in Bone Marrow Transplantation, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume VII, Gale RP ed., Alan R. Liss, Inc., New York, NY; 1983:105-114. ISBN: 0845126067.

115. Peterson BA, Bloomfield CD, Oliphant TH, Conroy JA. Patterns of relapse following chemotherapy in non-Hodgkin's lymphoma. Cancer Treatment Symposia. 1983;2:137-144.

116. Bloomfield CD, Arthur DC, Frizzera G, Peterson BA, Gajl-Peczalska KJ. Chromosomal abnormalities in non-Hodgkin's malignant lymphoma. In B and T Cell Tumors. Volume XXIV, E. Vitetta, ed., New York, Academic Press; 1983 Jan: 227-231. ISBN: 0127223800.

117. Gajl-Peczalska KJ, Bloomfield CD, Frizzera G, Kersey JH, LeBien TW. Diversity of phenotypes of non-Hodgkin's malignant lymphoma. In B and T Cell Tumors. Volume XXIV, E. Vitetta,., New York, Academic Press; 1983 Jan: 63-67. ISBN: 0127223800.

118. Kincade PW, Bloomfield CD. Phenotyping and properties of T and B tumors. In B and T Cell Tumors. Volume XXIV, E. Vitetta, ed., New York, Academic Press; 1983 Jan: 557-560. ISBN: 0127223800.

119. Bloomfield CD, Rowley JD, Goldman AI, Lawler SD, Secker-Walker LM, Mitelman F. Third International Workshop on Chromosomes in Leukemia: Chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia. Cancer Res. 1983 Feb;43(2):868-873. PMID: 6571719.

120. Arthur DC, Bloomfield CD. Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: A new association. Blood. 1983 May;61(5):994-998. PMID: 6831056.

121. Bloomfield CD, Arthur DC, Frizzera G, Levine EG, Peterson BA, Gajl-Peczalska KJ. Nonrandom chromosome abnormalities in lymphoma. Cancer Res. 1983 Jun;43(6):2975-2984. PMID: 6850608.

122. Shipman G, Bloomfield CD, Gajl-Peczalska KJ, Munck A, Smith KA: Glucocorticoids and lymphocytes. III. Effects of glucocorticoid administration on lymphocyte glucocorticoid receptors. Blood. 1983 Jun;61(6):1086-1090. PMID: 6601502.


25


123. Holbrook NJ, Bloomfield CD, Munck A. Analysis of activated and nonactivated cytoplasmic glucocorticoid-receptor complexes from human leukemia cells by rapid DNA-Diethylaminoethyl minicolumn chromatography. Cancer Res. 1983 Sep;43(9):4478-4482. PMID: 6871878.

124. Foster CM, Eisen HJ, Bloomfield CD. Covalent labeling of rat thymocyte and human lymphoid glucocorticoid receptor. Cancer Res. 1983 Nov;43(11):5273-5277. PMID: 6577947.

125. Bloomfield CD, Gajl-Peczalska KJ, Frizzera G, LeBien TW. The clinical utility of cell surface markers in malignant lymphoma. In: New Perspectives in Human Lymphoma, RJ Ford, LM Fuller, FB Hagemeister (eds), Raven Press, New York; 1984: 263-276.

126. Bloomfield CD, Munck AU, Smith KA. Glucocorticoid receptor levels predict response to treatment in human lymphoma. In: Hormones and Cancer (Progress in Clinical and Biological Research, Vol. 142), Gurpide E, Calandra R, Levy C, Soto RJ (eds), Alan R. Liss, Inc., New York; 1984: 223-233. ISBN: 0845101420

127. Holbrook NJ, Bloomfield CD, Munck A. Characteristics, stability and regulation of glucocorticoid-receptor complexes in normal and neoplastic cells as studied with a new mini-column technique. In: Hormones and Cancer (Progress in Clinical and Biological Research, Vol. 142), Gurpide E, Calandra R, Levy C, Soto RJ (ed), Alan R Liss, Inc., New York; 1984:195-206. ISBN: 0845101420.

128. Holbrook NJ, Bloomfield CD, Munck A. Stabilization of labile glucocorticoid-receptor complexes from acute nonlymphocytic leukemia cells by a factor from chronic lymphocytic leukemia cells. Cancer Res. 1984 Jan;44(1):407-414. PMID: 6690056.

129. Bloomfield CD. Acute lymphoblastic leukemia: Clinical and biologic features. In: Leukemias, (Hematology 1), JM Goldman, HD Preisler (eds), Butterworths International Medical Reviews, Kingsway, London; 1984 Feb:163-189. ISBN: 0407023364.

130. Levitt SH, Lee CKK, Bloomfield CD. Radical radiation therapy in the treatment of laparotomy staged Hodgkin's disease patients. Int J Radiat Oncol Biol Phys. 1984 Feb;10(2):265-74. PMID: 6706723.

131. Bloomfield CD, Goldman A, Hossfeld D, de la Chapelle A. The Fourth International Workshop on Chromosomes in Leukemia: The clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet. 1984 Mar;11(3):332-350. PMID: 6704938.

132. Bloomfield CD. Glucocorticoid receptors in leukemia and lymphoma. J Clin Oncol. 1984 Apr;2(4):323-328. PMID: 6368761.

133. Lee CKK, Bloomfield CD, Levitt SH. Liver irradiation in Stage IIIA Hodgkin's disease patients with splenic involvement. Am J Clin Oncol. 1984 Apr;7(2):149-57. PMID: 6702719.

134. Royston I, Minowada J, LeBien T, Pavlov G, Vosika G, Bloomfield CD, Ellison RR. Phenotypes of adult acute lymphoblastic leukemia defined by monoclonal antibodies. In: Leucocyte Typing: Human Leucocyte Differentiation Antigens Detected by Monoclonal Antibodies, A Bernard, L Boumsell, J Dausset, C Milstein, SF Schlossman eds., Springer-Verlag, New York; 1984 Apr 9:558-564. ISBN: 3540120564.

135. Gregg SL, Gajl-Peczalska KJ, LeBien TW, Bloomfield CD, Brunning R, Sagawa K. Monoclonal antibody MCS-2 as the marker of phorbol diester-induced myeloid differentiation in acute undifferentiated leukemia. Cancer Res. 1984 Jun;44(6):2724-2730. PMID: 6372996.

136. Arthur DC, Bloomfield CD. Banded chromosome analysis in patients with treatment-associated acute nonlymphocytic leukemia (t-ANLL). Cancer Genet Cytogenet. 1984 Jul;12(3):189-199. PMID: 6722761.


26


137. Bloomfield CD, Holbrook NJ, Munck AU, Foster CM, Eisen H, Smith KA. Glucocorticoid receptors: In vitro--clinical correlations in human leukemia and lymphoma. In: Hormones and Cancer 2; Proceedings of the Second International Congress, (Progress in Cancer Research and Therapy, Volume 31), F Bresciani, RJB King, ME Lippman, M Namer, J-P Raynaud, eds, Raven Press, New York, NY; 1984 Jul: 229-244. ISBN: 0881670316.

138. Cooper MR, Pajak TF, Gottlieb AJ, Glicksman AS, Nissen N, Richards F, Bloomfield C, Holland JF. The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease. J Clin Oncol. 1984 Jul;2(7):748-755. PMID: 6376718.

139. Berger R, Bloomfield CD, Sutherland G: Report of the committee on chromosome rearrangements in neoplasia and on fragile sites. Eighth International Human Gene Mapping Workshop. Cytogenet Cell Genet. 1985;40(1-4):490-535. PMID: 3864602.

140. Bloomfield CD. Acute myelocytic leukemia in adults. In: Current Therapy in Hematology/Oncology 1984-1985, Brain MC, Carbone PP, eds, B.C. Decker Inc., Toronto; 1985: 72-76. ISBN: 0815111894.

141. Bloomfield CD, Arthur DC, Levine EG, Frizzera G, Gajl-Peczalska KJ, LeBien TW, Hurd DD, Peterson BA. Banded chromosome abnormalities in non-Hodgkin's lymphoma. Correlations with morphology, immunologic phenotype and clinical course. Section II Chapter 1. In: Cavalli F, Bonadonna G, Rozencweig M, eds. Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Hingham, MA: Martinus Nijhoff Publishers; 1985: 73-80. ISBN: 0898387272.

142. Bloomfield CD, Arthur DC, Levine EG, Frizzera G, Gajl-Peczalska KJ, LeBien TW, Hurd DD, Peterson BA. Chromosome abnormalities in malignant lymphoma: Biologic and clinical correlations. Haematol Blood Transfus. 1985;29:145-149. PMID: 4029729.

143. Bloomfield CD. The clinical importance of chromosome abnormalities in acute leukemia. In: Directions in Oncology, Mitchell MS, ed, Vol. 1, Nassau Publications, Inc., New Jersey; 1985: 2-7.

144. Bloomfield CD. The clinical significance of chromosomal changes in acute leukemia. In: Medical Genetics: Past, Present, Future, Berg K, ed, Alan R. Liss, Inc., New York, NY; 1985. Prog Clin Biol Res. 1985;177:153-170.

145. Bloomfield CD. The clinical significance of chromosomal changes in childhood acute leukemia. Eur Pediatr Hematol Oncol. 1985;2:1-5.

146. Duane SF, Peterson BA, Bloomfield CD, Michels SD, Hurd DD. Response of therapy-associated acute nonlymphocytic leukemia to intensive induction chemotherapy. Med Pediatr Oncol. 1985;13(4):207-213. PMID: 4010622.

147. Levine EG, Peterson BA, Smith KA, Hurd DD, Bloomfield CD. Glucocorticoid receptors in chronic lymphocytic leukemia. Leuk Res. 1985;9(8):993-999. PMID: 4046634.

148. Berard CW, Bloomfield C, Bonadonna G, Brown BW, Jr., Glatstein E, Hoppe R, Rosenberg SA, Rudders R, Simon R. Classification of non-Hodgkin's lymphomas: Reproducibility of major classification systems. Cancer. 1985 Jan 1;55(1):91-95. PMID: 3965089.

149. Levitt S, Lee K, Bloomfield CD, Frizzera G. The role of radiation therapy in the treatment of early stage large cell lymphoma. Hematol Oncol. 1985 Jan-Mar;3(1):33-37. PMID: 3886514.

150. Bloomfield CD. Cytogenetics of Malignant Lymphoma. In: Neoplastic Diseases of the Blood, Wiernik PH, Canellos GP, Kyle RA, Schiffer CA, eds, Churchill Livingstone, New York; 1985 Feb: 773-787. ISBN-10: 0443082804.


27


151. Sobol RE, Royston I, LeBien TW, Minowada J, Anderson K, Davey FR, Cuttner J, Schiffer C, Ellison RR, Bloomfield CD. Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies. Blood. 1985 Mar;65(3):730-735. PMID: 3855666.

152. Bloomfield CD, Brunning RD. FAB M7: Acute megakaryoblastic leukemia--beyond morphology. (Editorial) Ann Intern Med. 1985 Sep;103(3):450-452. PMID: 4040724.

153. Bloomfield CD, Brunning RD. The revised FAB classification of acute myeloid leukemia: Is new better? (Editorial) Ann Intern Med. 1985 Oct;103(4):614-616. PMID: 3862358.

154. Bloomfield CD. Chromosomal abnormalities in acute leukemia. Schweiz Med Wochenschr. 1985 Oct 26;115(43):1501-1505. PMID: 3909384.

155. Bloomfield CD, Garson OM, Volin L, Knuutila S, de la Chapelle A. The t(1;3)(p36;q21) in acute nonlymphocytic leukemia: A new cytogenetic-clinicopathologic association. Blood. 1985 Dec;66(6):1409-1413. PMID: 4063527.

156. Bloomfield CD. Postremission therapy in acute myeloid leukemia. (Editorial) J Clin Oncol. 1985 Dec;3(12):1570-1572. PMID: 3906047.

157. Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, Bloomfield CD. There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas. Blood. 1985 Dec;66(6):1414-1422. PMID: 4063528.

158. Bloomfield CD, Hurd DD, Peterson BA. Leukemias. In: Medical Oncology, Basic Principles and Clinical Management of Cancer. Calabresi P, Schein PS, Rosenberg SA, eds, Macmillan Publishing Co., New York; 1985 Dec 1: 523-575. ISBN: 0023180404.

159. Bloomfield CD. The clinical usefulness of chromosome abnormalities in acute leukemia. In: Tumor Aneuploidy, Büchner TH, Bloomfield CD, Hiddemann W, Hossfeld DK, Schumann J, eds. Springer, Verlag, Berlin; 1985 Dec 2: 13-24. ISBN: 3540153764.

160. Bloomfield CD. Chromosome abnormalities in secondary myelodysplastic syndromes. Scand J Hematol Suppl. 1986;45:82-90. PMID: 3515525.

161. Bloomfield CD. The clinical and biological relevance of cytogenetic studies in human acute leukemia. In: Proceedings of the XIIth Symposium for Comparative Research on Leukemia and Related Diseases, F. Deinhard, ed., Hamberg, Germany; 1986: 112-125.

162. Sobol RE, Mick R, LeBien TW, Ozer H, Minowada J, Anderson K, Ellison RR, Cuttner J, Morrison A, Richards F, Royston I, Bloomfield CD. The reproducibility of acute lymphoblastic leukemia phenotype determinations: Evaluation of monoclonal antibody and conventional hematopoietic markers. Leuk Res. 1986;10(5):481-5. PMID:2940420.

163. Bloomfield CD, Goldman AI, Alimena G, Berger R, Borgström GH, Brandt L, Catovsky D, de la Chapelle A, Dewald GW, Garson OM, Garwicz S, Golomb HM, Hossfeld DK, Lawler SD, Mitelman F, Nilsson P, Pierre RV, Philip P, Prigogina E, Rowley JD, Sakurai M, Sandberg AA, Secker Walker LM, Tricot G, Van Den Berghe H, Van Orshoven A, Vuopio P, Whang-Peng J. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood. 1986 Feb;67(2):415-420. PMID: 3455828.

164. Knuutila S, Elonen E, Teerenhovi L, Rossi L, Leskinen R, Bloomfield CD, de la Chapelle A. Trisomy 12 in B cells of patients with B-cell chronic lymphocytic leukemia. N Engl J Med. 1986 Apr 3;314(14):865-9. PMID:3081810.


28


165. Keinänen M, Knuutila S, Bloomfield CD, Elonen E, de la Chapelle A. The proportion of mitoses in different cell lineages changes during short-term culture of normal human bone marrow. Blood. 1986 May;67(5):1240-3. PMID: 3516250.

166. Levine EG, Bloomfield CD. Secondary myelodysplastic syndromes and leukaemias. Clin Haematol. 1986 Nov;15(4):1037-80. PMID: 3552347.

167. Griffin JD, Davis R, Nelson DA, Davey FR, Mayer RJ, Schiffer C, McIntyre OR, Bloomfield CD. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood. 1986 Dec;68(6):1232-41. PMID: 2946331.

168. Levine EG, Arthur DC, Gajl-Peczalska KJ, LeBien TW, Peterson BA, Hurd DD, Bloomfield CD. Correlations between immunologic phenotype and karyotype in malignant lymphoma. Cancer Res. 1986 Dec;46(12 Pt 1):6481-8. PMID: 3096564.

169. Bloomfield CD, Trent JM, van den Berghe H. Report of the committee on structural chromosome changes in neoplasia. Ninth International Human Gene Mapping Workshop. Cytogenet Cell Genet. 1987;46(1-4):344-66. PMID: 3507283.

170. Ginsberg SJ, Anderson JR, Gottlieb AJ, Bloomfield CD, Norton L, Barcos M, Holland JF. A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (Adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma--Preliminary report of Cancer and Leukemia Group B study 7851. NCI Monogr. 1987;(5):77-80. PMID: 2448657.

171. Ozer H, Anderson JR, Peterson B, Budman DR, Henderson ES, Bloomfield CD, Gottlieb A. Combination trial of subcutaneous interferon alpha-2b and oral cyclophosphamide in favorable histology non-Hodgkin's lymphoma. Invest New Drugs. 1987;5 Suppl:S27-33.

172. Bloomfield CD. Chromosome rearrangements in human neoplasia. Fragile sites in man. In: Genetic Maps. Vol. 4. O'Brien SJ, ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; 1987 Jan: 605-609. ISBN: 0879693037.

173. Keinänen M, Knuutila S, Bloomfield CD, Elonen E, de la Chapelle A. Bone marrow cytogenetics: The lineage of dividing cells changes during the first few hours in culture. Leukemia. 1987 Jan;1(1):32-7. PMID: 3669733.

174. Bloomfield CD. Acute myelocytic leukemia in adults. In: Current Therapy in Internal Medicine - 2, Bayless TM, Brain MC, Cherniack RM, eds, B. C. Decker Inc., Burlington, Ontario; 1987 Jan 12; 340-343.

175. Levitt SH, Lee CKK, Aeppli DM, Bloomfield CD. The radical treatment of Hodgkin's disease with radiation therapy: Results of a 15-year clinical trial. The 1985 Erskine Lecture. Radiology. 1987 Mar;162(3):623-30. PMID: 3544029.

176. Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, Cuttner J, Griffin JD, Collins H, Nelson DA, Bloomfield CD. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med. 1987 Apr 30;316(18):1111-7. PMID: 3494942.

177. Lee CKK, Aeppli DM, Bloomfield CD, Levitt SH. Hodgkin's disease: A reassessment of prognostic factors following modification of radiotherapy. Int J Radiat Oncol Biol Phys. 1987 Jul;13(7):983-91. PMID: 3597162.

178. Lakkala-Paranko T, Franssila K, Lappalainen K, Leskinen R, Knuutila S, de la Chapelle A, Bloomfield CD. Chromosome abnormalities in peripheral T-cell lymphoma. Br J Haematol. 1987 Aug;66(4):451-60. PMID: 3499166.


29


179. Peterson BA, Brunning RD, Bloomfield CD, Hurd DD, Gau JA, Peng G, Goldman AI. Central nervous system involvement in acute nonlymphocytic leukemia: A prospective study of adults in remission. Am J Med. 1987 Sep;83(3):464-70. PMID: 3661583.

180. Fifth International Workshop on Chromosomes in Leukemia-Lymphoma. Correlation of chromosome abnormalities with histologic and immunologic characteristics in non-Hodgkin's lymphoma and adult T-cell leukemia-lymphoma. Blood. 1987 Nov;70(5):1554-64. PMID: 2889485.

181. Bloomfield CD, de la Chapelle A. Chromosome abnormalities in acute nonlymphocytic leukemia: Clinical and biologic significance. Semin Oncol. 1987 Dec;14(4):372-83. PMID: 3321442.

182. Bloomfield CD. Introduction: Acute myeloid leukemia. Semin Oncol. 1987 Dec;14:357-358.

183. Lachant NA, Anderson JR, Ginsberg SJ, Cooper MR, Hurd DD, Bloomfield CD, Gottlieb AJ. Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine and dexamethasone: CALGB Study 7902. Med Ped Oncol. 1988;16(6):375-7.

184. Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, Bloomfield CD. Cytogenetic abnormalities predict clinical outcome in non-Hodgkin's lymphoma. Ann Intern Med. 1988 Jan;108(1):14-20. PMID: 3337492.

185. Sobol RE, Bloomfield CD, Royston I. Immunophenotyping in the diagnosis and classification of acute lymphoblastic leukemia, Clin Lab Med. 1988 Mar;8(1):151-62. PMID: 3282757.

186. Keinänen M, Griffin JD, Bloomfield CD, Machnicki J, de la Chapelle A. Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia. N Engl J Med. 1988 May 5;318(18):1153-8. PMID: 3163100.

187. Davey FR, Mick R, Nelson DA, MacCallum J, Sobol RE, Royston I, Cuttner J, Ellison RR, Bloomfield CD. Morphologic and cytochemical characterization of adult lymphoid leukemias which express myeloid antigen. Leukemia. 1988 Jul;2(7):420-6. PMID: 3164798.

188. Dusenbery KE, Peterson BA, Bloomfield CD. Chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) for Hodgkin's disease: Fourteen year follow-up results. Am J Hem. 1988 Aug;28(4):246-51. PMID: 3414672.

189. Hurd DD, LeBien TW, Lasky LC, Haake RJ, Ramsay NKC, Kim TH, Levine EG, McGlave PB, Bloomfield CD, Peterson BA, Kersey JH. Autologous bone marrow transplantation in non-Hodgkin's lymphoma: Monoclonal antibodies plus complement for ex vivo marrow treatment. Am J Med. 1988 Dec;85(6):829-34. PMID: 3057901.

190. Simon R, Durrleman S, Hoppe RT, Bonadonna G, Bloomfield CD, Rudders RA, Cheson BD, Berard CW. The non-Hodgkin lymphoma pathologic classification project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas. Ann Intern Med. 1988 Dec 15;109(12):939-45. PMID: 3057985.

191. Luikart SD, Fosdick L, Ogle KM, Peterson BA, Bloomfield CD. Serum and urine glycosaminoglycans in myeloid leukemia and myelodysplasia. Leukemia.1989;3:48-50. PMID: 3264379.

192. Davey FR, Davis RB, MacCallum JM, Nelson DA, Mayer RJ, Ball ED, Griffin CA, Bloomfield CD. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol. 1989 Apr;30(4):221-7. PMID: 2539013.

193. Levine EG, King RA, Bloomfield CD. The role of heredity in cancer. J Clin Oncol. 1989 Apr;7(4):527-40. PMID: 2647916.


30


194. Ball ED, McDermott J, Griffin JD, Davey FR, Davis R, Bloomfield CD. Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells. Blood. 1989 May 15;73(7):1951-6. PMID: 2469504.

195. Keinänen M, Bloomfield CD, Machnicki J, Griffin JD, de la Chapelle A. Human bone marrow cytogenetics: Growth factors stimulate metaphases for specific lineages. Leukemia. 1989 Jun;3(6):405-12. PMID: 2657230.

196. Arthur DC, Berger R, Golomb HM, Swansbury GJ, Reeves BR, Alimena G, van den Berghe H, Bloomfield CD, de la Chapelle A, Dewald GW, Garson OM, Hagemeijer A, Kaneko Y, Mitelman F, Pierre RV, Ruutu T, Sakurai M, Lawler SD, Rowley JD: The clinical significance of karyotype in acute myelogenous leukemia (AML): Cancer Genet Cytogenet. 1989 Jul 15;40(2):203-16. PMID: 2766244.

197. Bloomfield CD, Secker-Walker LM, Goldman AI, Van Den Berghe H, de la Chapelle A, Ruutu T, Alimena G, Garson OM, Golomb HM, Rowley JD, Kaneko Y, Whang-Peng J, Prigogina E, Philip P, Sandberg AA, Lawler SD, Mitelman F. Six year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1989 Jul 15;40(2):171-85. PMID: 2766242.

198. Secker-Walker LM, Alimena G, Bloomfield CD, Kaneko Y, Whang-Peng J, Arthur D, de la Chapelle A, Reeves BM, Rowley J, Lawler SD, Mitelman. Cytogenetic studies of 21 patients with acute lymphoblastic leukemia in relapse. Cancer Genet Cytogenet. 1989 Jul 15;40(2):163-9. PMID: 2766241.

199. Levine EG, Arthur DC, Machnicki J, Frizzera G, Hurd D, Peterson B, Gajl-Peczalska KJ, Bloomfield CD. Four new recurring translocations in non-Hodgkin lymphoma. Blood. 1989 Oct;74(5):1796-800. PMID: 2506953.

200. Bloomfield CD, Wurster-Hill D, Peng G, Le Beau M, Tantravahi R, Testa J, Davey FR, Ellison RR, Cuttner J, Schiffer C, Sobol RE, Lunghofer B, Carey M, Mick R, Arthur D. Prognostic significance of the Philadelphia chromosome in adult acute lymphoblastic leukemia. In: Acute Lymphoblastic Leukemia. UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 108, eds. RP Gale and D Hoelzer, Wiley-Liss, New York, NY; 1990:101-109. ISBN: 0471567191.

201. Hurd DD, Haake RJ, Lasky LC, Christiansen NP, McGlave PB, Bostrom B, Levine EG, Weisdorf DJ, Kim TH, Peterson BA, Bloomfield CD. Treatment of refractory and relapsed Hodgkin's Disease: Intensive Chemotherapy and Autologous Bone Marrow or Peripheral Blood Stem Cell Support. Med Pediatr Oncol. 1990;18(6):447-53. PMID: 1978232.

202. Levine EG, Bloomfield CD. Cytogenetics of non-Hodgkin lymphoma. Presented at: The Lymphomas: Current Concepts in Pathogenesis and Management: conference at the Georgetown University Medical Center, Washington, D.C., September 21-23, 1989. J Natl Cancer Inst Monogr. 1990;(10):7-12. PMID: 2189479.

203. Morrison VA, Peterson BA, Bloomfield CD. Nosocomial septicemia in the cancer patient: The Influence of Central Venous Access Devices, Neutropenia, and Type of Malignancy. Med Pediatr Oncol. 1990;18(3):209-16. PMID: 2329966.

204. Simon R, Durrleman S, Hoppe RT, Bonadonna G, Bloomfield CD, Rudders RA, Cheson BD, Berard CW. Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the Non-Hodgkin's Lymphoma Pathologic Classification Project. Med Pediatr Oncol. 1990;18(2):89-96. PMID: 2406556.

205. Bloomfield CD, Frestedt JL. Chromosome rearrangements in human neoplasia. In: Genetic Maps. Vol. 5. O'Brien SJ, ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; 1990 Feb:186-192.


31


206. Rybak ME, McCarroll K, Bernard S, Lester E, Barcos M, Ozer H, Bloomfield CD, Gottlieb AJ. Interferon therapy of relapsed and refractory Hodgkin's disease: Cancer and Leukemia Group B Study 8652. J Biol Response Mod. 1990 Feb;9(1):1-4. PMID: 2319256.

207. Uhlman DL, Bloomfield CD, Hurd DD, Peterson BA. Prognostic factors at relapse for adults with acute myeloid leukemia. Am J Hematol. 1990 Feb;33(2):110-6. PMID: 2301369.

208. Howell A, Stukel T, Bloomfield CD, Davey F, Ball E. Induction of differentiation in blast cells and leukemia colony-forming cells (L-CFC) from patients with acute myeloid leukemia. Blood. 1990 Feb 1;75(3):721-9. PMID: 2105108.

209. Levine EG, Juneja S, Arthur D, Garson OM, Machnicki JL, Frizzera G, Ironside P, Cooper I, Hurd DD, Peterson BA, Mosel D, Bloomfield CD. Sequential karyotypes in non-Hodgkin lymphoma: Their Nature and Significance. Genes Chromosomes Cancer. 1990 Mar;1(4):270-80. PMID: 2278958.

210. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods W. Report of the NCI-Sponsored Workshop on definitions of diagnosis and response in acute myeloid leukemia (AML). J Clin Oncol. 1990 May;8(5):813-9. PMID: 2185339.

211. Lee CK, Aeppli DM, Bloomfield CD, Levitt SH. Curative radiotherapy for laparotomy-staged IA, IIA, IIIA Hodgkin's disease: An evaluation of the gains achieved with radical radiotherapy. Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):547-59. PMID: 2211203.

212. Machnicki JL, Bloomfield CD. Clinical significance of the cytogenetics of acute leukemias. Oncology. 1990 Oct;4(10):23-30; discussion 35-6. PMID: 2149823.

213. Döhner H, Arthur DC, Ball ED, Sobol RE, Davey FR, Lawrence D, Gordon L, Patil SR, Surana RB, Testa JR, Verma RS, Schiffer CA, Wurster-Hill DH, Bloomfield CD. Trisomy 13 - A new recurring chromosome abnormality in acute leukemia. Blood. 1990 Oct 15;76(8):1614-21. PMID:1698482.

a. Döhner H, Arthur DC, Patil SR, Surana, RB, Testa JR, Wursterhill DH, Bloomfield CD. Author Response: Trisomy-13 in a patient with T-cell acute lymphoblastic-leukemia. Blood. 1991 Jul 1:78(1):252-252. PMID: 2070057.

214. Gottlieb AJ, Anderson JR, Ginsberg SJ, Bloomfield CD, Norton L, Barcos M, Peterson BA, Nissen N, Henderson ES, Holland JF. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas: Cancer and Leukemia Group B Study 7851. Cancer. 1990 Nov 1;66(9):1888-96. PMID: 1699653.

215. Machnicki JL, Bloomfield CD. Chromosomal abnormalities in myelodysplastic syndromes and acute myeloid leukemia. Clin Lab Med. 1990 Dec;10(4):755-67. PMID: 2272173.

216. Baer MR, Bloomfield CD. The clinical significance of biological characteristics of the cells in acute myeloid leukemia. In: Annu Rev Med. 1991;42:381-9. PMID: 2035983.

217. Baer MR, Bloomfield CD. The impact of chromosome studies on the diagnosis and management of leukemia. Finska Läkaresällskapets Handlingar (Finnish Medical Society Documents). 1991;151(135):221-226.

218. Baer MR, Bloomfield CD. The clinical use of cytogenetics in acute leukemia. Ann Med. 1991 Apr;23(2):117-9. PMID: 2069787.

219. Levine EG, Bloomfield CD. Cytogenetics of malignant lymphomas. In: Neoplastic Diseases of the Blood, P. H. Wiernik (ed), Churchill Livingstone, New York, NY; 1991 May:689-700. ISBN: 0443086931.


32


220. Swisher EM, Shawler DL, Collins HA, Bustria A, Hart S, Bloomfield C, Miller RA, Royston I. Expression of shared idiotypes in chronic lymphocytic leukemia and small lymphocytic lymphoma. Blood. 1991 May 1;77(9):1977-82. PMID: 1902123.

221. Cuttner J, Mick R, Budman DR, Mayer RJ, Lee EJ, Henderson ES, Weiss RB, Paciucci PA, Sobol R, Davey F, Bloomfield C, Schiffer C. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB study. Leukemia. 1991 May;5(5):425-31. PMID: 2033963.

222. Baer MR, Bloomfield CD. Multidrug Resistance in Acute Myeloid Leukemia. (Editorial). J Natl Cancer Inst. 1991 May 15;83(10):663-5. PMID:2023265.

a. Baer M, Bloomfield CD. Author Response: Multidrug resistance in acute myeloid leukemia. J Natl Cancer Inst. 1991 Oct 2;83(19):1418-1419. PMID: 1920485.

223. Ball ED, Davis RB, Griffin JD, Mayer RJ, Davey FR, Arthur DC, Wurster-Hill D, Noll W, Elghetany MT, Allen SL, Rai K, Lee EJ, Schiffer CA, Bloomfield CD. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood. 1991 May 15;77(10):2242-50. PMID:1709379.

a. Ball ED, Bloomfield CD. Author Response: Expression of CD7 antigen precludes T(8-21)(Q22-Q22) chromosome aberration in acute myeloblastic-leukemia. Blood. 1992 Jun 1;79(11): 3093-3093. PMID: 1375122.

224. Baer MR, Bloomfield CD: Acute Promyelocytic Leukemia: an Update. (Editorial) Ann Oncol. 1991 Jun;2(6):392-3. PMID: 1768623.

225. Cella DF, Orav EJ, Kornblith AB, Holland JC, Silberfarb PM, Lee KW, Comis RL, Perry M, Cooper R, Maurer LH, Hoth DF, Perloff M, Bloomfield CD, McIntyre OR, Leone L, Lesnick G, Nissen N, Glicksman A, Henderson E, Barcos M, Crichlow R, Faulkner CS II, Eaton W, North W, Schein PS, Chu F, King G, Chahinian AP for Cancer and Leukemia Group B. Socioeconomic Status and Cancer Survival. J Clin Oncol. 1991 Aug;9(8):1500-9. PMID: 2072149.

226. Ball ED, Schwarz LM, Bloomfield CD. Expression of the CD15 Antigen on Normal and Leukemic Myeloid Cells: Effects of Neuraminidase and Variable Detection with a Panel of Monoclonal Antibodies. Mol Immunol. 1991 Sep;28(9):951-8. PMID: 1681429.

227. Ellison RR, Mick R, Cuttner J, Schiffer CA, Silver RT, Henderson ES, Woliver T, Royston I, Davey FR, Glicksman AS, Bloomfield CD, Holland JF. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: A prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol. 1991 Nov;9(11):2002-15. PMID: 1941059.

228. Baer MR, Frankel SR, Christiansen NP, Caligiuri MA, Bernstein SH, Mrózek KA, Bloomfield CD, Herzig GP. High dose cytosine arabinoside, idarubicin and G-CSF therapy for de novo and secondary adult acute myeloid leukemia. Leukemia and Lymphoma. 1992;7(Suppl 2):8-10.

229. Lawrence DD, Reese PA, Bloomfield CD. Use of Bootstrapping to Evaluate Infrequent Genetic Abnormalities as Prognostic Factors for Survival in Human Acute Leukemias. In: Computing Science and Statistics; Proceedings of the 22nd Symposium on the Interface, East Lansing, MI, May 16-19, 1990, C Page, R LePage, eds, Springer-Verlag, New York, NY; 1992: 425-429. ISBN: 3540977198.

230. Schiffer CA, Larson RA, Bloomfield CD for the CALGB. Cancer and Leukemia Group B (CALGB) studies in adult acute lymphocytic leukemia. Leukemia. 1992;6 Suppl 2:171-4. PMID: 1578925.

231. Baer MR, Bloomfield CD. Cytogenetics and Oncogenes (review article). Curr Opin Oncol. 1992 Feb;4(1):24-32. PMID: 1591291.

232. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol. 1992 Feb;19(1):47-84. PMID: 1736370.


33


233. Baer MR, Bloomfield CD. Controversies in transfusion medicine: Prophylactic platelet transfusion therapy: PRO. Transfusion. 1992 May;32(4):377-80. PMID: 1585445.

234. Baer MR, Bloomfield CD. Trisomy 13 in acute leukemia. Leuk Lymphoma. 1992 May;7(1-2):1-6. PMID: 1472919.

235. Davey FR, Lawrence D, MacCallum J, Varney J, Hutchison R, Wurster-Hill D, Schiffer C, Sobol RE, Ciminelli N, LeBeau M, Bloomfield CD. Morphologic characteristics of acute lymphoblastic leukemia (ALL) with abnormalities of chromosome 8, band q24. Am J Hematol. 1992 Jul;40(3):183-91. PMID: 1609772.

236. Cimino G, Nakamura T, Gu Y, Canaani O, Prasad R, Crist WM, Carroll AJ, Baer M, Bloomfield CD, Nowell PC, Croce CM, Canaani E. An altered 11-kilobase transcript in leukemic cell lines with the t(4;11)(q21;q23) chromosome translocation. Cancer Res. 1992 Jul 1;52(13):3811-3. PMID: 1617652.

237. Niehans GA, Jaszcz W, Brunetto V, Perri RT, Gajl-Peczalska K, Wick MR, Tsuruo T, Bloomfield CD. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res. 1992 Jul 1;52(13):3768-75. PMID: 1352183.

238. Duggan DB, Santarelli MT, Zamkoff K, Lichtman S, Ellerton J, Cooper R, Poiesz B, Anderson JR, Bloomfield CD, Peterson BA, Gottlieb AJ. A phase II study of recombinant Interleukin-2 with or without recombinant interferon- in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B. J Immunother (1991). 1992 Aug;12(2):115-22. PMID: 1504052.

239. Howell AL, Stukel TA, Bloomfield CD, Ball ED. Predictive value of flow cytometric analyses of blast cells in assessing the phenotype of the leukemia colony-forming cell (L-CFC) population in AML. Bone Marrow Transplant. 1992 Sep;10(3):261-6. PMID: 1422480.

240. Elghetany MT, Sullivan AK, Kurec AS, MacCallum JM, Bloomfield CD, Sobol RE, Davey FR. The use of monoclonal antibodies against primary myeloid granules in normal and leukemic cells. Am J Clin Pathol. 1992 Oct;98(4):430-6. PMID: 1415023.

241. Bloomfield CD. Prognostic factors for selecting curative therapy for adult acute myeloid leukemia. Leukemia. 1992 Nov;6 Suppl 4:65-7. PMID: 1434837.

242. Döhner H, Bloomfield CD, Frizzera G, Frestedt J, Arthur DC. Recurring chromosome abnormalities in Hodgkin's disease. Genes Chromosomes Cancer. 1992 Nov;5(4):392-8. PMID: 1283328.

243. Taylor JA, Sandler DP, Bloomfield CD, Shore DL, Ball ED, Neubauer A, McIntyre OR, Liu E. ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst. 1992 Nov 4;84(21):1626-32.1632. PMID: 1433344.

a. Taylor JA, Sandler DP, Bloomfield CD, Shore DL, Ball ED, Neubauer A, McIntyre OR, Liu E. Author Response: Acute myelogenous leukemia. J Natl Cancer Inst. 1993 Jun 2;85(11):920-1. PMID: 8492321.

244. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davy FR, Wurster-Hill D, Sobol R, Schiffer CA, Bloomfield CD. Clinical Significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B study. Blood. 1992 Dec 15;80(12):2983-90. PMID: 1467514.

245. Baer MR, Bloomfield CD. Acute leukemia in adults. In: Current Therapy in Oncology, Niederhuber JE (ed), B.C. Decker, Philadelphia, PA; 1993: 585-591. ISBN: 155664-229-6.

246. Baer MR, Bloomfield CD: Acute Myeloid Leukemia. In: The Causes and Consequences of Chromosomal Aberrations, Kirsch IR, ed, CRC Press, Inc., Boca Raton, FL; 1993: 377-392. ISBN: 0849388937.


34


247. Bloomfield CD, Foon KA, Levine EG. Leukemias. Chapter 29. In: Calabresi P, Schein PS, eds. Medical Oncology. New York, NY: McGraw Hill, Inc; 1993: 459-501.

248. Bloomfield CD, Herzig, GP: Preface. Management of Acute Leukemia. In: Hematology/Oncology Clinics of North America, Bloomfield CD, Herzig GP, eds, W. B. Saunders Company, Philadelphia, PA; 1993;7(1):xi-xiii. ASIN: 0008898588.

249. Mir R, Anderson J, Strauchen J, Nissen NI, Cooper MR, Rafla S, Canellos GP, Bloomfield CD, Gottlieb AJ, Peterson B, Barcos M. Hodgkin disease in patients 60 years of age or older: histologic and clinical features of advanced-stage disease. Cancer. 1993 Mar 1;71(5):1857-66. PMID: 8448750.

250. Mrózek K, Karakousis CP, Perez-Mesa C, Bloomfield CD. Translocation t(12;22)(q13;q12.2-12.3) in a clear cell sarcoma of tendons and aponeuroses. Genes Chromosomes Cancer. 1993 Apr;6(4):249-52. PMID: 7685631.

251. Mrózek K, Karakousis CP, Bloomfield CD. Chromosome 12 breakpoints are cytogenetically different in benign and malignant lipogenic tumors: Localization of breakpoints in lipoma to 12q15 and in myxoid liposarcoma to 12q13.3. Cancer Res. 1993 Apr 1;53(7):1670-5. PMID: 8453640.

252. Newman RA, Peterson B, Davey FR, Brabyn C, Collins H, Brunetto VL, Duggan DB, Weiss RB, Royston I, Millard FE, Miller AA, Bloomfield CD. Phenotype markers and BCL-1 gene rearrangements in B cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B Study. Blood. 1993 Aug 15;82(4):1239-46. PMID: 8102560.

253. Mrózek K, Bloomfield CD. Cytogenetics of indolent lymphomas. Semin Oncol. 1993 Oct;20(5 Suppl 5):47-57. PMID: 8211207.

254. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood. 1993 Nov 15;82(10):2975-84. PMID: 8219189.

255. Shore DL, Sandler D, Davey F, McIntyre OR, Bloomfield CD. Acute leukemia and residential proximity to potential sources of environmental pollutants. Arch Environ Health. 1993 Nov-Dec;48(6):414-20. PMID: 8250593.

256. Baer MR, Christiansen NP, Frankel SR, Brunetto VL, Mrózek K, Bloomfield CD, Herzig GP. High dose cytarabine, idarubicin and G-CSF remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia. Semin Oncol. 1993 Dec;20(6 Suppl 8):6-12. PMID: 7507264.

257. Sandler DP, Shore DL, Anderson JR, Davey FR, Arthur D, Mayer RJ, Silver RT, Weiss RB, Moore JO, Schiffer CA, Wurster-Hill DH, McIntyre OR, Bloomfield CD. Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetics. J Natl Cancer Inst. 1993 Dec 15;85(24):1994-2003. PMID: 8246285.

258. Larson RA, Bloomfield CD, Schiffer CA. Cancer and Leukemia Group B Studies in Acute Lymphoblastic Leukemia. In: Acute Leukemias IV, Prognostic Factors. Büchner et al. (eds), Springer-Verlag, Berlin Heidelberg; 1994: 420-425.

259. Ozer H, Anderson JR, Peterson BA, Budman DR, Cooper MR, Kennedy BJ, Silver RT, Henderson ES, Duggan DB, Barcos M, Bloomfield CD, Gottlieb AJ. Combination trial of subcutaneous recombinant α2b interferon and oral cyclophosphamide in follicular low grade non-Hodgkin's lymphoma. Med Pediatr Oncol. 1994;22(4):228-35. PMID: 8107652.


35


260. Caligiuri MA, Schichman SA, Strout MP, Mrózek K, Baer MR, Frankel SR, Barcos M, Herzig GP, Croce CM, Bloomfield CD. Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Cancer Res. 1994 Jan 15;54(2):370-3. PMID: 8275471.

261. Mrózek K, Karakousis CP, Bloomfield CD. Band 11q13 is nonrandomly rearranged in hibernomas. Genes Chromosomes Cancer. 1994 Feb;9(2):145-7. PMID: 7513546.

262. Swansbury GJ, Lawler SD, Alimena G, Arthur D, Berger R, Van Den Berghe H, Bloomfield CD, de la Chapelle A, Dewald G, Garson OM, Hagemeijer A, Mitelman F, Rowley JD, Sakurai M. Long-term survival in acute myelogenous leukemia: A second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet. 1994 Mar;73(1):1-7. PMID: 8174068.

263. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, Mayer RJ, Ball ED, Wurster-Hill D, Bloomfield CD, Liu ET. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994 Mar 15;83(6):1603-11. PMID: 8123851.

264. Schichman SA, Caligiuri MA, Gu Y, Strout MP, Canaani E, Bloomfield CD, Croce CM. ALL-1 partial duplication in acute leukemia. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6236-9. PMID: 8016145.

265. Morrison VA, Frizzera G, Arthur DC, Ogle KM, Hurd DD, Bloomfield CD, Peterson BA. Prognostic factors for therapeutic outcome of diffuse small non-cleaved cell lymphoma in adults. Am J Hematol. 1994 Aug;46(4):295-303. PMID: 8037180.

266. Schichman SA, Caligiuri MA, Strout MP, Carter SL, Gu Y, Canaani E, Bloomfield CD, Croce CM. ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res. 1994 Aug 15;54(16):4277-80. PMID: 8044771.

267. Stock W, Thirman MJ, Dodge RK, Rowley JD, Diaz MO, Wurster-Hill D, Sobol RE, Davey FR, Larson RA, Westbrook CA, Bloomfield CD. Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B Study. Leukemia. 1994 Nov;8(11):1918-22. PMID: 7967737.

268. Baer MR, Herzig GP, Bloomfield CD. Acute Myeloid Leukemia. In: Current Therapy in Hematology-Oncology, Fifth Edition. Brain MC, Carbone PP (eds), Mosby, Philadelphia, PA; 1995: 259-265. ISBN: 0815111894.

269. Fleming RA, Capizzi RL, Rosner GL, Oliver LK, Smith SJ, Schiffer CA, Silver RT, Peterson BA, Weiss RB, Omura GA, Mayer RJ, Van Echo DA, Bloomfield CD, Schilsky RL. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 1995;36(5):425-30. PMID: 7634384.

270. Frankel SR, Herzig GP, Bloomfield CD. Acute lymphoblastic leukemia. In: Cancer Treatment, Fourth Edition, Haskell CM (ed), W. B. Saunders Company, Philadelphia, PA; 1995: 1051-1074.

271. Mrózek K, Karakousis CP, Bloomfield CD. High resolution cytogenetic study of a lipoma with the t(1;12): assignment of breakpoints to 1p31.3-32 and 12q15. Journal of Experimental & Clinical Cancer Research. 1995;14:69-71.

272. Mrózek K, Arthur DC, Karakousis CP, Koduru PRK, LeBeau MM, Pettenati MJ, Tantravahi R, Mrózek E, Perez-Mesa C, Rao UNM, Frankel SR, Davey FR, Bloomfield CD. Der(16)t(1;16) is a nonrandom secondary chromosome aberration in many types of human neoplasia, including myxoid liposarcoma, rhabdomyosarcoma and Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Oncol. 1995 Mar;6(3):531-8. PMID: 21556567.


36


273. Frankel SR, Herzig GP, Bloomfield CD. Acute lymphoid leukemia in adults. In: Clinical Oncology, Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds), Churchill Livingstone, New York, NY; 1995 April: 1925-1957. ISBN: 0443089418.

274. Stock W, Westbrook CA, Sher DA, Dodge R, Sobol RE, Wurster-Hill D, Davey FR, Larson RA, LeBeau MM, Aplan DP, Frankel SR, Stewart CC, Bloomfield CD: Low incidence of TAL1 gene in re-arrangements in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study (8762). Clin Cancer Res. 1995 Apr;1(4):459-63. PMID: 9816004.

275. Larson RA, Dodge RK, Burns P, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, Hooberman AL, Westbrook CA, Arthur DC, George SL, Bloomfield CD, Schiffer CA. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood. 1995 Apr 15;85(8):2025-37. PMID: 7718875.

276. Davey FR, Abraham N, Brunetto VL, Maccallum JM, Nelson DA, Ball ED, Griffin JD, Baer MR, Wurster-Hill D, Mayer RJ, Schiffer CA, Bloomfield CD. Morphologic Characteristics of Erythroleukemia (Acute Myeloid Leukemia: FAB-M6): A CALGB study. Am J Hematol. 1995 May;49(1):29-38. PMID: 7741135.

277. Rai KR, Davey F, Peterson B, Schiffer C, Silver RT, Ozer H, Golomb H, Bloomfield CD. Recombinant Alpha-2b-Interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia. 1995 Jul;9(7):1116-20. PMID: 7630181.

278. Bloomfield CD, Baer MR, Herzig GP. Recent advances in curing de novo acute myeloid leukemia. In: Cancer Chemotherapy, 10th Nagoya International Symposium on Cancer Treatment, Vol. 10, Noble A (ed), Elsevier Science International Congress Series, Excerpta Medica, Ltd., Amsterdam-Hong Kong-Princeton-Sydney-Tokyo;1995 Dec: 63-72. ISBN: 0444823204.

279. Mrózek K, Bloomfield CD. Cytogenetics of non-Hodgkin's lymphoma and Hodgkin's disease. In: Neoplastic Diseases of the Blood, 3rd Edition. Wiernik PH, Canellos GP, Dutcher JP, Kyle RA (eds), Churchill Livingstone, New York, New York; 1995 Dec: 835-862. ISBN: 0443076006.

280. Bloomfield CD, Baer MR, Herzig GP. Acute myeloid leukemia in adults. An update. In: Education Programme of the European Haematology Association, Paris, May 29 - June 1, 1996, Blackwell Science Ltd., pp. 91-96, 1996.

281. Bloomfield CD, Heinonen K, Mrózek K. Adult Acute Myeloid Leukemia Cytogenetics: Clinical and Biologic Significance. In: Haematology 1996: Education Programme of the 26th Congress of the International Society of Haematology, Singapore, August 25-29, 1996, McArthur JR, Lee SH, Wong JEL, Ong YW, eds. International Society of Haematology, Singapore; 1996: 352-358.

282. Chen H, Sandler DP, Taylor JA, Shore DL, Liu E, Bloomfield CD, Bell DA. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet. 1996 Feb 3;347(8997):295-7. PMID: 8569364.

283. Baer MR, Bernstein SH, Brunetto VL, Heinonen K, Mrózek K, Swann VL, Minderman H, Block AW, Pixley LA, Christiansen NP, Fay JW, Barcos M, Rustum Y, Herzig GP, Bloomfield CD. Biologic effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. Blood. 1996 Feb 15;87(4):1484-94. PMID: 8608239.

284. Caligiuri MA, Strout MP, Schichman SA, Mrózek K, Arthur DC, Herzig GP, Baer MA, Schiffer CA, Heinonen K, Knuutila S, Nousiainen T, Ruutu T, Block AW, Schulman P, Pedersen-Bjergaard JP, Croce CM, Bloomfield CD. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with Trisomy 11. Cancer Res. 1996 Mar 15;56(6):1418-25.


37


285. Mrózek K, Bloomfield CD. New recurrent structural chromosome aberrations in non-Hodgkin's lymphoma: A review of the published literature. Int J Oncol. 1996 May;8(5):851-858. PMID: 21544437.

286. Heinonen K, Rao PN, Slack JL, Cruz J, Bloomfield CD, Mrózek K. Isochromosome 12p in two cases of acute myeloid leukaemia without evidence of germ cell tumour. Br J Haematol. 1996 Jun;93(3):677-680.

287. Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfield CD. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British Criteria: A Cancer and Leukemia Group B Study. J Clin Oncol. 1996 Sep;14(9):2486-2494. PMID: 8823327.

288. Mayer RJ, Antman KH, Bailes JS, Bloomfield CD, Canellos GP, Glick JH, Jacobs CD. Status of the Medical Oncology Workforce. J Clin Oncol. 1996 Sep;14(9):2612-2621. PMID: 8823341.

289. Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR, Hoffmann L, Ball ED, Frei-Lahr DA, Christiansen NP, Block AW, Knuutila S, Herzig GP, Bloomfield CD. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood. 1996 Sep 15;88(6):2183-91. PMID: 8822938.

a. Jurlander J; Caligiuri MA; Bloomfield CD. Author Response: Detection of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia after allogeneic bone marrow transplantation or peripheral blood progenitor cell transplantation. Blood. 1997 Oct 15;90(8):3231-3231. PMID: 9376607.

290. Cooper GS, Kamel F, Sandler DP, Davey FR, Bloomfield CD. Risk of adult acute leukemia in relation to prior immune-related conditions. Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):867-72. PMID: 8922293.

291. Larson RA, Dodge RK, Bloomfield CD, Schiffer CA. Treatment of biologically determined subsets of acute lymphoblastic leukemia in adults: Cancer and Leukemia Group B Studies. In: Acute Leukemia VI: Prognostic Factors and Treatment Strategies. Büchner T, Hiddemann W, Ritter J, Wormann B, and Creutzig U (eds). Springer-Verlag, Berlin, Heidelberg; 1996 Dec 23: 677-687. ISBN: 3540607633.

292. Mrózek K, Bloomfield CD. Chromosome Aberrations. In: Encyclopedia of Cancer, Volume I, Bertino JR (ed), Academic Press, Inc., San Diego, CA.

a. 1st Edition, 1997: 380-391. b. 2nd Edition, 2002: 485-496.

293. Stock W, Westbrook CA, Peterson B, Arthur DC, Szatrowski TP, Silver RT, Sher DA, Wu D, LeBeau MM, Schiffer CA, Bloomfield CD. Value of molecular monitoring during the treatment of chronic myeloid leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 1997 Jan;15(1):26-36. PMID: 8996121.

294. Bloomfield CD, Herzig GP, Caligiuri MA (Guest Editors). Introduction: Acute Leukemia. Recent Advances. Semin Oncol. 1997;24(1):1-2. 1997 Feb;24(1):1-2. PMID: 9045295.

295. Byrd JC, Weiss RB, Arthur DC, Shah D, Baer MR, Lawrence D, Davey F, Trikha ES, Carroll AJ, Tantravahi R, Qumsiyeh M, Patil SR, Moore J, Mayer RJ, Schiffer CA, Bloomfield CD. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): Results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997 Feb;15(2):466-75. PMID: 9053467.

296. Mrózek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics of acute myeloid leukemia. Semin Oncol. 1997 Feb;24(1):17-31. PMID: 9045301.


38


297. Caligiuri MA, Strout MA, Oberkircher AR, Yu F, de la Chapelle A, Bloomfield CD. The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3899-902. PMID: 9108076.

298. Slack JL, Arthur DC, Lawrence D, Mrózek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD. Secondary cytogenetic changes in acute promyelocytic leukemia: Prognostic importance in patients treated with chemotherapy alone and association with the Intron 3 breakpoint of the PML gene. A Cancer and Leukemia Group B Study. J Clin Oncol. 1997 May;15(5):1786-95. PMID: 9164186.

299. Wetzler M, Baer MR, Bernstein SH, Blumenson L, Stewart C, Barcos M, Mrózek K, Block AW, Herzig GP, Bloomfield CD. Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. J Clin Oncol. 1997 Jun;15(6):2262-8. PMID: 9196139.

300. Mrózek K, Szumigala J, Brooks JSJ, Crossland DM, Karakousis CP, Bloomfield CD. Round cell liposarcoma with the insertion (12;16)(q13;p11.2p13). Am J Clin Pathol. 1997 Jul;108(1):35-9. PMID: 9208976.

301. Wetzler M, Bloomfield CD. Acute and chronic myelogenous leukemia. Chapter 112. In: Fauci AS et al., eds. Harrison's Principles of Internal Medicine 14th Edition. New York, New York: The McGraw-Hill Companies, Inc; 1997 Aug: 684-695. ISBN: 0-07-020291-5.

302. Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA, Bloomfield CD. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood. 1997 Aug 15;90(4):1643-8. PMID: 9269784.

303. Gallagher RE, Willman CL, Slack JL, Andersen J, Li Y, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH. Association of PML-RARα fusion mRNA type with pre-treatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood. 1997 Aug 15;90(4):1656-63. PMID: 9269786.

304. Elghetany MT, Peterson B, MacCallum J, Nelson DA, Varney JF, Sullivan AK, Silverman LR, Schiffer CA, Davey FR, Bloomfield CD. Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: A common deficiency in 216 patients studied by the Cancer and Leukemia Group B. Leuk Res 1997 Sep;21(9):801-6. PMID: 9393593.

305. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Bloomfield CD, Head DR, Weinstein HJ, Woods WG, Rowe JM, Wiernik PH. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997 Oct 9;337(15):1021-8. PMID: 9321529.

306. Baer MR, Herzig GP, Bloomfield CD. Acute Myeloid Leukemia. In: Current Therapy in Adult Medicine, 4e. Kassirer JP, Greene HL (eds), Mosby-Year Book, Inc., Philadelphia, PA; 1997 Dec: 831-836. ISBN: 0815154801.

307. van der Reijden BA, Bloomfield CD, Touw IP, Jansen JH. Acute leukemias with structurally altered core binding factor subunits (t(8;21), inv(16), t(12;21)). Leukemia. 1997 Dec;11(12):2217-9. PMID: 9447846.

308. Bloomfield CD, Herzig GP, Peterson BA, Wolff SN. Long-term survival of patients with acute myeloid leukemia: updated results from two trials evaluating postinduction chemotherapy. Cancer. 1997 Dec 1;80(11 Suppl):2186-90. PMID: 9395032.


39


309. Bloomfield CD, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM, Garson OM, Peterson BA, Sakurai M, Alimena G, Berger R, Rowley JD, Ruutu T, Mitelman F, Dewald GW, Swansbury J. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer. 1997 Dec 1;80(11 Suppl):2191-8. PMID: 9395033.

310. Mrózek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PRK, Rao KW, Strout MP, Hutchison RE, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: a Cancer and Leukemia Group B study. Blood. 1997 Dec 1;90(11):4532-8. PMID: 9373264.

311. Elghetany MT, Peterson B, MacCallum J, Nelson DA, Varney JF, Sullivan AK, Silverman LR, Schiffer CA, Davey FR, Bloomfield CD. Double esterase staining and other neutrophilic granule abnormalities in 237 patients with the myelodysplastic syndrome studied by the Cancer and Leukemia Group B. Acta Haematol. 1998;100(1):13-6. PMID: 9691140.

312. Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F, Knuutila S, Mrózek K, Oberkircher AR, Marcucci G, de la Chapelle A, Elonen E, Block AW, Rao PN, Herzig GP, Powell BL, Ruutu T, Schiffer CA, Bloomfield CD. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 1998 Jan 1;58(1):55-9. PMID: 9426057.

313. Mrózek K, Bloomfield CD. Major cytogenetic findings in non-Hodgkin lymphoma. In: The Lymphomas, 1e. Canellos GP, Lister TA, Sklar JL (eds), W. B. Saunders Company, Philadelphia, PA; 1998 Jan 15: 107-128. ISBN: 0721650309.

314. Marcucci G, Strout MP, Bloomfield CD, Caligiuri, MA. Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. Cancer Res. 1998 Feb 15;58(4):790-3. PMID: 9485036.

315. Baer MR, Stewart CC, Lawrence D, Arthur DC, Mrózek K, Strout MP, Davey FR, Schiffer CA, Bloomfield CD. Acute myeloid leukemia with 11q23 translocations: Myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia. 1998 Mar;12(3):317-25. PMID: 9529125.

316. Mrózek K, Bloomfield CD. Chromosome Aberrations in De Novo Acute Myeloid Leukemia in Adults: Clinical Implications. Reviews in Clinical and Experimental Hematology. 1998 Mar;5:44-67. ISBN: 8886563078.

317. Strout MP, Marcucci G, Bloomfield CD, Caligiuri MA. The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2390-5. PMID: 9482895.

318. Byrd JC, Lawrence D, Arthur DC, Pettanati MJ, Tantravahi R, Qumsiyeh M, Stamberg J , Davey F, Schiffer CA, Bloomfield CD. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: Results from CALGB 8461. Clin Cancer Res. 1998 May;4(5):1235-41. PMID: 9607582.

319. Heinonen K, Mrózek K, Lawrence D, Arthur DC, Pettenati MJ, Stamberg J, Qumsiyeh MB, Verma RS, MacCallum J, Schiffer CA, Bloomfield CD. Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study. Br J Haematol. 1998 Jun;101(3):513-20. PMID: 9633896.

320. Marcucci G, Strout MP, Caligiuri MA, Bloomfield CD. Core Binding Factor (CBF) and ALL1 (MLL)-Associated Adult Primary Acute Myeloid Leukemia: Biology and Clinical Implications of Two Major Genetic Subtypes. ASCO Educational Book, Chestnut Hill, MA. 1998 Jun:36-47.


40


321. Wetzler M, Bernstein SH, Baumann H, Fries KM, Stewart C, Blumenson L, Baer MR, Herzig GP, Bloomfield CD, Slack JL. Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts. Leuk Lymphoma. 1998 Aug;30(5-6):415-31. PMID: 9711904.

322. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia. 1998 Sep;12(9):1482-9. PMID: 9737700.

323. Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB Study 9111. Blood. 1998 Sep 1;92(5):1556-64. PMID: 9716583.

324. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998 Sep 15;58(18):4173-9. PMID: 9751631.

325. Iliszko M, Mandahl N, Mrózek K, Denis A, Pandis N, Pejovic T, Babinska M, Nedoszytko B, Debniak J, Emerich J, Hrabowska M, Bloomfield CD, Limon J. Cytogenetics of Uterine Sarcomas: Presentation of Eight New Cases and Review of the Literature. Gynecol Oncol. 1998 Nov;71(2):172-6. PMID: 9826456.

326. Vidal C, Baer MR, Bloomfield CD. Uncommon patterns of presentation of leukemia. a. In: Textbook of Uncommon Cancer Second Edition. Raghavan D, Brecher ML, Johnson DH,

Meropol NJ, Moots PL, Thigpen JT (eds), John Wiley and Sons, Ltd, New York NY; 1999: 163-175. ISBN: 0471929212.

b. Hematol Oncol. 1999 Mar;17(1):11-29. PMID: 10440889.

327. Plass C, Yu F, Yu L, Strout MP, El-Rifai W, Elonen E, Knuutila S, Marcucci G, Young DC, Held WA, Bloomfield CD, Caligiuri MA. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. Oncogene. 1999 May 20;18(20):3159-65. PMID: 10340388.

328. Strout MP, Marcucci G, Caligiuri MA, Bloomfield CD. Core binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications. Ann Hematol. 1999 Jun;78(6):251-64. PMID: 10422627.

329. Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8364. Blood. 1999 Jun 1;93(11):3931-9. PMID: 10339502.

330. Wetzler M, Dodge RK, Mrózek K, Carroll AJ, Tantravahi RR, Block AW, Pettenati MJ, Le Beau MM, Frankel SR, Stewart CC, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD. Prospective karyotype analysis in adult acute lymphoblastic leukemia – The Cancer and Leukemia Group B Experience. Blood. 1999 Jun 1;93(11):3983-93. PMID: 10339508.

331. Golub TR, Slonim D, Tamayo P, Huard C, Gaasenbeek M, Mesirov J, Coller H, Loh M, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7. PMID: 10521349.


41


332. Byrd JC, Dodge R, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, Bloomfield CD. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have a superior disease-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999 Dec;17(12):3767-75. PMID: 10577848.

333. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:

Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November, 1997. a. J Clin Oncol. 1999 Dec;17(12):3835-49. PMID:10577857.

i. Harris NL, Jaffe ES, Mueller-Hermelink HK, Diebold J, Lister AK, Bloomfield CD, Isaacson P. Author Response: Grading in Marginal-Zone Lymphomas. J Clin Oncol. 2000 Jul;18(14):2788-9. PMID: 10894880.

ii. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. Author Reply: Problematic WHO reclassification of myelodysplastic syndromes. J Clin Oncol. 2000 Oct 1;18(19): 3449-3451. PMID: 11013289.

b. Ann Oncol.1999 Dec;10(12):1419-32. PMID: 10643532 c. Histopathology. 2000 Jan;36(1):69-86. PMID: 10632755. d. Hematol J. 2000;1(1):53-66. PMID: 11920170. e. Mod Pathol. 2000 Feb;13(2):193-207. PMID: 10697278.

334. Marcucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor (CBF) primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest. 2000;18(8):768-80. PMID: 11107447.

335. Stock W, Byrd J, Frankel SR, Bloomfield CD. Adult Acute Lymphoblastic Leukemia. In: Clinical Oncology-2nd edition, Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds), Churchill Livingstone, New York, NY; 2000: 2451-2489.

336. Slack JL, Willman CL, Andersen JW, Li YP, Viswanatha DS, Bloomfield CD, Tallman MS, Gallagher RE. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARα isoform: results from intergroup Protocol 0129. Blood. 2000 Jan 15;95(2):398-403. PMID: 10627441.

337. Costello JF, Früwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O’Dorisio MS, Held WA, Cavenee WK, Plass C. Aberrant CpG-island methylation has non-random and tumor- type-specific patterns. Nat Genet. 2000 Feb;24(2):132-8.

338. Kourlas PJ, Strout MP, Becknell B, Veronese ML, Croce CM, Theil KS, Krahe R, Ruutu T, Knuutila S, Bloomfield CD, Caligiuri MA. Identification of a new gene at 11q23 encoding a guanine nucleotide exchange factor: Evidence for its fusion with MLL in acute myeloid leukemia. Proc Natl Acad Sci USA. 2000;97:2145-2150. PMID: 10655057.

339. Marcucci G, Caligiuri MA, Bloomfield CD. Core binding factor (CBF) primary acute myeloid leukemia: biology and clinical implications. Medscape Oncology. 2000 Mar/ Apr;3(2). http://www.medscape.com/viewarticle/408452

340. Strout MP, Caligiuri MA, Bloomfield CD. Recent advances in the biology and management of primary acute myeloid leukemia with rearrangements of the MLL gene. Medscape Oncology. 2000 May 3;3(3). http://www.medscape.com/viewarticle/408455

341. Bloomfield C. Acute Myeloid Leukemia. Disease Updates on WebMD.com (2000 Sep)

342. Mrózek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol.2000 Oct;72:261-271. PMID: 11185980.

http://www.medscape.com/viewarticle/408452

http://www.medscape.com/viewarticle/408455


42


343. Mrózek K, Heinonen K, Bloomfield CD. Acute Myeloid Leukemia and Myelodysplastic Syndromes: Clinical Implications of Cytogenetic Abnormalities. Advances in Oncology. 2000 Dec;16(4):10-16.

344. Caligiuri MA, Bloomfield CD. Molecular Biology of Leukemias. Chapter 46. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology, 6th edition. Philadelphia PA: Lippincott, Williams & Wilkins; 2001: 2389-2404.

345. Frankel SR, Stock W, Byrd J, Bloomfield CD. Acute Lymphoblastic Leukemia. Chapter 95. In: Haskell CM, ed. Cancer Treatment, Fifth Edition. Philadelphia, PA: W. B. Saunders Company; 2001: 1438-1474.

346. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans-retinoic acid maintenance for acute promyelocytic leukemia. In: Acute Leukemias VIII – Prognostic Factors and Treatment Strategies. Springer-Verlag, Heidelberg, Germany. 2001:565-569. ISBN: ASIN: B003Y94L5O.

347. Whitman SP, Strout MP, Marcucci G, Freud AG, Culley LL, Zeleznik-Le NJ, Mrózek K, Theil DS, Kees UR, Bloomfield CD, Caligiuri MA: The partial non-tandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia. Cancer Res. 2001 Jan 1;61(1):59-63. PMID: 11196198.

348. Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, Bloomfield CD, de la Chapelle A, Krahe R. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1124-9. PMID: 11158605.

349. Wetzler M, Byrd JC, Bloomfield CD. Acute and chronic myeloid leukemia. Chapter 111. In: Harrison's Principles of Internal Medicine, 15th Edition. Braunwald E, Hauser SL, Fauci AS, Longo DL, Kasper DL, Jameson JL (eds), McGraw-Hill Publishing; 2001 Feb 16: 706-714. ISBN: 0070072728.

350. Mrózek K, Heinonen K, Bloomfield CD. Clinical Importance of Cytogenetics in Acute Myeloid Leukaemia. Best Pract Res Clin Haematol. 2001 Mar;14(1):19-47. PMID: 11355922.

351. Byrd JC, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD. Recent genetic studies of adult patients with acute myeloid leukemia performed by the Cancer and Leukemia Group B. In: Acute Leukemias VIII – Prognostic Factors and Treatment Strategies. Springer-Verlag, Heidelberg, Germany. 2001 Mar 26:449-456. ISBN: 3540411232.

352. Mrózek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ, Koduru PRK, Theil KS, Pettenati MJ, Archer KJ, Caligiuri MA, Vardiman JW, Kolitz JE, Larson RA, Bloomfield CD. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 2001 May 1;19(9):2482-92. PMID: 11331327.

353. Rush LJ, Dai Z, Smiraglia DJ, Gao X, Wright FA, Früwald M, Costello JF, Held WA, Yu L, Krahe R, Kolitz JE, Bloomfield CD, Caligiuri MA, Plass C. Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. Blood. 2001 May 15;97(10):3226-33. PMID: 11342453.

354. Mrózek K, Iliszko M, Rys J, Babinska M, Niezabitowski A, Bloomfield CD, Limon J. Spectral karyotyping reveals 17;22 fusions in a cytogenetically atypical dermatofibrosarcoma protuberans with a large marker chromosome as a sole abnormality. Genes Chromosomes Cancer. 2001 Jun;31(2):182-6. PMID: 11319805.


43


355. Baer MR, Stewart CC, Dodge RK, Leget GA, Sule N, Mrózek K, Powell BL, Schiffer CA, Kolitz JE, Moore JO, Stone RM, Davey FR, Carroll AJ, Larson RA, Bloomfield CD. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection. (Cancer and Leukemia Group B Study 8361) Blood. 2001 Jun 1;97(11):3574-80. PMID: 11369653.

356. Marcucci G, Caligiuri MA, Döhner H, Archer K, Schlenk RF, Döhner K, Maghraby EA, Bloomfield CD. Quantification of CBFβMYH11 Fusion Transcript By Real Time RT-PCR In Patients With INV(16) Acute Myeloid Leukemia. Leukemia. 2001 Jul;15(7):1072-80. PMID: 11455976.

357. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, Lee EJ, Moore JO, Powell BL, Baer MR, Bloomfield CD, Schiffer CA. Post-remission therapy in older patients with de novo acute myeloid leukemia: A randomized trial of mitoxantrone and intermediate dose cytarabine with standard dose cytarabine (CALGB STUDY 8923) Blood. 2001 Aug 1;98(3):548-53. PMID: 11468148.

358. Cataland SR, Caligiuri MA, Bloomfield CD. Genetic subtyping of adult acute leukemias and their implications for treatment. Oncology Spectrums. 2001 Oct;2(9):617-625.

359. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, Carroll AJ, Mrózek K, Vardiman JW, George SL, Kolitz JE, Larson RA, Bloomfield CD, Caligiuri MA. Absence of the wild type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3. A study of the Cancer and Leukemia Group B. Cancer Res. 2001 Oct 1;61(19):7233-9. PMID: 11585760.

360. Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M, Frizzera G, Bloomfield CD, Peterson BA. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: Results of Cancer and Leukemia Group B Study 9251. J Clin Oncol. 2001 Oct 15;19(20):4014-22. PMID: 11600602.

361. Tanner SM, Austin JL, Leone G, Rush LJ, Plass C, Heinonen K, Mrózek K, Sill H, Knuutila S, Kolitz JE, Archer KJ, Caligiuri MA, Bloomfield CD, de la Chapelle A. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13901-6. Epub 2001 Nov 13. PMID: 11707601.

362. Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD. Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide. Oncologist. 2002;7 Suppl 1:1-13. PMID: 11961204.

363. Bloomfield CD, Archer KJ, Mrózek K, Lillington DM, Kaneko Y, Head DR, Cin PD, Raimondi SC. 11q23 Balanced Chromosome Aberrations in Treatment-Related Myelodysplastic Syndromes and Acute Leukemia: Report from an International Workshop. Genes Chromosomes Cancer. 2002 Apr;33(4):362-78. PMID: 11921271.

364. Mrózek K, Heinonen K, Theil KS, Bloomfield CD. Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype reveals hidden aberrations, including recurrent overrepresentation of 21q, 22q and 11q. Genes Chromosomes Cancer. 2002 Jun;34(2):137-53. PMID: 11979548.

365. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards C, Arthur DC, Pettenati MJ, Shivanand RP, Rao KW, Watson MS, Prasad RK, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD. Pre-Treatment Primary but Not Secondary Cytogenetic Abnormalities are Predictive of Induction Success and Overall Survival in Adult Patients with de novo Adult Myeloid Leukemia: Results from CALGB 8461. Blood. 2002 Dec 15;100(13):4325-36. Epub 2002 Aug 1. PMID: 12393746.


44


366. Baer MR, George SL, Dodge RK, O’Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA. Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002 Aug 15;100(4):1224-32. PMID: 12149202.

367. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans Retinoic Acid In Acute Promyelocytic leukemia: long term outcome and prognostic factor analysis from the North American Intergroup Protocol. Blood. 2002 Dec 15;100(13):4298-302. Epub 2002 Aug 15. PMID: 12393590.

368. Marcucci G, Byrd JC, Dai G, Klisovic MI, Young DC, Cataland SR, Fisher DB, Lucas D, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, Kraut EH, Balcerzak SP, Bloomfield CD, Grever MR, Caligiuri MA. Phase I and pharmacodynamic studies of G3139, a BCL-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 2003 Jan 15;101(2):425-32. Epub 2002 Aug 22. PMID: 12393493.

369. Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger T, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA. Post Remission Therapy with Low-dose Interleukin-2 with or without Intermediate Pulse Dose Interleukin-2 Therapy is well tolerated in Elderly Patients with Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 9420. Clin Cancer Res. 2002 Sep;8(9):2812-9. PMID: 12231521.

370. Rauscher GH, Sandler DP, Poole C, Pankow J, Mitchell B, Bloomfield CD, Olshan AF. Family History of Cancer and Incidence of Acute Leukemia in Adults. Am J Epidemiol. 2002 Sep 15;156(6):517-26. PMID: 12225999.

371. Farag SS, Archer KJ, Mrózek K, Vardiman JW, Carroll AJ, Pettenati MJ, Moore JO, Kolitz JE, Mayer RJ, Stone RM, Larson RA, Bloomfield CD. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002 Nov;21(5):1041-51. PMID: 12370753.

372. Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, Bloomfield CD, Appelbaum FR, Tallman MS, Slack JL, Willman CL. Quantitative real-time RT-PCR analysis of PML-RARα mRNA in acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood. 2003 Apr 1;101(7):2521-8. Epub 2002 Dec 5. PMID: 12468436.

373. Bloomfield CD, Archer KJ, Mrózek K, Byrd JC, Whitman SP, Dodge RK, Carroll AJ, Larson RA, Caligiuri MA. Cytogenetics for treatment stratification in de novo adult acute myeloid leukemia. In: Acute Leukemias IX-Basic Research, Experimental Approaches and Novel Therapies. Springer-Verlag, Berlin-Heidelberg, Germany. 2003: 366-376.

374. Mrózek K, Bloomfield CD. Cytogenetics of non-Hodgkin’s lymphoma and Hodgkin’s disease. Chapter 42. In: Wiernik PH, Goldman JM, Dutcher JP, Kyle RA, eds. Neoplastic Diseases of the Blood, 4th Edition. Cambridge, England: Cambridge University Press; 2003 Jun 9: 766-795. ISBN: 0521791367.

375. Silver RT, Peterson BL, Szatrowski TP, Powell BL, Stock W, Carroll AJ, Bloomfield CD, Schiffer CA, Larson RA. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: Results from CALGB study 9013. Leuk Lymphoma. 2003 Jan;44(1):39-48. PMID: 12691141.

376. Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, Hurd DD, Henderson ES, Sartiano GP, Johnson JL, Holland JF, Gottlieb AJ. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the Cancer and Leukemia Group B (CALGB 7951). J Clin Oncol. 2003 Jan 1;21(1):5-15. PMID: 12506163.


45


377. Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, Stewart C. Hurd D, Kolitz JE, Velez-Garcia E, Bloomfield CD, Schiffer CA, Larson RA. Lineage-specific treatment of adult acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: CALGB study 9311. Cancer. 2003 Mar 15;97(6):1471-80. PMID: 12627512.

378. Rauscher GH, Sandler DP, Poole C, Pankow J, Shore D, Bloomfield CD, Olshan AF. Is family history of breast cancer a marker of susceptibility to exposures in the incidence of de novo adult acute leukemia? Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):289-94. PMID: 12692102.

379. Baldus CD, Tanner SM, Ruppert A, Whitman SP, Archer KJ, Marcucci G, Caligiuri MA, Carroll AJ, Vardiman JW, Powell BL, Allen SL, Moore JO, Larson RA, Kolitz JE, de la Chapelle A, Bloomfield CD. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study. Blood. 2003 Sep 1;102(5):1613-8. Epub 2003 May 15. PMID: 12750167.

380. Bloomfield CD. Adult Acute Leukemia. Chapter 3. In: Thomas ED, Nathan DG, Goldman JM, eds. Classic Papers in Haematological Oncology. London, England: Martin Dunitz; 2003 Jul 24: 85-126. ISBN: 1901865460.

381. Poppe B, Vandesompele J, Schoch C, Lindvall C, Mrózek K, Bloomfield CD, Beverloo HB, Michaux L, Dastugue N, Herens C, Yigit N, De Paepe A, Hagemeijer A, Speleman F. Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain in myeloid malignancies. Blood First Edition Paper, prepublished online August 28, 2003. Blood; 2004 Jan 1;103(1):229-235. Epub 2003 Aug 28. PMID: 12946992.

382. Marcucci G, Caligiuri MA, Bloomfield CD. Core Finding Factor (CBF) Acute Myeloid Leukemia: Is molecular monitoring by RT-PCR useful clinically? Eur J Haematol. 2003 Sep;71(3):143-54. PMID: 12930314.

383. Baldus CD, Tanner SM, Kusewitt DF, Liyanarachchi S, Choi C, Caligiuri MA, Bloomfield CD, de la Chapelle A. BAALC, A Novel Marker Of Human Hematopoietic Progenitor Cells. Exp Hematol. 2003 Nov;31(11):1051-1056. PMID: 14585369.

384. Mrózek K, Tanner SM, Heinonen K, Bloomfield CD. Molecular cytogenetic characterization of the KG-1 and KG-1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence in situ hybridization. Genes Chromosomes Cancer. 2003 Nov;38(3):249-252. PMID: 14506699.

385. Ley TJ, Minx PJ, Walter MJ, Ries RE, Sun H, McLellan M, DiPersio JF, Link DC, Tomasson MH, Graubert TA, MCLeod H, Khoury H, Watson M, Shannon W, Trinkaus K, Heath S, Vardiman JW, Caligiuri MA, Bloomfield CD, Milbrandt D, Mardis ER, Wilson RK. A pilot study of high-throughput sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14275-14280. Epub 2003 Nov 12. PMID: 14614138.

386. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, , Döhner H, Tallman MS, Lister TA, LoCocco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-4649. PMID: 14673054.

387. Wetzler M, Dodge RK, Mrózek K, Stewart CC, Carroll AJ, Tantravahi R, Vardiman JW, Larson RA, Bloomfield CD. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia – A study of the Cancer and Leukemia Group B. Br J Haematol. 2004 Feb;124(3):275-288. PMID: 14717774.


46


388. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, Caligiuri MA, Bloomfield CD, Look AT. Prognostic Importance of TLX1 (HOX11) Oncogene Expression in Adults with T-cell Acute Lymphoblastic Leukaemia. Lancet. 2004 Feb 14;363(9408):535-536. PMID: 14975618.

389. Sekeres MA, Peterson B, Dodge RK, Mayer R, Moore J, Lee E, Kolitz J, Baer M, Schiffer CA, Carroll AJ, Vardiman JW, Davey FR, Bloomfield CD, Larson RA, Stone RM. Differences in prognostic factors and outcomes in African-Americans and Caucasians with acute myeloid leukemia. Blood. 2004 Jun 1;103(11):4036-42. Epub 2004 Feb 19. PMID: 14976037.

390. Baldus CD, Liyanarachchi S, Mrózek K, Auer H, Tanner SM, Guimond M, Ruppert AS, Mohamed N, Davuluri RV, Caligiuri MA, Bloomfield CD, de la Chapelle A. Acute myeloid with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3915-20. Epub 2004 Mar 8. PMID:15007164.

391. Byrd JC, Ruppert AS, Mrózek K, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Stamberg J, Koduru PR, Moore JO, Mayer RJ, Davey FR, Larson RA, Bloomfield CD. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. J Clin Oncol. 2004 Mar 15;22(6):1087-1094. PMID: 15020610.

392. Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004 Apr 1;100(7):1438-48. PMID: 15042678.

393. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004 Jun;18(2):115-136. PMID: 15010150.

394. Marcucci G Mrózek K, Ruppert AS, Archer KJ, Pettenati MJ, Heerema NA, Carroll AJ, Koduru PRK, Kolitz JE, Sterling LJ, Edwards CG, Anastasi J, Larson RA, Bloomfield CD. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia Group B (CALGB) 8461. J Clin Oncol. 2004 Jun 15;22(12):2410-8. PMID: 15197203.

395. Farag SS, Ruppert A, Mrózek K, Carroll AJ, Pettenati MJ, Le Beau MM, Peterson BL, Powell BL, Ozer H, Silver RT, Larson RA, Bloomfield CD. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-α: A Cancer and Leukemia Group B study. Int J Oncol. 2004 Jul;25(1):143-51. PMID: 15201999.

396. Wetzler M, Byrd JC, Bloomfield CD. Acute and chronic myeloid leukemia. Chapter 96. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine, 16th Edition. McGraw-Hill Publishing; 2004 Jul 27: 631-641. ISBN: 0071391401.

397. Blum W, Mrózek K, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, Anastasi J, Larson RA, Bloomfield CD for the Cancer and Leukemia Group B (CALGB). Adult de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): results from Cancer and Leukemia Group B study 8461 and review of the literature. Cancer. 2004 Sep 15;101(6):1420-1427. PMID: 15368330.

a. Blum W, Mrózek K, Ruppert AS, Bloomfield CD. Author Reply: Adult De Novo Acute Myeloid Leukemia with t(6;11)(q27;q23): Results from Cancer and Leukemia Group B Study 8461 and Review of the Literature. Cancer. 2005 Mar 15;103(6):1316-7.


47


398. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA. Dose escalation studies of cytarabine, daunorubicin and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia < 60 years old: final induction results of CALGB 9621. J Clin Oncol. 2004 Nov 1;22(21):4290-301. PMID: 15514371.

399. Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schiffer CA. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood. 2005 May 1;105(9):3420-7. Epub 2004 Nov 30. PMID: 15572587.

400. Marcucci G, Mrózek K, Bloomfield CD. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol. 2005 Jan;12(1):68-75. PMID: 15604894.

401. Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PRK, Stamberg J, Baer MR, Block AMW, Vardiman JW, Kolitz JE, Schiffer CA, Larson

RA, Bloomfield CD. Outcome of Induction and Post-remission Therapy in Younger Adults with Acute Myeloid Leukemia with Normal Karyotype: A Cancer and Leukemia Group B Study. J Clin Oncol. 2005 Jan 20;23(3):482-93. Epub 2004 Nov 8. PMID: 15534356.

402. Whitman SP, Liu S, Vukosavljevic T, Rush LJ, Yu L, Liu C, Klisovic MI, Maharry K, Guimond M, Strout MP, Becknell B, Dorrance A, Klisovic RB, Plass C, Bloomfield CD, Marcucci G, Caligiuri MA. The MLL partial tandem duplication. Evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular targeted therapy. Blood. 2005 Jul 1;106(1):345-52. Epub 2005 Mar 17. PMID: 15774615.

403. Fröhling S, Schlenk RF, Krauter J, Thiede C, Ehninger G, Haase D, Harder L, Kreitmeier S, Scholl C, Caligiuri MA, Bloomfield CD, Döhner H, Döhner K. Acute myeloid leukemia with deletion 9q is associated with CEBPA loss-of-function mutations. Genes Chromosomes Cancer. 2005 Apr;42(4):427-32. PMID: 15645492.

404. Marcucci G, Stock W, Dai G, Klisovic R, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Maharry K, Novick, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC. Phase I study of oblimersen sodium, an Antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics and clinical activity. J Clin Oncol. 2005 May 20;23(15):3404-11. Epub 2005 Apr 11. PMID: 15824414.

405. Mrózek K, Baldus C, Marcucci G, Bloomfield CD. Acute myeloid leukemia prognostic factors: from cytogenetics to chip. Hematology (EHA Educational Program). 2005 June;1:116-122.

406. Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD. Prognostic factors and outcomes of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B (CALGB) Study. J Clin Oncol. 2005 Aug 20;23(24):5705-17. PMID: 16110030.

407. Neviani P, Santhanam R, Trotta R, Notari M, Blaser B, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Klisovic RB, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005 Nov;8(5):355-68. PMID: 16286244.

408. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in Acute Myeloid Leukemia with normal karyotype: A Cancer and Leukemia Group B Study. J Clin Oncol. 2005 Dec 20;23(36):9234-42. Epub 2005 Nov 7. PMID: 16275934.


48


409. Döhner K, Mrózek K, Döhner H, Bloomfield CD. Leukemias: diagnosis and classifications. Chapter 27. In: Young NS, Gerson SL, High KA, eds. Clinical Hematology. Philadelphia, PA: Elsevier Inc.; 2006 Dec 20: 348-358.

410. Mrózek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2006:169-77. PMID: 17124057.

411. Greenberg PL, Baer MR, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Devetten MP, Emanual PD, Erba HP, Estey E, Foran J, Gore SD, Millenson M, Navarro WH, Nimer SD, O’Donnell MR, Saba HL, Spoers K, Stone RM, Tallman MS. Myelodyplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jan;4(1):58-77. PMID: 16403405.

412. Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G. BAALC Expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol. 2006 Feb 10;24(5):790-7. Epub 2006 Jan 17. PMID: 16418499.

413. Kolitz JE, George SL, Baer M, Lee EJ, Bloomfield CD, Larson RA. Cancer and Leukemia Group B (CALGB) multidrug resistance modulation trials in untreated acute myeloid leukemia. Ann Hematol. 2006 Feb;85(suppl 13): 78-79.

414. Mrózek K, Marcucci G, Ruppert AS, Baldus CD, Kolitz JE, Larson RA, Bloomfield CD. Molecular heterogeneity and its prognostic significance in acute myeloid leukemia (AML) with normal cytogenetics. Ann Hematol. 2006 Feb;85(suppl 13): 114-117.

415. Hoppe RT, Advani RH, Bierman PJ, Bloomfield CD, Buadi F, Djulgegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Kaminski MS, Love G, Maloney DG, Mauch PM, Moore JO, Schilder RJ, Weiss L, Winter JN, Yahalom J, Zelenetz AD. Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Mar 4(3):210-30. PMID: 18597713.

416. Farag SS, Archer KJ, Mrózek K, Ruppert AS, Carroll AJ, Vardiman JW, Pettenati MJ., Baer MR, Qumsiyeh MB, Koduru PR, Stamberg J, Mayer RJ, Stone RM, Larson RA, Bloomfield CD. Pretreatment Cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood. 2006;108(1):63-73. Epub 2006 Mar 7. PMID: 16522815. PMCID: 1895823.

417. Garzon R, Pichiorro F, Palumbo T, Luliano R. Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin GA, Lui CG, Bloomfield CD, Andreeff M, Croce CM. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5078-83. Epub 2006 Mar 20. PMID: 16549775. PMCID: 1458797.

418. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Bennett JM, Stirewalt DL, Meshinchi S, Willman CL, Ravindranath Y, Alonzo TA, Carroll AJ, Raimondi SC, Heerema NA. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ’poor prognosis’ myeloid malignancies. Leukemia. 2006 Jul;20(7):1295-7. Epub 2006 Apr 20. PMID: 16628187.

419. Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, Bloomfield CD. Quantitative Real Time RT-PCR Monitoring of BCR-ABL in CML Shows Lack of Agreement in Blood and Bone Marrow Samples: A Cancer and Leukemia Group B study (CALGB 29801). Int J Oncol. 2006 May;28(5):1099-103. PMID: 16596225.


49


420. Radmacher MD, Marcucci G, Ruppert AS, Mrózek K, Whitman SP, Vardiman JW, Paschka P, Vukosavljevic T, Baldus CD, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD. Independent confirmation of a prognostic gene expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood. 2006 Sep 1;108(5):1677-83. Epub 2006 May 2. PMID: 16670265. PMCID: 1895508.

421. Bloomfield CD, Mrózek K, Caligiuri MA. The CALGB Leukemia Correlative Science Committee: Major accomplishments and future directions. Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3564s-71s. PMID: 16740786.

422. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia in inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol. 2006 Aug 20;24(24):3904-11. PMID: 16921041.

423. Baldus CD, Burmeister T, Martus P, Schwartz S, Gökbuget N, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK: High expression of the ETS transcription Factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol. 2006 Oct 10;24(29):4714-20. Epub 2006 Sep 5. PMID: 16954520.

424. Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007 Jan 15;109(2):431-48. Epub 2006 Sep 7. PMID: 16960150. PMCID: 1785102.

425. Liu TX, Becker MW, Jelinek J, Wu W-S, Deng M, Mikhalkevich N, Hsu K, Bloomfield CD, Stone RM, DeAngelo DJ, Galinsky IA, Issa J-P, Clarke MF, Look AT. Chromosome 5q deletion and epigenetic suppression of the gene encoding ά-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007 Jan;13(1):78-83. Epub 2006 Dec 10. PMID: 17159988.

426. Stewart FM, Wasserman R, Bloomfield CD, Petersdorf S, Witherspoon R, Appelbaum F, Ziskind A, McKenna B, Dodson J, Weeks J, Vaughn W, Storer B, Perkel S, Waldinger M. Benchmarks in Clinical Productivity: An NCCN Survey. J Oncol Pract. 2007 Jan;3(1):2 – 8. PMID:20859362. PMCID: 2793722.

427. Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia -- Cancer and Leukemia Group B Study 9511. Blood. 2007 May 15;109(10):4164-7. Epub 2007 Jan 30. PMID: 17264295. PMCID: 1885493.

428. Mrózek K, Döhner H, Bloomfield CD. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol. 2007 Mar;14(2):106-14. PMID: 17255787.

429. Whitman SP, Ruppert AS, Marcucci G, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Vukosavljevic T, Powell BL, Carroll AJ, Kolitz JE, Larson RA, Caligiuri MA, Bloomfield CD. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: A Cancer and Leukemia Group B study. Blood. 2007 Jun 15;109(12):5164-7. Epub 2007 Mar 6. PMID: 17341662. PMCID: 1890839.

430. Mrózek K, Baldus CD, Bloomfield CD. Acute myeloid leukemia. Molecular biology, pathology and cytogenetics of acute myeloid leukemia. Chapter 2. In: Sekeres MA, Kalaycio ME, Bowell BJ, eds. Clinical Malignant Hematology. New York: Mc Graw Hill Medical; 2007 Mar 23: 9-23. ISBN: 0071436502.


50


431. Wetzler M, Mrózek K, Bloomfield CD. Acute lymphoblastic leukemia. Molecular biology, pathology and cytogenetics of acute lymphoblastic leukemia. In: Clinical Malignant Hematology. Chapter 11. Sekeres MA, Kalaycio ME, Bowell BJ, eds. Mc Graw Hill Medical, New York; 2007 Mar 23: 111-120. ISBN: 0071436502.

432. Caligiuri MA, Briesewitz R, Yu J, Wang L, Wei M, Arnoczky KJ, Marburger TB, Wen J, Bloomfield CD, Whitman S. Novel c-CBL and CBL-b Ubiquitin Ligase Mutations in Human Acute Myeloid Leukemia. Blood, 2007 Aug 1;110(3):1022-4. Epub 2007 May 2. PMID: 17475912. PMCID: 1924768.

433. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007 Aug 15;110(4):1092-7. Epub 2007 May 8. PMID: 17488875. Author reply: Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: a paradigm of effective collaboration among clinicians, pathologists, and scientists. Blood. 2008 Feb 1;111(3):1742. PMID: 18223176. PMCID: 2214764.

434. Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanne-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CD, Dipersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, Ley TJ. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood. 2007 Sep 1;110(5):1648-55. Epub 2007 May 9. PMID: 17494858.

435. Baldus CD, Mrózek K, Marcucci G, Bloomfield CD. Clinical outcome of De Novo acute myeloid leukemia patients with normal cytogenetics is affected by molecular genetic alterations: A concise review. Br J Haematol. 2007 Jun;137(5):387-400. PMID: 17488484.

436. Mrózek K, Paschka P, Marcucci G, Whitman SP, Bloomfield CD. Clinical use of molecular markers in adult acute myeloid leukemia. Hematology Education: the education program for the annual congress of the European Hematology Association. 2007 Jun;1(1):183 – 192.

437. Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, Mrózek K, Baldus CD, Carroll AJ, Powell BL, Kolitz JE, Larson RA, Bloomfield CD. High expression levels of the ETS-Related Gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 2007 Aug 1;25(22):3337-43. Epub 2007 Jun 18. PMID: 17577018.

438. Baldus CD, Martus P, Burmeister T, Schwartz S, Gökbuget N, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol. 2007 Aug 20;25(24):3739-45. Epub 2007 Jul 23. PMID: 17646667.

439. Mrózek K, Paschka P, Marcucci G, Whitman SP, Bloomfield CD. E01 Biology, cytogenetics and molecular studies in acute myeloid leukemia. Leuk Res. 2007 Sep;31 Suppl 2:S3-7.

440. Neviani P, Santhanam R, Oaks J, Ering A, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen C-S, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphocytic leukemia (ALL). J Clin Invest. 2007 Sep;117(9):2408-21. PMID: 17717597. PMCID: 1950458.

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Martus%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Burmeister%20T%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Schwartz%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22G%C3%B6kbuget%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bloomfield%20CD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Hoelzer%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Thiel%20E%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus


51


441. Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell ML, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with De Novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008 Feb 1;111(3):1552-1559. Epub 2007 Oct 16. PMID: 17940205. PMCID: 2214747.

a. Whitman SP, Marcucci G, Ruppert AS, Mrózek K, Bloomfield CD. Author Response: Conflicting data on the prognostic significance of FLT3-TKD mutations in cytogenetically normal acute myeloid leukemia (CN-AML) might be related to many factors, including techniques used to detect differences in patient populations studied, and treatment regimens. Blood. 2008 Jul 15;112:445.

442. Garzon R, Volinia S, Liu C-G, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008 Mar 15;111(6):3183-9. Epub 2008 Jan 10. PMID: 18187662. PMCID: 2265455.

443. Ferketich AF, Katz ML, Kauffman RM, Paskett ED, Lemeshow S, Westman JA, Clinton SK, Bloomfield CD, Wewers ME. Tobacco Use among the Amish in Holmes County, Ohio. J Rural Health. 2008 Winter;24(1):84-90. Epub 2008 Feb 1. PMID: 18257875.

444. Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T, Ries RE, Lubman O, Fremont D, McLellan MD, Payton J, Westervelt P, DiPersio JF, Link DC, Walter MJ, Graubert TA, Watson M, Baty J, Heath S, Shannon WD, Nagarajan R, Bloomfield CD, Mardis ER, Wilson RK, Ley TJ. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood. 2008 May 1;111(9):4797-808. Epub 2008 Feb 12. PMID: 18270328. PMCID: 2343607.

445. Wetzler M, Byrd JC, Bloomfield CD: Acute and chronic myeloid leukemia. Chapter 104. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscaizo J, eds. Harrison's Principles of Internal Medicine, 17th Edition. McGraw-Hill Publishing; 2008 Mar 6: 667-686. ISBN: 0071466339.

446. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Liu C-G, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD. High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study. Blood. 2008 Jun 1;111(11):5371-9. Epub 2008 Mar 31. PMID: 18378853. PMCID: 2396728

447. Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen S-S, Blagitko-Dorfs N, Maharry K, Whitman SP, Schmittgen TD, Lübbert M, Marcucci G, Bloomfield CD, Plass C. Epigenetic modification of CCAAT/enhancer binding protein α expression in acute myeloid leukemia. Cancer Res, 2008 May 1;68(9):3142-3151. PMID: 18451139.

448. Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu C-G, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD. MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B study. N Engl J Med. 2008 May 1;358(18):1919-28. PMID: 18450603.

a. Marcucci G, Radmacher MD, Bloomfield CD. Authors Response: MicroRNA in Acute Myeloid Leukemia. N Engl J Med. 2008 Aug 7;359(6):653-654.


52


449. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 1;112(5):1646-54. Epub 2008 May 23. PMID: 18502832. PMCID: 2518876.

450. Neubauer A, Maharry K, Mrózek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission treatment with high-dose cytarabine: A Cancer and Leukemia Group B study. J Clin Oncol. 2008 Oct 1;26(28):4603-9. Epub 2008 Jun 16. PMID: 18559876. PMCID: 2653132.

451. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrózek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell B, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD. Wilms Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults with Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 2008 Oct 1;26(28):4595-602. Epub 2008 Jun 16. PMID: 18559874. PMCID: 2653131.

452. Whitman SP , Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, Margeson D, Davaluri R, Wen J, Witte T, Yu L, Liu C, Bloomfield CD, Marcucci G, Plass C, Caligiuri MA. DNA Hypermethylation and Epigenetic Silencing of the Tumor Suppressor Gene, SLC5A8 In Acute Myeloid Leukemia with the MLL Partial Tandem Duplication. Blood. 2008 Sep 1;112(5):2013-6. Epub 2008 Jun 19. PMID: 18566324. PMCID: 2518901.

453. Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrózek KM, Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, Larson RA. Low-dose Interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B study 9720. J Clin Oncol. 2008 Oct 20;26(30):4934-9. Epub 2008 Jun 30. PMID: 18591543. PMCID: 2652081.

454. Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney MS, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD. Hodgkin Disease/Lymphoma. J of the Natl Comp Cancer Network, 2008 Jul;6(6):594-622. PMID: 18597713.

455. Mrózek K, Bloomfield CD. Clinical Significance of the Most Common Chromosome Translocations in Adult Acute Leukemia. J Natl Cancer Inst Monogr. 2008 July;(39):52-7. PMID: 18648004.

456. Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and Leukemia Group B study 10107. Leuk Lymphoma. 2008 Jul;49(7):1274-1278. PMID: 18452072.

457. Bloomfield CD, Marcucci G, Döhner K, and Döhner H. Acute Myeloid Leukemia. Semin Oncol. 2008 Aug;35(4):324 – 325. PMID: 18692682.

458. Mrózek K, Carroll AJ, Maharry K, Rao KW, Patil SR, Pettenat MJ, Watson MW, Arthur DC, Tantravahi R, Heerema NA, Koduru PR, Block AW, Qumsiyeh MB, Edwards CG, Sterling LJ, Holland KB, Bloomfield CD. Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol. 2008 Aug;33(2):239-244. PMID: 18636143.

459. Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, DeAngelo DJ, Marcucci G, Bloomfield CD, Larson RA. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB Study 19804. Cancer Chemother Pharmacol. 2009 Apr;63(5):859-64. Epub 2008 Aug 1. PMID: 18670778.


53


460. Metzeler KH , Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland M-C, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Büchner T, Wörmann B, Mansmann U, Hiddemann W, Bohlander SK, and Buske C. Cancer and Leukemia Group B (CALGB) and the German AML Cooperative Group (AMLCG). An 86 probe set gene expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008 Nov 15;112(10):4193-201. Epub 2008 Aug 20. PMID: 18716133.

461. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu C-G, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD. Prognostic Significance of and Gene- and microRNA-Expression Signatures Associated with CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia with High-Risk Molecular Features: A Cancer and Leukemia Group B Study. J of Clin Oncol. 2008 Nov 1;26(31):5078-87. Epub 2008 Sep 22. PMID: 18809607.

a. Marcucci G, Maharry K, Mrózek K, Bloomfield CD. Author Reply: Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia. J of Clin Oncol. 2009 Apr 20;27(12):2106.

462. Arber DA, Vardiman JW, Brunning RD, Porwit A, Le Beau MM, Thiele J, Falini B, Bloomfield CD. Acute myeloid leukaemia with recurrent genetic abnormalities. In: World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC WHO Classification of Tumours). Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J, Vardiman JW (eds), Lyon; 2008 Oct: 110-123. ISBN: 9283224310.

463. Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O’Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P. Myelodysplastic Syndromes – Clinical Practice Guidelines in Oncology. J of the Natl Comp Cancer Network. 2008 Oct;6(9):902 – 926. PMID: 18926100.

464. Vardiman JW, Brunning RD, Arber DA, Le Beau MM, Porwit A, Tefferi A, Bloomfield CD, Thiele J. Introduction and overview of the classification of the myeloid neoplasms. Chapter 6. In: Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J, Vardiman JW, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IACR; 2008 Oct: 18-30. ISBN: 9283224310.

465. Mrózek K, Marcucci G, Paschka P, Bloomfield CD. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin in Oncol. 2008 Nov;20(6):711-8. PMID: 18841055.

466. Radmacher MD, Bloomfield CD, Marcucci G. MicroRNAs in Acute Myeloid Leukemia. The Hematologist. Nov/ Dec 2008;5(6):5.

467. Grinblatt DL, Yu D, Hars V, Vardiman JW, Powell BL, Nattam S, Silverman LR, Castro III C, Stone RM, Bloomfield CD, Larson RL. Treatment of Myelodysplastic Syndrome with two schedules and doses of oral topotecan: A randomized phase II trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 1;115(1):84-93. PMID: 19025972.

468. Marcucci G, Bloomfield CD. Book Review: Innovative Leukemia and Lymphoma Therapy (Basic and Clinical Oncology. 35.) Edited by Gertjan J. L. Kaspers, Bertrand Coiffier, Michael C. Heinrich, and Elihu Estey. 598 pp., illustrated. New York, Informa Healthcare, 2008. N Engl J Med. 2009 Jan 15;360(3):313.

469. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy C, Callegari E, Pang J, Yu J, Muthusamy R, Volinia S, Blum W, Rush LJ, Bloomfield CD, Andreeff M, Chan K, Croce CM, Marcucci G. MicroRNA 29b induces global DNA hypermethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009 Jun 18;113(25):6411-8. Epub 2009 Feb 11. PMID: 19211935. PMCID: 2710934.


54


470. Mrózek K, Radmacher MD, Bloomfield CD, Marcucci G. Molecular Signatures in Acute Myeloid Leukemia. Curr Opin Hematol. 2009 Mar;16(2):64-9. PMID: 19468266. PMCID: 4209289.

471. Marcucci G, Radmacher MD, Mrózek K, Bloomfield CD. MicroRNA Expression in Acute Myeloid Leukemia. Curr Hematol Malig Rep. 2009 Apr;4(2):83-8. PMID: 20425419.

472. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51. Epub 2009 Apr 8. PMID: 19357394.

a. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. Author Response: Factors considered in the 2008 WHO classification of myeloid neoplasms and acute leukemias. Blood, 2010 Jan 21;115(3):749-50.

473. Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrózek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD. Prognostic Importance of MN1 Transcript Levels, and Biologic Insights from MN1-associated Gene and microRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 2009 Jul 1;27(19):3198-204. Epub 2009 May 18. PMID: 19451432. PMCID: 2716941.

474. Marcucci G, Mrózek K, Radmacher MD, Bloomfield CD, Croce CM. MicroRNA Expression Profiling in Acute Myeloid and Chronic Lymphocytic Leukemias. Best Pract Res Clin Haematol. 2009 Jun;22(2):239-48. PMID: 19698931.

475. Walter M, Payton J, Ries R, Shannon W, Deshmukh H, Zhao Y, Baty J, Heath S, Westervelt P, Watson M, Tomasson M, Nagarajan R, O'Gara B, Bloomfield C, Mrózek K, Selzer R, Richmond T, Kitzman J, Geoghegan J, Eis P, Maupin R, Fulton R, McLellan M, Wilson R, Mardis E, Link D, Graubert T, DiPersio J, Ley T. Acquired Copy Number Alterations in Adult Acute Myeloid Leukemia Genomes. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12950-5. Epub 2009 Jul 27. PMID: 19651600. PMCID: 2716381.

476. Marcucci G, Wetzler M, Byrd JC, Mrózek K, Bloomfield CD. Leukemias. Chapter 4. In: Cavalli F, Kaye SB, Hansen HH, Armitage JO, Piccart M, eds. Textbook of Medical Oncology, 4th Edition. Informa Healthcare Publishing; 2009 Aug 27: 215-235. ISBN: 0415477484.

477. Reiter PL, Katz ML, Ferketich AK, Paskett ED, Clinton SK, Bloomfield CD. Complementary and alternative medicine use among Amish and non-Amish residents of Ohio Appalachia. Online J Rural Nurs Health Care. 2009 Fall; 9(2):33-44.

478. Westman JA, Ferketich AK, Kauffman RM, MacEachern SN, Wilkins III JR, Wilcox PP, Pilarski RT, Nagy R, Lemeshow S, de la Chapelle A, Bloomfield CD. Low cancer incidence rates in Ohio Amish. Cancer Causes Control. 2010 Jan;21(1):69-75. Epub 2009 Sep 25. PMID: 19779840.

479. Baldus CD, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M, Burmeister T, Schwartz S, Bloomfield CD, Hoelzer D, Thiel E, Hofmann W-K. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica. 2009 Oct;94(10):1383-90. PMID: 19794083. PMCID: 2754954.

480. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe, T, Niederwieser D, Ossenkoppele GJ. Sanz M, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD. Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations from an International Expert Panel, on Behalf of the European LeukemiaNet. Blood. 2010 Jan 21;115(3):453-74. Epub 2009 Oct 30. PMID: 19880497.


55


481. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD. Favorable Prognostic Impact of NPM1 Mutations in Older Patients with Cytogenetically Normal de novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-expression Signatures: A Cancer and Leukemia Group B Study. J Clin Oncol. 2010 Feb 1;28(4):596-604. Epub 2009 Dec 21. PMID: 20026798. PMCID: 2815994

482. Khandanpour C, Thiede C, Valk P, Sharif-Askari E, Nueckel H, Lohmann D, Hortshemke B, Siffert W, Neubauer A, Grzeschik G, Bloomfield CD, Marcucci G, Maharry K,. Slovak ML, Van der Reijden B, Jansen J, Schackert H, Kroschinsky F, Afshar K, Schnittger S, Peeters J, Ehninger G, Löwenberg B, Duehrsen U, Moroy T. A variant allele of growth factor independence 1 is associated with acute myeloid leukemia. Blood. 2010 Mar 25;115(12):2462-72. Epub 2010 Jan 14. PMID: 20075157. PMCID: 2919174.

483. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010 Apr 20;107(16):7473-8. Epub 2010 Apr 5. PMID: 20368434; PMCID: 2867720.

484. Marcucci G, Maharry K, Wu Y, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD. IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 2010 May 10;28(14):2348-55. Epub 2010 Apr 5. (one of the 50 most-cited articles published in 2010). PMID: 20368543. PMCID: 2881719.

485. Liu S, Wu L, Pang J, Santhanam R, Schwind S, Wu Y, Hickey C, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KC, Paschka P, Caligiuri MA, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci G. Sp1/NFκB/HDAC/miR-29b Regulatory Network in KIT-driven Myeloid Leukemia. Cancer Cell. 2010 Apr 13;17(4):333-47. PMID: 20385359. PMCID: 2917066.

486. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Aug 5;116(5):788-92. Epub 2010 May 4. PMID: 20442368; PMCID: 2918333.

487. Wetzler M, Byrd JC, Bloomfield CD: Acute and chronic myeloid leukemia. Chapter 104. In: Longo DL, ed. Harrison's Hematology and Oncology. McGraw-Hill Publishing; 2010 May 10:166-181. ISBN: 0071663355.

488. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, Larson RA; Cancer and Leukemia Group B. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 2;116(9):1413-21. Epub 2010 Jun 3. PMID: 20522709. PMCID: 2938834.

489. Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Nov 4;116(18):3622-6. Epub 2010 Jul 23. PMID: 20656931. PMCID: 2981481.


56


490. Schwind S, Marcucci G, Maharry K, Radmacher D, Mrózek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu Y-Z, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD. BAALC and ERG expression levels are associated with outcome and distinct gene- and microRNA-expression profiles in older cytogenetically normal acute myeloid leukemia patients: a Cancer and Leukemia Group B study. Blood. 2010 Dec 16;116(25):5660-9. Epub 2010 Sep 14. PMID: 20841507. PMCID: 3031412.

491. Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH, Gonzalez M, Larson RA, Gonzalez-San Miguel JD, Ogden A, Milone G, Rowe JM, Rayon C, Shepherd L, Rivas C, Schiffer CA, Vellenga E, Wiernik PH, Willman CL, Sanz MA. Does Microgranular Variant Morphology of Acute Promyelocytic Leukemia Independently Predict For A Less Favorable Outcome Compared With Classical M3 APL? A Joint Study of The North American Intergroup and The PETHEMA Group. Blood. 2010 Dec 16;116(25):5650-9. Epub 2010 Sep 21. PMID: 20858857. PMCID: 3031411.

492. Marcucci G, Mrózek K, Radmacher M, Garzon R, Bloomfield CD. The Prognostic and Functional Role of MicroRNAs in Acute Myeloid Leukemia. Blood. 2011 Jan 27;117(4):1121-9. Epub 2010 Nov 2. PMID: 21045193. PMCID: 3056468.

493. Katz ML, Ferketich AK, Paskett ED, Harley A, Reiter PL, Lemeshow S, Westman JA, Clinton SK, Bloomfield CD. Cancer screening practices among Amish and non-Amish adults living in Ohio Appalachia. J Rural Health. 2011 Jun;27(3):302-9. Epub 2010 Nov 15. PMID:21729158. PMCID: 3130935.

494. Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson M, Whitman SP, Hickey C, Becker H, Metzeler KH, Paschka P, Baldus CD, Liu S, Garzon R, Powell BL, Kolitz JE, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G*, Bloomfield CD*. Prognostic Significance of Expression of a Single microRNA, miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol. 2010 Dec 20;28(36):5257-64. Epub 2010 Nov 15. PMID: 21079133. PMCID: 3018359. *indicates co-senior author.

495. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P. Myelodysplastic Syndromes. J Natl Compr Canc Netw. 2011 Jan 13;9:30-56. PMID: 21233243. PMCID: 3768131.

496. Baer MR, George SL, Sanford B, Mrózek K, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, Larson RA. Escalation of Daunorubicin and Addition of Etoposide in the ADE Regimen Does Not Improve Outcome of Acute Myeloid Leukemia Patients 60 Years and Older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011 May;25(5):800-7. Epub 2011 Feb 15. PMID: 21321569. PMCID: 3821040.

497. Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu Y-Z, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G*, Bloomfield CD*. TET2 mutations improve the new European LeukemiaNet (ELN) risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol. 2011 Apr 1;29(10):1373-81. Epub 2011 Feb 22. PMID: 21343549. PMCID: 3084003. *indicates co-senior author

498. Buyse M, Squifflet P, Lange BJ, Alonzo TA, Larson RA, Kolitz JE, George SL, Bloomfield CD, Castaigne S, Chevret S, Blaise D, Maraninchi D, Lucchesi KJ, Burzykowski T. Individual patient data meta-analysis of randomized trials evaluating interleukin-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011 Jun 30;117(26):7007-13. Epub 2011 Apr 25. PMID: 21518931. PMCID: 3539044.


57


499. Becker H, Maharry K, Radmacher MD, Mrózek K, Metzeler KH, Whitman SP, Schwind S, Kohlschmidt J, Wu Y-Z, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Marcucci G*, Bloomfield CD*. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. Haematologica. 2011 Oct 1;96(10):1488-95. Epub 2011 Jun 9. PMID: 21659357. PMCID: 3186310. *indicates co-senior author.

500. Farag SS, Maharry K, Zhang M-J, Pérez WS, George SL, Mrózek K, DiPersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringdén O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ. Comparison of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Chemotherapy in Patients Aged 60-70 Years with Acute Myeloid Leukemia in First Remission: A Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B Study. Biol Blood Marrow Transplant. 2011 Dec;17(12):1796-803. Epub 2011 Jun 21. PMID: 21699879. PMCID: 3817558.

501. Wetzler M, Marcucci G, Bloomfield CD. Acute and chronic myeloid leukemia. Chapter 109. In: Longo DL, ed. Harrison's Principles of Internal Medicine, 18th Edition. McGraw-Hill Publishing; 2011 July 21:905-918. ISBN: 007174889X.

502. Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrózek K, Maharry K, Becker H, Metzeler KH, Whitman SP, Wu YZ, Powell BL, Baer MR, Kolitz JE, Carroll AJ, Larson RA, Caligiuri MA*, Bloomfield CD*. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood. 2011 Oct 13;118(15):4188-98. Epub 2011 Aug 9. PMID: 21828125. PMCID: 3291490. *indicates co-senior author.

503. Katz ML, Ferketich AK, Broder-Oldach B, Harley A, Reiter PL, Paskett ED, Bloomfield CD. Physical Activity Among Amish and Non-Amish Adults Living in Ohio Appalachia. J Community Health. 2012 Apr;37(2):434-40. Epub 2011 Aug 21. PMID: 21858689. PMCID: 3625537.

504. Kühnl A, Kaiser M, Neumann M, Fransecky L, Heesch S, Radmacher M, Marcucci G, Bloomfield CD, Hofmann WK, Thiel E, Baldus CD. High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk Res. 2011 Dec;35(12):1585-90. Epub 2011 Sep 6. PMID: 21899885. PMCID: 4023812.

505. Cuyun Carter GB, Katz ML, Ferketich AK, Clinton SK, Grainger EM, Paskett ED, Bloomfield CD. Dietary Intake, Food Processing, and Cooking Methods Among Amish and Non-Amish Adults Living in Ohio Appalachia: Relevance to Nutritional Risk Factors for Cancer. Nutr Cancer. 2011 Nov 17;63(8):1208-17. Epub 2011 Oct 25. PMID: 22026912. PMCID: 3800012.

506. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G*, Bloomfield CD*. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011 Dec 22;118(26):6920-9. Epub 2011 Oct 26. PMID: 22031865. PMCID: 3245212. *indicates co-senior author.

507. Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic R, Bloomfield CD, Blum W, and Marcucci G. DNMT3A Mutations and Response to the Hypomethylating Agent Decitabine in Acute Myeloid Leukemia. Letter to the editor. Leukemia. 2012 May; 26(5):1106-1107. Epub 2011 Nov 29. PMID: 22124213. PMCID: 3696987.


58


508. Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Döhner K, Neilly MB, Price C, Lussier YA, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Bullinger L, Valk PJM, Delwel R, Löwenberg B, Liu PP, Marcucci G, Bloomfield CD, Rowley JD, Chen J. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 2012 Mar 8;119(10):2314-24. Epub 2012 Jan 17. PMID: 22251480. PMCID: 3311258.

509. Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu Y-Z, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012 Mar 1;30(7):742-50. Epub 2012 Jan 30. PMID: 22291079. PMCID: 3295550.

510. Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt, J, Becker H, Mrózek K, Wu Y-Z, Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Larson RA, Marcucci G*, Bloomfield CD*. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia. 2012 Jul;26(7):1713-7. Epub 2012 Feb 7. PMID: 22382894. PMCID: 3565839. *indicates co-senior author.

511. Eisfeld A-K, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K, Leffel B, Döhner H, Radmacher MD, Bloomfield CD*, Tanner SM*, de la Chapelle A*. Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6668-73. Epub 2012 Apr 9. PMID: 22493267. PMCID: 3340094 *indicates co-senior author.

512. Eisfeld A-K, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrózek K, Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, de la Chapelle A, Bloomfield CD. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. (Plenary Paper) Blood. 2012 Jul 12;120(2):249-58. Epub 2012 Apr 23. PMID: 22529287. PMCID: 3398762. Chosen as “Best of Alliance Published Manuscripts from 2011-2012, Leadership by junior investigator.”

513. Blum W, Schwind S, Tarighat SS, SG, Eisfeld A-K, Whitman S, Walker A, Klisovic RB, Byrd JC, Santhanam R, Wang H, Curfman JP, Devine SM, Jacob S, Garr C, Kefauver C, Perrotti D, Chan KK, Bloomfield CD, Caligiuri MA, Grever MR, Garzon R, Marcucci G. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012 Jun 21;119(25):6025-31. Epub 2012 May 7. PMID: 22566605. PMCID: 3383015.

514. Shlush LI, Chapal-Ilani N, Adar R, Pery N, Maruvka Y, Shouval R, Rowe JM, Tzukerman M, Bercovich D, Izraeli S, Marcucci G, Bloomfield CD, Zuckerman T, Skorecki K, Shapiro E. Cell Lineage Analysis of Acute Leukemia Relapse Uncovers the Role of Replication-rate Heterogeneity and Microsatellite Instability. Blood. 2012 Jul 19;120(3):603-12. Epub 2012 May 29. PMID: 22645183.

515. Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou D-C, Chen I-ML, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Larson RA, Powell BL, Appelbaum FR, Paietta E, Willman CL, Stock W. Treatment-influenced associations of PML-RARα Mutations, FLT3 mutations and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 2012 Sep 6;120(10):2098-108. Epub 2012 Jun 25. PMID: 22734072. PMCID: 3437597.

516. Stock W, Johnson JL, Stone, RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Mrózek K, Bloomfield CD, Larson RA. Dose Intensification of Daunorubicin and Cytarabine during Treatment of Adult Acute Lymphoblastic Leukemia: Results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 1;119(1):90-8. Epub 2012 Jun 28. PMID: 22744771. PMCID: 4220742.


59


517. Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler K, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G*, Bloomfield CD*. RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures. J Clin Oncol. 2012 Sep 1;30(25):3109-18. Epub 2012 Jul 2. PMID: 22753902. PMCID: 3732007. *indicates co-senior author.

518. Yan P, Frankhouse D, Murphy M, Tam H-H, Rodriguez B, Curfman J, Trimarchi M, Geyer S, Wu Y-Z, Whitman SP, Metzeler K, Walker A, Klisovic R, Jacob S, Grever M, Byrd JC, Bloomfield CD, Garzon R, Blum W, Caligiuri MA, Bundschuh R, Marcucci G. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 2012 Sep 20;120(12):2466-74. Epub 2012 Jul 11. PMID: 22786882. PMCID: 3448258.

519. Mrózek K, Bloomfield CD. Acute Myeloid Leukemia With Adverse Cytogenetic Risk. Oncology. 2012 Aug;26(8):714, 723. PMID: 22957404. PMCID: 3831632.

520. Mrózek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu Y-Z, Kohlschmidt J, Pettenati MJ, Heerema NA, Block AW, Patil SR, Baer MR, Kolitz JE, Moore JO, Carroll AJ, Stone RM, Larson RA, Bloomfield CD. Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia. J Clin Oncol. 2012 Dec 20;30(36):4515-4523. Epub 2012 Sep 17. PMID: 22987078. PMCID: 3518729.

a. Mrózek K, Nicolet D, Maharry KS, Carroll AJ, Marcucci G, Bloomfield CD. Author Reply: Reply to K. Orendi et al. J Clin Oncol. 2013 Jun 20;31(18):2361-2362. Epub 2013 May 6. PMID: 23930275.

521. Cuyun Carter G, Katz ML, Ferketich AK, Clinton SK, Grainger EM, Paskett ED, Bloomfield CD. The Use of Daily Aspirin, Nutritional Supplements and Alternative Medications among Amish and non Amish living in Ohio Appalachia. Nutr Cancer. 2012 Oct;64(7):911-8. Epub 2012 Oct 4. PMID: 23035923. PMCID: 3650902.

522. Hickey C, Schwind S, Radomska H, Dorrance AM, Santhanam R, Mishra A, Wu Y-Z, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu L-C, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G. Lenalidomide-mediated enhanced translation of C/EBP -p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood. 2013 Jan 3;121(1):159-69. Epub 2012 Oct 25. PMID: 23100311. PMCID: 3538328.

523. Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA. Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to75 years: CALGB (Alliance) Study 10502. J Clin Oncol. 2013 Mar 1;31(7):923-9. Epub 2012 Nov 5. PMID: 23129738. PMCID: 3577952.

524. Schwind S, Edwards CG, Nicolet D, Mrózek K, Maharry K, Wu Y-Z, Paschka P, Eisfeld A-K, Hoellerbauer P, Becker H, Metzeler KH, Curfman J, Kohlschmidt J, Prior TW, Kolitz JE, Blum W, Pettenati MJ, Dal Cin P, Carroll AJ, Caligiuri MA, Larson RA, Volinia S, Marcucci G*, Bloomfield CD*. inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood. 2013 Jan 10;121(2):385-91. Epub 2012 Nov 16. PMID: 23160462. PMCID: 3544117. *indicates co-senior author.


60


525. Mims A, Walker AR, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hollerbauer P, Huang X, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen C-S, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 2013 Apr;27(4):871-8. Epub 2012 Nov 26. PMID: 23178755. PMCID: 3764604.

526. Li Y, Gao L, Luo X, Wang L,Gao X, Wang W, Sun J, Dou L, Li J, Xu C,Wang L, Zhou M, Jiang M, Zhou J, Caligiuri MA, Nervi C, Bloomfield CD, Marcucci G, Yu L. Epigenetic Silencing of microRNA-193a Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia by Activating the PTEN/PI3K Signal Pathway. Blood. 2013 Jan 17;121(3):499-509. Epub 2012 Dec 6. PMID: 23223432.

527. Walker A, Mrózek K, Kohlschmidt J, Rao KW, Pettenati MJ, Sterling LJ, Marcucci G, Carroll AJ, Bloomfield CD. New Recurrent Balanced Translocations in Acute Myeloid Leukemia and Myelodysplastic Syndromes: Cancer and Leukemia Group B (CALGB) 8461. Genes Chromosomes Cancer. 2013 Apr;52(4):385-401. Epub 2012 Dec 10. PMID: 23225546. PMCID: 3874732.

528. Becker H, Bloomfield CD. Acute Myeloid Leukaemia in 2012: En route to improved treatment options. Year in Review 2012 - Special Collection from Nature Publishing Group. Nat Rev Clin Oncol. 2013 Feb;10(2):76-9. Epub 2013 Jan 8. PMID: 23296115.

529. Becker H, Marcucci G, Bloomfield CD. Genetic Markers in Older Cytogenetically Normal Acute Myeloid Leukemia Patients. Ann Hematol. 2013 Feb; 92 (suppl 1):S30-S33.

530. Li Z, Herold T, He C, Valk P, Chen P, Jurinovic V, Mansmann U, Radmacher M, Maharry K, Sun M, Yang X, Huang H, Jiang X, Sauerland M-C, Büchner T, Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Dohner K, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield CD, Rowley JD, Bohlander SK, Chen J. Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study of 1,324 Patients. (Accompanying Editorial) J Clin Oncol. 2013 Mar 20;31(9):1172-81. Epub 2013 Feb 4. PMID: 23382473. PMCID: 3595425.

531. Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR,Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci G. Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia. Clin Cancer Res. 2013 May 1;19(9):2355-67. Epub 2013 Mar 14. PMID: 23493348. PMCID: 3644023.

532. Douer D, Zickl LN, Schiffer CA, Appelbaum FR, Feusner JH, Shepherd L, Willman CL, Bloomfield CD, Paietta E, Gallagher RE, Park JH , Rowe JM, Wiernik PH, Tallman MS. All-trans retinoic acid and late relapses in acute promyelocytic leukemia; very long-Term follow-up of the North American Intergroup Study I0129. Leuk Res. 2013 Jul;37(7):795-801. Epub 2013 Mar 23. PMID: 23528262. PMCID: 4174301.

533. Katz ML, Ferketich AK, Paskett ED, Bloomfield CD. Health Literacy among the Amish: Measuring a complex concept among a unique population. J Community Health. 2013 Aug;38(4):753-8. Epub 2013 Mar 26. PMID: 23529449. PMCID: 3790258.

534. Marcucci G, Maharry K, Metzeler KH, Volinia S, Wu Y-Z, Mrózek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld A-K, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CD. The Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients. J Clin Oncol. 2013 Jun 10;31(17):2086-93. Epub 2013 May 6. PMID: 23650424. PMCID: 3731981.


61


535. Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA. A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105. Invest New Drugs. 2013 Oct;31(5):1311-20. Epub 2013 May 23. PMID: 23700288. PMCID: 3773017.

536. Mendler JH, Maharry K, Becker H, Eisfeld A-K, Senter L, Mrózek K, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Khalife J, Caligiuri MA, Klisovic RB, Moore JO, Carter TH, Marcucci G*, Bloomfield CD*. In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline. Letter to the Editor. Haematol. 2013 Aug;98(8):e92-4. Epub 2013 Jun 10. PMID: 23753029. PMCID: 3729891. *indicates co-senior author.

a. Mendler JH, Marcucci G, Bloomfield CD. Reply to “Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases”. Haematol. 2014 Feb 1;99(2):e22. Epub 2013. PMID: 24497566. PMCID: 3912980.

537. Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrózek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld A-K, Wu Y-Z, Powell BL, Carter TH, Wetzler M, Kolitz JE, Baer MR, Carroll AJ, Stone RM, Caligiuri MA, Marcucci G*, Bloomfield CD*. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia. 2013 Oct;27(10):2023-31. Epub 2013 Jun 14. PMID: 23765227. PMCID: 3890747. *indicates co-senior author.

538. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M. Myelodysplastic Syndromes. J Natl Compr Canc Netw. 2013 Jul 1;11(7):838-74. PMID: 23847220. PMCID: 4000017.

539. Goldberg L, Tijssen MR, Birger Y, Hanna RL, Kinston SJ, Schütte J, Beck D, Knezevic K, Schiby G, Jacob-Hirsch J, Biran A, Kloog Y, Marcucci G, Bloomfield CD, Aplan PD, Pimanda JE, Göttgens B, Izraeli S. Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. Blood. 2013 Oct 10;122(15):2694-703. Epub 2013 Aug 23. PMID: 23974202. PMCID: 3795462.

540. Woods W, Franklin ARK, Alonzo TA, Gerbing RB, Donohue KA, Othus M, Horan J, Appelbaum FR, Estey EH, Bloomfield CD, Larson RA. Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. Cancer. 2013 Dec 1;119(23):4170-9. Epub 2013 Sep 19. PMID: 24104597. PMCID: 3833872.

541. Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation - results of CALGB Study 10001 (Alliance). Haematologica. 2014 Jan;99(1):111-5. Epub 2013 Sep 27. PMID: 24077846. PMCID: 4007937.

542. Wetzler M, Mrózek K, Kohlschmidt J, Dombret H, Döhner H, Pilorge S, Krug U, Carroll AJ, Larson RA, Marcucci G, Hiddemann W, Büchner T, Bloomfield CD. Intensive induction is effective in select octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European Leukemia-Net classification. Haematologica. 2014 Feb;99(2):308-13. Epub 2013 Oct 4. PMID: 24097631. PMCID: 3912961.

543. Poiré X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman M, Appelbaum FR, Sher D, Willman C, Paietta E, Stock W. Arsenic Trioxide in Front-line Therapy of Acute Promyelocytic Leukemia (C9710): Prognostic Significance of FLT3 Mutations and Complex Karyotype. Leuk Lymphoma. 2014 Jul;55(7):1523-32. Epub 2013 Oct 28. PMID: 24160850. PMCID: 4273565.


62


544. Whitman S, Kohlschmidt J, Maharry K, Volinia S, Mrózek K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mendler JH, Eisfeld A-K, Carroll AJ, Powell BL, Carter TH, Baer MR, Kolitz JE, Park I-K, Stone RM, Caligiuri MA*, Marcucci G*, Bloomfield CD*. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 2014 Jun;28(6):1252-8. Epub 2013 Dec 11. PMID: 24326683. PMCID: 4047202. *indicates co-senior author.

545. Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrózek K, Wu Y-Z, Bucci D, Whitman SP, Eisfeld A-K, Mendler JH, Schwind S, Becker H, Bär C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Byrd JC, Plass C, Garzon R, Caligiuri MA, Stone RM, Volinia S, Bundschuh R*, Bloomfield CD*. Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score. J Clin Oncol. 2014 Feb 20;32(6):548-56. Epub 2013 Dec 30. PMID: 24378410. PMCID: 3918538. *indicates co-senior author.

546. Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808. Cancer. 2014 Apr 1;120(7):1010-1017. Epub 2013 Dec 31. PMID: 24382782. PMCID: 4139069.

547. Eisfeld A-K, Schwind S, Hoag K, Walker CJ, Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan W, Otterson G, Carson WE, Marcucci G, Bloomfield CD*, de la Chapelle A*. NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4179-84. Epub 2014 Feb 28. PMID: 24586049. PMCID: 3964043. *indicates co-senior author.

548. Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Samadzadeh ST, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu Y-Z, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD*, Marcucci G*. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest. 2014 Apr 1;124(4):1512-24. Epub 2014 Mar 3. PMID: 24590286. PMCID: 3973087.*indicates co-senior author.

549. Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreef M, Croce CM, Marcucci G, Bloomfield CD, Garzon R. Implications of miR-10 family in chemotherapy response of NPM1 mutated AML. Blood. 2014 Apr 10;123(15):2412-5. Epub 2014 Mar 4. PMID: 24596420. PMCID: 3983615.

550. Becker H, Maharry K, Mrózek K, Volinia S, Eisfeld A-K, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu Y-Z, Nicolet D, Paschka P, Powell BL, Carter TH, Wetzler M, Kolitz JE, Carroll AJ, Baer MR, Caligiuri MA, Stone RM, Marcucci G*, Bloomfield CD*. Prognostic gene mutations and distinct gene- and microRNA-expression in acute myeloid leukemia with a sole trisomy 8. Letter to the editor. Leukemia. 2014 Aug 6;28(8):1754-8. Epub 2014 Mar 21. PMID: 24651097. PMCID: 4151613. *indicates co-senior author.

551. Pastore F, Dufour A, BenthausT, Metzeler KH, Maharry KS, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Sauerland MC, Heinecke A, Krug U, Berdel WE, Buechner T, Woermann B, Hiddemann W, Bohlander SK, Marcucci G, Spiekermann K, Bloomfield CD*, Hoster E*. Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia. J Clin Oncol. 2014 May 20;32(15):1586-94. Epub 2014 Apr 7. PMID: 24711548. PMCID: 4876345. *indicates co-senior author.

552. Eisfeld A-K, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, Markowitz R, Hoag KW, Jarvinen TM, Leffel B, Perrotti D, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle A. Intronic miR-3151 hosted by BAALC drives leukemogenesis by direct deregulation of the TP53 pathway. Sci Signal. 2014 Apr 15;7(321):ra36. PMID: 24736457. PMCID: 4165404.


63

PUBLICATIONS - Excluding Letters, Abstracts and Edited Books (cont.).

553. Claus R, Mrózek K, Steidl C, Haase D, Koeffler HP, Bloomfield CD. Cytogenetics and molecular diagnostic genetics in MDS and AML. Chapter 3. In: Lübbert M, Gore SD, eds. Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Biological and Therapeutical Continuum. UNI-MED Verlag AG, D-28323 Bremen. London UK. Boston MA, USA: International Medical Publishers; 2014 Aug:76-107. ISBN: 978-3-8374-1271-0.

554. Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld A-K, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu Y-Z, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R, Larson RA, Stone RM, Mrózek K*, Marcucci G*, Bloomfield CD*. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 2015 Mar;29(3):567-75. Epub 2014 Sep 10. PMID: 25204569. PMCID: 4351165 . *indicates co-senior author.

555. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y-L, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen S-C, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen I-M, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui C-H, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG. Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. N Engl J Med. 2014 Sep 11;371(11):1005-1015. PMID: 25207766. PMCID: 4191900.

556. Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, Harvey RC, Payne-Turner D, Devidas M, Chen I-M, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Gastier-Foster JM, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui C-H, Jeha S, Relling MV, Evans WE, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG, Yang JJ. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. 2015 Jan 22;125(4):680-6. Epub 2014 Dec 2. PMID: 25468567. PMCID: 4304112.

557. Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan P, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld A-K, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD. Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18679-18684. Epub 2014 Dec 15. PMID: 25512507. PMCID:4284555.

558. Marcucci G, Bloomfield CD. Acute Myeloid Leukemia. Chapter 132. In: Longo DL, ed. Harrison's Principles of Internal Medicine, 19th Edition. McGraw-Hill Publishing; 2015 Apr 8:1020-1029. ISBN: 978-0-07-180215-4.

559. Khalife JC, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu Y-Z, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros B, Perrotti D, Lee LJ, Lee R, Caligiuri MA, Pichiorri F, Croce CM, Garzon R, Guzman ML, Mendler JH, Marcucci G. Pharmacological Targeting of miR-155 via the NEDD8-Activating Enzyme Inhibitor MLN4924 (Pevonedistat) in FLT3-ITD Acute Myeloid Leukemia. Leukemia. 2015 Oct;29(10):1981-92. Epub 2015 May 14. PMID: 25971362. PMCID: 4868182.

560. Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, Maharry KS, Ozer HG, Hoellarbauer P, Kalife J, Hill EB, Bolon BN, Lee RJ, Lee LJ, Croce CM, Garzon R, Caligiuri MA, Bloomfield CD*, Marcucci G*. Targeting Leukemia Stem Cells in vivo with AntagomiR-126 Nanoparticles in Acute Myeloid Leukemia. Leukemia. 2015 Nov;29(11):2143-53. Epub 2015 Jun 9. PMID: 26055302. PMCID: 4633325. *indicates co-senior author.


64


561. Sood R, Hansen NF, Donovan FX, Carrington B, Bucci D, Maskeri B, Young A, Trivedi NS, Kohlschmidt J, Stone RM, Caligiuri MA, Chandrasekharappa SC, Marcucci G, Mullikin JC, Bloomfield CD, Liu P. Somatic mutational landscape of AML with inv(16) and t(8;21) identifies patterns of clonal evolution in relapse leukemia. Leukemia. 2016 Feb;30(2):201-4. Epub 2015 Jun15. PMID: 26139325. PMCID: 4679720.

562. Voorhees PM, Orlowski RZ, Mulkey F, Watson P, Geyer S, Sanford BL, Bennett E, Chanan-Khan AA, Bloomfield CD, Larson RA. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicenter phase II study. Br J Haematol. 2015 Nov;171(3):373-7. Epub 2015 Jul 22. PMID: 26202857.

563. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug;90(8):996-1000. Epub 2015 Jul 23. PMID: 26211600.

564. Döhner H, Weisdorf DJ, Bloomfield CD. Review article: Acute Myeloid Leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52. PMID: 26376137.

565. Goyama S, Schibler J, Gasilina A, Lin S, Link KA, Shrestha M, Chen J, Whitman SP, Bloomfield CD, Nicolet D, Assi S, Ptasinska A, Heidenreich O, Bonifer C, Nassar N, Mulloy JC. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human AML1-ETO. Leukemia.2016 Mar ;30(3):728-39. Epub 2015 Oct 9. PMID: 26449661. PMCID: 4775400.

566. Mrózek K, Bloomfield CD. Chromosome abnormalities in AML and their clinical importance. Chapter 13. In: Rowley JD, Le Beau M, Rabbitts TH, eds. Chromosomal Translocations and Genome Rearrangements in Cancer. Switzerland: Springer Science+Business Media B.V.; 2015 Dec 10:275-317. ISBN-13: 978-3319199825.

567. Bhatnagar B, Blachly JS, Kohlschmidt J, Eisfeld A-K, Volinia S, Nicolet D, Carroll AJ, Block AM, Kolitz JE, Stone RM, Mrózek K, Byrd JC, Bloomfield CD. Clinical features, and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3). Leukemia. 2016 Jul;30(7):1586-9. Epub 2015 Dec 16. PMID: 26669971. PMCID: 5004206.

568. Kroll KW, Eisfeld A-K, Lozanski G, Bloomfield CD, Byrd JC, Blachly JS. MuCor: Mutation Aggregation and Correlation. Bioinformatics. 2016 May 15;32(10):1557-8. Epub 2016 Jan 23. PMID: 26803155. PMCID: 4866525.

569. DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan C, Stock W. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 Oct;57(10):2298-306. Epub 2016 Feb 18. PMID: 26892479. PMCID: 5008253.


65

PUBLICATIONS - Excluding Letters, Abstracts and Edited Books (cont.) 570. Khwaja A, Bjorkholm M, Gale R, Levine R, Jordan C, Ehninger G, Bloomfield CD, Estey E, Burnett

A, Cornelissen J, Scheinberg D, Bouscary D, Linch D. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016 Mar 10;2:1-22. PMID: 27159408. PMCID: 5089920.

571. Alachkar H, Fulton N, Sanford B, Malnassy G, Mutonga M, Larson RA, Bloomfield CD, Marcucci G, Nakamura Y, Stock W. Expression and polymorphism of mitochondrial superoxide dismutase (SOD2) and drug induced hepatotoxicity in patients with Acute Lymphoblastic Leukemia; (CALGB 9862, 21001). Pharmacogenomics J. 2017 Jun;17(3):274-279. Epub 2016 Mar 29. PMID: 27019981. PMCID: 5089920.

572. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. Epub 2016 Apr 11. PMID: 27069254.

573. Maharry SE, Walker CJ, Liyanarachchi S, Mehta S, Patel M, Bainazar MA, Huang X, Lankenau MA, Blachly JS, Guttridge DC, Bloomfield CD*, de la Chapelle A*, Eisfeld A-K*. Dissection of the major hematopoietic quantitative trait locus in chromosome 6q23.3 identifies miR-3662 as a novel player in hematopoiesis. Cancer Discov. 2016 Sep;6(9):1036-51. Epub 2016 Jun 27. PMID: 27354268. PMCID: 5168803

574. Link KA, Lin S, Shrestha M, Bowman M, Wunderlich M, Bloomfield CD, Huang G, Mulloy JC. Supra-physiologic levels of the AML1-ETO Isoform AE9a are Essential for Transformation. Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9075-80. Epub 2016 Jul 25. PMID: 27457952. PMCID: 4987773.

575. Niederwieser C, Nicolet D, Carroll AJ, Kolitz JE, Powell BL, Kohlschmidt J, Stone RM, Byrd JC, Mrózek K, Bloomfield CD. Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). Haematologica. 2016 Dec;101(12):1516-1523. Epub 2016 Jul 28. PMID: 27470602. PMCID: 5479622.

576. Bhatnagar B, Eisfeld A-K, Nicolet D, Mrózek K, Blachly JS, Orwick S, Lucas DM, Kohlschmidt J, Blum W, Kolitz JE, RM, Bloomfield CD*, Byrd JC*. Persistence of isolated DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukemia. Br J Haematol. 2016 Oct;175(2):226-236. Epub 2016 Aug 1. PMID: 27476855. PMCID: 5063708.

577. Huang X, Schwind S, Santhanam R, Eisfeld A-K, Chiang C-L, Lankenau M, Yu B, Hoellerbauer P, Jin Y, Tarighat SS, Khalife J, Walker A, Perrotti D, Bloomfield CD, Wang H, Lee RJ , Lee JL, Marcucci G. Targeting the RAS/MAPK pathway with miR-181 in Acute Myeloid Leukemia. Oncotarget. 2016 Sep 13;7(37):59273-59286. Epub 2016 Aug 9. PMID: 27517749. PMCID: 5312311.

578. Eisfeld A-K, Kohlschmidt J, Mrózek K, Blachly JS, Nicolet D, Kroll K, Orwick S, Carroll AJ, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD. Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2. Leukemia. 2016 Nov;30(11):2254-2258. Epub 2016 Aug 12. PMID: 27435003. PMCID: 5244485.

579. Blum W, Sanford B, Klisovic R, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wetzler M, Hoke E, Mrózek K, Kohlschmidt J, Bloomfield CD, Geyer S, Marcucci G, Stone RM, Larson RA. Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia in First Remission: a Phase II Cancer and Leukemia Group B Study (CALGB 10503). Leukemia. 2017 Jan;31(1):34-39. Epub 2016 Oct 7. PMID: 27624549. PMCID: 5214595.


66


580. Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, Wu G, Li Y, Wei L, Iacobucci I, Liu Y, Qu C, Shao Y, Wen J, Edmonson M, Payne-Turner D, Kaufmann KB, Takayanagi S-I, Wienholds E, Waanders E, Ntziachristos P, Bokogianni S, Wang J, Aifantis I, Roberts KG, Ma J, Song G, Easton J, Mulder HL, Chen X, Newman S, Ma X, Rusch M, Gupta P, Boggs K, Vadodaria B, Dalton J, Liu Y, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Yang J, Evans WE, Relling MV, Pui C-H, Jeha S, Harvey RC, Chen I-ML, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Mrozek K, Paietta E, Tallman MS, Stock W, Foster MC, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Dick JE, Hunger SP, Loh ML, Downing JR, Mullighan CG. Deregulation of DUX4 and ERG in Acute Lymphoblastic Leukemia. Nat. Genet. 2016 Dec;48(12):1481-1489. Epub 2016 Oct 24. PMID: 27776115. PMCID: 5144107.

581. Eisfeld A-K, Kohlschmidt J, Mrózek K, Volinia S, Blachly JS, Nicolet D, Oakes C, Kroll K, Orwick S, Carroll AJ, Stone RM, Byrd JC, de la Chapelle A, Bloomfield CD. The mutational landscape and gene-expression patterns of adult patients with acute myeloid leukemia and monosomy 7 as a sole abnormality. Cancer Res. 2017 Jan 1;77(1):207-218. Epub 2016 Oct 26. PMID: 27784745. PMCID: 5215102.

582. Gu Z, Li Y, Liu Y, Reshmi S, Roberts K, Harvey RC, McCastlain K, Payne-Turner D, Churchman M, Iacobucci I, Shao Y, Chen I-M, Valentine M, Mungall K, Mungall A, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster J, Devidas M, Dai Y, Wood B, Borowitz M, Larsen E, Maloney K, Mattano LA, Angiolillo A, Salzer WL, Burke MJ, Rambaldi A, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh M, Hunger S, Mullighan C. Genomic analysis identify recurrent MEF2D fusions in Acute Lymphoblastic Leukemia. Nat Commun. Epub 2016 Nov 8;7: article no.13331. PMID: 27824051. PMCID: 5105166.

583. Eisfeld A-K, Kohlschmidt J, Schwind S, Nicolet D, Blachly JS, Orwick S, Shah C, Bainazar M, Kroll K, Walker CJ, Carroll AJ, Powell BL, Stone RM, Kolitz JE, Baer MR, de la Chapelle A, Byrd JC, Mrozek K, Bloomfield CD. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;122) acute myeloid leukemia. Leukemia. 2017 Jun;31(6):1278-1285. Epub 2016 Nov 15. PMID: 27843138. PMCID: 5462855.

584. Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen I-M, Pei D, Iacobucci I, Valentine M, Pounds SB, Shi L, Li Y, Zhang J, Cheng C, Rambaldi A, Tosi M, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Wiernik PH, Bhatia R, Aldoss I, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau SM, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Mullighan CG. High frequency and poor outcome of Philadelphia chromosome-like Acute Lymphoblastic Leukemia in adults. J Clin Oncol. 2017 Feb;35(4):394-401. Epub 2016 Nov 21. PMID: 27870571. PMCID: 5455698.

585. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert B, Fenaux P, Larson RA, Levine R, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei A, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424-447. Epub 2016 Nov 28. PMID: 27895058. PMCID: 5291956.

586. Jentzsch M, Bill M, Nicolet D, Leiblein S, Schubert K, Pleß M, Bergmann U, Wildenberger K, Schuhmann L, Cross M, Pönisch W, Franke G-N, Vucinic V, Lange T, Behre G, Mrózek K, Bloomfield CD, Niederwieser D, Schwind S. Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. Am J Hematol. 2017 Apr;92(4):388-396. Epub 2017 Jan 30. PMID: 28133783.


67


587. Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA. A Phase 2 study incorporating Sorafenib into the Chemotherapy for older adults with FLT3-Mutated acute myeloid leukemia: CALGB 11001 (Alliance). Blood Advances. 2017 Jan 24; 1(5):331-340. PMID: 29034366. PMCID: 5637402.

588. Metzeler K, Bloomfield CD. Clinical relevance of RUNX1 and CBFB alterations in acute myeloid leukemia and other hematological disorders. Chapter 12. In: Groner Y, Ito Y, Liu P, Neil JC, Speck NA, van Wijnen A, eds. Adv Exp Med Biol. (AEMB). Springer; 2017;962:175-199. ISBN-13: 978-981-10-3231-8

589. Eisfeld A-K, Mrozek K, Kohlschmidt J, Nicolet D, Orwick S, Kroll K, Blachly JS, Carroll AJ, Kolitz JE, Powell BL, Wang E, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD. The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia. 2017 Oct;31(10):2211-2218. Epub 2017 Apr 18. PMID: 28321123. PMCID: 5628133.

590. Walker CJ, Eisfeld A-K, Genutis L, Bainazar M, Kohlschmidt J, Mrózek K, Carroll AJ, Kolitz JE, Powell BL, Wang ES, Stone RM, Bundschuh R, de la Chapelle A, Bloomfield CD. No evidence for microsatellite instability in acute myeloid leukemia. Leukemia. 2017 Jun 31;(6):1474-1476. Epub 2017 Mar 24. PMID: 28336936. PMCID: 5462842.

591. Papaioannou D, Nicolet D, Volinia S, Mrózek K, Yan P, Bundschuh R, Carroll AJ, Kohlschmidt J, Blum W, Powell BL, Uy GL, Kolitz JE, Wang ES, Eisfeld A-K, Orwick SJ, Lucas DM, Caligiuri MA, Stone RM, Byrd JC, Garzon R, Bloomfield CD. Prognostic and biologic significance of long non-coding RNA profiling in younger adult patients with cytogenetically normal acute myeloid leukemia. Haematologica. 2017 Aug;102(8):1391-1400. Epub 2017 May 4. PMID: 28473620. PMCID: 5541873.

592. Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Appelbaum FR, Erba HP. A Randomized Phase II Study of Azacitidine alone or in combination with Lenalidomide or with Vorinostat in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. PMID: 28486043. PMCID: 5562170.

593. Papaioannou D, Schen C, Nicolet D, McNeil B, Karunasiri M, Burke MH, Ozer HG, Yilmaz SA, Zitzer N, Behbehani GK, Steiner DJ, Marcucci G, Powell BL, Kolitz JE, Carter TH, Wang E, Mrozek K, Croce CM, Caligiuri MA, Bloomfield CD, Garzon R, Dorrance AM. Prognostic and Biological Significance of the Pro-Angiogenic factor EGFL7 in acute myeloid leukemia (AML). Proc Natl Acad Sci U.S.A. 2017 Jun 6;114(23):E4641-E4647. Epub 22 May 2017. PMID: 28533390. PMCID: 5468639

594. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior T, Döhner K, , Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017 Aug 3;377(5):454-464. Epub 2017 Jun 23. PMID: 28644114. PMCID: 5754190.

595. Arber DA, Orazi A, Hasserjian RP, Brunning RD, Le Beau MM, Porwit A, Tefferi A, Levine R, Bloomfield CD, Cazzola M, Thiele J. Introduction and overview of the classification of the myeloid neoplasms. Chapter 1. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Ed. Lyon. IARC 2017 Sept:15-27. ISBN: 9283244943.


68


596. Peterson LC, Bloomfield CD, Niemeyer CM, Döhner H, Godley LA. Myeloid Neoplasms with Germline Predisposition. Chapter 7. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Ed. Lyon. IARC 2017 Sept: 121-128. ISBN: 9283244943.

597. Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J, Foucar K, Döhner H, Bloomfield CD. Acute myeloid leukaemia with recurrent genetic abnormalities. Chapter 8.1. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, eds World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Ed. Lyon. IARC 2017 Sept: 130-145. ISBN: 9283244943.

598. Rizzotto L, Lai T-H, Bottoni A, Woyach JA, Lapalombella R, Bloomfield CD, Byrd JC, Sampath D. Role and regulation of MicroRNAs targeting BTK in acute myelogenous leukemia. Leuk Lymphoma. 2018 Jun;59(6):1461-1465. Epub 2017 Sept 18. PMID: 28918688.

599. Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD and Garzon R. Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget. 2017 Dec 12;9(4):4354-4365. PMID: 29435107. PMCID: 5796978.

600. Eisfeld A-K, Kohlschmidt J, Mrozek K, Blachly JS, Walker CJ, Nicolet Dr, Orwick S, Maharry SE, Papaioannou D, Kroll KW, Carroll AJ, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD. Mutation pattern identifies adult patients with De Novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: An Analysis of Alliance Studies. Leukemia. Epub 2018 Feb 25. PMID: 29563537.

601. Mims AS, Mishra A, Orwick S, Blachly J, Klisovic RB, Garzon R, Walker AR, Devine SM, Walsh KJ, Vasu S, Whitman S, Marcucci G, Heerema NA, Lozansi G, Caligiuri MA, Bloomfield CD, Byrd JC, Piekarz R, Grever MR, Blum W. A Novel Regimen for Relapsed/Refractory Acute Myeloid Leukemia Using a KMT2A Partial Tandem Duplication Targeted Therapy: Results of Phase 1 Study NCI 8485. Haematologica. Epub 2018 Mar 22. PMID: 29567781.

602. Bloomfield CD, Estey E, Pleyer L, Schuh AC, Stein EM, Tallman M, Wei A. Time to repeal and replace response criteria for acute myeloid leukemia? Blood Reviews. Epub 2018 Mar 27. PMID: 29706486.

603. Eisfeld A-K, Kohlschmidt J, Mrózek K, Mims A, Walker CJ, Blachly JS, Nicolet D, Orwick S, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Wang ES, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD. NF1 Mutations are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome. Leukemia. In Press.

604. Blum W, Bloomfield CD. Acute Myeloid Leukemia. Chapter for Harrison's Principles of Internal Medicine, 20th Edition. In Press


69

LETTERS 1. McKenna R, Connelly D, Matsen J, Bloomfield CD, Kennedy BJ, McCullough J. Letter: Hepatitis

surveillance in an oncology unit. N Eng J Med. 1975;292:1191.

2. Moldow CF, Bloomfield CD. Letter to the Editor: Haemochromatosis and anthracyclines: Free radical mediated tissue injury? Lancet ii. 1978;154-155.

3. Arthur DC, Bloomfield CD. Letter to the Editor. Blood.1983 Oct; 62(4):931. a. Arthur DC, Bloomfield CD. Author Reply: Oncogenes and Acute Leukemias. Blood. 1984

Jan; 63(1):242.

4. Bloomfield CD, Garson OM, Volin L, Knuutila S, de la Chapelle. Letter to the Editor: Trans-(1-3)(P36-Q21) In Acute Nonlymphocytic Leukemia – A New Clinicopathological Association. Blood. 1986 Jul:68:320-322.

5. Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, Cuttner J, Griffin JD, Collins H, Nelson DA, Bloomfield CD. Author Response: Myeloid-antigen expression in adult acute lymphoblastic leukemia. N Engl J Med. 1987 Oct 29:317(18):1156-1157.

6. Lee CK, Aeppli DM, Bloomfield CD, Levitt SH. Author Response: A plea for prospective clinical trials by John D. Earle, M.D. Int J Radiat Oncol Biol Phys. 1987 Sep;13(9):1429.

7. Mrózek K, Bloomfield CD. Letter to the Editors: Have cancer cytogeneticists been wrong in assigning chromosome 12 breakpoints in benign tumors? Genes, Chromosomes and Cancer.1996 Mar;15:195-196.

8. Marcucci G, Caligiuri MA, Bloomfield CD. Letter to the Editor: Defining the “absence” of the CBFβ/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long term complete remission. A call for definitions. Blood.1997 Dec 15;90(12):5022-5024.

9. Mrózek K, Bloomfield CD. Letter to the Editors: Der(16)t(1;16) is a secondary chromosome aberration in at least eighteen different types of human cancer. Genes, Chromosomes & Cancer. 1998 Sep; 23:78-80.

10. Rush LJ, Heinonen K, Mrózek K, Wolf BJ, Abdel-Rahman M, Szymanska J, Peltomäki P, Kapadia F, Bloomfield CD, Caligiuri MA, Plass C. Letter to the Editor: Comprehensive cytogenetic and molecular genetic characterization of the TI-1 acute myeloid leukemia cell line reveals cross-contamination with K-562 cell line. Blood. 2002 Mar 1; 99(5):1874-1876.

11. Marcucci G, Bloomfield CD. Commentary: Molecular Landscaping of Acute Myeloid Leukemia: Are We Relearning the Past or Informing the Future? The ASCO Post. 2013 Jul 10;4(11):42-3.

12. Gale R, Bloomfield CD. Obituary: Geoffrey Peter Herzig, MD Leukemia Pioneer (1941-2013). Leukemia. 2014 May;28(5):1177. Epub 2014 Mar 21. PMID: 24651051.


70

ABSTRACTS

1. Bloomfield CD, Brunning RD, Theologides A, Kennedy BJ. Combination daunorubicin-prednisone treatment of adult acute myelogenous leukemia. [abstract]. Proc Amer Assoc Cancer Res. 1972; 13:36.

2. Bloomfield CD, Dick F, Brunning R, Kennedy BJ. The prognostic implications of bone marrow involvement in non-Hodgkin's lymphomas. [abstract]. Proc Amer Assoc Cancer Res. 1973;14:69.

3. Bloomfield CD, Brunning RD, Kennedy BJ. Daunorubicin treatment of erythroleukemia. [abstract]. Proc Amer Assoc Cancer Res.1974;15:17.

4. Bloomfield CD, Twito D, Brunning RD, Theologides A. Blastic crisis of chronic myelocytic leukemia (CML-bc): Compared to acute myeloblastic leukemia (AMbL). [abstract]. Proc Amer Soc Clin Oncol. 1974;15:163.

5. McKenna R, Bloomfield CD, Nesbit M, Brunning RD. Nonspecific esterase positive acute leukemia--a distinctive cytologic and clinical entity. [abstract]. Proc Amer Assoc Cancer Res. 1975;16:61.

6. Gajl-Peczalska KJ, Bloomfield CD, Sosin H, Kersey JH. Value of lymphocyte study by surface markers in non-Hodgkin's malignant lymphoma. [abstract]. Proc Amer Assoc Cancer Res. 1975;16:60.

7. Kennedy BJ, Hill J, Bloomfield CD, Kiang DT, Fortuny I, Theologides A. Combination (COP) versus successive single agent chemotherapy (C-O-P) in lymphocytic lymphoma. [abstract]. Proc Amer Assoc Cancer Res. 1975;16:142.

8. Dick F, Bloomfield CD, Brunning RD. Incidence, cytology and histopathology of non-Hodgkin's lymphomas in the bone marrow. [abstract]. Cancer. 1974;33:1382-1398. Year Book of Cancer. 1975, pp 303-306.

9. Bloomfield CD, Theologides A. Acute granulocytic leukemia in elderly patients. [abstract]. JAMA. 1973;226:1190-1193. Year Book of Cancer. 1975, pp 224-225.

10. Bloomfield CD, Peterson LC, Brunning RD. Philadelphia chromosome positive (Ph+) acute leukemia: Clinical features, morphology and response to treatment in nine patients. [abstract]. Blood. 1975;46:1012.

11. Bloomfield CD, Edson JR, Brunning RD: A new treatment (Rx) regimen for disseminated intravascular coagulation (DIC) in acute non-lymphocytic leukemia (ANLL). [abstract]. Proc Amer Soc Clin Oncol. 1976;17:291.

12. Bloomfield CD, Brunning R, Kersey J, Gajl-Peczalska KJ. Adult acute lymphocytic leukemia (ALL): The therapeutic significance of surface markers (SM) and the Philadelphia chromosome (Ph). [abstract]. Proc Amer Assoc Cancer Res. 1976;17:166.

13. Bowers T, Moldow CF, Bloomfield CD, Yunis EJ. Familial Hodgkin's disease: Association with major histocompatibility Loci. [abstract]. Clin Res. 1976;24:375A.

14. Kennedy BJ, Theologides A, Fortuny I, Bloomfield CD, Kelley RT. Advanced cancer: New concepts of medical therapy. [abstract]. Geriatrics. 1973;28:51-72. Year Book of Cancer. 1975, pp 461-462.

15. McKenna RW, Bloomfield CD, Dick F, Nesbit ME, Brunning RD. Acute monoblastic leukemia: Diagnosis and treatment of ten cases. [abstract]. Blood. 1975;46:481-494. Year Book of Pathology and Clinical Pathology. 1977, pp 391-394.

16. McKenna RW, Bloomfield CD, Bowers TK, Brunning RD. Treatment associated acute non-lymphocytic leukemia (ANLL): The morphologic pattern. [abstract]. Proc Amer Assoc Cancer Res. 1977;18:222.


71

ABSTRACTS (cont.)

17. Chen KTK, Bloomfield CD, McKenna RW, Brunning RD. Double bilateral bone marrow biopsies in staging patients with lymphoma. [abstract]. Proc Amer Assoc Cancer Res. 1977;18:179.

18. Peterson BA, Bloomfield CD. Asymptomatic central nervous system (CNS) leukemia in adults with acute non-lymphocytic leukemia (ANLL) in extended remission. [abstract]. Proc Amer Soc Clin Oncol. 1977;18:341.

19. Gajl-Peczalska KJ, Bloomfield CD, Coccia PF, Sosin H, Brunning RD, Kersey JH. B & T cell lymphomas: Analysis of blood and lymph nodes in 87 patients. [abstract]. Am J Med.1975;59:674-685. Year Book of Cancer. 1977, pp 169-170.

20. Peterson BA, Bloomfield CD. Treatment of refractory adult acute lymphocytic leukemia with high dose methotrexate and citrovorum factor. [abstract]. Blood. 1977;50 (suppl 1):389.

21. Lee CKK, Levitt SH, Bloomfield CD. Results of curative radiation therapy in surgically staged Hodgkin's diseases: University of Minnesota experience from 1970 to 1975. [abstract]. Int J Radiat Oncol Biol Phys. 1977;2(suppl 2):48.

22. Rosenberg SA, Glatstein E, Castellino R, Goffinet DR, Ultmann JE, Colineas, DeVita VT, Chabner BA, Arrell, Antinez, Bloomfield CD, Jones SE, Coleman M, Crawford, Jaffe N, Hedsall. Discussion I. [abstract]. Cancer Treat Rep. 1977;61:1029-1035.

23. Berard CW, Jaffe E, Rappaport H, Lukes R, Seligmann M, Bloomfield CD, Dorfman R, Byrne G, Shaw M. Discussion II: Roundtable discussion of histopathologic classification. [abstract]. Cancer Treat Rep. 1977;61:1037-1048.

24. Frei III E, Anderson T, Bertino JR, Bloomfield CD, Richardson, Coltman Jr. CA, Dansker G, Salmon SE, Durant J, Bonadonna G, Collanio F, Portlock CS, Rosenberg SA, Nissen NI, Justice G, Rosen P, Johnston. Discussion III: Chemotherapy of the non-Hodgkin's lymphomas. [abstract]. Cancer Treat Rep. 1977;61:1125-1127.

25. DeVita VT, Muggia FM, Levy, Royston I, Glatstein E, Rosenberg SA, Frei III E, Sullivan MP, Seligmann M, Bloomfield CD, Klein J, Rick W, Grossman L, Gibbs F. Discussion V: Overview of the non-Hodgkin's lymphomas. [abstract]. Cancer Treat Rep. 1977;61:1219-1221.

26. Bloomfield CD, Kurvink K, Levitt S, Cervenka J. Sister chromatid exchange (SCE) in lymphocytes from patients with malignant lymphomas. [abstract]. Proc Amer Assoc Cancer Res. 1978;19:126.

27. Levitt SH, Lee CKK, Bloomfield C. Extended field radiation in non-Hodgkin's lymphoma. [abstract]. Int J Radiat Oncol Biol Phys. 1978;4(suppl 1):37.

28. Peterson BA, Bloomfield CD. Multiple remissions in adult acute non-lymphocytic leukemia (ANLL). [abstract]. Proc Amer Assoc Cancer Res. 1978;19:126.

29. Tormey D, Weinberg V, Leone L, Perloff M, Bloomfield C. Evaluation of intermittent vs. continuous and of Adriamycin vs. methotrexate 5-drug chemotherapy regimens for breast cancer. [abstract]. Proc Amer Soc Clin Oncol. 1978;19:320.

30. Bloomfield CD, Frizzera G, Gajl-Peczalska KJ, Brunning RD, Kersey J. Malignant lymphoma lymphoblastic (MLLB) in the adult. [abstract]. Proc Amer Soc Oncol. 1978;19:378.

31. Peterson BA, Bloomfield CD, Levitt SH. Maintenance therapy of adult acute lymphocytic leukemia (ALL) resulting in prolonged complete remission. [abstract]. Proc Amer Soc Clin Oncol. 1978;19:378.

32. Bloomfield CD, Brunning RD. Acute leukemia as a terminal event in non-leukemic hematopoietic disorders. [abstract]. Semin Oncol. 1976;3:279-317. Year Book of Cancer. 1978, pp 145-147.


72

ABSTRACTS (cont.)

33. Bloomfield CD, Crabtree G, Smith KA, Gibbs G, Peterson BA, Jeffries M, Gajl-Peczalska K, Kersey J, McKenna R, Frizzera G, Munck A. The therapeutic utility of glucocorticoid (GCD) receptor studies in non-Hodgkin's malignant lymphoma (ML). [abstract]. Blood. 1978;52(suppl 1):240.

34. Peterson BA, Bloomfield CD, Bosl G, Gibbs G, Malloy M. Rapid remission induction with intensive chemotherapy in adult acute non-lymphocytic leukemia (ANLL). [abstract]. Blood. 1978;52(suppl 1):269.

35. Ginsberg SJ, Lachant NA, DiFino SM, Crooke ST, Strong JE, Bloomfield CD, Gottlieb AJ. Continuous infusion, low dose bleomycin in lymphoma. [abstract]. Blood. 1978;52(suppl 1):251.

36. Pajak T, Gottlieb AJ, Bloomfield CD. Acute non-lymphocytic leukemia (ANLL) following therapy of Hodgkin's disease. [abstract]. Blood. 1978;52(suppl 1):268.

37. Frizzera G, Gajl-Peczalska KJ, Bloomfield CD, Kersey JH. Predictability of surface characteristics of malignant lymphoma by conventional morphology: A blind study of 70 cases. [abstract]. Lab Invest. 1978;38:345.

38. Peterson BA, Bloomfield CD. Prolonged disease-free survival in adult acute non-lymphocytic leukemia (ANLL). [abstract]. Proc Amer Soc Clin Oncol. 1979;20:441.

39. Lee CKK, Bloomfield CD, Levitt S. Prophylactic whole lung irradiation for extensive mediastinal Hodgkin's disease (HD). [abstract]. Proc Amer Soc Clin Oncol. 1979;20:441.

40. Kostraba NC, Bloomfield CD, Peterson BA, Kennedy BJ. Restaging laparotomy (LAP) in the management of nodular sclerosing Hodgkin's disease (NSHD). [abstract]. Proc Amer Soc Clin Oncol. 1979;20:334.

41. Ginsberg SJ, Gottlieb AJ, Bloomfield CD, Blom J, Strong JE. Combination chemotherapy with continuous infusion, low dose bleomycin in lymphoma. [abstract]. Proc Amer Soc Clin Oncol. 1979;20:322.

42. Gibbs G, Bloomfield CD, Peterson BA, Kennedy BJ, Voskia G. Therapy of Hodgkin's disease (HD) with cyclophosphamide, vinblastine, procarbazine, prednisone (CVPP): 5-year follow-up. [abstract]. Proc Amer Assoc Cancer Res. 1979;20:101.

43. Bloomfield CD, Gajl-Peczalska KJ, Frizzera G, Kersey JH, Goldman AI. Clinical utility of lymphocyte surface markers (SM) combined with the Lukes-Collins histologic classification (LCC) in adult malignant lymphoma (ML). [abstract]. Proc Amer Assoc Cancer Res. 1979;20:101.

44. Peterson BA, Bloomfield CD. Treatment of acute nonlymphocytic leukemia in elderly patients: A prospective study of intensive chemotherapy. [abstract]. Cancer. 1977;40:647-652. Year Book of Cancer. 1979, pp 264-266.

45. Bloomfield CD, Peterson LC, Yunis JJ, Brunning RD. The Philadelphia chromosome (Ph1) in adults presenting with acute leukaemia: A comparison of Ph1+ and Ph1- patients. [abstract]. Br J Haematol. 1977;36:347-358. Year Book of Cancer. 1979, pp 139-141.

46. Gajl-Peczalska KJ, Kersey JH, Bloomfield C, Frizzera G. The value of combined cell suspension and tissue frozen section studies in surface marker evaluation of non-Hodgkin's malignant lymphomas. [abstract]. Lab Invest. 1979;40(2):254.

47. Frizzera G, Lee CKK, Bloomfield CD, Levitt SH. Non-Hodgkin's lymphoma: The significance of the Lukes-Collins classification for curative radiotherapy. [abstract]. Int J Radiat Oncol Biol Phys. 1979;5 (suppl 2):167.


73

ABSTRACTS (cont.)

48. Lee CKK, Bloomfield CD, Nesbit ME, Levitt SH. Large mediastinal masses in Hodgkin's disease: Comparison of the results of whole lung and regular mantle field irradiation. [abstract]. Int J Radiat Oncol Biol Phys. 1979;5 (suppl 2):136.

49. Shipman GF, Bloomfield CD, Smith KA, Peterson BA, Munck A. Possible down-regulation of glucocorticoid receptors in patients with leukemia and lymphoma. [abstract]. Clin Res. 1979;27:690a.

50. Collins AJ, Vogelzang NJ, Bloomfield CD, Peterson BA. Severe renal tubular dysfunction during 5-azacytidine chemotherapy. [abstract]. Clin Res. 1979;27(4):708a.

51. McKenna RW, Brynes RK, Nesbit ME, Bloomfield CD, Kersey JH, Spanjers E, Brunning RD. Cytochemical profiles in acute lymphoblastic leukemia. [abstract]. Blood. 1979;54(suppl 1):197a.

52. Peterson BA, Bloomfield CD, Vogelzang NJ, Collins AJ. Renal tubular dysfunction during 5-azacytidine chemotherapy for acute leukemia. [abstract]. Blood. 1979;54(suppl 1):202a.

53. Peterson LC, Bloomfield CD, Brunning RD. Prognostic significance of clinical staging and lymphocyte morphology in CLL patients followed for at least 5 years. [abstract]. Blood. 1979;54(suppl 1):202a.

54. Shipman GF, Bloomfield CD, Smith KA, Peterson BA, Munck A. Possible down-regulation of glucocorticoid receptors and its therapeutic implications in patients with leukemia and lymphoma. [abstract]. Blood. 1979;54(suppl 1):209a.

55. Bloomfield CD, Smith KA, Peterson BA, Gajl-Peczalska KJ, Munck A. Glucocorticoid (GCD) receptor levels and in vitro GCD sensitivity predict tumor response to GCD therapy in adults with malignant lymphoma (ML). [abstract]. Proc Amer Soc Clin Oncol. 1980;21:469.

56. Hurd DD, Peterson BA, Bloomfield CD, McKenna RW. VP 16-213 (VP) and cyclophosphamide (CTX) in the treatment of refractory acute nonlymphocytic leukemia (ANLL) with monocytic features. [abstract]. Proc Amer Soc Clin Oncol. 1980;21:439.

57. Bloomfield CD, Lindquist LL, Gajl-Peczalska KJ, Frizzera G, Peterson BA, Hozier JC. Chromosome abnormalities in B-cell malignant lymphomas (ML): Correlation with surface immunoglobulin (SIg) type and histology. [abstract]. Proc Amer Assoc Cancer Res. 1980;21:191.

58. Bloomfield CD. Clinical significance of chromosomal abnormalities in acute lymphoblastic leukemia (ALL). A preliminary report of the Third International Workshop on Chromosomes in Leukemia (TIWCL). [abstract]. Proc Amer Soc Clin Oncol. 1981;22:477.

59. Hasbrouck D, Bloomfield CD, Peterson BA, Hurd D: Management of patients with acute non-lymphocytic leukemia (ANLL) who fail first cycle of induction therapy. [abstract]. Proc Amer Soc Clin Oncol. 1981;22:477.

60. Arthur DC, Bloomfield CD, Lindquist LL, Peterson BA, Nesbit ME. Chromosome abnormalities in acute lymphoblastic leukemia (ALL): Frequency and clinical implications. [abstract]. Proc Amer Soc Clin Oncol. 1981;22:345.

61. Arthur DC, Bloomfield CD, Lindquist LL, LeBien TW. The 14q+ chromosome abnormality in acute lymphoblastic leukemia (ALL). [abstract]. Proc Amer Assoc Cancer Res. 1981;22:182.

62. Lachant NA, Cooper MR, Bloomfield CD, Ginsberg SJ, Gottlieb AJ, Pajak TF. Methotrexate, VM-26, procarbazine and dexamethasone (MV26PD) in the treatment of refractory lymphoma. [abstract]. Proc Amer Soc Clin Oncol. 1981;22:518.


74

ABSTRACTS (cont.)

63. Strauss RG, Connett JE, McCullough J, Winston DJ, Bloomfield CD, Herzig GP, Gale RP. A collaborative, randomized trial of prophylactic granulocyte transfusions (GTX) during first remission induction chemotherapy for acute nonlymphocytic leukemia (ANLL). [abstract]. Proc Amer Soc Clin Oncol. 1981;22:485.

64. Chartrand SL, Bloomfield CD, Gajl-Peczalska K. Abnormal immunoregulatory responses in non-Hodgkin's malignant lymphomas. [abstract]. Proc Federation of American Societies for Experimental Biology. 1981.

65. Howe RB, Bloomfield CD, McKenna RW. Hypocellular acute leukemia. [abstract]. Clin Res. 1981;29:437A.

66. Hoppe RT, Rosenberg SA, Berard CW, Bloomfield CD, Bonadonna G, Glatstein E, Rudders RA. A working formulation of non-Hodgkin's lymphoma for clinical usage--Clinicopathologic correlations of low-grade and follicular lymphomas. [abstract]. Proc Amer Soc Clin Oncol. 1981;22:519.

67. Bloomfield CD, Gajl-Peczalska KJ, Frizzera G, Kersey JH, Goldman AI. Clinical utility of lymphocyte surface markers combined with the Lukes-Collins histologic classification in adult lymphoma. [abstract]. N Engl J Med. 1979;301:512-518. Year Book of Cancer. 1981, pp 205-207.

68. Peterson BA, Sartiano GP, Frizzera G, Pajak TF, Bloomfield CD, Gottlieb AJ: Asymptomatic patients with favorable histologic subtypes of non-Hodgkin's lymphoma. [abstract]. Blood. 1981;58(suppl 1):162a.

69. Hurd DD, Peterson BA, Bloomfield CD. 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA), VP-16-213 (VP), cytosine arabinoside (ARA-C), and 6-thioguanine (6TG) in the treatment of relapsed and refractory acute nonlymphocytic leukemia (ANLL). [abstract]. Blood. 1981;58(suppl 1):142a.

70. Bloomfield CD, Arthur DC. DEL(16)(q21 or 22) and marrow eosinophilia in acute non-lymphoblastic leukemia (ANLL): A new cytogenetic-clinical association. [abstract]. Proc Amer Soc Clin Oncol. 1982;1:191 (C-742).

71. Peterson BA, Sartiano GP, Frizzera G, Pajak TF, Bloomfield CD, Gottlieb AJ. Symptoms in patients with favorable subtypes of non-Hodgkin's lymphoma. [abstract]. Proc Amer Soc Clin Oncol. 1982;1:158 (C-616).

72. Hurd DD, LeBien TW, Peterson B, Kersey J, Gajl-Peczalska K, Bloomfield CD. Prognostic significance of immunologic phenotype in adult acute lymphocytic leukemia (ALL). [abstract]. Proc Amer Soc Clin Oncol. 1982;1:124 (C-481).

73. Kenyon PD, Hurd DD, Peterson BA, McCullough J, Bloomfield CD. Therapeutic leukapheresis (TL) for hyperleukocytosis (HWBC) at diagnosis in acute non-lymphocytic leukemia (ANLL). [abstract]. Proc Amer Soc Clin Oncol. 1982;1:124 (C-482).

74. Levine EG, Arthur DC, Frizzera G, Gajl-Peczalska KJ, Lindquist L, Peterson BA, Hurd DD, Bloomfield CD. Cytogenetic analysis of 55 cases of malignant lymphoma (ML): Correlation with histologic and immunologic phenotype. [abstract]. Proc Amer Assoc Cancer Res. 1982;23:116 (C-453).

75. Gajl-Peczalska KJ, Bloomfield CD, Frizzera G, Kersey J, LeBien T. Diversity of phenotypes of malignant lymphomas (ML) defined by a panel of 14 monoclonal antibodies and other lymphocyte markers. (abstract). Proc Amer Assoc Cancer Res. 1982;23:115 (C-452).

76. Gajl-Peczalska KJ, Bloomfield CD, Frizzera G, Kersey JH, LeBien TW. Heterogeneity of non-Hodgkin's lymphomas (NHL) as defined by a panel of monoclonal antibodies. [abstract]. J Cell Biochem. 1982;(suppl 6):50 (0140).


75

ABSTRACTS (cont.)

77. Bloomfield CD, Preisler H, Cuttner J, Yates J, Rai K, Wiernik P, Berkowitz, Anderson J. Treatment-induced acute non-lymphocytic leukemia (t-ANLL): Response to cytarabine-anthracycline therapy. [abstract]. 24th Annual Meeting of the American Society of Hematology (ASH). Blood. 1982;60:152a.

78. Arthur DC, Bloomfield CD. Banded chromosome studies in patients with treatment-induced acute nonlymphocytic leukemia (t-ANLL): Influence of prior therapy on karyotype. [abstract]. 24th Annual Meeting of the American Society of Hematology (ASH). Blood. 1982;60:120a.

79. Blazer BR, Brunning RD, Bloomfield CD, McKenna RW, Robison LL, LeBien TW, Gajl-Peczalska K, Nesbit ME, Kersey JH. Correlation of monoclonal antibody (MoAb) phenotypes with FAB morphology in acute nonlymphocytic leukemia (ANLL). [abstract]. 24th Annual Meeting of the American Society of Hematology (ASH). Blood. 1982;60:120a.

80. Capizzi RL, Davis R, Cooper MR, Cuttner J, Hoagland HC, Cornwell G, Bloomfield C, McIntyre OR. Comparison of high dose ARA-C (HIDAC) alone vs HIDAC with sequential asparaginase (A'ASE) for remission induction in patients (pts) with previously treated acute non-lymphocytic leukemia (ANLL). [abstract]. 24th Annual Meeting of the American Society of Hematology (ASH). Blood. 1982;60:153a.

81. Norton L, Green M, Pajak TF, Gottlieb A, Bloomfield C, Cooper MR, Cuttner J, Holland JF. Feasibility of late-intensification chemotherapy (LI) of advanced Hodgkin's disease (AHD) in complete remission (CR). [abstract]. 24th Annual Meeting of the American Society of Hematology (ASH). Blood. 1982;60:162a.

82. Royston I, Minowada J, LeBien T, Anderson J, Vosika G, Bloomfield CD, Ellison RR. Phenotypes of adult acute lymphoblastic leukemia (ALL) defined by monoclonal antibodies (MoAbs). [abstract]. Proceedings of the 19th Annual Meeting of the American Society of Clinical Oncology (ASCO). Proc Amer Soc Clin Oncol. 1983;2:177. Abstract # C-690.

83. McClean JW, Kiely-Grandbois K, Hurd DD, Peterson BA, Bloomfield CD. Glucocorticoid (GCD) toxicity in patients (pts) treated for non-Hodgkin's lymphoma (NHL). [abstract]. Proceedings of the 19th Annual Meeting of the American Society of Clinical Oncology (ASCO). Proc Amer Soc Clin Oncol. 1983;2:217. Abstract # C-847.

84. Duane SF, Peterson BA, Bloomfield CD, Hurd DD. The role of intensive chemotherapy in treatment-related acute nonlymphocytic leukemia (t-ANLL). [abstract]. Proceedings of the 19th Annual Meeting of the American Society of Clinical Oncology (ASCO). Proc Amer Soc Clin Oncol. 1983;2:177. Abstract # C-688.

85. Foster CM, Eisen HJ, Bloomfield CD. Dexamethasone-21-mesylate as an affinity label of the glucocorticoid receptor in human malignant cells. [abstract]. The Endocrine Society. 1983.

86. Bloomfield CD, Gajl-Peczalska KJ, Frizzera G, LeBien T. The clinical utility of cell surface markers in malignant lymphoma. [abstract]. Proceedings of the 27th Annual Clinical Conference. Houston, TX 1983.

87. Peterson BA, Brunning RD, Bloomfield CD, Hurd DD, Conroy JA, Peng G, Goldman AI. Central nervous system surveillance during complete remission in acute nonlymphocytic leukemia. [abstract]. 25th Annual Meeting of the American Society of Hematology (ASH). Blood. 1983;62:206a.

88. Blazar BR, Bloomfield CD, Robison LL, Nesbit ME, Kersey JH. Prognostic significance of monoclonal antibody (MoAB) phenotypes in acute nonlymphocytic leukemia. [abstract]. 25th Annual Meeting of the American Society of Hematology (ASH). Blood. 1983;62:166a.

89. Arthur DC, Bloomfield CD. Possible association of fragile site 16q22 with development of acute leukemia. [abstract]. 25th Annual Meeting of the American Society of Hematology (ASH). Blood. 1983;62:165a.


*Indicates abstract was presented orally (starting in1984) 76

ABSTRACTS (cont.)

90. Arthur DC, Bloomfield CD. Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: A new association. [abstract]. 25th Annual Meeting of the American Society of Hematology (ASH). Blood. 1983;61:994-998. Year Book of Cancer. 1984; p155.

91. Duane SF, Peterson BA, Hurd DD, Bloomfield CD, Kenyon PD. Cytarabine (AraC) induced hypotension. [abstract]. Proceedings of the 20th Annual Meeting of the American Society of Clinical Oncology (ASCO). Proc Amer Soc Clin Oncol. 1984;3:98. Abstract # C-383.

*92. Griffin J, Nelson D, Davis R, Davey F, McIntyre OR, Minowada J, Bloomfield C. Clinical correlations of surface antigen phenotypes in acute non-lymphocytic leukemia (ANLL): A prospective, multi-institutional study. [abstract]. Proceedings of the 20th Annual Meeting of the American Society of Clinical Oncology (ASCO). Proc Amer Soc Clin Oncol. 1984;3:195. Abstract # C-760.

*93. Hurd DD, Canafax DM, Kenyon PD, Peterson BA, Bloomfield CD, Peterson PK. Randomized trial of high-dose ketoconazole (KETO) or nystatin (NYS) as fungal prophylaxis during intensive chemotherapy. [abstract]. Proceedings of the 20th Annual Meeting of the American Society of Clinical Oncology (ASCO). Proc Amer Soc Clin Oncol. 1984;3:99. Abstract # C-384.

*94. Lee CK, Bloomfield CD, Levitt SH. Delayed cardiovascular injuries following radiotherapy for Hodgkin's disease. [abstract]. Int J Radia Oncol Biol Phys. 1984.

*95. Bloomfield CD. Advances in the diagnosis and treatment of acute myelocytic leukemia. [abstract]. XX Congress of the International Society of Hematology (ISH). Buenos Aires, Argentina. 1984 Sep 1-7.

*96. Sobol RE, Royston I, LeBien T, Minowada J, Anderson K, Mick R, Davey F, Cuttner J, Schiffer C, Ellison RR, Bloomfield CD. Clinical significance of adult acute lymphoblastic leukemia (ALL) phenotypes defined by monoclonal antibodies (MoAbs). [abstract]. 26th Annual Meeting of the American Society of Hematology (ASH). 1984 December 1-4. Miami Beach, FL. Blood. 1984;64:150a.

*97. Levine EG, Arthur DC, Frizzera G, Gajl-Peczalska KJ, LeBien TW, Hurd DD, Peterson BA, Bloomfield CD. Chromosome analysis correlates with histology, immunologic phenotype and survival in 120 patients with non-Hodgkin's lymphomas. [abstract]. 26th Annual Meeting of the American Society of Hematology (ASH). 1984 December 1-4. Miami Beach, FL. Blood. 1984;64:157a.

*98. Peterson BA, Frizzera G, Anderson J, Bloomfield CD, Gottlieb AJ. Response of low grade lymphomas to cyclophosphamide (CTX) or cyclophosphamide, Adriamycin, vincristine, prednisone and bleomycin (CABPB). [abstract]. Proceedings of the 21st Annual Meeting of the American Society of Clinical Oncology (ASCO). 1985 May 19-21. Houston, TX. Proc Amer Soc Clin Oncol. 1985;4:211. Abstract # C-822.

*99. Ginsberg S, Anderson J, Bloomfield C, Norton L, Barcos M, Gottlieb AJ. Therapy of advanced, intermediate grade lymphoma with cyclophosphamide, Adriamycin, vincristine and prednisone with or without bleomycin (CAVPB vs. CAVP) followed by high dose methotrexate or standard dose methotrexate (HMTX vs. LMTX): A randomized trial. [abstract]. Proceedings of the 21st Annual Meeting of the American Society of Clinical Oncology (ASCO). 1985 May 19-21. Houston, TX. Proc Amer Soc Clin Oncol. 1985;4:202. Abstract # C-786.

*100. Ozer H, Anderson J, Ginsberg S, Peterson B, Gottlieb A, Bloomfield CD. The clinical significance of peripheral cytofluorographic clonal excess (CE) determinations in non-Hodgkin's lymphoma (NHL). [abstract]. Proceedings of the 21st Annual Meeting of the American Society of Clinical Oncology (ASCO). 1985 May 19-21. Houston, TX. Proc Amer Soc Clin Oncol. 1985;4:18. Abstract # C-69.



ABSTRACTS (cont.)

*101. Bloomfield CD, Goldman A, Hossfeld D, de la Chapelle A. Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. [abstract]. Cancer Genet Cytogenet. 1984;11:332-350. Year Book of Cancer 1985, p 158-161.

*102. Arthur DC, Levine EG, Frizzera G, Gajl-Peczalska KJ, LeBien TW, Peterson BA, Hurd DD, Bloomfield CD. There are differences in cytogenetic abnormalities among histologic and immunologic subtypes of non-Hodgkin's lymphomas. [abstract]. 8th International Human Gene Mapping Workshop. 1985 August 4-10. Helsinki, Finland.

*103. Bloomfield CD, Garson OM, Volin L, Knuutila S, de la Chapelle A. The t(1;3)(p36;q21) in acute nonlymphocytic leukemia (ANLL): A new cytogenetic-clinicopathologic association. [abstract]. 8th International Human Gene Mapping Workshop. 1985 August 4-10. Helsinki, Finland.

*104. Arthur DC, Aaseng SM, Bloomfield CD. Acute myelomonocytic leukemia with marrow eosinophilia (M4Eo) and inv(16)(p13q22) in a patient with a heritable fragile site 16q22. [abstract]. 8th International Human Gene Mapping Workshop. 1985 August 4-10. Helsinki, Finland.

*105. Peterson BA, Anderson JR, Frizzera G, Bloomfield CD, Gottlieb AJ, Holland JF. Nodular mixed lymphoma (NML): A comparative trial of cyclophosphamide (CTX) and cyclophosphamide, Adriamycin, vincristine, prednisone and bleomycin (CAVPB). [abstract]. 27th Annual Meeting of the American Society of Hematology (ASH). 1985 December 6-10. New Orleans, LA. Blood. 1985;66:216a.

*106. Hurd D, LeBien T, Peterson B, Ramsay N, Levine E, Lasky L, Kim T, Bloomfield C, Filipovich A, Vallera D, McGlave P, Kersey J. Intensive therapy and autologous bone marrow support (abms) for the treatment of refractory non-Hodgkin's lymphoma (NHL). [abstract]. Proceedings of the 22nd Annual Meeting of the American Society of Clinical Oncology (ASCO). 1986 May. Los Angeles, CA. Proc Amer Soc Clin Oncol. 1986;5:193. Abstract # 756.

*107. Sobol RE, Royston I, Mick R, Cuttner J, Ellison RR, Davey F, Nelson D, Bloomfield CD. Clinical significance of mixed lymphoid and myeloid characteristics in adult acute lymphoblastic leukemia. [abstract]. Proceedings of the 22nd Annual Meeting of the American Society of Clinical Oncology (ASCO). 1986 May. Los Angeles, CA. Proc Amer Soc Clin Oncol. 1986;5:159. Abstract # 623.

*108. Hurd DD, LeBien TW, Peterson BA, Ramsay NKC, Levine EG, Lasky LC, Kim T, Bloomfield CD, Filipovich L, Vallera D, McGlave PB, Kersey JH. Intensive therapy and autologous bone marrow support (ABMS) for the treatment of refractory non-Hodgkin's lymphoma (NHL). [abstract]. J Cell Biochem. 1986;(suppl 10D):256.

*109. Davey FR, Mick R, Nelson DA, MacCallum J, Sobol RE, Royston I, Cuttner J, Ellison RR, Bloomfield CD. Morphologic and cytochemical characterization of adult acute lymphoid leukemia (ALL). [abstract]. 28th Annual Meeting of the American Society of Hematology (ASH). 1986 December 6-9. San Francisco, CA. Blood. 1986;68:197a.

*110. Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, Bloomfield CD. Prognostic significance of cytogenetic abnormalities in non-Hodgkin's lymphomas (NHL). [abstract]. 28th Annual Meeting of the American Society of Hematology (ASH). 1986 December 6-9. San Francisco, CA. Blood. 1986;68:211a.

*111. Cannistra SA, Davis R, Nelson D, Davies FR, Bloomfield C, Griffin JD. The expression of HLA-DQ antigens in acute myeloid leukemia (AML) identifies a population of blasts which lack progenitor cell properties. [abstract]. Blood. 1986;68:244a.

*112. Rai K, Mick R, Ozer H, Silver R, Papish S, Bloomfield C. Alpha interferon therapy in untreated active hairy cell leukemia: A Cancer and Leukemia Group B (CALGB) study. [abstract]. Proceedings of the 23rd Annual Meeting of the American Society of Clinical Oncology (ASCO). 1987 May 17-19. Atlanta, GA. Proc Amer Soc Clin Oncol. 1987;6:159. Abstract # 624.



ABSTRACTS (cont.) *113. Ozer H, Anderson J, Ginsberg S, Gottlieb A, Bloomfield CD. Prognostic significance of peripheral

cytofluorographic clonal excess (CE) determination in diffuse large cell (histiocytic) lymphoma. [abstract]. Proceedings of the 23rd Annual Meeting of the American Society of Clinical Oncology (ASCO). 1987 May 17-19. Atlanta, GA. Proc Amer Soc Clin Oncol. 1987;6:194. Abstract # 765.

*114. Ozer H, Anderson JR, Peterson BA, Budman DR, Henderson ES, Bloomfield CD, Gottlieb A. Combination trial of subcutaneous α2 interferon and oral cyclophosphamide in favorable histology non-Hodgkin's lymphoma. [abstract]. Proceedings of the 78th Annual Meeting of the American Association for Cancer Research (AACR). 1987 May 17-19. Atlanta, GA. Proc Amer Assoc Cancer Res. 1987;28:212. Abstract # 841.

*115. Rai KR, Mick R, Ozer H, Bloomfield C. Current Cancer and Leukemia Group B (CALGB) trials in the treatment of active hairy cell leukemia (HCL): A status report. [abstract]. Proceedings of the International Congress on Acute Leukemia. 1987 February. Rome, Italy.

*116. Bloomfield CD, Goldman AI, Alimena G, Berger R, Borgstrom GH, Brandt L, Catovsky D, de la Chapelle A, Dewald GW, Garson OM, Garwicz S, Golomb HM, Hossfeld DK, Lawler SD, Mitelman F, Nilsson P, Pierre RV, Philip P, Prigogina E, Rowley JD, Sakurai M, Sandberg AA, Secker Walker LM, Tricot G, Van Den Berghe H, Van Orshoven A, Vuopio P, Whang-Peng J. Chromosomal abnormalities identify high risk and low risk patients with acute lymphoblastic leukemia. [abstract]. Blood. 1986;67:415-420. Year Book of Cancer. 1987; pp 200-203.

*117. Baker MA, Bloomfield CD, Powles R, Gyger M, Phillips GC, Turner RA. Leukemia Videotape. Core Communications. 1987 January 19. Toronto, Ontario, [abstract].

*118. Bloomfield CD, Sobol R, Arthur D, Testa J, Le Beau M, Tantravahi R, Warburton D, Royston I, Davey F, Mick R, Wurster-Hill D. Correlations between immunophenotype and specific chromosome abnormalities in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study. [abstract]. 9th International Human Gene Mapping Workshop. 1987 September 6-11. Paris, France. Cytogenet Cell Genet. 1987;46:584.

*119. Bloomfield CD, Levine EG, Machnicki J, Frizzera G, Gajl-Peczalska KJ, Arthur DC. Recurring chromosome translocations in B-cell malignant lymphoma. [abstract]. 9th International Human Gene Mapping Workshop. 1987 September 6-11. Paris, France. Cytogenet Cell Genet. 1987;46:583.

*120. Arthur DC, Aaseng SM, Bloomfield CD. A new recurring chromosome abnormality in acute nonlymphocytic leukemia: del(2)(q23q33). [abstract]. 9th International Human Gene Mapping Workshop. 1987 September 6-11. Paris, France. Cytogenet Cell Genet. 1987;46:572.

*121. Bloomfield CD, Arthur DC, Wurster-Hill D, Testa J, Tantravahi R, Shanske A, Warburton D, Le Beau M, Nelson D, Davey F, Mayer R, Schiffer C, Anderson J. Recurring chromosome abnormalities in de novo AML. A preliminary report of CALGB 8461. [abstract]. 9th International Human Gene Mapping Workshop. 1987 September 6-11. Paris, France. Cytogenet Cell Genet. 1987;46:583.

*122. Bloomfield CD, Goldman AI, Alimena G, Berger R, Borgstrom GH, Brandt L, Catovsky D, de la Chapelle A, Dewald GW, Garson OM, Garwicz S, Golomb HM, Hossfeld DK, Lawler SD, Mitelman F, Nilsson P, Pierre RV, Philip P, Prigogina E, Rowley JD, Sakurai M, Sandberg AA, Secker Walker LM, Tricot G, Van Den Berghe H, Van Orshoven A, Vuopio P, Whang-Peng J. Chromosomal abnormalities identify high risk and low risk patients with acute lymphoblastic leukemia. [abstract]. Blood. 1986;67:415-420. Year Book of Hematology. 1988 pp. 249-250.

*123. Hurd D, Lasky L, Haake R, Peterson B, Kim T, Christiansen N, Weisdorf D, Bostrom B, Levine E, McGlave P, Bloomfield C. Autologous transplantation (TXN) in Hodgkin's disease (HD) using bone marrow (BMSC) or peripheral blood (PBSC) derived stem cells. [abstract]. Proceedings of the 24th Annual Meeting of the American Society of Clinical Oncology (ASCO). 1988 May 22-24. New Orleans, LA. Proc Amer Soc Clin Oncol. 1988;7:177,682.



ABSTRACTS (cont.)

*124. Ozer H, Mick R, Testa J, Arthur D, Cooper R, Pettenati M, Rao K, Peterson BA, Schiffer C, Bloomfield CD. Subcutaneous α-interferon (aIFN) shows substantial activity in untreated chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). Proceedings of the 24th Annual Meeting of the American Society of Clinical Oncology (ASCO). 1988 May 22-24. New Orleans, LA. Proc Amer Soc Clin Oncol. 1988;7:177, 684.

*125. Morrison VA, Peterson BA, Bloomfield CD. Central venous access devices and nosocomial septicemia. [abstract]. Proceedings of the 79th Annual Meeting of the American Association for Cancer Research (AACR). 1988 May 22-24. New Orleans, LA. Proc Amer Assoc Cancer Res. 1988;29:227,904.

*126. Uhlman DL, Bloomfield CD, Hurd DD, Peterson BA. Prognostic factors in relapsed acute nonlymphocytic leukemia. [abstract]. Proceedings of the 79th Annual Meeting of the American Association for Cancer Research (AACR). 1988 May 22-24. New Orleans, LA. Proc Amer Assoc Cancer Res. 1988;29:210, 834.

*127. Ball ED, Griffin JD, Davis R, Davey FR, Arthur D, Wurster-Hill D, Schiffer C, Bloomfield CD. Prognostic value of lymphocyte surface markers in acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study. [abstract]. 30th Annual Meeting of the American Society of Hematology (ASH). December 3-6. San Antonio, TX. Blood. 1988;72:187a.

*128. Duggan D, Anderson J, Zamkoff K, Poiesz B, Ozer H, Bloomfield C, Gottlieb A. Interleukin-2 (IL-2) alone or with β−interferon (β-IFN) in relapsed non-Hodgkin's lymphoma (NHL) - preliminary report of CALGB 8653. [abstract]. 30th Annual Meeting of the American Society of Hematology (ASH). December 3-6. San Antonio, TX. Blood. 1988;72:241a.

*129. Ozer H, Mick R, Testa J, Arthur D, Cooper R, Pettenati M, Rao K, Peterson BA, Schiffer C, Bloomfield CD. Subcutaneous alpha-interferon (aIFN) shows substantial activity in untreated chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). [abstract]. XXII Congress of the International Society of Hematology (ISH): Symposia of the Giovanni Lorenzini Foundation. 1988 August 28-September 2. Milan, Italy. 1988;173. p1 (SYM-M-1-1).

*130. Davey F, Davis R, MacCallum J, Nelson D, Mayer R, Ball E, Griffin J, Schiffer C, Bloomfield C. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Cancer and Leukemia Group B (CALGB). [abstract]. Meeting of the International Academy of Pathology. 1989 March 5-10. San Francisco. CA. Lab Invest. 1989;60:22a, 127.

*131. Rai KR, Davis R, Davey F, Schiffer C, Silver RT, Ozer H, Golomb H, Bloomfield CD. Splenectomy may be avoidable in patients (pts) with active hairy cell leukemia (HCL) who are responsive to alfa-2b interferon (aIF). A Cancer and Leukemia Group B (CALGB) study. [abstract]. Proceedings of the 25th Annual Meeting of the American Society of Clinical Oncology (ASCO). 1989 May 21-23. San Francisco, CA. Proc Amer Soc Clin Oncol. 1989; 8:209, 813.

*132. Ozer H, Mick R, Testa J, Arthur D, Cooper R, Pettenati M, Rao K, Peterson BA, Schiffer C, Bloomfield CD. Clinical and cytogenetic response of untreated chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) to subcutaneous α-interferon (aIFN). [abstract]. 1st International Symposium: Cytokines in Hemopoiesis, Oncology, and AIDS. Hannover, West Germany. 1989 June 14-17.

*133. Döhner H, Arthur DC, Ball ED, Wurster-Hill D, Royston I, Gordon L, Patil SR, Surana R, Testa JR, Verma RS, Davey FR, Bloomfield CD. Trisomy 13 - A new recurring chromosome abnormality in acute leukemia. [abstract]. 31st Annual Meeting of the American Society of Hematology (ASH). December 2-5. Atlanta, GA. Blood. 1989;74(7):19.

*134. Hooberman AL, Westbrook CA, Davey F, Schiffer C, Spino C, Bloomfield CD. Molecular Detection of the Philadelphia chromosome (PH1) in adult acute lymphoblastic leukemia (ALL): Clinical, Cytogenetic, and Immunophenotypic Correlations in a CALGB Study. [abstract]. 31st Annual Meeting of the American Society of Hematology (ASH). December 2-5. Atlanta, GA. Blood. 1989;74(7):52.



ABSTRACTS (cont.)

*135. Döhner H, Bloomfield CD, Frizzera G, Arthur DC. Recurring chromosome abnormalities in Hodgkin's disease. [abstract]. 31st Annual Meeting of the American Society of Hematology (ASH). December 2-5. Atlanta, GA. Blood. 1989;74(7):82.

*136. Davey F, Spino C, Davis R, MacCallum J, Nelson D, Rai K, Ozer H, Golomb H, Schiffer C, Bloomfield CD. Hematologic features of hairy cell leukemia (HCL). [abstract]. Lab Invest. 1990;62:24A.

*137. Elghetany MT, Sullivan AK, Kurec AS, Bloomfield CD, Sobol RE, Davey FR. Characterization of a panel of antibodies against primary myeloid granule antigens: H36-71, D46 and K101. [abstract]. Lab Invest. 1990;62:30A.

*138. Niehans G, Jaszcz W, Wick M, Gajl-Peczalska K., Tsuruo T, Bloomfield CD. Identification of multi-drug resistance-associated P-glycoprotein in some diffuse large cell lymphomas by frozen section immunohistochemistry. [abstract]. Lab Invest. 1990;62:73A.

*139. Lawrence DD, Reese PA, Bloomfield CD. Use of bootstrapping to evaluate infrequent genetic abnormalities as prognostic factors for survival in human acute leukemias. [abstract]. Interface '90. 1990 May 17.

*140. Peterson BA, Anderson JR, Frizzera G, Bloomfield CD, Propert KJ, Gottlieb AJ. Combination chemotherapy prolongs survival in follicular mixed lymphoma (FML). [abstract]. Proc Amer Soc Clin Oncol. 1990 May;9:259.

*141. Ozer H, Dear K, Testa J, Arthur D, Cooper R, Pettenati M, Rao K, Peterson BA, Schiffer C, Bloomfield CD. Prolonged administration of subcutaneous α-interferon induces major clinical and complete cytogenetic remissions in untreated Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). [abstract]. Proc Amer Soc Clin Oncol. 1990 May;9:203.

*142. Morrison V, Frizzera G, Ogle K, Bloomfield C, Hurd D, Peterson B. Diffuse small non-cleaved cell lymphoma in adults. [abstract]. Proceedings of the 81st Annual Meeting of the American Association for Cancer Research (AACR). 1990 May 23-26. Washington D.C. Proc Am Assoc Cancer Res. 1990 May; 31:192.

*143. Neubauer A, Hurst L, Ball T, Bloomfield CD, Liu E. Prospective investigation of the role of mutations in the RAS protooncogenes in acute myeloid leukemia (AML): A CALGB study. [abstract]. Gemainsame Jahrestagung der Deutschen und der Oesterreichischen gesellschaft fur Haematologie und Onkologie (Joint Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Ongology). Germany. 1990 Oct.

*144. Ball ED, Lawrence D, Malnar M, Ciminelli N, Mayer R, Wurster-Hill D, Davey F, Bloomfield CD. Correlation of CD34 and multi-drug resistance P170 with FAB and cytogenetics but not prognosis in acute myeloid leukemia (AML). [abstract]. 32nd Annual Meeting of the American Society of Hematology (ASH). 1990 November 28-December 4. Boston, MA. Blood. 1990 Nov;76(10):252a.

*145. Ball ED, Miller R, Malnar M, Davey FR, Bloomfield CD. Proto-oncogene expression in acute myeloid leukemia (AML). [abstract]. 32nd Annual Meeting of the American Society of Hematology (ASH). 1990 November 28-December 4. Boston, MA. Blood. 1990 Nov;76(10):252a.

*146. Elghetany MT, MacCallum JM, Nelson DA, Varney JF, Sullivan AD, Silverman L, Bloomfield CD, Davey FR. Abnormal granulocytes in myelodysplastic syndromes: A morphologic, cytochemical and immunocytochemical study of 71 patients. [abstract]. 32nd Annual Meeting of the American Society of Hematology (ASH). 1990 November 28-December 4. Boston, MA. Blood. 1990 Nov;76(10):267a.

*147. Newman R, Davey F, Kornfeld SB, Collins H, Brabyn C, Bloomfield CD, Royston I. Correlation of immunophenotype and BCL-1 gene rearrangement with morphology in B cell chronic lymphocytic leukemia. [abstract]. 32nd Annual Meeting of the American Society of Hematology (ASH). 1990 November 28-December 4. Boston, MA. Blood. 1990 Nov;76(10):304a.



ABSTRACTS (cont.) *148. Davey FR, Lawrence D, Varney J, MacCallum J, Hutchinson R, Wurster-Hill D, Sobol R, Bloomfield

CD. Morphologic characteristics of acute lymphoblastic leukemia (ALL) with the 8q24 karyotype. [abstract]. Mod Pathol. 1991 Jan;4:1. Abstract # 407.

*149. Hutchinson R, Lawrence D, MacCallum J, Varney J, DeHority D, Wurster-Hill D, Bloomfield C, Davey F. Morphology of t(8;21) acute leukemia; myelodysplastic syndrome (AML/MDS). [abstract]. Mod Pathol. 1991 Jan;4:1. Abstract # 435.

*150. Hooberman A, Westbrook C, Spino C, Wurster-Hill D, Sobol R, Davey F, Larson R, Bloomfield CD. Clinical significance of molecular detection of the BCR-ABL fusion gene in acute lymphoblastic leukemia (ALL): a Cancer and Leukemia Group B (CALGB) study. [abstract]. Proc Amer Soc Clin Oncol. 1991 Mar;10:222.

*151. Silverman LR, Holland JF, Nelson D, Davey F, Clamon G, Cooper MR, Bloomfield CD, Larson D, Demakos EP, George S, Davis RB, Liu E, Davis B, Schiffer C, McIntyre OR. Trilineage (TLR) response of myelodysplastic syndromes (MDS) to subcutaneous (SQ) azacytidine (Aza C). [abstract]. Proc Amer Soc Clin Oncol. 1991 Mar;10:222.

*152. Lawrence DD, Bloomfield CD. Deviations from normality in the distribution computed from bootstrapping of the log-rank statistic. [abstract]. Proceedings of the 1991 AMA Joint Statistical Meetings. Atlanta, GA. 1991 August 18-22.

*153. Schiffer CA, Larson RA, Bloomfield CD. Cancer and Leukemia Group B (CALGB) studies in acute lymphocytic leukemia (ALL) for the CALGB. [abstract]. Haematologica. 1991;2076(suppl 4)106.

*154. Silverman LR, Holland JF, Davis RB, Nelson D, Ellison RR, Demakos EP, Clamon G, Powell BL, Larson R, Bloomfield C, Hars V, Schiffer C, McIntyre OR. Azacytidine (Aza C) induces trilineage responses (TLR) in patients with myelodysplastic syndromes (MDS): The Cancer and Leukemia Group B (CALGB) Experience. [abstract]. Haematologica. 1991 Oct;76(suppl 4)42.

*155. Baer MR, Naughton MJ, Nettleton AC, Stewart SJ, Barcos M, Block AM, Brecher ML, Bloomfield CD, Stewart CC. Multiparameter flow cytometric analysis of acute myeloid leukemia (AML) cells. [abstract]. 33rd Annual Meeting of the American Society of Hematology (ASH). Blood. 1991 Nov;78(10):447a.

*156. Liu ET, Sandler D, Neubauer A, Taylor J, Dodge R, Shore D., Ball E, McIntyre R, Bloomfield CD. Clinical and etiologic importance of mutant ras genes in adult acute myeloid leukemia (AML). [abstract]. 33rd Annual Meeting of the American Society of Hematology (ASH). Blood. 1991 Nov;78(10):337a.

*157. Larson RA, Schiffer CA, Bloomfield CD for the CALGB, Lebanon NH. Cancer and Leukemia Group B studies in acute lymphoblastic leukemia (ALL). [abstract]. Proceedings International Symposium on Acute Leukemias: Prognostic Factors and Treatment Strategies III. Munster, Germany. 1992 Feb.

*158. Larson RA, Burns CP, Dodge RK, George SL, Bloomfield CD, Davey FR, Hooberman AL, Sobol RE, Schiffer CA. A 5-drug induction regimen with intensive consolidation for adult acute lymphoblastic leukemia (ALL). [abstract]. Proceedings of the 28th Annual Meeting of the American Society of Clinical Oncology (ASCO). 1992 May 17-19. San Diego, CA. Proc Amer Soc Clin Oncol. 1992;11:263.

*159. Taylor JA, Sandler DP, Bloomfield CD, Shore DL, Ball ED, Neubauer A, McIntyre OR, Liu E. ras oncogene activation and occupational exposures in AML. [abstract]. Proceedings of the 83rd Annual Meeting of the American Association for Cancer Research (AACR). 1992 February 10-14. Honolulu, HI. Proc Amer Assoc Cancer Res. 1992;33:291.

*160. Taylor JA, Sandler DP, Bloomfield CD, Shore DL, Ball ED, Neubauer A, McIntyre OR, Liu E. ras oncogene activation and occupational exposures in acute myeloid leukemia. [abstract]. Am J Epidemiol. 1992;136:1020.



ABSTRACTS (cont.)

*161. Sandler DP, Shore DL, Bloomfield CD, and Cancer and Leukemia Group B. Cigarette smoking and risk of acute leukemia. [abstract]. Am J Epidemiol. 1992;136:1020.

*162. Lawrence DD, Brunetto VL, Bloomfield CD. Sample size considerations for cytogenetics in oncology. [abstract]. Abstracts American Statistical Association. 1992;28.

*163. Neubauer A, Dodge R, George S, Davey F, Silver R, Schiffer C, Mayer R, Ball E, Bloomfield C, Liu E. Clinical importance of mutations in the ras protooncogenes in de novo acute myeloid leukemia (AML). [abstract]. Ann of Hematol. 1992;65(suppl):99.

*164. Frankel SR, Wurster-Hill D, Lawrence D, LeBeau M, Larson R, Tantravahi R, Arthur D, Cuttner J, Rao K, Sobol R, Davey F, Ciminelli N, Schiffer CA, Bloomfield CD. Cytogenetics is the most important prognostic factor in adult acute lymphoblastic leukemia (ALL). [abstract]. 34th Annual Meeting of the American Society of Hematology (ASH). 1992 December 4-8. Cleveland, OH. Blood. 1992;80(suppl 1):257a.

*165. Ozer H, George S, Testa J, Deer K, Sawitsky A, Schiffer C, Bloomfield CD. Subcutaneous a-interferon (alFN) does not yield improved survival in untreated chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). [abstract]. 34th Annual Meeting of the American Society of Hematology (ASH). 1992 December 4-8. Cleveland, OH. Blood. 1992;80(suppl 1):358a.

*166. Stock W, Sher D, Sobol RE, Larson RA, Frankel SR, Stewart C, Wurster-Hill DH, Bloomfield CD, Westbrook CA: Absence of TAL1 rearrangements in adult T-cell acute lymphoblastic leukemia (T-ALL). [abstract]. 34th Annual Meeting of the American Society of Hematology (ASH). 1992 December 4-8. Cleveland, OH. Blood. 1992;80(suppl 1):194a.

*167. Silverman LR, Holland JF, Davis RB, Nelson DA, Ellison RR, Demakos EP, George SL, Clamon G, Powell BL, Larson R, Bloomfield C, Schiffer C, McIntyre OR. Azacytidine (Aza C) in myelodysplastic syndromes (MDS). [abstract]. Cancer Invest. 1993;vol. II(suppl 1):52.

*168. Mrózek K, Karakousis CP, Bloomfield CD. High resolution cytogenetic study of adipose tissue tumors: localization of chromosome 12 breakpoints in lipoma to q15 and in myxoid liposarcoma to q13.3. [abstract]. Cancer Genet Cytogenet. 1993;66:158(A34).

*169. Mrózek K, Karakousis CP, Perez-Mesa C, Bloomfield CD. Translocation (12;22(q13;q12) is characteristic for clear cell sarcoma of tendons and aponeuroses. [abstract]. Cancer Genet Cytogenet. 1993;66:165(B25).

*170. Frankel SR, Baer MR, Stewart CC, Nettleton A, Lawrence D, Schiffer CA, Herzig GP, Bloomfield CD. Relapse in AML is consistently detected by multiparameter flow cytometry (MFC). [abstract]. Proceedings of the 29th Annual Meeting of the American Society of Clinical Oncology (ASCO). 1993 May 16-18. Orlando, FL. Proc Amer Soc Clin Oncol. 1993;12:308.

*171. Baer MR, Minderman H, Frankel SR, Herzig GP, Rustum Y, Stewart CC, Bloomfield CD. High frequency of CD34 and MDR1 expression in acute myeloid leukemia evolved from antecedent bone marrow disorders. [abstract]. Proceedings of the 29th Annual Meeting of the American Society of Clinical Oncology (ASCO). 1993 May 16-18. Orlando, FL. Proc Amer Soc Clin Oncol. 1993;12:315.

*172. Sandler DP, Shore DL, Bloomfield CD, and Cancer and Leukemia Group B (CALGB). Hair dye use and leukemia. [abstract]. Am J Epidemiol. 1993;138:636-637.

*173. Baer MR, Bernstein SH, Brunetto VL, Minderman H, Rustum Y, Block AW, Mrózek K, Bloomfield CD, Herzig GP. In vivo recombinant human G-CSF priming in previously untreated acute myeloid leukemia. [abstract]. 35th Annual Meeting of the American Society of Hematology (ASH). 1993 December 3-7. St. Louis, MO. Blood. 1993;82(10):328a.



ABSTRACTS (cont.)

*174. Stock W, Westbrook CA, Peterson B, Szatrowski TP, Silver RT, Schiffer CA, Bloomfield CD. Molecular monitoring of BCR/ABL fusion gene in chronic myelogenous leukemia (CML): peripheral blood (PB) analysis is comparable to a bone marrow (BM) examination (CALGB 8761). [abstract]. 35th Annual Meeting of the American Society of Hematology (ASH). 1993 December 3-7. St. Louis, MO. Blood. 1993;82(10):331a.

*175. Stock W, Thirman MJ, Dodge RK, Rowley JD, Wurster-Hill D, Sobol RE, Davey FR, Larson RA, Liles D, Westbrook CA, Bloomfield CD. Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia (CALGB 8762). [abstract]. 35th Annual Meeting of the American Society of Hematology (ASH). 1993 December 3-7. St. Louis, MO. Blood. 1993;82(10):58a.

*176. Bernstein SH, Brunetto VL, Davey FR, Mayer RJ, Wurster-Hill D, Schiffer CA, Bloomfield CD. Intensive chemotherapy for patients with myelodyplastic syndromes (MDS). [abstract]. 35th Annual Meeting of the American Society of Hematology (ASH). 1993 December 3-7. St. Louis, MO. Blood. 1993;82(10):196a.

*177. Hooberman AL, Westbrook CA, Dodge RK, Wurster-Hill DH, Larson RA, Sobol RE, Schiffer CA, Bloomfield CD. Clinical similarity of the P190+ and P210+ forms of the bcr/abl gene in adult acute lymphoblastic leukemia (ALL) in a prospective study: CALGB 8762. [abstract]. 35th Annual Meeting of the American Society of Hematology (ASH). 1993 December 3-7. St. Louis, MO. Blood. 1993;82(10):442a.

*178. Davey FR, Abraham N, Brunetto V, MacCallum JM, Nelson DA, Wurster-Hill D, Schiffer CA, Bloomfield CD. Morphologic characteristics of erythroleukemia (Acute Myeloid Leukemia; FAB-M6). [abstract]. Modern Pathol. 1994;7:106A.

*179. Baer MR, Stewart CC, Lawrence D, Arthur DC, Schiffer CA, Bloomfield CD. Differences in antigen expression among cytogenetic groups in acute myeloid leukemia (AML). [abstract]. Proceedings of the 30th Annual Meeting of the American Society of Clinical Oncology (ASCO). 1994 May 15-17. Dallas, TX. Proc Amer Soc Clin Oncol. 1994;13:307.

*180. Bloomfield CD, Lawrence D, Arthur DC, Berg DT, Schiffer CA, Mayer RJ. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. [abstract]. Plenary Session of the 36th Annual Meeting of the American Society of Hematology (ASH). 1994 December 2-6. Nashville, TN. Blood. 1994;84(10):111a.

*181. Baer MR, Stewart CC, Lawrence D, Arthur DC, Davey FR, Mrózek K, Caligiuri MA, Herzig GP, Schiffer CA, Bloomfield CD. Acute myeloid leukemia with 11q23 chromosome/ALL-1 gene rearrangements does not exhibit mixed lineage antigen expression by multiparameter flow cytometry. [abstract]. 36th Annual Meeting of the American Society of Hematology (ASH). 1994 December 2-6. Nashville, TN. Blood. 1994;84(10):308a.

*182. Baer MR, Lo CH, Means J, Salzman G, Frankel SR, Lawrence D, Moore JO, Herzig GP, Schiffer CA, Bloomfield CD, Stewart CC. Multiparameter flow cytometry (MFC) monitors residual disease (RD) during complete remission (CR) of acute myeloid leukemia (AML). [abstract]. 36th Annual Meeting of the American Society of Hematology (ASH). 1994 December 2-6. Nashville, TN. Blood. 1994;84(10):307a.

*183. Byrd JC, Weiss RB, Arthur DC, Schiffer CA, Brunetto VL, Carroll D, Omura G, Davey F, Moore J, Mayer RJ, Bloomfield CD. The presence of the t(8;21) and extramedullary leukemia (EML) at presentation of acute myeloid leukemia (AML) may influence prognosis. [abstract]. 36th Annual Meeting of the American Society of Hematology (ASH). 1994 December 2-6. Nashville, TN. Blood. 1994;84(10):306a.

*184. Frankel SR, Li K, Baer MR, Stewart CC, Davey F, Regal L, Lawrence D, Schiffer CA, Bloomfield CD. Multiparameter immunophenotype of acute promyelocytic leukemia (APL). [abstract]. 36th Annual Meeting of the American Society of Hematology (ASH). 1994 December 2-6. Nashville, TN. Blood. 1994;84(10):309a.



ABSTRACTS (cont.) *185. Szumigala J, Mrózek K, Brooks JJ, Crossland DM, Karakousis CP, Bloomfield CD. Insertion

(12;16)(q13;p11.2p13) in round cell liposarcoma: possible relation to myxoid liposarcoma. [abstract]. Lab Invest. 1995;72(1):12a.

*186. Block AW, Mrózek K, Kakati S, Heinonen K, Wnek AL, Laudico TJ, Baer MR, Bloomfield CD. Loss of Y chromosome during remission in a patient with karyotypically normal acute myeloid leukemia. [abstract]. Proceedings of the 86th Annual Meeting of the American Association for Cancer Research (AACR). 1995 March 18-22. Toronto, Canada. Proc Amer Assoc Cancer Res. 1995;36:206.

*187. Mrózek K, Arthur DC, Karakousis CP, Koduru PRK, LeBeau MM, Pettanati MJ, Tantravahi R, Mrózek E, Perez-Mesa C, Rao UNM, Frankel SR, Davey FR, Bloomfield CD. Der(16)t(1;16) as a nonrandom secondary chromosome aberration in Philadelphia chromosome-positive acute lymphoblastic leukemia, rhabdomyosarcoma, myxoid liposarcoma, and some other types of human neoplasia. [abstract]. Proceedings of the 86th Annual Meeting of the American Association for Cancer Research (AACR). 1995 March 18-22. Toronto, Canada. Proc Amer Assoc Cancer Res. 1995;36:145.

*188. Stock W, Westbrook CA, Peterson B, Szatrowski TP, Silver RT, Arthur DC, Schiffer CA, Bloomfield CD. Blood molecular analysis is highly correlated to bone marrow cytogenetics as a biologic endpoint in chronic myelogenous leukemia (CML). [abstract]. Proc Amer Soc Clin Oncol. 1995;14:429.

*189. Sandler DP, Shore DL, Liu E, Bloomfield CD. Exposure to chemicals and risk for myelodysplastic syndrome (MDS). [abstract]. Am J Epidemiol. 1995;S60:141.

*190. Strout MP, Caligiuri MA, Schichman SA, Mrózek K, Herzig GP, Arthur DC, Heinonen K, Knuutila S, Nousiainen T, Ruutu T, Block AW, Croce CM, Bloomfield CD. The partial tandem duplication of ALL1 is a recurrent novel molecular defect in acute myeloid leukemia (AML) with trisomy 11. [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):429a.

*191. Jurlander J, Caligiuri MA, Strout MP, Ball ED, Frei-Lahr DA, Hoffman L, Oberkircher AR, Christiansen NP, Block AW, Herzig GP, Bloomfield CD. Persistence of the t(8;21) fusion transcript following allogeneic (ALLO) bone marrow transplantation (BMT) for acute myeloid leukemia (AML). [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):569a.

*192. Frankel SR, Stewart CC, Dodge R, Davey F, Larson RA, Szatrowski TP, Schiffer CA, Bloomfield CD. Value of immunophenotype (IP) in intensively treated adult acute lymphoblastic leukemia (ALL): CALGB 8364. [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995; 86(10):173a.

*193. Szatrowski TP, Larson RA, George S, Dodge R, Hurd D, Kolitz J, Velez-Garcia E, Sklar J, Reynolds C, Westbrook CA, Frankel SR, Stewart C, Bloomfield CD, Schiffer CA. Anti-B4-blocked ricin as consolidation therapy for patients with B-lineage acute lymphoblastic leukemia (ALL). [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):783a.

*194. Elghetany MT, MacCallum JM, Nelson DA, Varney JF, Sullivan AK, Silverman LR, Schiffer CA, Davey FR, Bloomfield CD. Acquired specific granule deficiency in the myelodysplastic syndromes (MDS): a study of 191 previously untreated patients entered on CALGB protocol for MDS. [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):336a.

*195. Gallagher R, Willman C, Slack J, Andersen J, Li J, Viswanatha D, Bloomfield C, Appelbaum K, Schiffer C, Wiernik P, Tallman M. Correlation of PML-RARα mRNA type with pretreatment clinical characteristics and achievement of complete remission (CR) in acute promyelocytic leukemia (APL): an intergroup laboratory study. [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):729a.



ABSTRACTS (cont.) *196. Baer MR, Stewart CC, Yosuico V, Lawrence D, Arthur DC, Bloomfield CD: High frequency of

change in immunophenotype of acute myeloid leukemia (AML) at first relapse demonstrated by multiparameter flow cytometry (MFC)(CALGB 8361). [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):332a.

*197. Baer MR, Stewart CC, Lawrence D, Powell BL, Schiffer CA, Davey FR, Arthur DC, Bloomfield CD: Multiparameter flow cytometry (MFC) analysis of de novo acute myeloid leukemia (AML) reveals low frequencies of lymphoid antigen expression and strong associations between immunophenotype and karyotype (CALGB 8361). [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):266a.

*198. Liu ET, Dodge R, Myer A, Zhang XX, Schiffer C, Mayer R, Bloomfield CD. De novo acute myeloid leukemias harboring ras mutations exhibit preferential sensitivity to dose intensive cytarabine as consolidation therapy. [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):598a.

*199. Byrd JC, Edenfield WJ, Arthur DC, Lawrence D, Shah D, Trikha E, Weiss RB, Schiffer CA, Bloomfield CD. Extramedullary leukemia (EML) is associated with pre-treatment cytogenetic abnormalities in patients with acute myeloid leukemia (AML). [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):43a.

*200. Slack JL, Baer MR, Bernstein SH, Stewart C, Lawrence D, Herzig GP, Bloomfield CD, Wetzler M: Acute myeloid leukemia (AML) blast cell proliferation and differentiation in response to megakaryocyte growth and development factor (MGDF). [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):520a.

*201. Bernstein SH, Baer MR, Lawrence D, Herzig GP, Bloomfield CD, Wetzler M. Serial determination of thrombopoietin (TPO), IL-3, IL-6, IL-11 and leukemia inhibitory factor (LIF) levels in patients undergoing chemotherapy for acute myeloid leukemia (AML). [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):46a.

*202. Bernstein SH, Baer MR, Stewart C, Slack JL, Lawrence D, Herzig GP, Lawrence D, Bloomfield CD, Wetzler M. Expression of the C-MPL receptor on leukemic blasts from patients with acute myeloid leukemia (AML). [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):45a.

*203. Stock W, Sher DA, Dodge RK, Westbrook CA, Larson RA, Arthur D, Frankel SR, Sobol RE, Davey FR, Schneider D, Diaz MO, Bloomfield CD. High incidence of p16 deletion in adult acute lymphoblastic leukemia (ALL): correlation with clinical features and response to treatment: CALGB 8762. [abstract]. 37th Annual Meeting of the American Society of Hematology (ASH). 1995 December 1-5. Seattle, WA. Blood. 1995;86(10):268a.

*204. Mrózek K, Blin N, Karakousis CP, Holzmann K, Perez-Mesa C, Bloomfield CD. Novel type of jumping translocation in a desmoid tumor. [abstract]. Sixth International Workshop on Chromosomes in Solid Tumors.1995 February 19-21, Tucson, AZ. Cancer Genet Cytogenet. 1995;84(2):143.

*205. Byrd JC, Lawrence D, Arthur DC, Davey F, Schiffer CA, Bloomfield CD. Acute myeloid leukemia (AML) patients with pre-treatment isolated trisomy 8 are a poor prognostic group who are rarely cured with chemotherapy: Results of CALGB 8461. [abstract]. Proceedings of the 87th Annual Meeting of the American Association for Cancer Research (AACR). 1996 April 20-24. Washington D.C. Proc Amer Assoc Cancer Res. 1996;37:188.

*206. Slack JL, Arthur DC, Lawrence D, Moshier A, Mrózek K, Tantravahi R, Pettenati MJ, Bigner S, Davey FR, Mayer RJ, Moore JO, Schiffer CA, Bloomfield CD. Secondary cytogenetic changes in acute promyelocytic leukemia (APL): prognostic importance and association with the intron 3 breakpoint of the PML gene. [abstract]. Proceedings of the 87th Annual Meeting of the American Association for Cancer Research (AACR). 1996 April 20-24. Washington D.C. Proc Amer Assoc Cancer Res. 1996;37:557.



ABSTRACTS (cont.) *207 Strout MP, Bloomfield CD, Oberkircher AR, Herzig GP, Caligiuri MA. The partial tandem duplication

of ALL1 in acute myeloid leukemia (AML) with trisomy 11 or normal cytogenetics involves only one allele of chromosome 11. [abstract]. Proceedings of the 87th Annual Meeting of the American Association for Cancer Research (AACR). 1996 April 20-24. Washington D.C. Proc Amer Assoc Cancer Res. 1996;37:570.

*208. Heinonen K, Mrózek K, Lawrence D, Arthur D, Davey F, Pettenati M, Bigner S, Moore J, Mayer R, Schiffer C, Bloomfield CD. Trisomy 11 as the sole karyotypic abnormality identifies a group of older patients with acute myeloid leukemia (AML) with FAB M2 or M1 and unfavorable clinical outcome. Results of CALGB 8461. [abstract]. Proceedings of the 87th Annual Meeting of the American Association for Cancer Research (AACR). 1996 April 20-24. Washington D.C. Proc Amer Assoc Cancer Res. 1996;37:186.

*209 Wetzler M, Bernstein SH, Stewart C, Shah D, Baer MR, Herzig GP, Bloomfield CD, Slack JL. C-MPL expression by leukemic blasts from adult acute myeloid leukemia (AML) patients and in vitro response to thrombopoietin (TPO). [abstract]. Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO). 1996 May 18-21. Philadelphia, PA. Proc Amer Soc Clin Oncol 1996;15:273. Abstract # 727.

*210. Caligiuri MA, Strout MP, Arthur DC, Baer MR, Shah D, Block AW, Mrózek K, Yu F, Oberkircher A, Lawrence D, Knuutila S, Ruutu T, Herzig GP, Schiffer CA, Bloomfield CD. Rearrangement of ALL1 is a recurrent molecular defect in adult acute myeloid leukemia (AML) with normal cytogenetics that predicts a short complete remission (CR) duration. [abstract]. Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO). 1996 May 18-21. Philadelphia, PA. Proc Amer Soc Clin Oncol. 1996;15:360. Abstract # 1060.

*211. Elghetany MT, MacCallum J, Nelson DA, Varney JF, Sullivan AK, Silverman LR, Schiffer CA, Davey FR, Bloomfield CD. Double esterase in the myelodysplastic syndromes: correlation with other granular abnormalities in 258 patients. [abstract]. 38th Annual Meeting of the American Society of Hematology (ASH). 1996 December 6-10. Orlando, FL. Blood. 1996;88(10):205b.

*212 Wetzler M, Baer MR, Bernstein SH, Blumenson L, Stewart C, Barcos M, Mrózek K, Block AMW, Herzig GP, Bloomfield CD. Expression of mRNA encoding c-mpl, the receptor for thrombopoietin, in acute myeloid leukemia (AML) blasts identifies a group of patients (pts) with poor outcome to intensive chemotherapy. [abstract]. 38th Annual Meeting of the American Society of Hematology (ASH). 1996 December 6-10. Orlando, FL. Blood. 1996;88(10):634a.

*213. Slack JL, Willman CL, Li Y-P, Viswanatha D, Bloomfield CD, Wiernik PH, Tallman MS, Gallagher RE. Molecular characteristics and clinical features of adult APL patients with the type V PML-RARα isoform: results from intergroup protocol 0129. [abstract]. 38th Annual Meeting of the American Society of Hematology (ASH). 1996 December 6-10. Orlando, FL. Blood. 1996;88(10):635a.

*214. Westbrook CA, Dodge R, Szatrowski TP, Horrigan SK, Kim SJ, Wu D, Jantzen N, Schiffer CA, Bloomfield CD. PCR monitoring of minimal residual disease identifies good outcome in BCR/ABL positive acute lymphoblastic leukemia (ALL): CALGB 8762. [abstract]. 38th Annual Meeting of the American Society of Hematology (ASH). 1996 December 6-10. Orlando, FL. Blood. 1996;88(10):477a.

*215. Silver RT, Szatrowski TP, Peterson B, Powell B, Larson R, Stock W, Arthur D, Schiffer C, Bloomfield CD. Combined α2b-interferon (rIFNα-2B) and low dose cytosine arabinoside (Ara-C) for PH+ chronic phase chronic myeloid leukemia (CML). [abstract]. 38th Annual Meeting of the American Society of Hematology (ASH). 1996 December 6-10. Orlando, FL. Blood. 1996;88(10):638a.

*216. Szatrowski TP, Larson RA, Dodge R, Sklar J, Reynolds C, Westbrook CA, Hurd D, Kolitz J, Velez-Garcia E, Frankel SR, Stewart C, Bloomfield CD, Schiffer CA. The effect of anti-B4-blocked ricin (anti-B4-BR) on minimal residual disease (MRD) in adults with B-lineage acute lymphoblastic leukemia (ALL) (CALGB 9311, 8762, 8763). [abstract]. 38th Annual Meeting of the American Society of Hematology (ASH). 1996 December 6-10. Orlando, FL. Blood. 1996;88(10):669a.



ABSTRACTS (cont.) *217. Stock W, Sher D, Dodge R, Schneider D, Diaz M, Czuczman M, Szatrowski T, Frankel S, Larson

RA, Schiffer C, Bloomfield CD. Transcriptional silencing is an alternative means of p16 inactivation: further evidence for p16 role in pathogenesis of adult acute lymphoblastic leukemia (ALL) - a Cancer and Leukemia Group B Study (8762). [abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology (ASCO). 1997 May 17-20. Denver, CO. Proc Amer Soc Clin Oncol. 1997;16:552a. Abstract # 1992.

*218. Mrózek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PRK, Rao KW, Schiffer CA, Bloomfield CD. t(9;11)(p22;q23) confers better prognosis than other translocations of 11q23 in adults with de novo acute myeloid leukemia (AML): A Cancer and Leukemia Group B study. [abstract]. The 1st European Cytogenetics Conference. 1997 June 22-25. Athens, Greece. Cytogenet Cell Gene. 1997;77(1-2):136:P332.

*219. Bloomfield CD. Clinical outcome of acute myeloid leukemia (AML) involving CBF. [abstract]. First Meeting on Acute Leukemias with Structurally Altered Core Binding Factor Subunits [t(8;21), inv(16) and t(12:21)]. 1997 June 27-28. Erasmus University Rotterdam, The Netherlands. Leukemia. 1997;11:39.

*220. Strout MP, Marcucci G, Bloomfield CD, Caligiuri MA. ALU-mediated homologous recombination in somatic cells is a consistent mechanism responsible for the partial tandem duplication of ALL1 in acute myeloid leukemia (AML). [abstract]. 39th Annual Meeting of the American Society of Hematology (ASH). 1997 December 5-9. San Diego, CA. Blood. 1997;90(10)(suppl 1):317a.

*221. Marcucci G, Livak KJ, Bi WL, Strout MP, Bloomfield CD, Caligiuri MA. Detection of AML1/ETO transcript in patients (pts) with t(8;21) associated AML using a novel “real time” quantitative RT-PCR assay. [abstract]. 39th Annual Meeting of the American Society of Hematology (ASH). 1997 December 5-9. San Diego, CA. Blood. 1997; 90:390a.

*222. Marcucci G, Strout MP, Bloomfield CD, Caligiuri MA. Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. [abstract]. 39th Annual Meeting of the American Society of Hematology (ASH). 1997 December 5-9. San Diego, CA. Blood. 1997;90:317a.

*223. Marcucci G, Caligiuri MA, Oberkircher AR, Bloomfield CD. Absence of minimal residual disease (MRD) by reverse transcription polymerase chain reaction (RT-PCR) in CBFβ/MYH11-associated acute myeloid leukemia. [abstract]. 39th Annual Meeting of the American Society of Hematology (ASH). 1997 December 5-9. San Diego, CA. Blood. 1997;90:62a.

*224. Iliszko M, Mandahl N, Mrózek K, Denis A, Pandis N, Pejovic T, Babinska M, Nedoszytoko B, Debniak J, Emerich J, Hrabowska M, Bloomfield C, Limon J. Charakterystyka cytogenetyczna miesaków macicy. [abstract]. 19th Meeting of the Polish Society of Oncology. 1998 Sep;p. 131.

*225. Wetzler M, Dodge RK, Mrózek K, Carroll AJ, Larson RA, Bloomfield CD. Trisomy 8 represents a poor risk group in adult acute lymphoblastic leukemia (ALL) – Results from Cancer and Leukemia Group B (CALGB) 8461. [abstract]. 40th Annual Meeting of the American Society of Hematology (ASH). 1998 December 4-8. Miami Beach, FL. Blood. 1998;92(10)(suppl 1):223a.

*226. Byrd JC, Dodge R, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M., Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD. Adult acute myeloid leukemia (AML) patients (PTS) with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HDAC) are administered. [abstract]. 40th Annual Meeting of the American Society of Hematology (ASH). 1998 December 4-8. Miami Beach, FL. Blood. 1998;92:312a.



ABSTRACTS (cont.) *227. Mrózek K, Prior TW, Edwards C, Snyder PJ, Carroll AJ, Koduru PRK, Pettenati MJ, Archer KJ,

Caligiuri MA, Kolitz J, Larson RA, Bloomfield CD. A comparison of cytogenetic and molecular genetic detection of t(8;21)(q22;q22) and inv(16)(p13q22) in adults with de novo acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study. [abstract]. 40th Annual Meeting of the American Society of Hematology (ASH). 1998 December 4-8. Miami Beach, FL. Blood. 1998;92(10)(suppl 1):77a.

*228. Stock W, Sher D, Dodge R, Murciano E., Caligiuri M, Frankel S, Larson RA, Bloomfield CD. High level of Wilms Tumor Gene (WT1) expression is detected in the majority of newly diagnosed acute lymphoblastic leukemia (ALL) of adults: Implications for prognosis and monitoring of minimal residual disease (MRD). [abstract]. 40th Annual Meeting of the American Society of Hematology (ASH). 1998 December 4-8. Miami Beach, FL. Blood. 1998;91(10)(suppl 1):223a.

*229. Baer MR, Pixley LA, Lawrence D, O’Loughlin KL, Abdel-Razeq S, Block AW, Sait SNJ, Wetzler M, Christiansen NP, Frankel SR, Herzig GP, Bloomfield CD. High-dose cytarabine and idarubicin (HDAC/IDA) is effective remission induction therapy for older de novo but not for secondary acute myeloid leukemia (AML) patients. [abstract]. 40th Annual Meeting of the American Society of Hematology (ASH). 1998 December 4-8. Miami Beach, FL. Blood. 1998;92:231a.

*230. Whitman SP, Strout MP, Freud RG, Mrózek K, Theil K, Kees UR, Bloomfield CD, Caligiuri MA. A novel, partial, non-tandem duplication of MLL in a B-acute lymphoblastic leukemia (B-ALL) cell line. [abstract]. 40th Annual Meeting of the American Society of Hematology (ASH). 1998 December 4-8. Miami Beach, FL. Blood. 1998;92:71a.

*231. Bloomfield CD. Adult Acute Myeloid Leukemia (AML) patients (PTS) with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HDAC) are administered. [abstract]. International Symposium ACUTE LEUKEMIAS VIII Prognostic Factors and Treatment Strategies. 1999 February 27-March 3. Munster, Germany. Ann Hematol. 1999;78(suppl II) S13.

*232. Mrózek K, Theil KS, Heinonen K, Bloomfield CD. Spectral karyotyping (SKY) in acute myeloid leukemia (AML): A study of 20 cases. [abstract]. 2nd European Cytogenetic Conference. 1999 July 3-7. Vienna, Austria. Cytogenet Cell Genet. 1999;85(1-2):40:P140.

*233. Theil KS, Mrózek K, Glasure CE, Caligiuri MA, Bloomfield CD. der(7)t(7:11)(q11.1;q12) as a new non-random abnormality associated with acute myeloid leukemia (AML). [abstract]. 2nd European Cytogenetic Conference. 1999 July 3-7. Vienna, Austria. Cytogenet Cell Genet. 1999;85(1-2)88:P347.

*234. Tanner SM, Virtaneva K, Rush L, Caligiuri MA, Bloomfield CD, Plass C, Krahe R, de la Chapelle A. Gene Expression in acute myeloid leukemia with trisomy 8. [abstract]. 31st Annual Meeting of the European Society of Human Genetics. 1999 May 29-June 1. Geneva, Switzerland. Eur J Hum Genet. 1999;7(suppl I):92(P-300).

*235. Tanner SM, Virtaneva K, Rush L, Caligiuri MA, Bloomfield CD, Mrόzek, Plass C, Krahe R, de la Chapelle A. Novel genes in acute myeloid leukemia with trisomy 8. [abstract]. Meeting of the American Society of Human Genetics (ASHG). 1999 October 19-23. San Francisco, CA. Am J Hum Genet. 1999;65(4)(suppl);A325. Abstract # 1834.

*236. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans retinoic acid in acute promyelocytic leukemia: Long term outcome results and prognostic factor analysis from intergroup protocol 0129. [abstract]. 41st Annual Meeting of the American Society of Hematology (ASH). 1999 December 3-7. New Orleans, LA. Blood. 1999;94(10)(suppl 1):168a.



ABSTRACTS (cont.)

*237. Kolitz JE, George SL, Hurd D, Hoke E, Dodge RK, Velez-Garcia E, Powell BL, Moore J, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA: Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients (PTS) with acute myeloid leukemia (AML) < 60 years old: preliminary results of CALGB 9621. [abstract]. 41st Annual Meeting of the American Society of Hematology (ASH). 1999 December 3-7. New Orleans, LA. Blood. 1999; 94(10)(suppl 1):384a.

*238. Kolitz JE, George SL, Hurd D, Hoke E, Dodge RK, Caligiuri MA, Velez-Garcia E, Powell BL, Moore J, Vardiman JW, Bloomfield CD, Larson RA. Cytogenetic risk-adapted intensification followed by immunotherapy with recombinant interleukin-2 (rIL-2) in patients (PTS) < 60 years old with acute myeloid leukemia (AML) in first complete remission (CR): preliminary results of CALGB 9621. [abstract]. 41st Annual Meeting of the American Society of Hematology (ASH). 1999 December 3-7. New Orleans, LA. Blood. 1999;94(10)(suppl 1):579a.

*239. Golub T, Slonim D, Tamayo P, Huard C, Gaasenbeek M, Mesirov J, Coller H, Loh M, Downing J, Caligiuri MA, Bloomfield CD, Lander E. Gene expression pattern recognition for cancer classification. [abstract]. 41st Annual Meeting of the American Society of Hematology (ASH). 1999 December 3-7. New Orleans, LA. Blood. 1999;94(10)(suppl 1):656a.

*240. Willhauck M, Marcucci G, Döhner K, Schlenk RF, Lichter P, Bloomfield CD, Caligiuri MA, Döhner H. Quantitative detection of AML1/ETO transcripts in patients with t(8;21) associated AML by real time RT-PCR. [abstract]. 41st Annual Meeting of the American Society of Hematology (ASH). 1999 December 3-7. New Orleans, LA. Blood. 1999; 94:287a.

*241. Whitman SP, Strout MP, Maghraby EA, Marcucci G, Bloomfield CD, Caligiuri MA. Partial tandem duplication of MLL (MLL PTD): quantitative assessment of transcript copy number in acute myeloid leukemia (AML) with and without evidence of MLL gene rearrangement. [abstract]. 41st Annual Meeting of the American Society of Hematology (ASH). 1999 December 3-7. New Orleans, LA. Blood. 1999;94(10)(suppl 1):53a.

*242. Kourlas PJ, Strout MP, Becknell B, Veronese ML, Croce CM, Theil KS, Krahe R, Knuutila S, Bloomfield CD, Caligiuri MA. Identification of a new gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its rearrangement in acute myeloid leukemia (AML). [abstract]. 41st Annual Meeting of the American Society of Hematology (ASH). 1999 December 3-7. New Orleans, LA. Blood. 1999;94:52a.

*243. Stock W, Sher D, Dodge R, Caligiuri MA, Frankel S, Larson RA, Bloomfield CD. Quantitative molecular monitoring of BCR/ABL transcripts in adult acute lymphoblastic leukemia (ALL) using a real-time PCR assay: pilot study from CALGB 8762. [abstract]. 41st Annual Meeting of the American Society of Hematology (ASH). 1999 December 3-7. New Orleans, LA. Blood. 1999;94(10)(suppl 1): 287a.

*244. Marcucci G, Caligiuri MA, Maghraby E, Archer K, Döhner K, Schlenk RF, Döhner H, Bloomfield CD. Quantification of CBFβ/MYH11 transcripts in inv(16) acute myeloid leukemia (AML) by real time RT-PCR. [abstract]. 41st Annual Meeting of the American Society of Hematology (ASH). 1999 December 3-7. New Orleans, LA. Blood. 1999;94:625a.

*245. Caligiuri MA, Lee EJ, Baer MR, Dodge R, Cooke K, Szatrowski T, Schiffer CA, Bloomfield CD, Larson RA. Daily low dose interleukin 2 (IL-2) therapy with or without intermediate dose pulsing in acute myeloid leukemia (AML) patients (PTS) > 60 years old in first complete remission (CR1): A feasibility study (CALGB 9420). [abstract]. 41st Annual Meeting of the American Society of Hematology (ASH). 1999 December 3-7. New Orleans, LA. Blood. 1999;94(10)(suppl 1):76a.

*246. Rush L, Yu L, Bloomfield CD, Caligiuri MA, Plass C. Aberrant DNA Methylation in Acute Myeloid Leukemia. [abstract]. 50th Annual Meeting of the American College of Veterinary Pathologists. 1999 November 14-19. Chicago, IL. Vet Path. 1999;36(5):488.



ABSTRACTS (cont.)

*247. Whitman SP, Strout MP, Marcucci G, Kees UR, Bloomfield CD, Caligiuri MA. A cryptic MLL (ALL1) partial non-tandem duplication gene rearrangement generates three distinct fusion transcripts in a B-cell acute lymphoblastic leukemia cell line. [abstract]. Proceedings of the 91st Annual Meeting of the American Association for Cancer Research (AACR). 2000 April 1-5. San Francisco, CA. Proc Amer Assoc Cancer Res. 2000 Mar;41:188.

*248. Vardiman JW, Mrózek K, Anastasi J, Kolitz J, Carroll AJ, Caligiuri M, Marcucci G, Price TW, Hoke E, Larson R, Bloomfield CD. Morphology and CBFß/MYH11 in AML (CALGB study 9621). [abstract]. Annual Meeting of the United States and Canadian Academy of Pathology. 2000 March 25-31. Lab Invest. 2000 Jan;80(1):165A:967.

*249. Willman CL, Yeap B, Bi W, Slack JL, Harrington DP, Livak KJ, Appelbaum FR, Bloomfield CD, Tallman MS, Gallagher RE. Predictive Value of Automated, Quantitative Real-Time RT-PCR Performed at the End of Consolidation of Acute Promyelocytic Leukemia (APL): A SWOG, CALGB, and ECOG Intergroup Study (INT-0129). [abstract]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2000 May 20-24. New Orleans, LA. Proc Amer Soc Clin Oncol. 2000;19:5a. Abstract # 9.

*250. Anastasi J, Kolitz J, Baer MR, Carroll AJ, Larson RA, Bloomfield CD, Vardiman JW. Two distinct subtypes of AML without differentiation (FAB-M1): Analysis of 74 cases from CALGB studies 9621 and 9720. [abstract]. Lab Invest. 2000;80:142A.

*251. Baer MR, Pixley LA, Ford LA, Donohue K, O’Loughlin KL, Minderman H, Block AW, Wetzler M, Slack JL, Herzig GP, Bloomfield CD. High-dose cytarabine and idarubicin induction produces a high complete remission (CR) rate in previously untreated de novo acute myeloid leukemia (AML) patients (pts) ≥60 years. [abstract]. 42nd Annual Meeting of the American Society of Hematology (ASH). 2000 December 1-5. San Francisco, CA. Blood. 2000;96:322a.

*252. Marcucci G, Bloomfield CD, Balcerzak SP, Kourlas PJ, Stanley HR, Fingert H, Mahraby EA, Lucas D, Chen KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA. Phase I trial of genasense (G3139, Genta, Inc.), a BCL-2 antisense (AS) , in refractory (REF) or relapsed (REL) acute leukemia (AL). [abstract]. 42nd Annual Meeting of the American Society of Hematology (ASH). 2000 December 1-5. San Francisco, CA. Blood. 2000;96:119a.

*253. Stock W, Sather H, Dodge RK, Bloomfield CD, Larson A, Nachman J. Outcome of adolescents and young adults with ALL: a comparison of Children’s Cancer Group (CCG) and Cancer and Leukemia, Group B (CALGB) regimens. [abstract]. 42nd Annual Meeting of the American Society of Hematology (ASH). 2000 December 1-5. San Francisco, CA. Blood. 2000;96(11):467a.

*254. Wetzler M, Dodge RK, Mrózek K, Carroll AJ, Larson RA, Bloomfield CD. Karyotype change in adult acute myeloid leukemia (AML) at first relapse – CALGB 8461. [abstract]. 42nd Annual Meeting of the American Society of Hematology (ASH). 2000 December 1-5. San Francisco, CA. Blood. 2000;96(11):706a.

*255. Alexander RL, Ramage J, Klein B, Kucera GL, Caligiuri MA, Bloomfield CD, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. [abstract]. 42nd Annual Meeting of the American Society of Hematology (ASH). 2000 December 1-5. San Francisco, CA. Blood. 2000;96(11):304a.

*256. Rush LJ, Gao X, Wright FA, Kolitz JE, Bloomfield CD, Caligiuri MA, Plass C. DNA hypermethylation in acute myeloid leukemia (AML): nonrandom patterns with preferential involvement of chromosome 11. [abstract]. 42nd Annual Meeting of the American Society of Hematology (ASH). 2000 December 1-5. San Francisco, CA. Blood. 2000;96:501a.

*257. Virtaneva KI, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, Bloomfield CD, de la Chapelle A, Krahe R. Gene expression profiling reveals fundamental biological differences in AML with trisomy 8 and normal cytogenetics. [abstract]. Nature Genetics. 2001.



ABSTRACTS (cont.)

*258. Bloomfield CD, Byrd JC, Farag SS, Mrózek K, Dodge RK, Archer KJ, Whitman S, Larson RA, Carroll AJ, Caligiuri MA. Cytogenetics for treatment stratification in adult acute myeloid leukemia (AML). [abstract]. Acute Leukemias IX Basic Research, Experimental Approaches and Novel Therapies. 2001 February 24-28. Munich, Germany. Ann Hematol. 2001;80:(suppl 2):S10.

*259. Farag S, Archer K, Carroll A, Pettenati MJ, Mayer RJ, Stone R, Larson R, Bloomfield C: Isolated Trisomy (IT) is an adverse prognostic factor in patients with acute myeloid leukemia (AML) - results from Cancer and Leukemia Group B (CALGB 8461). [abstract]. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2001 May 12-15. San Francisco, CA. Proc Amer Soc Clin Oncol. 2001;20:282a. Abstract # 1124.

*260. Marcucci G, Bloomfield CD, Balcerzak SP, Fingert H, Maghraby EA, Lucas D, Chen KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA. Biologic activity and pharmacokinetics of Genasensetm (G3139, Genta, Inc.), a BCL-2 antisense (AS), in refractory (REF) or relapsed (REL) acute leukemia (AL). [abstract]. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2001 May 12-15. San Francisco, CA. Proc Amer Soc Clin Oncol. 2001;20:288a. Abstract # 1149.

*261. Silver RT, Peterson BL, Szatrowski TP, Powell BL, Bloomfield CD, Schiffer CA, Larson RA. Treatment of chronic myeloid leukemia (CML) with an intermittent schedule of interferon α-B. [abstract]. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2001 May 12-15. San Francisco, CA. Proc Amer Soc Clin Oncol. 2001;20:306a. Abstract # 1222.

*262. Wetzler M, Dodge RK, Mrózek K, Stewart CC, Carroll AJ, Vardiman JW, Larson RA, Bloomfield CD. Secondary chromosome aberrations in adult acute lymphoblastic leukemia (ALL) with t(9;22) – A Cancer and Leukemia Group B (CALGB) study. [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001; 98(11) 111a. Abstract # 466.

*263. Rush LJ, Mrózek K, Heinonen K, Abdel-Rahman M, Symanuska J, Bloomfield CD, Caligiuri MA, Plass C. Cytogenetic and molecular genetic characterization the TI-1 acute myeloid leukemia cell line reveals cross-contamination with K-562. [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001; 98(11):154b.

*264. Olney HJ, Raimondi SC, Huo D, Karrison T, Bloomfield CD, Rowley JD. Relationship of prior therapy and balanced chromosomal abnormalities in therapy-related myelodysplatic syndrome or acute leukemia (t-MDS/t-AL) of children and adults: Report from an International Workshop. [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001; 98(11):458a.

*265. Bloomfield C, Archer K, Lillington D, Kaneko Y, Head D, Cin PD, Rowley J, Raimondi S. 11q23 balanced translocations (BT) in therapy-associated acute leukemia or myelodysplastic syndrome (t-AL/MDS) are associated with distinctive prior therapeutic exposures and clinical features, including adverse outcome: Report from an International Workshop (IW). [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001; 98(11):458a.

*266. Marcucci G, Archer KJ, Mrózek K, Carroll AJ, Sterling JL, Edwards CG, Larson RA, Bloomfield CD. Abnormal karyotype during complete remission (CR) predicts short relapse-free survival (RFS) in acute myeloid leukemia (AML): Results from CALGB 8461. [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001; 98(11):577a. Abstract # 2421.



ABSTRACTS (cont.)

*267. Mrózek K, Heinonen K, Theil KS, Bloomfield CD: Spectral karyotyping (SKY) uncovers cryptic chromosome abnormalities, including recurrent overrepresentation of 21q, 11q and 22q in patients with acute myeloid leukemia (AML) and a complex karyotype. [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001; 98(11):578a.

*268. Tanner SM, Baldus CD, Austin JL, Leone G, Rush LJ, Archer KJ, Caligiuri MA, Bloomfield CD, de la Chapelle A. Involvement of BAALC, a novel human gene, in hematopoiesis and acute leukemia. [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001; 98(11):800a-801(a). Abstract # 3330.

*269. Kolitz JE, George SL, Dodge RK, Hoke E, Hurd D, Powell B, Velez-Garcia E, Caligiuri MA, Moore JO, Vardiman JW, Bloomfield CD, Larson RA. Dose escalation studies of Ara-C (A), Daunorubicin (D) and Etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML) < 60 years: final induction results of CALGB 9621. [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001; 98(11):461a. Abstract # 1928.

*270. Kolitz JE, George SL, Dodge RK, Hoke E, Hurd DD, Powell B, Velez-Garcia E, Caligiuri MA, Moore J, Vardiman JW, Linker CA, Bloomfield CD, Larson RA. Consolidation therapy by cytogenetic risk in adults with acute myeloid leukemia (AML) < 60 years in first complete remission (CR): Results of CALGB 9621. [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001; 98(11):688a-689a. Abstract # 2879.

*271. Baer MR, George SL, Dodge RK, O’Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Sciffer CA, Bloomfield CD, Larson RA. Phase III study of the multidrug resistance (MDR) modulator PSC-833 in previously untreated acute myeloid leukemia (AML) patients ≥ 60 years old: correlation of outcome with functional MDR (CALGB studies 9720 and 9760). [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001; 98(11):461a.

*272. Stock W, Dodge RK, Vardiman JW, Bloomfield CD, Caligiuri MA, Frankel S, Stone RM, Larson RA. Treatment of adult acute lymphoblastic leukemia (ALL): Phase II trial of dose intensification of daunorubicin and cytarabine followed by high-dose methotrexate and intrathecal methotrexate in place of cranial irradiation (CALGB 19802). [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001; 98(11):590a. Abstract # 2472.

*273. Byrd JC, Mrózek K, Dodge R, Carroll AJ, Edwards C, Pettenati MJ, Patil SR, Larson RA, Bloomfield CD. Pre-treatment cytogenetics predict initial induction success and overall survival in adult patients with de novo acute myeloid leukemia: results from CALGB 8461. [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001; 98(11):457a.

*274. Marcucci G, Byrd C, Cataland SR, Fisher DB, Lucas D, Chan KK, Klisovic M, Young DC, Didier LA, Balcerzak SP, Frankel SR, Kraut EH, Bloomfield CD, Grever MR, Caligiuri MA. Clinical and biological activity of Genasense (G3139, Genta, Inc.)(GS), a BCL-2 antisense, in refractory (REF) or relapsed (REL) acute leukemia (AL): A Phase I Study. [abstract]. 43rd Annual Meeting of the American Society of Hematology (ASH). 2001 December 7-11. Orlando, FL. Blood. 2001;98(11):216b.

*275. Virtaneva KI, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, Bloomfield CD, de la Chapelle A, Krahe R. Gene expression profiling reveals fundamental biological differences in AML with trisomy 8 and normal cytogenetics. [abstract]. Joint Conference of Nature Genetics and the American Association for Cancer Research (AACR)- Oncogenomics 2001: Dissecting Cancer through Genome Research. 2001 January 25-28. Tucson, AZ. 2001;pg65. Abstract # 30.



ABSTRACTS (cont.)

*276. Marcucci G, Byrd JC, Cataland SR, Fisher DB, Lucas D, Chen KK, Young D, Didier LA, Bloomfield CD, Balcerzak SP, Frankel SR, Kraut EH, Grever MR, Caligiuri MA. Significant disease response to Genasense (Genta Inc)(GS), a BCL-2 antisense, in combination with chemotherapy in refractory (REF) or relapsed (REL) acute leukemia (AL). [abstract]. Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research (AACR). 2001 March 24-28. New Orleans, LA. Clin Cancer Res. 2001;7(11):3681s. Abstract # 139.

*277. Whitman SP, Archer KJ, Feng L, Baldus C, Becknel B, Carlson BD, Carroll AJ, Mrózek K, Vardiman JW, George SL, Kolitz JE, Larson RA, Bloomfield CD, Caligiuri MA. The FLT3 internal tandem duplication in normal karyotype adult de novo AML lacking the wildtype FLT3 gene predicts poor prognosis: A Cancer and Leukemia Group B study. [abstract]. Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research (AACR). 2001 March 24-28. New Orleans, LA. Clin Cancer Res. 2001;7(11):3767s. Abstract # 564.

*278. Tanner SM, Baldus CD, Austin JL, Whitman SP, Marcucci G, Caligiuri MA, de la Chapelle A, Archer KJ, Bloomfield CD. Expression of BAALC predicts adverse prognosis in adult de novo acute myeloid leukemia (AML) with normal cytogenetics: a Cancer and Leukemia Group B (CALGB) study. [abstract]. Proceedings of the 93rd Annual Meeting of the American Association for Cancer Research (AACR). 2002 April 6-10. San Francisco, CA. Proc Amer Assoc Cancer Res. 2002;(suppl). Abstract # LB-138.

*279. Rauscher GH, Sandler DP, Poole C, Pankow J, Mitchell B, Bloomfield CD, Olshan AF. Interdependence of Family Histories of Cancer and Exposure in Adult Acute Leukemia Incidence. [abstract]. Am J Epidemiol. 2002;155(11)(suppl):s12. Abstract # 48.

*280. Bloomfield CD. Clinical importance of genetic findings in adult AML. [abstract]. Int J Hematol. 2002;76(suppl II):176-177.

*281. Sekeres MA, Dodge RK, Bloomfield CD, Larson RA, Stone RM. Racial Differences in Prognostic Factors and Outcome in Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study. [abstract]. 44th Annual Meeting of the American Society of Hematology (ASH). 2002 December 6-10. Philadelphia, PA. Blood. 2002;100(11):88a. Abstract # 323.

*282. Sher D, Dodge RK, Bloomfield CD, Larson RA, Caligiuri MA, Stock W. Clone-Specific Quantitative Real-Time PCR of IgH or TCR Gene Rearrangements in Adult Acute Lymphoblastic Leukemia (ALL) Following Induction Chemotherapy Identifies Patients with a Poor Prognosis: Pilot Study from the Cancer and Leukemia Group B (CALGB 20101). [abstract]. 44th Annual Meeting of the American Society of Hematology (ASH). 2002 December 6-10. Philadelphia, PA. Blood. 2002;100(11):153a. Abstract # 574.

*283. Baldus CD, Tanner SM, Guimond M, Mao C, Caligiuri MA, Bloomfield C, de la Chapelle A. Overexpression of BAALC Suppresses Normal Hematopoiesis. [abstract]. 44th Annual Meeting of the American Society of Hematology (ASH). 2002 December 6-10. Philadelphia, PA. Blood. 2002;100(11):164b. Abstract # 4147.

*284. Olney HJ, Block AW, Olopade OI, Larson RA, Levitan D, Baer MR, Bloomfield CD, Huo D, Karrison T, Rowley JD. The Clinical and Cytogenetic Findings in Therapy-Related Myelodysplastic Syndrome and Acute Leukemia with a Balanced Chromosomal Abnormality Following Treatment of Breast Cancer. [abstract]. 44th Annual Meeting of the American Society of Hematology (ASH). 2002 December 6-10. Philadelphia, PA. Blood. 2002;100 (11):325a. Abstract # 1259.

*285. Grinblatt DL, Yu D, Hars V, Miller A, Carroll A, Powell BL, Bloomfield CD, Larson RA. Relationships of Response to Oral Topotecan (Topo) For Myelodysplastic Syndrome (MDS) With IPSS Group and Cytogenetics-CALGB Study 19803. [abstract]. 44th Annual Meeting of the American Society of Hematology (ASH). 2002 December 6-10. Philadelphia, PA. Blood. 2002;100(11):794a. Abstract # 3137.



ABSTRACTS (cont.)

*286. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, Bloomfield CD, Caligiuri MA, Look AT. Adult T-cell ALL Patients Whose Lymphoblasts Express the HOX11 Oncogene Have an Excellent Prognosis When Treated With Chemotherapy And Are Not Candidates for Allogeneic Bone Marrow Transplantation in First Remission. [abstract]. 44th Annual Meeting of the American Society of Hematology (ASH). 2002 December 6-10. Philadelphia, PA. Blood. 2002;100(11):154a. Abstract # 578.

*287. Baldus CD, Tanner S, Ruppert A, Whitman SP, Marcucci G, Caligiuri MA, Kolitz JE, Larson RA, de la Chapelle A, and Bloomfield CD. High BAALC expression identifies a new risk group of de novo acute myeloid leukemia (AML) patients: A Cancer and Leukemia Group B (CALGB) Study. [abstract]. Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2003 May 21-June 3. Chicago, IL. Proc Amer Soc Clin Oncol. 2003;22:563. Abstract # 2266.

*288. Levitan DA, Olney HJ, Huo D, Karrison T, Bloomfield CD, Larson RA, Rowley JD, Olopade OI. Patients who develop therapy-related myelodysplastic syndrome and acute leukemia with a balanced chromosomal abnormality following breast cancer therapy have differences in cytogenetic characteristics and clinical outcome when analyzed by age at diagnosis of breast cancer. [abstract]. Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2003 May 21-June 3. Chicago, IL. Proc Amer Soc Clin Oncol. 2003;22: 568. Abstract # 2286.

*289. MacEachern, SN, Ferketich, AK, Lemeshow, S, Shen, L, Westman, J, de la Chapelle, A, Bloomfield, C. Estimating Incidence Rates Using Pedigree Sampling. [abstract]. Am J Epidemiol. 2003;157:S54.

*290. Westman JA, MacEachern SN, Ferketich AK, Lemeshow S, Pilarski R, Nagy R, de la Chapelle A, Bloomfield CD. Low cancer incidence rates in Ohio Amish. [abstract]. Meeting of the American Society of Human Genetics (ASHG). 2003 November 4-8. Los Angeles, CA. Am J Hum Genet. 2003 Nov;73(suppl 5):373. Abstract # 1186.

*291. Baldus CD, Liyanarachchi S, Mrózek K, Auer H, Guimond M, Davuluri R, Ruppert AS, Mohamed N, Vardiman JW, Caligiuri MA, Bloomfield C, de la Chapelle A. High Resolution Mapping of Chromosome 21 Genomic Dosage and Gene Expression Studies Reveal Frequent Amplification of the 25-30 MB Region in 21q21 and Overexpression of the APP Gene in Acute Myeloid Leukemia (AML) Subsets. [abstract]. 45th Annual Meeting of the American Society of Hematology (ASH). 2003 December 6-9. San Diego, CA. Blood. 2003 Nov;102(11):363a. Abstract # 1319.

*292. Kolitz JE, George SL, Barrier R, Hoke E, Hurd DD, Velez-Garcia E, Powell BL, Marcucci G, Brooks PL, Carroll AJ, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA. A novel post-remission consolidation regimen for patients with acute myeloid leukemia (AML) <60 years old with normal or unfavorable cytogenetics: results from CALGB 9621. [abstract]. 45th Annual Meeting of the American Society of Hematology (ASH). 2003 December 6-9. San Diego, CA. Blood. 2003 Nov;102(11):175a. Abstract # 609.

*293. Kolitz JE, George SL, Barrier R, Hoke E, Hurd DD, Velez-Garcia E, Powell BL, Marcucci G, Baer MR, Hohl RJ, Mrózek K, Carroll AJ, Edwards CG, Caligiuri MA, Vardiman JW, Bloomfield C, Larson RA. Treatment of core binding factor (CBF) acute myeloid leukemia (AML) with post-remission high-dose cytarabine (HiDAC): results from CALGB 9621. [abstract]. 45th Annual Meeting of the American Society of Hematology (ASH). 2003 December 6-9. San Diego, CA. Blood. 2003 Nov;102(11):176a. Abstract # 612.

*294. Whitman SP, Liu S, Klisovic MI, Vukosavljevic T, Guimond M, Rush LJ, Ruppert AS, Strout MP, Becknell B, Dorrance AM, Bruner RJ, Plass C, Bloomfield CD, Marcucci G, Caligiuri MA. Activation of the silenced MLL (ALL-1) wild-type allele in acute myeloid leukemia (AML) with the MLL partial tandem duplication results in enhancement of cell death. [abstract]. 45th Annual Meeting of the American Society of Hematology (ASH). 2003 December 6-9. San Diego, CA. Blood. 2003 Nov;102(11):221a. Abstract # 775.



ABSTRACTS (cont.)

*295. Stock W, Yu D, Johnson J, Bloomfield CD, Stone RM, Kolitz JE, Wetzler M, Powell M, Vardiman JW, Larson RA. Intensified Daunorubicin during Induction and Post-Remission Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Results of CALGB 19802. [abstract]. 45th Annual Meeting of the American Society of Hematology (ASH). 2003 December 6-9. San Diego, CA. Blood. 2003 Nov;102(11):379a. Abstract # 1375.

*296. Baldus CD, Tanner SM, Ruppert A, Whitman SP, Marcucci G, Caligiuri MA, Kolitz JE, Larson RA, de la Chapelle A, Bloomfield CD. High BAALC expression predicts adverse outcome in de novo acute myeloid leukemia (AML) patients: a CALGB study update. [abstract]. Hematol. 2004 Feb;83(suppl 1):S13. Abstract # 1.

*297. Kolitz JE, George SL, Baer MR, Lee EJ, Bloomfield CD, Larson RA. P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults. [abstract]. Ann Hematol. 2004 Feb;83(suppl 1):S103-104.

*298. Bloomfield CD, Ruppert AS, Mrózek K, Kolitz JE, Moore JO, Mayer RJ, Edwards CG, Sterling LJ, Vardiman JW, Carroll AJ, Pettenati MJ, Stamberg J, Byrd JC, Marcucci G, Larson RA. Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. [abstract]. Ann Hematol. 2004 Feb;83(suppl 1):S84-85.

*299. Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucas D, Zwiebel JA, Larson RA, Caligiuri MA, Bloomfield CD, Chan KK, Grever MR, Byrd JC. G3139, a bcl-2 antisense oligonucleotide, in AML. [abstract]. Ann Hematol. 2004 Feb;83(suppl 1): S93-94.

*300. MacEachern SN, Ferketich AK, Lemeshow S, Shen L, Westman JA, de la Chapelle A, Bloomfield CD. Estimating incidence rates using pedigree sampling. [abstract]. International Biometric Society. 2004 Mar.

*301. Blum W, Mrózek K, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, Vardiman JW, Larson RA, Bloomfield CD. Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): Results from CALGB 8461. [abstract]. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2004 June 5-8. New Orleans, LA. J Clin Oncol. 2004 Jul 15;22(14s, suppl):566. Abstract # 6543.

*302. Marcucci G, Mrózek K, Ruppert A, Bloomfield CD. Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461. [abstract]. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2004 June 5-8. New Orleans, LA. J Clin Oncol. 2004 Jul 15;22(14s). Abstract # 6514.

*303. Farag SS, Ruppert AS, Mrózek K, Kolitz JE, Mayer RJ, Carroll AJ, Powell BL, Moore JO, Larson RA, Bloomfield CD. Post-remission therapy with 4 cycles of intermediate (I) or high-dose (HD) cytarabine (AC) or autologous hematopoietic stem cell transplantation (ASCT) for acute myeloid leukemia (AML) patients <60 years with normal cytogenetics: A Cancer and Leukemia Group B (CALGB) Study. [abstract]. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2004 June 5-8. New Orleans, LA. J Clin Oncol. 2004 Jul 15;22(14s). Abstract # 6542.

*304. Ferketich A, de la Chapelle A, Westman J, Lemeshow S, Bloomfield CD. Barriers to sampling an isolated population: The Ohio State University Amish population study experience. [abstract]. Am J Epidemiol. 2004;159:S27.

*305. Baldus CD, Thiede C, Bloomfield CD, Thiel E, Ehninger G. High BAALC Expression Predicts Adverse Outcome in Acute Myeloid Leukemia with Normal Cytogenetics: Results of The SHG’96 Study. [abstract]. Gemainsame Jahrestagung der Deutschen und der Oesterreichischen gesellschaft fur Haematologie und Onkologie (Joint Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Ongology). Onkologie. 2004 Oct;27(suppl 3):117. Abstract # P546.



ABSTRACTS (cont.)

306. Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD. t(8;21) Acute Myeloid Leukemia (AML) Differs from inv(16) AML in Pretreatment Characteristics, Outcome and Prognostic Factors Predicting Outcome: A Cancer and Leukemia Group B (CALGB) Study. [abstract]. 46th Annual Meeting of the American Society of Hematology (ASH). 2004 December 4-7. San Diego, CA. Blood. 2004 Nov;104(11): 556a. Abstract # 2017.

*307. Farag SS, Archer KJ, Mrózek K, Vardiman JW, Carroll AJ, Pettenati MJ, Powell BL, Moore JO, Kolitz JE, Baer MR, Bigner SH, Koduru PR, Stamberg J, Mayer RJ, Stone RM, Schiffer CA, Larson RA, Bloomfield CD. Pre-Treatment Cytogenetics Predict Complete Remission and Long-Term Outcome in Patients (Pts) 60 Years with Acute Myeloid Leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461. [abstract]. 46th Annual Meeting of the American Society of Hematology (ASH). 2004 December 4-7. San Diego, CA. Blood. 2004 Nov;104(11):164a. Abstract # 568.

*308. Slovak ML, Bloomfield CD, Gundacker H, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Willman C, Ravindranath Y, Alonzo TA, Carroll A, Hirsch B, Raimondi S, Heerema NA. Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases.[abstract]. 46th Annual Meeting of the American Society of Hematology (ASH). 2004 December 4-7. San Diego, CA. Blood. 2004 Nov;104(11):164a. Abstract # 567.

309. Mrózek K, Carroll AS, Maharry K, Rao KE, Patil SR, Pettenati MJ, Watson MS, Arthur CD, Tantravahi R, Heerema N, Kodura PRK, Bigner SH, Stamberg J, Block AW, Edwards CG, Sterling LJ, Bloomfield CD. Central Review of Cytogenetics Is Essential for Cooperative Group Clinical and Correlative Studies of Acute Leukemia: The Cancer and Leukemia Group B (CALGB) 8461 Experience. [abstract]. 46th Annual Meeting of the American Society of Hematology (ASH). 2004 December 4-7. San Diego, CA. Blood. 2004 Nov;104(11):307a. Abstract # 1081.

*310. Walter MJ, Ries RE, Armstrong J, O’Gara B, Vardiman JW, Caligiuri MA, Bloomfield CD, Hodgson G, Gray JW, Wilson RK, Mardis ER, Ley TJ and members of the Genomics of AML PPG. Genomic DNA Copy Number Alterations Present in AML Bone Marrow Samples with Normal Cytogenetics. [abstract]. 46th Annual Meeting of the American Society of Hematology (ASH). 2004 December 4-7. San Diego, CA. Blood. 2004 Nov;104(11):44a. Abstract # 142.

*311. Liu TX, Becker M, Hsu K, Jelinke J, Deng M, Bloomfield CD, Issa J-P, Clarke MF, Look AT. Epigenetic Suppression of the CTNNA1 Gene, Encoding the α-Catenin Protein, which Is Located in the 5q31 Critical Deleted Region in Malignant Myeloid Disorders with del(5q). [abstract]. 46th Annual Meeting of the American Society of Hematology (ASH). 2004 December 4-7. San Diego, CA. Blood. 2004 Nov;104(11):62a. Abstract # 203.

*312. Tallman MS, Kim HT, Schiffer CA, Appelbaum FR, Feusner JH, Ogden AK, Shepherd L, Willman CL, Bloomfield CD, Rowe JM, Larson RA, Wiernik PH, Marting G, Rayon C, de la Serna J, Rivas C, Gonzalez-San Miguel JD, Deben G, Sanz MA. Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99. [abstract]. 46th Annual Meeting of the American Society of Hematology (ASH). 2004 December 4-7. San Diego, CA. Blood. 2004 Nov;104(11):116a. Abstract # 394.

313. Baldus CD, Thiede C, Bloomfield CD, Thiel E, Ehninger G. High BAALC Expression as an Independent Adverse Risk Factor in 309 Patients with Acute Myeloid Leukemia (AML) and Normal Cytogenetics: Results of the SHG’96 Study. [abstract]. 46th Annual Meeting of the American Society of Hematology (ASH). 2004 December 4-7. San Diego, CA. Blood. 2004 Nov;104(11):554a. Abstract # 2009.

*314. Look TA, Liu TX, Hsu K, Deng M, Becker M, Clarke MF, Jelinek J, Issa JP, Bloomfield CD. Alpha-Catenin as a del(5q) suppressor in AML: Expression analysis of purified human hematopoietic stem cells and zebrafish. [abstract]. 46th Annual Meeting of the American Society of Hematology (ASH). 2004 December 4-7. San Diego, CA. Blood. 2004 Nov;104(11):79.



ABSTRACTS (cont.)

315. Fröhling S, Schlenk RF, Krauter J, Ganser A, Thiede C, Ehninger G, Haase D, Harder L, Scholl C, Caligiuri MA, Bloomfield CD, Döhner H, Döhner K. Acute Myeloid Leukemia with Deletion 9q Is Associated with CEBPA Loss-of-Function Mutations. [abstract]. 46th Annual Meeting of the American Society of Hematology (ASH). 2004 December 4-7. San Diego, CA. Blood. 2004 Nov;104(11):791-792a. Abstract # 2896.

*316. Neviani P, Santhanam R, Trotta R, Notari M, Uttam A, Blaser BW, Liu S, Roy DC, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D. Activation of PP2A: A novel mechanism for a potential targeted therapy of blast crisis and imatinib-resistant chronic myelogenous leukemia. [abstract]. Proceedings of the 96th Annual Meeting of the American Association for Cancer Research (AACR). 2005 April 16-20. Anaheim, CA. Proc Amer Assoc Cancer Res. 2005 Apr;46:358. Abstract # 1528.

*317. Katz ML, Ferketich A, Harley A, Paskett ED, Lemeshow S, Westman J, Clinton S, de la Chapelle A, Bloomfield CD. Cancer screening among Amish adults. [abstract]. American Society of Preventive Oncology Meeting. 2005 March 13-15. San Francisco, CA.

318. Blum W, Mrózek K, Maharry K, Raimondi SC, Carroll AJ, Larson RA, Rowley JD, Bloomfield CD. Comparison of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations of 11q23. [abstract]. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). 2005 May 13-17. Orlando, FL. J Clin Oncol. 2005 Jun 1;23(16s):572s. Abstract # 6549.

*319. Neubauer A, Maharry K, Marcucci G, Mrózek K, Mayer RJ, Larson RA, Liu ET, Bloomfield CD. Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: A Cancer and Leukemia Group B (CALGB) study. [abstract]. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). 2005 May 13-17. Orlando, FL. J Clin Oncol. 2005 Jun 1;23(16s):563s. Abstract # 6514.

*320. Baldus CD, Thiede C, Soucek S, Bloomfield CD, Eckhard T, Ehninger G. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.[abstract]. 10th Congress of the European Hematology Association (EHA). 2005 June 2-5. Stockholm, Sweden. Haematologica. 2005;90(s2):323. Abstract # 0811.

*321. Stock W, Yu D, Sanford B, Lozanski G, Cataland S, Vij R, Byrd J, Powell B, Wetzler M, Albitar M, Sher D, Edwards C, Hoke E, Bloomfield CD, Larson R. Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102). [abstract]. 47th Annual Meeting of the American Society of Hematology (ASH). 2005 December 10-13. Atlanta, GA. Blood. 2005 Nov 16;106(11): 46a. Abstract # 145.

322. Stock W, Johnson J, Yu D, Bennett D, Sher D, Stone RM, Kolitz J, Powell BL, Wetzler M, Vardiman JW, Bloomfield CD, Larson RA. Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802. [abstract]. 47th Annual Meeting of the American Society of Hematology (ASH). 2005 December 10-13. Atlanta, GA. Blood. 2005 Nov 16;106(11):521a. Abstract #1833.

*323. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD. Overexpression of the ERG Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B Study (CALGB). [abstract]. 47th Annual Meeting of the American Society of Hematology (ASH). 2005 December 10-13. Atlanta, GA. Blood. 2005 Nov 16;106(11):101a. Abstract # 335.



ABSTRACTS (cont.)

*324. Marcucci G, Radmacher MD. Ruppert AS, Mrózek K, Kolitz JE, Whitman SP, Edwards CG, Vardiman JW, Caligiuri MA, Carroll AJ, Larson RA, Bloomfield CD. Independent Validation of Prognostic Relevance of a Previously Reported Gene-Expression Signature in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B (CALGB) Study. [abstract]. 47th Annual Meeting of the American Society of Hematology (ASH). 2005 December 10-13. Atlanta, GA. Blood. 2005 Nov 16;106(11):223a. Abstract # 755.

325. Wetzler M, Sanford BL, Owzar K, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA. CALGB, Chicago, IL. Effective Asparagine Depletion with Pegylated Asparaginase Results in Improved Outcomes in Adult Acute Lymphoblastic Leukemia (ALL) -- Cancer and Leukemia Group B (CALGB) Study 9511. [abstract]. 47th Annual Meeting of the American Society of Hematology (ASH). 2005 December 10-13. Atlanta, GA. Blood. 2005 Nov 16; 106(11):519a. Abstract # 1825.

*326. Baer MR, Cuviello NW, Shoemaker JS, Barrier Jr RC, Caligiuri MA, Kolitz JE, Powell BL, Larson RA, Bloomfield CD. Treatment Failure Is Strongly Predicted by P-Glycoprotein (Pgp) Function but Not by Multidrug Resistance Protein (MRP-1), Breast Cancer Resistance Protein (BCRP) or Lung Resistance Protein (LRP) in Acute Myeloid Leukemia (AML) Patients 60 Years and Older Receiving Intensive Chemotherapy (CALGB 9720/9760). [abstract]. 47th Annual Meeting of the American Society of Hematology (ASH). 2005 December 10-13. Atlanta, GA. Blood. 2005 Nov 16;106(11):661a. Abstract # 2349.

*327. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, De Angelo DJ, Shea T, Stock W, Hars V, Hoke E, Vardiman JW, Bloomfield CD, Larson RA. A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808. [abstract]. 47th Annual Meeting of the American Society of Hematology (ASH). 2005 December 10-13. Atlanta, GA. Blood. 2005 Nov 16;106(11):122a. Abstract # 407.

*328 Rowe JM, Li X, Cassileth PA, Appelbaum FR, Schiffer CA, Litzow MR, Cripe LD, Lazarus HM, Paietta E, Dewald GW, Weinstein HJ, Ogden AK, Woods WG, Shepherd L, Feusner JH, Bloomfield CD, Tallman MS. Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: the Eastern Cooperative Oncology Group Experience. [abstract]. 47th Annual Meeting of the American Society of Hematology (ASH). 2005 December 10-13. Atlanta, GA. Blood. 2005 Nov 16;106(11):162a. Abstract # 546.

329. Baldus CD, Radmacher M, Marcucci G, Hoelzer D, Thiel E, Bloomfield CD, Hofmann WK. Co-Expression of BAALC with ERG, TCF4, and CD133 Indicates a Shared Pathway in Acute Myeloid and Lymphoblastic Leukemia. [abstract]. 47th Annual Meeting of the American Society of Hematology (ASH). 2005 December 10-13. Atlanta, GA. Blood. 2005 Nov 16;106(11):773a. Abstract # 2755.

330. Walter M, Ries R, Li X, Shannon W, Payton J, DiPersio J, Link D, Tomasson M, Graubert T, McLeod H, Devine S, Watson M, Heath S, Baty J, Trinkaus K, Ruppert A, Mrózek K, Bloomfield C, Armstrong J, Mardis E, Wilson R, Selzer R, Richmond T, Eis P, Ley TJ. Detection of Microdeletions and Amplifications in Primary Human Acute Myeloid Leukemia (AML) Genomes Using Ultradense Oligomer Tiling Path Arrays and Comparative Genomic Hybridization (CGH). [abstract]. 47th Annual Meeting of the American Society of Hematology (ASH). 2005 December 10-13. Atlanta, GA. Blood. 2005 Nov 16;106(11):661a. Abstract # 2350.

331. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Chang J, Liu S, Mao H, Oaks JJ, Galietta AM, Roy DC, Valtieri M, Klisovic RB, Caligiuri MA , Bloomfield CD, Marcucci G, Perrotti D. ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML. [abstract]. 47th Annual Meeting of the American Society of Hematology (ASH). 2005 December 10-13. Atlanta, GA. Blood. 2005 Nov 16;106(11):545a. Abstract # 1992.



ABSTRACTS (cont.)

332. Lee S, Chen J, Zhou G, Shi R, Kocherginsky M, Karrison TG, Kim YC, Ge X, Jayathilaka N, Neilly MB, Bouffard G, Young A, Kornblau S, Bloomfield C, Sohlander S, Liu PP, Sun M, Wang SM, Rowley JD. Gene Expression Profiles in Acute Myeloid Leukemia (AML): From Diagnosis to Prognosis. [abstract]. 47th Annual Meeting of the American Society of Hematology (ASH). 2005 December 10-13. Atlanta, GA. Blood. 2005 Nov 16;106(11):839-840a. Abstract # 2996.

*333. Baldus CD, Burmeister T, Martus P, Schwartz S, Gökbuget N, Bloomfield CD, Hoelzer D, Hofmann WK, Thiel E. High expression of the transcription factor ERG predicts unfavorable outcome in acute T-lymphoblastic leukemia (T-ALL) in adults. [abstract]. Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO). 2006 June 2-6. Atlanta, GA. J Clin Oncol. 2006 Jun 20;24(suppl 18):6505. Abstract # 6505.

334. Wetzler M, Stock W, Owzar K, Sher DA, Hoke EE, Linker CA, Bloomfield CD, Larson RA. Sequential imatinib and chemotherapy yield reverse-transcriptase polymerase chain reaction (RT-PCR)-negative peripheral stem cell collections in Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL) - preliminary results of CALGB 10001. [abstract]. Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO). 2006 June 2-6. Atlanta, GA. J Clin Oncol. 2006 Jun 20;24(suppl 18):349S. Abstract # 6549.

*335. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Larson RA, Bloomfield CD. Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study. [abstract]. Plenary Session of the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO). 2006 June 2-6. Atlanta, GA. J Clin Oncol. 2006 Jun 20;24(suppl 18):1S. Abstract # 2.

*336. Stock W, Moser B, Sher DA, Schachter-Tokarz E, Myers M, Powell BL, Bloomfield CD, Bucci D, Tallman MS, Larson RA, Gallagher RE. PML-RARα isoform at diagnosis is associated with disease-free survival (DFS) in patients enrolled in the intergroup trial (C-9710) for treatment of Acute Promyelocytic Leukemia (APL). [abstract]. Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO). 2006 June 2-6. Atlanta, GA. J Clin Oncol. 2006 Jun 20;24(suppl 18):338S. Abstract # 6504.

*337. Baldus CD, Radmacher M, Marcucci G, Hoelzer D, Thiel E, Bloomfield CD, Hofmann WK. Co-expression of BAALC with ERG, TCF4 and CD133 indicates a shared pathway in acute myeloid and lymphoblastic leukemia. [abstract]. International Symposium Acute Leukemias XI Prognostic Factors and Treatment Strategies. 2006 February 18 – 22. Munich, Germany. Ann Hematol. 2006;85(suppl 1):13. Abstract # 4.

*338. Baldus CD, Burmeister T, Martus P, Schwartz S, Gökbuget N, Bloomfield CD, Hoelzer D, Thiel E, Hofmann W-K. A new molecular risk factor in adult acute T-lymphoblastic leukemia (T-ALL): high expression of the ETS transcription factor ERG predicts unfavorable outcome. Ein neuer molekularer Risikofaktor in akuter T-lymphoblastischer Leukämie (T-ALL) bei Erwachsenen: Hohe Expression des ETS Transkriptionsfaktors ERG ist assoziiert mit einer ungünstigen Prognose. [abstract]. DGHO Meeting. 2006 November. Leipzig, Germany.

339. Lozanski G, Sanford B, Yu D, Pearson R, Edwards C, Byrd JC, Larson RA, Bloomfield CD, Stock W. CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights. [abstract]. 48th Annual Meeting of the American Society of Hematology (ASH). 2006 December 9-12. Orlando, FL. Blood. 2006 Nov 16;108(11): 650a. Abstract # 2293.

*340. Gallagher RE, Schachter-Tokarz EL, Moser BK, Sher D, Paietta E, Tallman MS, Bloomfield CD, Powell BL, Larson RA, Appelbaum FR, Willman CL, Harvey RC, Stock W. Frequent PML-RARα Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710. [abstract]. 48th Annual Meeting of the American Society of Hematology (ASH). 2006 December 9-12. Orlando, FL. Blood. 2006 Nov 16;108(11):663a. Abstract # 2342.



ABSTRACTS (cont.)

*341. Baer M, Caligiuri MA, George SL, Sanford BL, Bothun S, O’Loughlin KL, Mrózek K, Kolitz JE, Bloomfield CD, Larson RA. Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients [ge] 60 Years in First Complete Remission (CALGB 9720). [abstract]. 48th Annual Meeting of the American Society of Hematology (ASH). 2006 December 9-12. Orlando, FL. Blood. 2006 Nov 16;108(11):129a. Abstract # 424.

*342. Stock W, Harvey R, Moser B, Sher D, Schachter- Tokarz E, Myers M, Slack J, Powell B, Bloomfield CD, Larson RA, Tallman MS, Appelbaum FR, Feusner J, Willman C, Gallagher R. Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710. [abstract]. 48th Annual Meeting of the American Society of Hematology (ASH). 2006 December 9-12. Orlando, FL. Blood. 2006 Nov 16;108(11):150a. Abstract # 494.

343. Baldus CD, Radmacher MD, Bloomfield CD, Martus P, Schwartz S, Gökbuget N, Hoelzer D, Thiel E, Hofmann W-K. The Identification of ERG Related Pathways Pinpoints to Mechanisms Implicated in the Inferior Outcome of Acute T-Lymphoblastic Leukemia (T-ALL) with High ERG Expression. [abstract]. 48th Annual Meeting of the American Society of Hematology (ASH). 2006 December 9-12. Orlando, FL. Blood. 2006 Nov 16;108(11):243. Abstract # 1828.

344. Gupta P, Sanford BL, Yu D, Vij R, Hurd DD, Odenike O, Bloomfield CD, Hasserjian RP, Larson RA. A Phase II Study Of An Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) In Patients With Myelodysplastic Syndrome (MDS): Cancer and Leukemia Group B Study 10105. [abstract]. 48th Annual Meeting of the American Society of Hematology (ASH). 2006 December 9-12. Orlando, FL. Blood. 2006 Nov 16;108(11):753a. Abstract # 2665.

*345. Santhanam R, Neviani P, Eiring A, Oaks J, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Marcucci G, Passerini CG, Roy DC, Caligiuri MA, Bloomfield CD, Chen CS, Byrd JC, Perrotti D. FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients. [abstract]. 48th Annual Meeting of the American Society of Hematology (ASH). 2006 December 9-12. Orlando, FL. Blood. 2006 Nov 16;108(11):89a. Abstract # 288.

*346. Neviani P, Santhanam R, Oaks J, Eiring A, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerine C, Druker BJ, Cortes J, Marcucci G, Chen C-S, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D. FTY720, a new and alternative strategy for treating blast crisis CML and Ph1 ALL patients. [abstract]. Proceedings of the 98th Annual Meeting of the American Association for Cancer Research (AACR). 2007 April 14-18. Los Angeles, CA. Proc. Am. Assoc. Cancer Res. 2007;48:389. Abstract # 1638.

*347. Whitman SP, Ruppert AS, Marcucci G, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Vukosavljevic T, Powell BL, Carroll AJ, Kolitz JE, Larson RA, Caligiuri MA, Bloomfield CD. Improved clinical outcome of cytogenetically normal acute myeloid leukemia with the MLL partial tandem duplication: A Cancer and Leukemia Group B (CALGB) study. [abstract]. Proceedings of the 98th Annual Meeting of the American Association for Cancer Research (AACR). 2007 April 14-18. Los Angeles, CA. Proc. Am. Assoc. Cancer Res. 2007;48:580. Abstract # 2439.

*348. Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, Mrózek K, Baldus CD, Carroll AJ, Powell BL, Kolitz JE, Larson RA, Bloomfield CD. High ERG expression predicts adverse outcome and refines molecular risk-based classification of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study. [abstract]. Proceedings of the 98th Annual Meeting of the American Association for Cancer Research (AACR). 2007 April 14-18. Los Angeles, CA. Proc. Am. Assoc. Cancer Res. 2007;48:580. Abstract # 2440.

*349. Paschka P, Radmacher MD, Marcucci G, Ruppert AS, Vukosavljevic T, Whitman SP, Mrózek K, Liu C, Larson RA, Bloomfield CD. Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study. [abstract]. Proceedings of the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). 2007 June 1-5. Chicago, IL. J Clin Oncol. 2007 Jun 20;25(18s):359S. Abstract # 7011.



ABSTRACTS (cont.)

*350. Radmacher MD, Marcucci G, Paschka P, Vukosavljevic T, Whitman SP, Ruppert AS, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD. MicroRNA (miR) expression signatures in molecular subsets of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study. [abstract]. Proceedings of the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). 2007 June 1-5. Chicago, IL. J Clin Oncol. 2007 Jun 20;25(18s):359S. Abstract # 7010.

351. Stock W, Moser B, Powell BL, Bloomfield CD, Larson RA, Appelbaum FR, Tallman MS, Feusner FR, Willman C, Gallagher RE. Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): Results from the North American Intergroup Trial, C9710. [abstract]. Proceedings of the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). 2007 June 1-5. Chicago, IL. J Clin Oncol. 2007 Jun 20;25(18s):361S. Abstract # 7016.

352. Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. FLT3 D835/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without FLT3 internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study. [abstract]. Proceedings of the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). 2007 June 1-5. Chicago, IL. J Clin Oncol. 2007 Jun 20;25(18s):573S. Abstract # 10532.

353. Langer C, Ruppert AS, Radmacher MD, Whitman SP, Paschka P, Baldus C, Mrózek K, Kolitz JE, Marcucci G, Bloomfield CD. High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene expression signature in cytogenetically normal Acute Myeloid Leukemia (CN AML): A Cancer and Leukemia Group B Study. [abstract]. Proceedings of the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). 2007 June 1-5. Chicago, IL. J Clin Oncol. 2007 Jun 20;25(18s):360S. Abstract # 7013.

354. Baldus CD, Martus P, Burmeister T, Schwartz S, Gökbuget N, Bloomfield CD, Hoelzer C, Thiel E, Hofmann WK. Identification of a new subgroup of adult acute T-lymphoblastic leukemia (T-ALL) with a very favorable outcome using low ERG and BAALC expression. [abstract]. Proceedings of the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). 2007 June 1-5. Chicago, IL. J Clin Oncol. 2007 Jun 20;25(18s):360s. Abstract # 7014.

*355. Katz ML, Ferketich A, Paskett ED, Harley A, Lemeshow S, Clinton S, Bloomfield CD. Physical Activity Levels among the Amish and Non-Amish Living in Ohio Appalachia. [abstract]. Epidemiol Biomarkers Prev. 2007 Feb;16:358.

*356. Paschka P, Marcucci G, Maharry K, Whitman SP, Ruppert AS, Vukosavljevic T, Mrózek K, Powell BL, Kolitz JE, Larson RA, Bloomfield CD. Prognostic Impact of NPM1 Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) is Adversely Affected by High Expression of the ERG Gene: A Cancer and Leukemia Group B (CALGB) Study. [abstract]. 12th Congress of the European Hematology Association (EHA). 2010 June 7-10. Vienna, Austria. Haematologica 2007;92(suppl 1):145. Abstract # 396.

*357. Baldus CD, Martus P, Burmeister T, Schwartz S, Goekbuget N, Bloomfield CD, Hoelzer D, Thiel E, Hofmann W-K. Expression of ERG and BAALC identifies new molecular subgroups of adult acute T-lymphoblastic leukemia with distinct clinical outcome Die Expression der Gene ERG und BAALC charakterisieren neue molekulare Risikogruppen bei Patienten mit akuter T-lymphoblastischer Leukämie. [abstract]. Meeting: Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. (Joint Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Ongology). 2007 October 5-9. Basel, Switzerland. Onkologie. 2007 Oct;30(suppl):43. Abstract # V177.

*358. Mrózek K, Paschka P, Marcucci G, Whitman SP, Bloomfield CD. Biology, cytogenetics and molecular studies in acute myeloid leukemia. [abstract]. Meeting: Leukemia and Lymphoma: East and West Together. 2007. Dubrovnik Croatia. Leukemia Res. 2007;31(suppl 2):S3-S7.



ABSTRACTS (cont.)

*359. Thiede C, Bloomfield C, Lo Coco F, Fröhling S, Hiddemann W, Krauter J, Schaich M, Whitman S, Saglio G, Döhner K, Spiekermann K, Schnittger S, Ganser A, Heil G, Büchner T, Döhner H, Larson R, Ehninger G. The high prevalence of FLT3-ITD mutations is associated with the poor outcome in adult patients with t(6;9)(p23;q34) positive AML-Results of an international metaanalysis. [abstract]. Meeting: Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie (Joint Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Ongology). 2007 October 5-9. Basel, Switzerland. Onkologie. 2007 Oct;30(suppl 3):113. Abstract # 214.

*360. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Whitman SP, Maharry K, Langer C, Baldus CD, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA. Bloomfield CD. Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study. [abstract]. 49th Annual Meeting of the American Society of Hematology (ASH). 2007 December 8-11. Atlanta, GA. Blood. 2007 Nov 16;110(11):113a. Abstract # 362.

*361 Kolitz JE, Hars V, DeAngelo DJ, Allen SL, Shea TC, Vij R, Hoke E, Bloomfield CD, Caligiuri MA, George SG, Larson RA. Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808. [abstract]. 49th Annual Meeting of the American Society of Hematology (ASH). 2007 December 8-11. Atlanta, GA. Blood. 2007 Nov 16;110(11):53a-54a. Abstract # 157.

362. Wetzler M, Stock W, Donohue KA, Owzar K, Sher DA, Hoke EE, McCarty JM, Blum WG, Powell BL, Bloomfield CD, Linker CA, Larson RA. Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) -- CALGB study 10001. [abstract]. 49th Annual Meeting of the American Society of Hematology (ASH). 2007 December 8-11. Atlanta, GA. Blood. 2007 Nov 16;110(11):843a-844a. Abstract # 2869.

363. Lozanski G, Sanford B, Mrózek K, Edwards C, Pearson R, Bloomfield CD, Larson RA, Stock W. Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102). [abstract]. 49th Annual Meeting of the American Society of Hematology (ASH). 2007 December 8-11. Atlanta, GA. Blood. 2007 Nov 16;110(11):704a. Abstract # 2386.

*364. Walter MJ, R Ries R, X Li X, Shannon W, J Payton J, Books J, Bloomfield C, Mrózek K, Ruppert A, DiPersio J, Link D, Tomasson M, Graubert T, Westervelt P, Watson M, Heath S, Baty J, Armstrong J, Mardis E, Wilson R, Selzer R, Richmond T, Kitzman J, Eis P, Ley T. High Resolution Array-Based CGH and SNP Studies of AML Genomes. [abstract]. 49th Annual Meeting of the American Society of Hematology (ASH). 2007 December 8-11. Atlanta, GA. Blood. 2007 Nov 16;110(11):40a. Abstract # 107.

*365. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Büchner T, Wörmann B, Mansmann U, Hiddemann W, Bohlander SK, Buske C. An 86-Probe Gene Expression Signature Can Predict Survival in AML with Normal Karyotype Independently of FLT3 ITD and NPM1 Mutation Status - a Collaborative Study from the AMLCG and CALGB Study Groups. [abstract]. 49th Annual Meeting of the American Society of Hematology (ASH). 2007 December 8-11. Atlanta, GA. Blood. 2007 Nov 16;110(11):183a. Abstract # 596.

*366. Thiede C, Bloomfield C, LoCoco F, Fröhling S, Hiddemann W, Krauter J, Schaich M, Whitman S, Saglio G, Döhner K, Spiekermann K, Ganser A, Schnittger S, Larson R, Büchner T, Döhner H, Heil G, Ehninger G. The High Prevalence of FLT3-ITD Mutations Is Associated with the Poor Outcome in Adult Patients with t(6;9)(p23;q34) Positive AML-Results of an International Metaanalysis. [abstract].49th Annual Meeting of the American Society of Hematology (ASH). 2007 December 8-11. Atlanta, GA. Blood. 2007 Nov 16;110(11):243a. Abstract # 761.



ABSTRACTS (cont.)

*367. Baer MR, George SL, Sanford BL, Bothun SM, Mrózek K, O’Loughlin KL, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, Larson RA. Cytarabine, Daunorubicin and Etoposide (ADE) Chemotherapy in Acute Myeloid Leukemia (AML) Patients ≥60 Years (CALGB 9720). [abstract]. 49th Annual Meeting of the American Society of Hematology (ASH). 2007 December 8-11. Atlanta, GA. Blood. 2007 Nov 16;110(11):94a. Abstract # 296.

*368. Corbacioglu A, Fröhling S, Paschka P, Marcucci G, Anhalt A, Urlbauer K, Krauter J, Larson R, Mrózek K, Ruppert AS, Ganser A, Caligiuri MA, Döhner H, Schlenk RF, Bloomfield CD, Döhner K. Acute myeloid leukemia (AML) with 9q aberrations occurring within a non-complex Karyotype is highly associated with CEBPA and NPM1 mutations – A joint analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB). [abstract]. 49th Annual Meeting of the American Society of Hematology (ASH). 2007 December 8-11. Atlanta, GA. Blood. 2007 Nov 16;110(11):234a-235a. Abstract # 762.

*369. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD. Gene and microRNA (miRNA) Expression Signatures and Prognostic Significance of CEBPA Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) with High-Risk Molecular Features: A Cancer and Leukemia Group B (CALGB) Study. [abstract]. 49th Annual Meeting of the American Society of Hematology (ASH). 2007 December 8-11. Atlanta, GA. Blood. 2007 Nov 16;110(11):39a. Abstract # 104.

370. Hackanson B, Bennett K, Brena R, Jiang J, Maharry K, Whitman SP, Schmittgen, TD, Lübbert M, Marcucci G, Bloomfield CD, Plass C. Dual Epigenetic Control of CCAAT/Enhancer Binding Protein α (C/EBPα) Expression in Acute Myeloid Leukemia. [abstract]. 49th Annual Meeting of the American Society of Hematology (ASH). 2007 December 8-11. Atlanta, GA. Blood. 2007 Nov 16;110 (11):630a. Abstract # 2116.

*371. Langer C, Maharry K, Mrózek K, Paschka P, Whitman SP, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD. Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study. [abstract]. Proceedings of the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2008 May 30-June 3. Chicago, IL. J Clin Oncol. 2008 May 20;26(15S):374S. Abstract # 7011.

*372 Stock W, Najib K, Moser BK, Powell BL, Holowka N, Gulati K, Bloomfield CD, Larson RA, Sher D. High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710) [abstract]. Proceedings of the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2008 May 30-June 3. Chicago, IL. J Clin Oncol. 2008 May 20;26(15S):372S. Abstract # 7002.

373. Hasserjian RP, Gupta P, Donohue K, Owzar K, Larson RA, Racke F, Bloomfield CD. Application of 2008 WHO Classification Criteria for Myelodysplastic Syndromes (MDS) Without Excess Blasts: Observations from Cancer and Leukemia Group B Study 10105. [abstract].United States and Canadian Academy of Pathology Annual Meeting. 2009 March 7-13. Boston, MA. Mod Pathol. 2009 Jan;22 (suppl 1):266a. Abstract # 1208.

*374. Schwind S, Marcucci G, Maharry K, Radmacher MD, Whitman SP, Paschka P, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD. MicroRNA 181α (miR-181 α) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML). [abstract]. Proceedings of the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2009 May 29-June 2. Orlando, FL. J Clin Oncol. 2009 May 20;27:15s. Abstract # 7001.

*375. Marcucci G, Maharry K, Whitman SP, Paschka P, Baldus CD, Langer C, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD. Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts). [abstract]. Proceedings of the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2009 May 29-June 2. Orlando, FL. J Clin Oncol. 2009 May 20;27:15s. Abstract # 7002.



ABSTRACTS (cont.)

*376. Becker H, Marcucci G, Maharry K, Margeson D, Radmacher MD, Whitman SP, Mrózek K, Baer MR, Larson RA, Bloomfield CD. NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML). [abstract]. Proceedings of the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2009 May 29-June 2. Orlando, FL. J Clin Oncol. 2009 May 20;27:15s. Abstract # 7000.

*377. Schwind S, Marcucci G, Maharry K, Mrózek K, Radmacher MD, Holland KB, Becker H, Whitman SP, Wu YZ, Baer MR, Powell BL, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD. Aberrant Gene Expression of BAALC and ERG in Older [≥60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study. [abstract]. 51st Annual Meeting of the American Society of Hematology (ASH). 2009 December 5-8. New Orleans, LA. Blood. 2009 Nov 20;114(22):93-4. Abstract # 214.

*378. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Whitman SP, Paschka P, Margeson D, Wu YZ, Schwind S, Langer MD, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson, MD, Bloomfield CD. Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study. [abstract]. 51st Annual Meeting of the American Society of Hematology (ASH). 2009 December 5-8. New Orleans, LA. Blood. 2009 Nov 20;114(22):138. Abstract # 326.

*379. Smooha G, Birger Y, Goldberg L, Jacob-Hirsch J, Amariglia N, Rechavi G, Levanon D, Groner Y, Taragan A, Kloog Y, Wen J, Crispino J, Radmacher MD, Marcucci G, Bloomfield CD, Izraeli S. Modeling and Targeting ERG-induced Acute Myeloid Leukemia (AML). [abstract]. 51st Annual Meeting of the American Society of Hematology (ASH). 2009 December 5-8. New Orleans, LA. Blood. 2009 Nov 20; 114(22):196. Abstract # 475.

*380. Farag S, Maharry K, Perez WS, Zhang MJ, DiPersio JF, Bunjes D, Marcucci G, Baer MR, Larson RA, Tallman M, Bloomfield CD, Weisdorf DJ. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/Cancer and Leukemia Group B (CALGB) Study. [abstract]. 51st Annual Meeting of the American Society of Hematology (ASH). 2009 December 5-8. New Orleans, LA. Blood. 2009 Nov 20;114(22):274. Abstract # 657.

*381. Stock W, Sanford B, Lozanski G, Cataland S, Vij R, Byrd JC, Powell BL, Wetzler M, Sher D, Edwards C, Sung C, Richards S, Kelly M, Hoke E, Bloomfield CD, Larson RA. Alemtuzumab Can Be Incorporated into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102). [abstract]. 51st Annual Meeting of the American Society of Hematology (ASH). 2009 December 5-8. New Orleans, LA.Blood. 2009 Nov 20;114(22):345. Abstract # 838.

382. Whitman SP, Maharry K, Radmacher MD, Mrózek K, Margeson D, Holland KB, Becker H, Wu YZ, Schwind S, Baer MR, Powell BL, Stone RM, Carroll JA, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study. [abstract]. 51st Annual Meeting of the American Society of Hematology (ASH). 2009 December 5-8. New Orleans, LA. Blood. 2009 Nov 20;114(22):631-2. Abstract # 1579.

383. Payton JE, Marcucci G, Radmacher MD, Maharry K, Langer C, Baldus CD, Bloomfield CD, Ley TJ. Multiplexed Digital Quantification of mRNA Abundance: a Highly Reproducible, PCR–independent Assessment of BAALC, ERG, and MN1 mRNA Levels in Acute Myeloid Leukemia (AML) Bone Marrow (BM) and Peripheral Blood (PB) Samples. [abstract]. 51st Annual Meeting of the American Society of Hematology (ASH).2009 December 5-8. New Orleans, LA. Blood. 2009 Nov 20;114(22):639. Abstract # 1599.



ABSTRACTS (cont.)

384. Attar EC, Maharry K, Mrózek K, Radmacher MD, Whitman SP, Paschka P, Langer C, Holland KB, Powell BL, Kolitz JE, Carroll AJ, Larson RA, Marcucci G, Bloomfield CD. Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study. [abstract]. 51st Annual Meeting of the American Society of Hematology (ASH). 2009 December 5-8. New Orleans, LA. Blood. 2009 Nov 20;114(22):645-6. Abstract # 1616.

*385. Mrózek K, Holland KB, Pettanati MJ, Maharry K, Marcucci G, Baer MR, Kolitz JE, Margeson D, Edwards CG, Carroll AJ, Larson RA, Bloomfield CD. Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define “Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes” in Adults: a Cancer and Leukemia Group B (CALGB) Study. [abstract]. 51st Annual Meeting of the American Society of Hematology (ASH). 2009 December 5-8. New Orleans, LA. Blood. 2009 Nov 20;114(22):1021. Abstract #2602.

386. Schwind S, Marcucci G, Holland KB, Mrózek K, Radmacher MD, Maharry K, Becker H, Whitman SP, Wu Y, Carter TH, Powell BL, Caligiuri MA, Baer MR, Larson RA, Bloomfield CD. Higher MN1 expression is an unfavorable prognosticator in older patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A CALGB study. [abstract]. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research (AACR). 2010 April 19-21. Washington D.C. Proc. Am. Assoc. Cancer Res. 2010;51:660. Abstract # 2717.

*387. Becker H, Marcucci G, Maharry K, Radmacher MD, Wu Y, Mrózek K, Whitman SP, Margeson D, Holland KB, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD. CEBPA double mutations impact favorable on the outcome of older adults with wild-type NPM1 cytogenetically normal acute myeloid leukemia and are associated with distinct gene and microRNA expression. [abstract]. 15th Congress of the European Hematology Association (EHA), 2010 June 10-13. Barcelona, Spain. Haematologica. 2010 Jun;95(suppl 2):247-248. Abstract # 0593.

*388. Marcucci G, Maharry K, Wu Y, Radmacher MD, Mrózek K, Margeson D, Holland, KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Baer MR, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study. [abstract]. 15th Congress of the European Hematology Association (EHA). 2010 June 10-13. Barcelona, Spain. Haematologica. 2010 Jun;95(suppl 2):456. Abstract # 1107.

389. Metzeler K, Maharry K, Margeson D, Curfman J, Becker H, Radmacher MD, Mrózek K, Holland KB, Whitman SP, Wu YZ, Schwind S, Blum W, Powell BL, Carter TH, Baer, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD. TET2 mutations occur in over 20% of adults with de novo cytogenetically normal acute myeloid leukemia, and their prevalence increases with age: A Cancer and Leukemia Group B study. [abstract]. 15th Congress of the European Hematology Association (EHA). 2010 June 10-13. Barcelona, Spain. Haematologica. 2010 Jun;95(suppl 2):12-13. Abstract # 0030.

*390. Bloomfield, CD. The Role of Molecular Markers in the Classification of Leukemias: Diagnostic and Therapeutic Implications. [abstract]. ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer. October 18-20, 2010. Hollywood, FL.

*391. Becker H, Maharry K, Radmacher, Margeson D, Mrózek K, Whitman SP, PhD1*, Wu Y-Z, Metzeler KH, Schwind S, Holland KB, Kolitz JE, Carroll AJ, Caligiuri MA, Baer MR, Larson RA, Marcucci G, Bloomfield CD. Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study. [abstract]. 52nd Annual Meeting of the American Society of Hematology (ASH). 2010 December 4-7. Orlando, FL. Blood. 2010 Nov 19;116(21):255. Abstract # 577.



ABSTRACTS (cont.)

392. Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, Ketterling R, Ralston D, Schachter-Tokarz E, Zhou D, Chen IL, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Appelbaum FR, Larson RA, Powell BL, Paietta E, Willman CL, Stock W. Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710. [abstract]. 52nd Annual Meeting of the American Society of Hematology (ASH). 2010 December 4-7. Orlando, FL. Blood. 2010 Nov 19;116(21):456. Abstract # 1038.

*393. Metzeler KH, Maharry K, Radmacher, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu Y-Z, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. Mutations In the Tet Oncogene Family Member 2 (TET2) gene refine the New European LeukemiaNet (ELN) Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B Study. [abstract]. 52nd Annual Meeting of the American Society of Hematology (ASH). 2010 December 4-7. Orlando, FL. Blood. 2010 Nov 19;116(21):48-49. Abstract # 98.

*394. Bloomfield CD. Molecular Markers in Cytogenetically Normal Elderly Acute Myeloid Leukemia. [abstract]. International Symposium Acute Leukemias XIII. 2011 February 27-March 2. Munich, Germany. Ann Hematol. 2011 Feb;90 (suppl 1):S34-S35.

*395. Metzeler KH, Maharry K, Radmacher M, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB,

Schwind S, Whitman SP, Wu Y-Z, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. Mutations in the TET Oncogene Family Member 2 (TET2) Gene Refine the New European Leukemia Net Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia in Adults: a Cancer and Leukemia Group B Study. [abstract]. International Symposium Acute Leukemias XIII. 2011 February 27-March 2. Munich, Germany. Ann Hematol. 2011 Feb; 90 (suppl 1):S8. Abstract #8.

*396. Schwind S, Marcucci G, Holland KB, Mrózek K, Radmacher MD, Maharry K, Becker H, Whitman SP, Wu Y, Carter TH, Powell BL, Caligiuri MA, Baer MR, Larson RA, Bloomfield CD. Higher MN1 expression is an unfavorable prognosticator in older patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A CALGB study. [abstract]. 9th Annual Midwest Blood Club Symposium. 2011 April 21-22. Cincinnati, OH.

*397. Douer D, Zickl L, Schiffer C, Appelbaum FR, Feusner JH, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH, Tallman MS. Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia are Uncommon, Respond Well to Salvage Therapy and Occur Independently Of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129. [abstract]. 53rd Annual Meeting of the American Society of Hematology (ASH). 2011 December 10-13. San Diego, CA. Blood. 2011 Nov 18;118(21):40. Abstract #83.

398. Edwards CG, Maharry K, Mrózek K, Schwind S, Paschka P, Nicolet D, Kohlschmidt J, Prior TW, Wu YZ, Kolitz JE, Blum W, Pettenati MJ, Dal Cin P, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD. Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16). [abstract]. 53rd Annual Meeting of the American Society of Hematology (ASH). 2011 December 10-13. San Diego, CA. Blood. 2011 Nov 18;118(21):1077. Abstract #2514.

399. Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Whitman SP, Metzeler KH, Mrózek K, Wu YZ, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, de la Chapelle A, Bloomfield CD. MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). [abstract]. 53rd Annual Meeting of the American Society of Hematology (ASH). 2011 December 10-13. San Diego, CA. Blood. 2011 Nov 18;118(21):635. Abstract #1462.



ABSTRACTS (cont.)

*400. Huang X, Schwind S, Yu B, Pang J, Santhanam R, Chan K, Garzon R, Blum W, Bloomfield CD, Liu S, Perrotti D, Lee RJ, Byrd JC, Muthasamy N, Lee LJ, Marcucci G. Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML). [abstract]. 53rd Annual Meeting of the American Society of Hematology (ASH). 2011 December 10-13. San Diego, CA. Blood. 2011 Nov 18;118(21):39. Abstract #81.

401. Koval G, Wetzler M, Owzar K, Bloomfield CD, Malnassy G, Sher D, Larson RA, Stock W. Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001. [abstract]. 53rd Annual Meeting of the American Society of Hematology (ASH). 2011 December 10-13. San Diego, CA. Blood. 2011 Nov 18;118(21):1090. Abstract #2541.

*402. Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, Price C, Dohner K, Zhang Z, Shen C, Neilly MB, Lussier YA, Zhang Y, Larson RA, le Beau MM, Caligiuri MA, Bullinger L, Valk PJM, Delwel R, Lowenberg B, Liu PP, Marcucci G, Bloomfield CD, Rowley JD, Chen J. Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia. [abstract]. 53rd Annual Meeting of the American Society of Hematology (ASH). 2011 December 10-13. San Diego, CA. Blood. 2011 Nov 18;118(21):108. Abstract # 236.

403. Mendler JH, Maharry K, Radmacher MD, Mrózek K, Kohlschmidt J, Nicolet D, Becker H, Metzeler KH, Schwind S, Whitman SP, Blum W, Powell BL, Kolitz JE, Carter TH, Wetzler M, Moore JO, Carroll AJ, Baer MR, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures. [abstract]. 53rd Annual Meeting of the American Society of Hematology (ASH). 2011 December 10-13. San Diego, CA. Blood. 2011 Nov 18;118(21):1476-1477. Abstract #3454.

*404. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Cartder TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet ‘Favorable’ Genetic Category. [abstract]. 53rd Annual Meeting of the American Society of Hematology (ASH). 2011 December 10-13. San Diego, CA. Blood. 2011 Nov 18;118(21):192. Abstract #417.

*405. Mrózek K, Marcucci G, Maharry K, Nicolet D, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu YZ, Kohlschmidt J, Pettenati MJ, Koduru PRK, Heerema NA, Block AW, Patil SR, Baer ME, Kolitz JE, Moore JO, Carroll AJ, Larson RA, Bloomfield CD. Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts). [abstract]. 53rd Annual Meeting of the American Society of Hematology (ASH). 2011 December 10-13. San Diego, CA. Blood. 2011 Nov 18;118(21):190-191. Abstract #414.

406. Wetzler M, Kohlschmidt J, Mrózek K, Dombret H, Döhner H, Pilorge S, Krug U, Larson RA, Marcucci G, Hiddemann W, Buchner T, Bloomfield CD. Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML) - An International Study. [abstract]. 53rd Annual Meeting of the American Society of Hematology (ASH). 2011 December 10-13. San Diego, CA. Blood. 2011 Nov 18;118(21):1080-1081. Abstract #2521.

407. Becker H, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu Y, Metzeler KH, Schwind S, Holland KB, Kolitz JE, Carroll AJ, Caligiuri MA, Baer MR, Larson RA, Marcucci G, Bloomfield CD. Sole Trisomy 8 In Patients with De Novo Acute Myeloid Leukemia Is Associated with Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and microRNA-Signatures a Cancer and Leukemia Group B (CALGB) Study. [abstract]. 5th Mildred Scheel Cancer Conference. 2011 July 13-15. Königswinter, Germany.



ABSTRACTS (cont.)

408. Eisfeld AK, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K, Nicolet D, Radmacher MD, Döhner H, Tanner SM, Bloomfield CD, de la Chapelle A. Heritable polymorphism predisposes to high expression of BAALC in cytogenetically normal acute myeloid leukemia (CN-AML). [abstract]. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research (AACR). 2012 March 31-April 4. Chicago, IL. Cancer Res. 2012;72(suppl 8):316. Abstract # 1307.

409. Huang X, Schwind S, Eisfeld AK, Yu B, Hickey CJ, Pang J, Santhanam R, Chan K, Perrotti D, Muthusamy N, Byrd JC, Blum W, Bloomfield CD, Liu S, Garzon R, Lee RJ, Lee LJ, Marcucci G. Synthetic microRNA (miR)-181α nanoparticles (NP) target RAS and sensitize cells to daunorubicin (DNR) in acute myeloid leukemia (AML). [abstract]. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research (AACR). 2012 March 31-April 4. Chicago, IL. Cancer Res. 2012;72(suppl 8):271-272. Abstract #1111.

*410. Schwind S, Blum W, Liu S, Tarighat SS, Geyer S, Klisovic R, Eisfeld AK, Walker A, Whitman SP, Santhanam R, Wu YZ, Jacob S, Caligiuri MA, Grever MR, Perrotti D, Byrd JC, Bloomfield CD, Garzon R, Marcucci G. The Combination of Bortezomib (BOR) and Decitabine (DEC): a Phase I Trial in Patients (Pts) with Acute Myeloid Leukemia (AML) targeting FLT3 expression. [abstract]. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research (AACR). 2012 March 31-April 4. Chicago, IL. Cancer Res. 2012;72(suppl 8): Abstract # CT-06.

*411. Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees PM, Wang ES, Blum WG, Marcucci G, Bloomfield CD, Moser BK, Stone RM, Larson RA, CALGB. A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. [abstract]. Proceedings of the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO). 2012 June 1-5. Chicago IL. J Clin Oncol. 2012 May 30;30(suppl 15). Abstract # 6526.

*412. Metzeler KH, Maharry K, Kohlschmidt J, Mrózek K, Volinia S, Becker H, Schwind S, Mendler JH, Eisfeld A-K, Whitman SP, Wu Y-Z, Powell BL, Carter TH, Kolitz JE, Baer MR, Carroll AJ, Caligiuri MA, Stone RM, Marcucci G, Bloomfield CD. A leukemia stem cell gene expression signature associates with a distinct microRNA expression profile and worse treatment outcomes in older adults with primary cytogenetically normal acute myeloid leukemia. [abstract]. 17th Congress of the European Hematology Association (EHA). 2012 June 14-17. Amsterdam, The Netherlands. Haematologica. 2012 Jun; 97(suppl 1):465. Abstract # 1128.

*413. Huang X, Schwind S, Yu B, Liu S, Pang J, Santhanam R, Wu Y-Z, Chan KK, Blum W, Bloomfield CD, Perroti D, Garzon R, Byrd JC, Muthusamy N, Lee RJ, Marcucci G, Lee LJ. A Novel Anionic Nanoparticle Delivery System for microRNA-29b Targets FLT3 and KIT Receptor Tyrosine Kinase Expression in Acute Myeloid Leukemia. [abstract]. American Institute of Chemical Engineers 2012 Annual Meeting. 2012 October 28-November 2. Pittsburgh, PA. Abstract # 326a.

*414. Alachkar H, Maharry K, Santhanam R, Neviani P, Volinia S, Kohlschmidt J, Metzeler KH, Dorrance AM, Schwind S, Becker H, Mendler J, Eisfeld A-K, Whitman SP, Mrózek K, Garzon R, Perrotti D, Caligiuri MA, Stone RM, Marcucci G, Bloomfield CD. SPARC Contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML). [abstract]. 54th Annual Meeting of the American Society of Hematology (ASH). 2012 December 8-11. Atlanta, GA. Blood. 2012 Nov 16:120(21). Abstract # 773.

*415. Blum W, Geyer S, Klisovic R, Sanford B, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wetzler M, Hoke E, Bloomfield CD, Mrozek K, Marcucci G, Stone RM, Larson RA. Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: a Phase II Cancer and Leukemia Group B Study (CALGB 10503). [abstract]. 54th Annual Meeting of the American Society of Hematology (ASH). 2012 December 8-11. Atlanta, GA. Blood. 2012 Nov 16:120(21). Abstract # 44.



ABSTRACTS (cont.)

416. Huang X, Schwind S, Eisfeld AK, Yu B, Santhanam R, Hoellerbauer P, Jin Y, Hickey CJ, Pang J, Perrotti D, Muthusamy N, Byrd JC, Blum W, Bloomfield CD, Liu S,Garzon R, Lee RJ, Lee LJ, Marcucci G. Therapeutic Targeting of the RAS-pathway by Synthetic miR-181a Nanoparticles in Acute Myeloid Leukemia (AML). [abstract]. 54th Annual Meeting of the American Society of Hematology (ASH). 2012 December 8-11. Atlanta, GA. Blood. 2012 Nov 16:120(21). Abstract # 2422.

417. Marcucci G, Maharry K, Metzeler KH, Volinia S, Wu Y-Z, Mrózek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld A-K, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CD. The Clinical Role of microRNAs (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts). [abstract]. 54th Annual Meeting of the American Society of Hematology (ASH). 2012 December 8-11. Atlanta, GA. Blood. 2012 Nov 16:120(21). Abstract # 1387.

*418. Wetzler M, Watson D, Owzar K, Koval G, Stock W, Hoke EE, McCarty JM, Blum W, Powell B, Marcucci G, Bloomfield CD, Linker CA, Larson RA. Autologous Transplantation for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001. [abstract]. 54th Annual Meeting of the American Society of Hematology (ASH). 2012 December 8-11. Atlanta, GA. Blood. 2012 Nov 16:120(21). Abstract # 816.

419. Whitman S, Kohlschmidt J, Maharry K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mrózek K, Mendler JH, Eisfeld A-K, Volinia S, Powell BL, Carter TH, Kolitz JE, Stone RM, Park I-K, Caligiuri MA, Marcucci G, Bloomfield CD. Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance). [abstract]. 54th Annual Meeting of the American Society of Hematology (ASH). 2012 December 8-11. Atlanta, GA. Blood. 2012 Nov 16:120(21). Abstract # 1293.

420. Eisfeld A-K, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, Jarvinen TM, Leffel B, Perrotti D, Marcucci G, Bloomfield CD, de la Chapelle A. Overexpression of Intronic mIR-3151 and Its Host gene BAALC Increases Leukemogenesis in Acute Myeloid Leukemia (AML) By Direct Deregulation of TP53 and May Be Targeted By Bortezomib. [abstract]. 18th Congress of the European Hematology Association (EHA). 2013 June 13-16. Stockholm, Sweden. Haematol. 2013 Jun:98(suppl 1):8. Abstract # P020.

*421. Goldberg L, Tijssen M, Birger Y, Hannah RL, Kinston SJ, Jacob-Hirsch J, Schiby G, Biran A, Kloog Y, Marcucci G, Bloomfield CD, Göttgens B, Izraeli S. Genome-scale Expression and Transcription Factor Binding Profiles Reveal Therapeutic Targets in Transgenic ERG Myeloid Leukemia. [abstract]. 18th Congress of the European Hematology Association (EHA). 2013 June 13-16. Stockholm, Sweden. Haematol. 2013 Jun:98(suppl 1):233. Abstract # S557.

*422. Niederwieser C, Kohlschmidt J, Maharry K, Mrózek K, Metzeler KH, Volinia S, Yan P, Frankhouser

D, Whitman SP, Becker H, Eisfeld A-K, Schwind S, Curfman J, Wu Y-Z, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Marcucci G, Bloomfield CD. High Expression of DNMT3B Negatively Impacts on Clinical Outcome of Older Patients (pts) With Primary Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) [CALGB 20202 (Alliance)]. [abstract]. 18th Congress of the European Hematology Association (EHA). 2013 June 13-16. Stockholm, Sweden. Haematol. 2013 Jun:98(suppl 1):484. Abstract # S1168.

423. Schwind S, Jentzsch M, Lange T, Pönisch W, Heyn S, Vucinic V, Franke GN, Krahl R, Jäkel N, Al-Ali

H, Cross M, Behre G, Marcucci G, Bloomfield CD, Niederwieser D. Low Pre-treatment mIR-181A-1 and mIR-181A-2 Expression Associates With Relapse in Intermediate Risk Acute Myeloid Leukemia (AML) After Reduced-intensity Conditioning (RIC) Allogeneic Transplantation. [abstract]. 18th Congress of the European Hematology Association (EHA). 2013 June 13-16. Stockholm, Sweden. Haematol. 2013 Jun:98(suppl 1):154. Abstract # P362.



ABSTRACTS (cont.)

*424. Eisfeld A-K, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrózek K, Whitman SP, Metzeler KH, Mendler JH, Wu Y-Z, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, de la Chapelle A, Bloomfield CD. miR-3151 interplays with its host gene BAALC and independently impacts on outcome of older patients with cytogenetically normal acute myeloid leukemia by direct deregulation of TP53. [abstract]. Society of Hematologic Oncology (SOHO) Annual Meeting. 2013 September 18-21. Houston, Texas. Clin Lymphoma Myeloma Leuk. 2014 Sept:14(suppl):S157. Selected for an oral and poster presentation.

*425. Schwind S, Jentzsch M, Lange T, Pönisch W, Heyn S, Vucinic V, Franke GN, Krahl R, Jäkel N, Al-Ali HK, Cross M, Behre G, Marcucci G, Bloomfield CD, Niederwieser D. High pretreatment miR-181a-1 and/or miR-181a-2 expression in intermediate risk acute myeloid leukemia (AML) patients (pts) associates with lower relapse rates after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT). [abstract]. Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO). German Society of Hematology and Medical Oncology Annual Meeting. 2013 October 18-22. Vienna, Austria. Onkologie. Abstract # V652.

426. Niederwieser C, Kohlschmidt J, Mrózek K, Maharry K, Metzeler KH, Volinia S, Yan P, Frankhouser D, Whitman SP, Becker H, Eisfeld A-K, Schwind S, Curfman J, Wu Y-Z, Baer M-R, Powell B-L, Kolitz JE, Moore JO, Carter TH, Marcucci G, Bloomfield CD. High Expression of DNMT3B Negatively Impacts on Clinical Outcome of Older Patients with de novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). [abstract]. Alliance for Clinical Trials in Oncology 2013 Group Meeting. 2013 November 7-10. Chicago, IL.

*427. Marcucci G, Geyer S, Zhao W, Carroll AJ, Bucci D, Powell BL, Blum W, Uy GL, Wetzler M, Stock W, Bloomfield CD, Larson RA, Stone RM. Adding the KIT Inhibitor Dasatinib (DAS) to Standard Induction and Consolidation Therapy for Newly Diagnosed Patients (pts) with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results of the CALGB 10801 (Alliance) Study. [abstract]. 55th Annual Meeting of the American Society of Hematology (ASH). 2013 December 6-10. New Orleans, Louisiana. Blood. 2013 Oct 21:122(21). Abstract # 357.

428. Papaioannou D, Maharry K, Mrózek K, MD, Becker H, Metzeler KH, Mendler JH, Whitman SP, Eisfeld A-K, Schwind S, Wu Y-Z, Nicolet D, Kolitz JE, Baer MR, Powell BL, Bucci D, Carroll AJ, Volinia S, Stone RM, Marcucci G, Bloomfield CD. Differential Clinical Impact of Gene Mutations and Their Combinations in Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). [abstract]. 55th Annual Meeting of the American Society of Hematology (ASH). 2013 December 6-10. New Orleans, Louisiana. Blood. 2013 Oct 21:122(21). Abstract # 2540.

429. Pastore F, Dufour A, BenthausT, Metzeler KH, Maharry K, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Sauerland C, Heinecke A, Krug U, Berdel WE, Buechner T, Woermann B, Hiddemann W, Bohlander SK, Marcucci G, Spiekermann K, Bloomfield CD, Hoster E. A combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal AML (PINA). [abstract]. 55th Annual Meeting of the American Society of Hematology (ASH). 2013 December 6-10. New Orleans, Louisiana. Blood. 2013 Oct 21:122(21). Abstract # 1303.

*430. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Cheng J, Zhang J, Song G, Yang Y-L, Santiago-Morales N, Ping D, Cheng C, Ma J, Chen S-C, Rusch M, Gupta P, Devidas M, Chen I-M, Larsen E, Winick N, Carroll W, Heerema N, Carroll AJ, Gastier-Foster J, Raetz E, Pui C-H, Jeha S, Downing J, Paietta E, Kornblau SM, Marcucci G, Bloomfield CD, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG. Genomic Characterization and Experimental Modeling of BCR-ABL1-like Acute Lymphoblastic Leukemia. [abstract]. 55th Annual Meeting of the American Society of Hematology (ASH). 2013 December 6-10. New Orleans, Louisiana. Blood. 2013 Oct 21:122(21). Abstract # 232.



ABSTRACTS (cont.)

*431. Roberts KG, Payne-Turner D, Pei D, Becksfort J, Harvey RC, Li Y, Song G, Cheng J, Zhang J, Ma J, Cheng C, Chen S-C, Pui C-H, Jeha S, Paietta E, Kornblau SM, Marcucci G, Bloomfield CD, Gerhard DS, Loh ML, Hunger SP, Willman CL, Mullighan CG. Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. [abstract]. 55th Annual Meeting of the American Society of Hematology (ASH). 2013 December 6-10. New Orleans, Louisiana. Blood. 2013 Oct 21:122(21). Abstract # 825.

432. Maharry SE, Mehta S, Liyanarachchi S, Marcucci G, Bloomfield CD, de la Chapelle A, Eisfeld A-K. Identification of microRNA-3662 as a novel tumor suppressor miR. [abstract]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research (AACR). 2014 April 5-9. San Diego, CA. Cancer Res. 2014 Apr:55(1):1260. Abstract # 5235.

Awards received for this abstract: a) Sophia E. Maharry - AACR Special High School Competition Achievement Award b) Sujay Mehta - AACR-Gerry J. Miller Undergraduate Student Prize for Cancer and Cancer Related Biomedical Research Third Place Award

433. Roberts KG, Li Y, Payne-Turner D, Zhang J, Harvey RC, Yang Y-L, Song G, Ma J, Chen S-C, Cheng J, Santiago-Morales N, Devidas M, Chen I-M, Reshmi S, Rusch M, Gupta P, Winick NJ, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Marcucci G, Bloomfield CD, Stock W, Kornblau SM, Paietta E, Pui C-H, Jeha S, Downing J, Gerhard DS, Gastier-Foster JM, Loh ML, Willman C, Hunger SP, Mullighan CG. The genetic landscape of Ph-like acute lymphoblastic leukemia. [abstract]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research (AACR). 2014 April 5-9. San Diego, CA. Cancer Res. 2014 Apr:55(1):745-6. Abstract # 3083.

*434. Kohlschmidt JK, Maharry KS, Bloomfield CD. The Role of Akaike Weights in Model Selection. [abstract]. Proceedings of the 2014 Annual Joint Statistical Meeting (JSM) of the American Statistical Association (ASA). 2014 August 2-7. Boston, Massachusetts. 2014. Abstract # 313242.

435. Bloomfield CD. Clinical significance of molecular findings in acute myeloid leukemia. [abstract]. Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies. 2014 September 20-23. Philadelphia, PA. Clin Cancer Res. 2015;21(17 Suppl). Abstract # IA01.

436. Maharry SE, Mehta S, Liyanarachchi S, Walker CJ, Bloomfield CD, de la Chapelle A, Eisfeld A-K. MicroRNA-3662 Located within the Major Hematopoietic Differentiation Quantitative Trait Locus on Chromosome 6q23 Acts as a Tumor Suppressor by Direct Targeting of the NF-ĸB Transcriptional Activation Pathway. [abstract]. 56th Annual Meeting of the American Society of Hematology (ASH). 2014 December 6-9. San Francisco, California. Blood. 2014 Nov 14:124(21). Abstract # 2216.

Awards received for this abstract: a) Sophia E. Maharry – ASH Abstract Achievement Award

*437. Marcucci G, Geyer S, Zhao W, Carroll AJ, Bucci D, Uy G, Blum W, Pardee T, Wetzler M, Stock W, Kolitz JE, Eisfeld A-K, Bloomfield CD, Stone RM, Larson RA. Adding the KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from Alliance CALGB study 10801. [abstract]. 56th Annual Meeting of the American Society of Hematology (ASH). 2014 December 6-9. San Francisco, California. Blood. 2014 Nov 14:124(21). Abstract # 8.

*438. Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, Harvey RC, Payne-Turner D, Devidas M, Chen I-M, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Gastier-Foster JM, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui C-H, Jeha S, Relling MV, Evans WE, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG, Yang JJ. A Genome-wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescent and Young Adults. [abstract]. 56th Annual Meeting of the American Society of Hematology (ASH). 2014 December 6-9. San Francisco, California. Blood. 2014 Nov 14:124(21). Abstract # 132.



ABSTRACTS (cont.)

439. Sood R, Hansen N, Donovan F, Carrington B, Maskeri B, Young A, Bucci D, Chandrasekharappa S, Mullikin J, Bloomfield CD, Marcucci G, Liu P. Somatic Mutational Landscape of AML with inv(16) and t(8;21) Identifies Two Distinct Patterns In Relapse Tumors. [abstract]. 56th Annual Meeting of the American Society of Hematology (ASH). 2014 December 6-9. San Francisco, California. Blood. 2014 Nov 14:124(21). Abstract # 2362.

*440. Bloomfield CD. New Molecular Diagnostic Characterization of AML in the 2015 WHO Classification. [abstract]. International Symposium Acute Leukemias XV. 2015 February 22-25. Munich, Germany. Ann Hematol. 2015 Feb;94 (suppl. 1):S19.

*441. Bloomfield CD. Biological Heterogeneity of Acute Myeloid Leukemia: Implications for Prognosis and Treatment. 5th Annual Meeting of the Society for Translational Oncology (STO). 2015 April 10-11. Columbus, Ohio. The Oncologist. 2015 Apr;20(Suppl. 1):S2.

442. Mitchell S, Orwick S, Cannon M, Goettl V, Lafollette T, Baloglu E, Senapedis W, Walker A, Bhatnagar B, Mims A, Klisovic R, Vasu S, Blum W, Lucas DM, Blachly B, Garzon R, Bloomfield CD, Lapalombella R*, Byrd JC* *Co-senior author. In vitro and in vivo anti-leukemic effects of KPT-9274, a, Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in this disease. [abstract]. 57th Meeting of the American Society of Hematology (ASH). 2015 December 5-8. Orlando, Florida. Blood. 2015 Dec 3:126(23). Abstract # 2471.

443. Rizzotto L, Lai T-H, Liu C, Bottoni A, Bloomfield CD, Byrd JC, Sampath D. Histone deacetylase

inhibitors induce microRNAs targeting BTK in acute myeloid leukemia. [abstract]. 57th Annual Meeting of the American Society of Hematology (ASH). 2015 December 5-8. Orlando, Florida. Blood. 2015 Dec 3:126(23). Abstract # 1222.

444. Roberts KG, Payne-Turner D, McCastlain K, Iacobucci I, Harvey RC, Chen I-M, Gu Z, Valentine M,

Pei D, Cheng C, Rambaldi A, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Marcucci G, Kohlschmidt J, Mrozek K, Bloomfield CD, Stock W, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Mullighan CG. High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults . [abstract]. 57th Annual Meeting of the American Society of Hematology (ASH). 2015 December 5-8. Orlando, Florida. Blood. 2015 Dec 3:126(23). Abstract # 2618.

*445. Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M,

Roulston D, Bloomfield CD, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Appelbaum FR,. Erba HP. Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. [abstract]. 57th Meeting of the American Society of Hematology (ASH). 2015 December 5-8. Orlando, Florida. Blood. 2015 Dec 3:126(23). Abstract # 908.

*446. Stone RM, Mandrekar S, Sanford BL, Geyer S, Bloomfield CD, Dohner K, Thiede C, Marcucci G,

Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, MD14, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Dohner H. The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (Pts) Age 18-60 with FLT3 Mutations (muts) : An International Prospective Randomized (rand)Â P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). [abstract]. 57th Annual Meeting of the American Society of Hematology (ASH). 2015 December 5-8. Orlando, Florida. Blood. 2015 Dec3:126(23). Abstract # 6.

mailto:[email protected]



ABSTRACTS (cont.)

*447. Uy GL, Mandrekar S, Laumann K, Sanford B, Marcucci G, Zhao W, Levis M, Klepin HD, Powell BL, Baer MR, Westervelt P, DeAngelo DJ, Stock W, Bloomfield CD, Byrd JC, Stone RM, Larson RA. Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults With FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001). [abstract]. 57th Annual Meeting of the American Society of Hematology (ASH). 2015 December 5-8. Orlando, Florida. Blood. 2015 Dec 3:126(23). Abstract # 319.

*448. Zhang J, McCastlain K, Qu C, Wu G, Li Y, Wei L, Payne-Turner D, Yoshihara H, Churchman M,

Waanders E, Ntziachristos P, Aifantis I, Roberts K, Ma J, Song G, Easton J, Parker M, Chen X, Rusch M, Edmonson M, Boggs K, Vadodaria B, Valentine M, Hedlund E, Ding L, Lu C, Fulton RS, Fulton LL, Tabib Y,Ochoa K, Devidas M, Pei D, Cheng C, Evans WE, Pui C-H, Jeha S, Harvey R, Chen I-M, Willman C, Marcucci G, Bloomfield CD, Stock W, Kohlschmidt J, Mrozek K, Paietta E, Tallman M, Kornblau S, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Hunger SP, Loh ML, Downing JR, Mullighan CG, and the St Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project. Expression of an oncogenic ERG isoform characterizes a distinct subtype of B-progenitor acute lymphoblastic leukemia. [abstract]. 57th Annual Meeting of the American Society of Hematology (ASH). 2015 December 5-8. Orlando, Florida. Blood. 2015 Dec 3:126(23). Abstract # 693.

449. Maharry SE, Walker CJ, Liyanarachchi S, Mehta S, Blachly JS, Guttridge DC, Bloomfield CD, de la Chapelle A, Eisfeld A-K. Dissection of the major hematopoietic quantitative trait locus in chromosome 6q23.3 identifies miR-3662 as a player in hematopoiesis and AML. [abstract]. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR). 2016 April 16-20. San Diego, CA. Cancer Res. 2016 Jul 15:76(suppl 14). Abstract # 1117.

*450. Papaioannou D, Nicolet D, Volinia S, Mrózek K, Yan P, Carroll AJ, Kohlschmidt J, Blum W, Powell BL, Uy GL, Kolitz JE, Wang ES, Eisfeld A-K, Lucas DM, Caligiuri MA, Stone RM, Byrd JC, Garzon R, Bloomfield CD. Long non-coding RNA profiling providers important prognostic information and biologic insights in younger patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML). [abstract]. 21st Congress of the European Hematology Association (EHA). 2016 June 9-12. Copenhagen, Denmark. Haematol. 2016 Jun 9:101(suppl 1):326. Abstract # S810.

*451. Eisfeld A-K, Mrozek K, Kohlschmidt J, Nicolet D, Orwik S, Kroll KW, Blachly JS, Carroll AJ, Kolitz JE, Powell BL, Wang E, Stone RM, de la Chapelle A, *Byrd JC, *Bloomfield CD. *Co-senior author. The mutational patterns associated with cytogenetic subsets of de novo acute myeloid leukemia (AML): A study of 1603 adult patients (pts).[abstract]. 58th Annual Meeting of the American Society of Hematology (ASH). 2016 December 3-6. San Diego, CA. Blood. 2016 Dec 3:128(22). Abstract # 287.

452. Eisfeld A-K, Kohlschmidt J, Schwind S, Nicolet D, Blachly JS, Orwick S, Shah C, Bainazar M, Kroll KW, Walker CJ, Carroll AJ, Powell BL, Stone RM, Kolits JE, Baer MR, de la Chapelle A, *Mrozek K, *Byrd JC, *Bloomfield CD. *Co-senior authors. CCND1 and CCND2 mutations are frequent in adults with core-binding factor acute myeloid leukemia (CBF-AML) with t(8;32)(q22;122). [abstract]. 58th Annual Meeting of the American Society of Hematology (ASH). 2016 December 3-6. San Diego, CA. Blood. 2016 Dec 3:128(22). Abstract # 2740.

*453. Mims A, Klisovic R, Garzon R, Walker A, Devine SM, Walsh K, Vasu S, Marcucci G, Caligiuri M, Bloomfield CD, Byrd JC, Grever MR, Blum W. A novel regimen for acute myeloid leukemia with MLL Partial tandem duplication: results of a phase 1 study NCI 8485. [abstract]. 58th Annual Meeting of the American Society of Hematology (ASH). 2016 December 3-6. San Diego, CA. Blood. 2016 Dec 3:128(22). Abstract # 900.

454. Papaioannou D, Petri A, Thrue CA, Stefano V, Kroll K, Yan P, Bundschuh R, Singh G, Kauppinen S, Bloomfield CD, Dorrance A, Garzon R. HOXB-AS3 regulates cell cycle progression and interacts with the drosophila splicing human behavior (DSHB) complex in NPM1-mutated acute myeloid leukemia. [abstract]. 58th Annual Meeting of the American Society of Hematology (ASH). 2016 December 3-6. San Diego, CA. Blood. 2016 Dec 3:128(22). Abstract # 1514.



ABSTRACTS (cont.)

455. Shen C, Papaioannou D, McNeil B, Nicolet D, Karunasiri M, Burke M, Zitzer N, Behbehani GK, Ozer HG, Yilmaz SA, Marcucci G, Caligiuri MA, Bloomfield CD, Garzon R, Dorrance AM. EGFL7 antagonized NOTCH signaling, stimulates blast proliferation and confers poor prognosis in cytogentically-normal acute myeloid leukemia (CN-AML). [abstract]. 58th Annual Meeting of the American Society of Hematology (ASH). 2016 December 3-6. San Diego, CA. Blood. 2016 Dec 3:128(22). Abstract # 2689.

*456. Bloomfield CD. New Molecular Diagnostic Characterization of Acute Myeloid Leukemia in the 2015 World Health Organization Classification [abstract]. International Symposium Acute Leukemias XVI. 2017 February 19-22. Munich, Germany. Ann Hematol. 2017 Feb;96 (suppl. 1):S17.

457. Blachly JS, Eisfeld A-K, Kohlschmidt J, Nicolet D, Orwick S, Kolitz JE, Powell BL, Wang ES, Stone

RM, Lucas DM, Wen J, Mrózek K, Bloomfield CD, Byrd JC. Quantification of FLT3 internal tandem duplication (FLT3-ITD) status by amplicon high throughput sequencing produces superior estimates of patient survival versus capillary electrophoresis. [abstract]. NCCN 22nd Annual Conference. 2017 March 23-25. Orlando, FL. JNCCN. 2017 May;15(5.5):667-668. Abstract# AB2017-25.

*458. Papaioannou D, Petri A, Terreri S, Thrue Ch, Volinia S, Yan P, Bundschuh R, Singh G, Kauppinen

S, Bloomfied CD, Dorrance A, Garzon R. The long non-coding RNA HOXB-AS3 regulated ribosomal biogenesis in NPM1-mutated acute myeloid leukemia [abstract]. 22nd Congress of the European Hematology Association (EHA). 2017 June 22-25. Stockholm, Sweden. Haematol. 2017 June 9:102(suppl 1): 36-37. Abstract # P174.

459. Walker C, Eisfeld A-K, Genutis L, Bainazar M, Kohlschmidt J, Mrozek K, Carroll A, Kolitz J, Powell B,

Wang E, Stone R, Bundschuh R, de la Chapelle A, Bloomfield CD. No evidence for microsatellite instability (MSI) in 1,394 patients (pts) with acute myeloid leukemia (AML) [abstract/ E-poster]. 22nd Congress of the European Hematology Association (EHA). 2017 June 22-25. Stockholm, Sweden. Haematol. 2017 June 9:102(suppl 1): 363. Abstract # E883.

460. Bill M, Karunasiri M, Burke M, Walker AE, Volina S, Bloomfield CD, Garzon R, Dorrance A.

Elucidating the role of the Long Non-Coding RNA DANCR in Leukemic Stem Cells in Acute Myeloid Leukemia [abstract]. 46th International Society for Experimental Hematology (ISEH) Annual Scientific Meeting. August 24-27, 2017. Frankfurt, Germany. Experimental Hematology, 2017;53:12. Abstract # 3227.

461. Bhatnagar B, Eisfeld A-K, Mrózek K, Kohlschmidt J, Nicolet D, Kolitz J, Powell BL, Byrd JC, and

Bloomfield CD. Acute myeloid leukemia (AML) patients with an isolated trisomy display increased frequency of spliceosome mutations. 59th Annual Meeting of the American Society of Hematology (ASH). 2017 December 8-11. Atlanta, GA. Blood. 2017 Dec 7:130(suppl 1). Abstract # 2691.

462. Bill M, Eisfeld A-K, Mrózek K, Kohlschmidt J, Nicolet D, Walker CJ, Blachly JS, Carroll AJ, Kolitz JE, Powell BL, Wang ES, Stone RM, de la Chapelle A, Byrd JC, and Bloomfield CD. Mutational Landscape and Clinical Outcome Associated with Different Rearrangements Involving 11q23/MLL in De Novo Acute Myeloid Leukemia (AML). [abstract]. 59th Annual Meeting of the American Society of Hematology (ASH). 2017 December 8-11. Atlanta, GA. Blood. 2017 Dec 7:130(suppl 1). Abstract # 3960.

*463. Döhner K, Thiede C, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Lo-Coco F, Ottone T, Nomdedeu JF, Mandrekar S, Sanford BL, Laumann K, Geyer S, Klisovic RB, Wei A, Sierra J, Sanz M, Brandwein JM, de Witte T, Janse J, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Cheng Y, Pallaud C, Stone RM, Döhner H, and Bloomfield CD. Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY Study. 59th Annual Meeting of the American Society of Hematology (ASH). 2017 December 8-11. Atlanta, GA. Blood. 2017 Dec 7:130(suppl 1). Abstract # 467.



ABSTRACTS (cont.) *464. Eisfeld A-K, Kohlschmidt J, Mrózek K, Mims A, Walker CJ, Blachly JS, Nicolet D, Orwick S, Maharry

SE, Carroll AJ, Powell BL, Kolitz JE, Wang ES, Stone RM, de la Chapelle A, Byrd JC, and Bloomfield CD. Neurofibromin 1 Gene Mutations are Recurrent Events in Adult Patients with Acute Myeloid Leukemia, Associate with Poor Outcome and Refine the Adverse European LeukemiaNet (ELN) Risk Category. 59th Annual Meeting of the American Society of Hematology (ASH). 2017 December 8-11. Atlanta, GA. Blood. 2017 Dec 7:130(suppl 1). Abstract # 186.

*465. Eisfeld A-K, Kohlschmidt J, Mrózek K, Blachly JS, Walker CJ, Nicolet D, Orwick S, Carroll AJ, Stone RM, Wang ES, Kolitz JE, Powell BL, de la Chapelle A, Byrd JC, and Bloomfield CD. Mutation patterns identify adult patients with de novo acute myeloid leukemia (AML) aged 60 years or older who respond favorably to standard chemotherapy: An analysis of Alliance studies. 59th Annual Meeting of the American Society of Hematology (ASH). 2017 December 8-11. Atlanta, GA. Blood. 2017 Dec 7:130(suppl 1). Abstract # 103.

*466. Larson RA, Mandrekar S, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Döhner H, and Stone RM. An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations. 59th Annual Meeting of the American Society of Hematology (ASH). 2017 December 8-11. Atlanta, GA. Blood. 2017 Dec 7:130(suppl 1). Abstract # 145.

467. Mrózek K, Eisfeld A-K, Kohlschmidt J, Carroll AJ, Nicolet D, Blachly JS, Walker CJ, Wang ES, Uy GL, Kolitz JE, Powell BL, Blum W, Stone RM, Byrd JC, and Bloomfield CD. Molecular Landscape and Clinical Features of Acute Myeloid Leukemia (AML) with Complex Karyotype (CK). 59th Annual Meeting of the American Society of Hematology (ASH). 2017 December 8-11. Atlanta, GA. Blood. 2017 Dec 7:130(suppl 1). Abstract # 1404.

468. Papaioannou D, Ozer GH, Nicolet D, Mrózek K, Volina S, Carroll AJ, Kohlschmidt J, Blum W, Powell BL, Uy GL, Wang ES, Kolitz JE, Eisfeld A-K, Stone RM, Byrd JC, Garzon R, and Bloomfield CD. Recurrent Genetic Variants of Long Non-Coding RNAs (lncRNAs) Independently Associate with Clinical Outcome of Younger Adults with Cytogenetically Normal Acute Myeloid Leukemia. 59th Annual Meeting of the American Society of Hematology (ASH). 2017 December 8-11. Atlanta, GA. Blood. 2017 Dec 7:130(suppl 1). Abstract # 1401.

469. Stone RM, Mandrekar S, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Döhner K, Thiede C, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Döhner H, and Larson RA. The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations. 59th Annual Meeting of the American Society of Hematology (ASH). 2017 December 8-11. Atlanta, GA. Blood. 2017 Dec 7:130(suppl 1). Abstract # 2580.

470. Bill M, Karunasiri M, Kohlschmidt J, Walker AE, Brannan Z, Volina S, Bloomfield CD, Garzon R and Dorrance A. The long non-coding RNA (lncRNA) DANCR in acute myeloid leukemia (AML) stem cells (LSC). [abstract]. Proceedings of the 197th Annual Meeting of the American Association for Cancer Research (AACR). 2018 April 13-18. Chicago, IL. Cancer Res. In Press. Abstract # 2455.

471. Papaioannou D, Petri A, Terreri S, Thrue CA, Nicolet D,Collins AF, Woodward LA, Kumchala P, Karunasiri M, Pepe F, Marius B, Singh G, Kauppinen S, Bloomfield CD, Dorrance AM and Garzon R. The long non-coding RNA (lncRNA) HOXB-AS3 regulates transcription of ribosomal RNA (rRNA) in NPM1-mutated (NPM1mut) acute myeloid leukemia (AML). [abstract]. Proceedings of the 197th Annual Meeting of the American Association for Cancer Research (AACR). 2018 April 13-18. Chicago, IL. Cancer Res. In Press. Abstract # 519.



ABSTRACTS (cont.)

*471. Papioannou D, Volinia S, Nicolet D, Swierniak M, Petri A, Mrózek K, Carroll AJ, Kohslchmidt J, Powell BL, Uy GL, Kolitz JE, Wang ES, Kauppinen S, Stone RM, Garzon R, Bloomfield CD. Prognostic and biologic significance of circular RNA profiling in younger adult patients with cytogenetically normal acture myeloid leukemia (CN-AML) [abstract]. 23rd Congress of the European Hematology Association (EHA). 2018 June 14-17. Stockholm, Sweden. Haematol. 2018 In press. Abstract # _____.


117

EDITED BOOKS

1. Editor, Annual series of volumes entitled “Adult Leukemias” in general series: Cancer Treatment and Research, William L. McGuire, editor. Martinus Nijhoff Publishers, 1979-85


118

MAJOR INVITED TALKS 1. Visiting Professor. Department of Medicine. West Virginia University. Morgantown, WV. January

24-26, 1973. "Prognostic Factors in the Non-Hodgkin's Malignant Lymphomas." (Medical Grand Rounds) "The Use of the Celltrifuge in Leukemia." (Seminar) "The Importance of Histology in Adult Acute Leukemia." (Seminar) 2. Continuing Medical Education Course. Annual Continuation Course in Surgery: Cancer Surgery.

University of Minnesota. Minneapolis, MN. June 16, 1975. "Non-Hodgkin's Lymphoma." 3. Continuing Medical Education Course. Current Concepts in Laboratory Hematology. University of

Minnesota. Minneapolis, MN. May 20, 1976. "Coagulation Problems in Acute Leukemia. Clinical Commentary." 4. Cancer Control Program Symposium. Modern Standards of Treatment in the Hematologic

Malignancies. Mount Sinai School of Medicine. New York, NY. June 10, 1976. "Acute Lymphocytic Leukemia in Adults." 5. National Cancer Institute Symposium. The Non-Hodgkin's Lymphomas. San Francisco, CA.

September 30 - October 2, 1976. "Functional Studies: Clinical Correlations with Immunologic Parameters." 6. Continuing Medical Education Course. Internal Medicine Review, Medical Oncology. University of

Minnesota. Minneapolis, MN. October 20, 1976. "Non-Hodgkin's Malignant Lymphoma." B. "Adult Acute Leukemia." 7. Continuing Medical Education Course. Recent Clinical Advances in the Management of the Patient

with Malignant Disease. Indiana University School of Medicine. Indianapolis, IN. November 5, 1976.

"Adult Acute Leukemia." 8. American Cancer Society Symposium. Leukemia-Lymphoma Seminar for Physicians. Kissimmee,

FL. May 27, 1977. "Chemotherapy of Non-Hodgkin's Lymphoma." 9. American Society of Hematology Subcommittee on Neoplasia. Advances in the Scientific

Understanding of Hematologic Malignancies. San Diego, CA. December 4, 1977. "Relevance of Cellular Immunologic Markers in Non-Hodgkin's Lymphomas." 10. Medical Grand Rounds. Baylor College of Medicine. Houston, TX. January 12, 1978. "Lymphoproliferative Disorders." 11. Seminar. Dartmouth Medical School. Hanover, NH. February 2, 1978. "Intensive 5-Drug Induction Chemotherapy for Adult ANLL." 12. Cancer and Leukemia Group B. Lymphoma Committee Seminar. New York, NY. February 16,

1978. "Influence of Lymphocyte Surface Markers on Response to Therapy." 13. Medical Grand Rounds. The University of Texas System Cancer Center. M.D. Anderson Hospital

and Tumor Institute. Houston, TX. February 24, 1978. "Significance of B and T Cell Markers in Non-Hodgkin's Lymphoma."

14. Continuing Medical Education Course. The Lymphomas and Leukemias--What do we know? What

do we do? Indiana University School of Medicine. Reid Memorial Hospital. Richmond, IN. March 23, 1978. "Treatment of Acute Leukemia - Childhood and Adult."


119

MAJOR INVITED TALKS (cont.) 15. Tutorial on Banded Chromosomal Abnormalities in Human Malignancies: Basic Mechanisms and

Clinical Implications. The International Academy of Cytology (IAC), The American Society of Clinical Pathologists (ASCP), The American Society of Cytology (ASC), and the Center for Continuing Education of the University of Chicago. Chicago, IL. March 31 - April 1, 1978.

"Philadelphia Chromosome in Acute Leukemia." 16. American Society of Clinical Oncology Education Session. Acute Leukemia--The Clinical Relevance

of Cytogenetics, Bone Marrow Culture and Lymphocyte Surface Markers. Washington, DC. April 3, 1978.

"Acute Leukemia--The Clinical Relevance of Lymphocyte Surface Markers." 17. Leukemia Society of America Symposium. Conference on Leukemia and Lymphomas. Washington

University. St. Louis, MO. May 17, 1978. "Immunopathology of Non-Hodgkin's Lymphomas." 18. Continuing Medical Education Course. Advances in Clinical Oncology. University of Maryland

School of Medicine. Baltimore, MD. May 18-20, 1978. "Staging of the Non-Hodgkin's Lymphomas." 19. Continuing Medical Education Course. Recent Advances in Laboratory Hematology and

Hematopathology. University of Minnesota. Minneapolis, MN. May 25, 1978. "Clinical Significance of Membrane Surface Markers in Lymphoproliferative Diseases." 20. Seminar. Dartmouth Medical School. Hanover, NH. July 13, 1978. "Clinical Significance of the Philadelphia Chromosome in Acute Leukemia." 21. Medical Grand Rounds. State University of New York at Syracuse. Upstate Medical Center.

Syracuse, NY. August 10, 1978. "Clinical Relevance of Lymphocyte Surface Markers in Oncology." 22. Continuing Medical Education Course. Chemotherapy. Mercy Hospital. Miami, FL. September 14,

1978. "Treatment of Non-Hodgkin's Lymphomas." 23. International Union Against Cancer Workshop. Steroid Receptors in Leukemia. Bermuda.

September 21, 1978. "Current Classification and Treatment of the Blood Dyscrasias." 24. Continuing Medical Education Course. Recent Advances in the Treatment of Leukemia. Leukemia

Research Foundation, Inc., University of Maryland School of Medicine. Ocean City, MD. October 19-21, 1978. (Canceled October 17, 1978).

"The Clinical Relevance of Lymphocyte Surface Marker Studies in Acute Leukemia." 25. Continuing Medical Education Course. Hematologic Malignancies. A Symposium of the

Investigation and Treatment of the Hematologic Malignancies. The Ontario Cancer Treatment and Research Foundation of the Princess Margaret Hospital. Toronto, Ontario. November 27, 1978.

"Malignant Lymphomas: Classification and Cell Surface Markers." 26. American Society of Hematology Education Session. Management of Acute Leukemia. New

Orleans, LA. December 2, 1978. "Treatment of Adult Acute Non-Lymphocytic Leukemia." 27. Canadian Oncology Society Postgraduate Course. Non-Hodgkin's Lymphomas. Montreal, Quebec.

February 6, 1979. "Prognostic Significance of Lymphocytic Surface Markers in Non-Hodgkin's Lymphomas." 28. Cancer and Leukemia Group B. Surface Marker Symposium. New York, NY. February 8, 1979. "Immune Cell Markers and Adult Malignancy."


120

MAJOR INVITED TALKS (cont.) 29. American Cancer Society Symposium. Second Annual Gateway Cancer Symposium. Lake Buena

Vista, FL. March 1, 1979. "Chemotherapy of Non-Hodgkin's Lymphoma." 30. Visiting Professor. Department of Medicine, The University of Arizona. Tucson, AZ. March 6-7,

1979. "Clinical Correlations with Functional (Immune) Classifications of Non-Hodgkin's Lymphoma." (Blood Club)

"Current Aspects of Acute Leukemia." (Medical Grand Rounds) "Glucocorticoid Receptors in Lymphoma." (Research Seminar) 31. Visiting Professor. Department of Medicine, University of Florida. Gainesville, FL. March 29-31,

1979. "Treatment of Leukemia in the Elderly." (Medical Grand Rounds) "1979 Postgraduate Hematology-Oncology Seminar." 32. Second Tutorial on Banded Chromosomal Abnormalities in Human Malignancies: Basic

Mechanisms and Clinical Implications. The International Academy of Cytology (IAC), The American Society of Clinical Pathologists (ASCP), The American Society of Cytology (ASC), The American Academy of Reproductive Medicine (AARM) and The Center for Continuing Education of the University of Chicago. Chicago, IL. April 6-7, 1979.

"Philadelphia Chromosome Positive Acute Leukemia." 33. Member International Faculty. International Union Against Cancer Postgraduate Course.

Antineoplastic Chemotherapy in Clinical Oncology. Buenos Aires, Argentina. April 23-28, 1979. "Hormonal Procedures in Chemotherapy." B. "Breast Cancer--Metastatic Disease." C. "Non-Hodgkin's Lymphomas."

34. Continuing Medical Education Course. Current Concepts in Radiation Therapy. University of

Minnesota. Minneapolis, MN. May 25, 1979. "Hodgkin's Disease, Chemotherapy in Adults." "Chemotherapy in Non-Hodgkin's Lymphoma in Adults." 35. Cancer and Leukemia Group B. Scientific Session. Glucocorticoid and Estrogen Receptors. New

York, NY. June 1, 1979. "Glucocorticoid Receptors and Clinical Correlation." 36. University of Minnesota Cancer Coordinating Committee Symposium. Minnesota Against Cancer.

Minneapolis, MN. June 21, 1979. "Immunologic Classification of Lymphoma--Clinical Relevance." 37. First International Congress on Hormones and Cancer. Rome, Italy. October 4-6, 1979. "The Therapeutic Utility of Glucocorticoid Receptor Studies in Non-Hodgkin's Malignant Lymphoma." 38. Seminar. The Royal Marsden Hospital. London, England. October 12, 1979.

"Clinical Utility of Immunologic Markers, Glucocorticoid Receptors and in vitro Glucocorticoid Sensitivity in Adult Lymphoma."

39. Symposium. Proliferation of Hemopoietic Cells and Their Diseases. Roswell Park Memorial

Institute. Buffalo, NY. October 24, 1979. "Adrenal Corticosteroid Receptors in Leukemia and Lymphoma Cells." 40. Continuing Medical Education Lecture. Des Moines VA Medical Center. University of Iowa College

of Medicine. Des Moines, IA. November 7, 1979. "Clinical Relevance of Lymphocyte Surface Markers in Leukemia and Lymphoma."


121

MAJOR INVITED TALKS (cont.) 41. American Society of Hematology Education Session. Management of Acute Leukemia. Phoenix,

AZ. December 1, 1979. "Treatment of Adult Acute Non-Lymphocytic Leukemia." 42. American Society of Hematology Subcommittee on Neoplasia. Malignant Lymphoma 1980: Biology

and Management. Phoenix, AZ. December 2, 1979. "Therapeutic Utility of Lymphocyte Surface Markers in Lymphoma." 43. Seminar. Texas Tech University School of Medicine. Amarillo, TX. February 1, 1980. "The Cure of Adult Acute Non-Lymphocytic Leukemia." 44. Medical Grand Rounds. University of Iowa. Iowa City, IA. February 14, 1980. "Immunologic Markers in Lymphoma and Leukemia." 45. Workshop. Markers in the Leukemias. National Cancer Institute. Bethesda, MD. March 3-4, 1980. "Chromosome Abnormalities in Acute Lymphoblastic Leukemia." "Glucocorticoid Receptors in Adult Acute Lymphocytic Leukemia." 46. Hematology Grand Rounds. Mount Sinai School of Medicine. New York City, NY. April 10, 1980. "Clinical Relevance of Lymphocyte Surface Markers in Leukemia and Lymphoma." 47. Scientific Presentation. Cancer and Leukemia Group B. New York, NY. April 12, 1980.

"Histologic and Clinical Classification of Non-Hodgkin's Lymphoma--Recommendations of the International Panel."

48. Visiting Professor. Department of Medicine. Emory University School of Medicine. Atlanta, GA.

April 17, 1980. "Clinical Relevance of Lymphocyte Surface Markers in Malignant Lymphoma." (Medical Grand Rounds)

"Glucocorticoid Receptors in Malignant Lymphoma." (Hematology-Oncology Seminar) 49. Seminar. Mayo Clinic. Rochester, MN. May 1, 1980. "Chemotherapy of Acute Leukemia. 50. Symposium. American Red Cross Twelfth Annual Scientific Symposium. Washington, DC. May 7,

1980. "Classification and Prognosis of Acute Lymphoblastic Leukemia." 51. American Society of Clinical Oncology Education Session. Controversies in the Non-Hodgkin's

Lymphomas. San Diego, CA. May 26, 1980. "The Clinician's View of the Pathologic Classification of the Non-Hodgkin's Lymphomas." 52. Hematology-Medical Oncology Grand Rounds. University of Oregon. Portland, OR. June 10, 1980. "Glucocorticoid Receptors in Non-Hodgkin's Lymphoma." 53. Grand Rounds. Good Samaritan Hospital and Medical Center. Portland, OR. June 11, 1980. "Contemporary Management of Acute Leukemia in the Adult." 54. Seminar. Indiana University. Indianapolis, IN. June 19, 1980. "Glucocorticoid Receptors in Leukemia and Lymphoma." 55. Seminar. The Finsen Institute. Copenhagen, Denmark. July 30, 1980. "Histologic Classification of the Non-Hodgkin's Lymphomas. International Formulation, 1980." 56. International Society of Hematology Education Session. Acute Leukemia. Montreal, Quebec,

Canada. August 16-17, 1980. "Treatment of Adult Acute Non-Lymphocytic Leukemia."


122

MAJOR INVITED TALKS (cont.) 57. International Society of Hematology Symposium. Cytogenetics in Hematology: Recent Advances

and their Clinical Relevance. Montreal, Quebec, Canada. August 18, 1980. "The Lymphomas." 58. Symposium. Leukemia and Lymphoma 1980 Update. Baystate Medical Center and Leukemia

Society of America. West Springfield, MA. October 8, 1980. "New Classification of Lymphomas--the Role of Staging." "Advances in Adult Acute Leukemia." 59. Chemotherapy Foundation Symposium IV. Current Optimum Strategies for Clinical Cancer

Chemotherapy. Mount Sinai School of Medicine. New York, NY. October 22, 1980. "Prognostic Cytoimmunological Classification of Lymphomas." 60. Second Biennial Scientific Symposium. Leukemia Update. Cornell University Medical College and

Leukemia Society of America. New York, NY. November 14, 1980. "Clinical Implications of Cytogenetics in the Lymphoproliferative Diseases." 61. Seminar. Albert Einstein College of Medicine. New York, NY. December 4, 1980. "The Clinical Significance of Cytogenetic Abnormalities in Acute Lymphoblastic Leukemia." 62. Seminar. New York University Medical Center. New York, NY. December 5, 1980. "Clinical Utility of Glucocorticoid Receptors in Leukemia and Lymphoma." "Clinical Significance of Cytogenetic Abnormalities in Acute Lymphoblastic Leukemia." 63. Symposium. New Advances in the Pathogenesis, Diagnosis, and Therapy of Neoplastic Diseases.

Downstate Medical Center, State University of New York. New York, NY. December 6, 1980. "Therapeutic Implications of the New Classification of Lymphomas." 64. Workshop-Symposium. Treatment Strategies for Non-Hodgkin's Lymphoma--An Update. University

of Florida. Gainesville, FL. January 15-16, 1981. "Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma." "Chemotherapy Approaches to Non-Hodgkin's Lymphoma." 65. Fifth Annual Seminar on Frontiers in Immunology, Hematology and Neoplastic Diseases. Bellwood

General Hospital. Bellflower, CA. February 20, 1981. “Cell Markers of Lymphomas." 66. The First Annual John Kenny Memorial Symposium. Mercy Hospital. Pittsburg, PA. March 12,

1981. "Adult Acute Leukemia." 67. Leukemia Conference. Leukemia Society of American and Chicago Blood Club. Chicago, IL. April

23, 1981. "Current Chemotherapy of Acute Leukemia." 68. Award Acceptance Speech. National Board Dinner. The Medical College of Pennsylvania.

Philadelphia, PA. May 29, 1981. "Towards the Cure of Adult Acute Leukemia." 69. Whittick Lecture. Cancer Symposium. University of Saskatchewan. Saskatoon, Saskatchewan,

Canada. June 19, 1981. "Pathology of Lymphomas." "Immunologic Aspects of Lymphoma Management." 70. Seminar. Walter Reed Army Medical Center. Bethesda, MD. June 30, 1981. "Prognostic Significance of Chromosomes in ALL."


123

MAJOR INVITED TALKS (cont.) 71. 5th International Symposium of the Journal of Steroid Biochemistry. Puerto Vallarta, México. July 15,

1981. "Recent Advances in Steroid Biochemistry." "In vitro Glucocorticoid Studies in Human Lymphoma; Clinical and Biologic Significance." 72. International Conference of Malignant Lymphomas. Current Status and Prospects. Lugano,

Switzerland. September 4, 1981. "Importance of Biologic Markers in NHL from the Point of View of the Clinician." 73. Symposium. Contemporary issues in Hodgkin's Disease: Biology, Staging and Treatment. National

Cancer Institute, San Francisco, CA. September 11, 1981. "Combined Modality Therapy. Conclusions from Cancer and Leukemia Group B Studies."

74. Lecture. Gunderson Medical Foundation. LaCrosse, WI. September 28, 1981.

"Towards the Cure of Adult Acute Leukemia." 75. III Latin American Congress of Haematology and X National Congress of Haematology and

Transfusion. Maracaibo, Venezuela. October 11-17, 1981. "The Clinical Relevance of Biological Markers in Acute Leukemia." "The Treatment and Cure of Adult Acute Nonlymphocytic Leukemia." "Pathology of Malignant Lymphomas. Clinical Relevance of the New Classifications."

76. Medical Symposium of The Leukemia Society of America. University of Pennsylvania, Philadelphia,

PA. October 23, 1981. "Tumor Cell Markers."

77. Genetics Mini-Symposium. Eastern Maine Medical Center, Bangor, ME. November 4, 1981.

"The Clinical Importance of Cytogenetics in Acute Lymphoblastic Leukemia." 78. Blood Cells Symposium. Leukemia: Contemporary Therapy and New Modalities of Treatment.

University of Texas Medical Branch. Galveston, TX. November 7, 1981. "Evaluation of Leukemic Cell Chromosomes as a Guide to Therapy."

79. Inaugural Scientific Symposium. Don and Sybil Harrington Cancer Center. Texas Tech University

School of Medicine. Amarillo, TX. November 13, 1981. "Curing Adult Acute Leukemia."

80. American Society of Hematology Education Session. Management of Acute Leukemia. San

Antonio, TX. December 5-6, 1981. "Treatment of Adult Acute Leukemia."

81. Workshop on Adult Acute Leukemia. National Institutes of Health. Bethesda, MD. December 10-

11, 1981. "Review of CALGB Data Employing Conventional Chemotherapy for Induction."

82. Visiting Professor. Department of Medicine. University of Chicago. Chicago, IL. January 17-18,

1982. "Recent Advances in the Treatment of Acute Myelogenous Leukemia."

83. UCLA Symposia on Molecular and Cellular Biology: "B and T Cell Tumors: Biological and Clinical

Aspects." Squaw Valley, CA. March 1, 1982. "Chairperson Workshop 13. Phenotyping and Properties of T and B Tumors."


124

MAJOR INVITED TALKS (cont.) 84. Visiting Professor. Baltimore Cancer Research Center, University of Maryland. Baltimore, MD. March

23, 1982. "Cell Markers in Lymphoma." (Seminar) "Chromosomes in Acute Leukemia." (Baltimore Blood Club)

85. Visiting Professor. American Cancer Society. Department of Medicine, George Washington

University. Washington, DC. March 24-25, 1982. "Clinical Utility of Biological Markers in Lymphoma." (Lecture, Washington Veterans Administration Hospital) "Treatment of Acute Leukemia." (Medical Grand Rounds, George Washington University)

86. Visiting Professor. The University of Texas, Health Science Center at San Antonio. San Antonio, TX.

March 30-31, 1982. "Glucocorticoid Receptors--Current Status." (Seminar) "The Clinical Use of Cytogenetic Analysis in Acute Leukemia." (Grand Rounds)

87. Visiting Professor. Brown University, Roger Williams General Hospital. Providence, Rhode Island.

May 12, 1982. "Markers in Leukemia and Lymphoma." (Lecture) "Hodgkin's Disease: Modern Treatment and the Consequences of its Success." (Waterman Cancer Dialogue)

88. Visiting Professor. Mayo Clinic. Mayo Foundation House. Rochester, Minnesota. June 24, 1982.

"Clinical Uses of Biologic Markers in Lymphoma." 89. Workshop. Adrenal Steroids and Lymphoid-Steroid Interactions. Universidad Autonoma de Mexico.

Mexico City. July 28, 1982. "In vitro Clinical Correlations in Human Lymphomas and Leukemias."

90. Symposium: Therapy-Related Leukemias. Society of Pharmacology and Experimental

Therapeutics. Louisville, KY. August 18, 1982. "Non-Random Chromosomal Abnormalities in Therapy-Related Leukemias."

91. Seminar: Cell Surface Markers and Receptors of Lymphomas and Leukemias. Co-Chairman. 13th International Cancer Congress. Seattle, WA. September 14, 1982. "The Clinical Utility of Cell Surface Markers in the Classification of Lymphomas."

92. Symposium: Chromosomes in Leukemia: Recent Developments. Cancer and Leukemia Group B. Philadelphia, PA. October 22, 1982. "Chromosomes in ALL: Report from the Third International Workshop on Chromosomes in Leukemia."

93. Lecture. Department of Internal Medicine, University of Basel. Basel, Switzerland. November 30, 1982. "Immunologic Classification of Non-Hodgkin's Lymphomas. Implications for Therapeutic Approaches."

94. Guest Lecturer. General Meeting. Swiss Group for Clinical Cancer Research (SAKK). Lucerne, Switzerland. December 3, 1982. "Current Controversial Issues in the Treatment of Acute Leukemia in Adults."

95. American Society of Hematology Education Session. Chronic Myelogenous Leukemia. Washington, DC. December 5, 1982. "Philadelphia Chromosome Positive (Ph1+) Leukemias."


125

MAJOR INVITED TALKS (cont.) 96. Plenary Session 1, UCLA Symposia on Molecular and Cellular Biology: "Recent Advances in Bone

Marrow Transplantation." Park City, UT. February 13, 1983. "Is Bone Marrow Transplantation the Optimal Treatment of Acute Myelogenous Leukemia? A

Forum." 97. Subspecialty Update Sessions. Annual Session of the American College of Physicians. San

Francisco, CA. April 11, 1983. "Update in Hematology: Treatment of Acute Leukemia." 98. Grand Rounds. University of Nebraska Medical Center. Omaha, NE. May 13, 1983. "Chromosomal Abnormalities in Leukemia and Lymphoma." 99. Seminar. Department of Medical Genetics, University of Helsinki. Helsinki, Finland. May 26, 1983. "The Clinical Usefulness of Chromosome Abnormalities in Acute Leukemia." 100. Visiting Professor. University of Zurich. Zurich, Switzerland. July 27, 1983. "The Clinical and Biologic Significance of Chromosome Abnormalities in Leukemia and Lymphoma." 101. Plenary Lecture. Second International Congress on Hormones and Cancer. Monte Carlo.

September 21, 1983. "Glucocorticoid Receptors: In vitro Clinical Correlations in Human Leukemia and Lymphoma." 102. Symposium on Tumor Aneuploidy. Annual meeting of der Deutschen Gesellschaft Für Hämatologie

und Onkologie (Joint Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Ongology). Münster, West Germany. October 11, 1983.

"The Clinical Usefulness of Chromosome Abnormalities in Acute Leukemia." 103. International Symposium. "Detection and Treatment of Minimal Residual Disease in Acute

Leukemia." Rotterdam, The Netherlands. October 12-14, 1983. "Bone Marrow Transplantation vs. Chemotherapy in Acute Leukemia." 104. Twenty-Seventh Annual Clinical Conference. "New Perspectives in Human Lymphoma." Houston,

TX. November 9-11, 1983. "The Clinical Utility of Cell Surface Markers in Malignant Lymphoma." 105. American Society of Hematology Education Session. Chronic Leukemia. San Francisco, CA.

December 3-6, 1983. "Ph1+ Adult Lymphocytic Leukemia and Acute Myelogenous Leukemia." 106. Visiting Professor. University of Puerto Rico. San Juan, Puerto Rico. February 20-25, 1984. "Clinical Use of Phenotyping in Adult Lymphoma." (Medicine Grand Rounds) "Clinical and Biological Significance of Chromosome Abnormalities in Leukemia and Lymphoma."

(Lecture) "Glucocorticoid Receptors in Leukemia and Lymphoma.” (Lecture) "Curative Therapy of Adult Acute Myeloblastic Leukemia." (Dr. Jenaro Haddock Memorial Lecture) 107. Visiting Professor. South Africa. March 9-23, 1984. University of the Witwatersrand. Johannesburg.

Department of Medicine. "Clinical Use of Immunologic Phenotyping in Adult Lymphoma." (Lecture) "Recent Advances in the Therapy of Adult AML." (Grand Rounds) "Clinical Use of Immunologic Phenotyping in Adult Lymphoma." (Baragwanath Hospital.

Johannesburg, South Africa.) "Curative Therapy of Adult AML." (Pretoria Medical School. Medical Oncology. Pretoria, South

Africa.) "Current Status of the Treatment of Acute Myeloblastic Leukemia." (University of Capetown Medical

School. Department of Haematology. Capetown, South Africa.)


126

MAJOR INVITED TALKS (cont.) 108. American Society of Clinical Oncology Educational Workshop. Toronto, Ontario. May 6, 1984. "Clinical Significance of Chromosome Abnormalities in Acute Leukemia." 109. Lecture. Current Concepts in Radiation Therapy. Minneapolis, MN. May 25, 1984. "Current Concepts in the Chemotherapy of Hodgkin's Disease." 110. Lecture. Second International Conference on Malignant Lymphoma. Lugano, Switzerland. June 14,

1984. "Banded Chromosome Abnormalities in Non-Burkitt's, Non-Hodgkin's Lymphoma. Correlations with

Morphology and Immunologic Phenotype." 111. Lecture. Modern Trends in Human Leukemias VI. Wilsede. West Germany. June 17-21, 1984. "Clinical Implications of Cytogenetics in Lymphatic Leukemia and Lymphoma." 112. Third Wilsede Joint Meeting in Pediatric Hematology and Oncology. University of Hamburg.

Hamburg, West Germany. June 22, 1984. "Oncogenes and Chromosomal Aberration in Human Leukemias." (special lecture at the Hoersaal

Kinderklinik) "Bleeding Problems in Cancer Patients: Laboratory and Clinical Approach." 113. Sig. K. Thoreson Fund and the Norwegian Academy of Science and Letters Symposium. "Medical

Genetics: Past, Present, Future." Oslo, Norway. August 24, 1984. "Chromosomal Changes in Acute Leukemia." 114. Lecturer. XX Congress of the International Society of Hematology. Buenos Aires, Argentina.

September 1-7, 1984. "Advances in the Diagnosis and Treatment of AML." (Canceled by illness) 115. Visiting Professor. Department of Medicine, Nihon University School of Medicine. Tokyo, Japan.

October 16, 1984. "Strategy and Recent Results in the Cure Oriented Treatment of Adult Acute Myeloid Leukemia." 116. American Society of Hematology. Neoplasia Subcommittee. Miami Beach, FL. December 1-4,

1984. "Clinical Significance of Chromosome Patterns in Adult Acute Non-Lymphoblastic Leukemia." 117. Medicine 85 Congress. Symposium of The Finnish Society of Hematology. Helsinki, Finland.

January 11, 1985. "Secondary Myelodysplastic Syndromes: Etiology, Clinical Course and Treatment." 118. Lecture. Karolinska Institute. Department of Clinical Genetics. Stockholm, Sweden. January 14,

1985. "Clinical Significance of Chromosome Abnormalities in Acute Leukemia." 119. Seminar. Department of Medical Genetics. University of Helsinki. Helsinki, Finland. February 13,

1985. "Chromosome Abnormalities in Acute Myeloid Leukemia." 120. Lecture. Department of Medical Genetics, University of Oulu. Oulu, Finland. February 15, 1985. "The Clinical Importance of Chromosomal Abnormalities in Acute Leukemia." 121. Meet the Professor Sessions. Leukemia Society of America First National Symposium. Reno, NV.

March 14-16, 1985. "Cytogenetics." 122. Main Lecture. Annual Meeting of The Swiss Society of Hematology. Interlaken, Switzerland. May 9-

10, 1985. "Chromosome Abnormalities in Leukemia and Lymphoma."


127

MAJOR INVITED TALKS (cont.) 123. 12th International Symposium for Comparative Research on Leukemia and Related Disease.

Hamburg, West Germany. July 7-12, 1985. "The Clinical and Biologic Relevance of Cytogenetic Studies in Human Leukemia." 124. Seminar. Department of Virology, University of Helsinki. Helsinki, Finland. October 17, 1985. "Chromosomes in Human Leukemia." 125. Lecture. Genetics in Clinical Oncology. Laboratory of Genetics, Department of Pathology.

Memorial Hospital for Cancer and Allied Diseases. New York City, NY. October 31 - November 1, 1985.

"Chromosome Changes in the Diagnosis and Prognosis of Lymphoma." 126. Workshop. Strategies for Controlling Cancer through Genetics. National Institutes of Health.

Fogarty International Center. January 21-22, 1986. "Cytogenetics of Cancer Predisposition." 127. Leukemia Society of America Second National Symposium. Wesley Chapel. Tampa, FL. March 19-

22, 1986. "What Can Cytogenetics Tell us about Malignant Phenotypes in Acute Leukemia?" 128. Meet the Professor. American Society of Clinical Oncology. Los Angeles, CA. May 4-5, 1986. "Cytogenetics of Acute Myelogenous Leukemia." 129. Symposiums. XXI Congress of the International Society of Haematology and the XIX Congress of

the International Society of Blood Transfusion (International Meeting of the Societies). Sydney, Australia. May 11-16, 1986.

"The Significance of Non-Morphological Markers in ALL." (Adult ALL) "Clinical Relevance of Chromosomal Abnormalities." (Cytogenetics) "Chromosomes, Oncogenes, Immunologic Markers." (Lymphoma) 130. Chromosomes and Malignancy Workshop. Anti-Cancer Council of Victoria. Melbourne, Australia.

May 19, 1986. "Relevance of Chromosome Abnormalities in NHL." 131. Lecture. Leukaemia and Marrow Transplantation Symposium. Alfred Hospital, Haematology and

Medical Oncology Unit. Melbourne, Australia. May 21, 1986. "Clinical Utility of Monoclonal Antibodies for Phenotyping Adult ALL and AML." 132. Lecture. XVIth International Congress of the International Academy of Pathology and 7th World

Congress of Academic and Environmental Pathology. Vienna, Austria. September 2, 1986. "The Contribution of Karyotype Analysis to the Characterization of NHL." 133. Lecture. Frederick Cancer Research Facility. Frederick, MD. October 7, 1986. "Clinical Significance of Chromosome Abnormalities in Acute Leukemia." 134. Medical Grand Rounds. UCLA School of Medicine. Los Angeles, CA. December 10, 1986. "Clinical and Biologic Significance of Chromosome Abnormalities in Leukemia and Lymphoma." 135. American Association for the Advancement of Science Symposium. Chromosome Abnormalities in

Human Cancer: Biological and Diagnostic Implications. Chicago, IL. February 16, 1987. "Diagnostic and Prognostic Significance of Clonal Chromosome Abnormalities." 136. Leukemia Committee. Southwest Oncology Group. San Antonio, TX. March 4, 1987. "Cytogenetics of Leukemia in the Cooperative Group Setting. A New Opportunity." 137. Seminar. St. Jude Children's Research Hospital. Memphis, TN. March 13, 1987. "Clinical Significance of Chromosome Abnormalities in Acute Leukemia."


128

MAJOR INVITED TALKS (cont.) 138. Award Acceptance Speech. Past State President's BPW Award. The University of Texas System

Cancer Center. M.D. Anderson Hospital and Tumor Institute. Houston, TX. April 3, 1987. “In Search of Selective Therapy to Cure Leukemia and Lymphoma." 139. Medical Grand Rounds. Wayne State University School of Medicine. Detroit, MI. April 15, 1987. "Chromosome Changes in Acute Leukemia." 140. Leukaemia Research Fund. International Research Symposium. The Treatment of Acute Myeloid

Leukaemia. London, England. April 21, 1987. "Diagnostic Significance of Chromosome Aberrations in Leukaemia/Lymphoma." 141. International Conference. New Genetics and the Human Gene Map. Paris, France. September 11,

1987. "Specific Rearrangements in Neoplasia." 142. Board Review Course. Medical Oncology. George Washington University. Washington, DC.

October 15, 1987. "Acute Myelocytic Leukemia." "Acute Lymphocytic Leukemia." 143. William A. Lamb, M.D., Memorial Lecture. Holston Valley Hospital and Medical Center. Kingsport,

TN. November 5, 1987. "Advances in the Diagnosis and Treatment of Acute Leukemia in the Adult." 144. UCLA Colloquium on Chronic Myelogenous Leukemia. Annapolis, MD. December 3, 1987. "Ph1 positive ALL." "Interferon in Newly Diagnosed Chronic Phase CML." 145. American Society of Hematology Education Session. Acute Leukemia. Washington, DC. December

5-6, 1987. "The Clinical Impact of Immunodiagnosis in ALL and AML." 146. XXII Congress of the International Society of Hematology. Milan, Italy. August 28 - September 2,

1988. "Acute Leukemia: Advances in Biology and Treatment." (Education Session: Clinical Topics) "Clinical Significance of Cellular Markers in Adult Acute Leukemia." (Main Symposium: Cellular and

Humeral Markers in Blood Malignancies) 147. Board Review Course. Hematology. George Washington University. Washington, DC. October 21,

1988. "Acute Leukemias of Adults." "Chromosomal Abnormalities and Oncogenes in Hematologic Malignancies." 148. Symposium. Innovative Cancer Chemotherapy for Tumors. Mount Sinai School of Medicine. New

York, NY. November 16, 1988. "Cytogenetics as Prognostic Indicators in Leukemia." 149. UCLA Symposia on Molecular and Cellular Biology. Acute Lymphoblastic Leukemia: Current

Controversies, Future Directions. San Antonio, TX. November 29 - December 2, 1988. "Cytogenetic Relationship of Ph+ ALL and CML." "CALGB Studies Identifying High Risk Adults Based on Immunophenotype and Cytogenetic

Abnormalities."


129

MAJOR INVITED TALKS (cont.) 150. American Society of Hematology Education Session. Acute Leukemia. San Antonio, TX. December

3-4, 1988. "Clinical Significance of Cytogenetics in Acute Leukemia." 151. 6th Annual Advances in Cancer Treatment Research. 1st Autologous Bone Marrow Transplantation

Symposium. Albert Einstein College of Medicine. New York, NY. March 16-18, 1989. "Correlations of Cytogenetic Abnormalities and Outcome in Acute Leukemia." 152. Bruce K. Wiseman Memorial Lecture. Ohio State University College of Medicine. Columbus, OH.

May 4, 1989. "Clinical and Biologic Significance of Chromosome Abnormalities in Acute Leukemia." 153. Women's Cancer Center Symposium. Minneapolis, MN. May 16, 1989 "Management of Pregnancy in Leukemia and Lymphoma." 154. Symposium. Dyslipidemia & Leukemia - Recent Advances. Ontario Medical Association. Toronto,

Ontario. May 18, 1989. "Chromosome Abnormalities in Leukemia." 155. American Society of Clinical Oncology Cancer Education Symposium. Contribution of Cytogenetics

and Molecular Biology to Leukemia. San Francisco, CA. May 21, 1989. “Clinical Significance of Cytogenetics in Acute Leukemia." 156. American Society of Hematology. San Diego, CA. June 23-24, 1989. "Clinical Significance of Cytogenetics in Acute Leukemia” 157. Symposium. Georgetown University Medical Center. Washington, DC. September 21, 1989. "Cytogenetics of the Lymphomas". 158. Board Review Course. Dana-Farber Cancer Institute. Boston, MA. October 2, 1989. "Cytogenetics and Cancer". 159. Board Review Course. Oncology. George Washington University. Washington, DC. October 16,

1989. "Acute Myelocytic Leukemia" 160. Symposium. Leukemia Strategies for the 90's. Tampa, FL. February 3, 1990. "Cytogenetics in Leukemia" 161. Symposium. Leukemia …the next question. International Medical Experience Exchange, USA, Inc.

University of Texas, MD Anderson Cancer Center. Houston, TX. March 8-10, 1990. "The Cytogenetic Pattern in ALL: Predictor of Response and Survival" 162. Cancer Center Grand Rounds. University of Michigan Cancer Center. Ann Arbor, MI. March 23,

1990. "Clinical Significance of Chromosome Analysis in Acute Leukemia" 163. Seminar. Kumamoto University Medical School. Kumamoto, Japan. April 16, 1990. "Prognostic Significance of Chromosome Abnormalities in Leukemia and Lymphoma" 164. The Third International Symposium of the Foundation for Promotion of Cancer Research.

Fundamental and Clinical Research in Multiple Primary Cancer. Tokyo, Japan. April 18-20, 1990. "Multiple primary cancers among patients with haematologic malignancies, including those treated

with bone marrow transplantation"


130

MAJOR INVITED TALKS (cont.) 165. Seminar. Department of Internal Medicine. National Cancer Center Hospital. Tokyo, Japan. April

20, 1990. "Prognostic Significance of Chromosome Abnormalities in Acute Leukemia" 166. Lecture. Nihon University School of Medicine. Tokyo, Japan. April 21, 1990. "Strategy and Results of the Treatments for Adult Acute Leukemias" 167. Meet the Professor. American Society of Clinical Oncology. Washington, DC. May 20-22, 1990. "Clinical Relevance of Cytogenetics in Leukemia/Lymphoma" 168. Symposium. Advances in Therapeutics in Selected Malignancies. Rush-Presbyterian -St. Luke's

Medical Center, Chicago, IL. September 12, 1990. "Prognostic Factors for Selecting Curative Therapy for Adult Acute Leukemia" 169. Hematology Conference. North Shore University Hospital, New York, NY. September 27, 1990. “Clinical Significance of Chromosomes in Acute Leukemias" 170. Plenary Session. 1990 Annual Scientific Meeting of the Hematology Society of Australia,

Christchurch, New Zealand. October 2, 1990. "Cytogenetics and Leukemia" 171. Symposium. 1990 Annual Scientific Meeting of the Hematology Society of Australia, Christchurch,

New Zealand. October 2, 1990. "Acute Leukemia in Adults" 172. Breakfast Session. 1990 Annual Scientific Meeting of the Hematology Society of Australia,

Christchurch, New Zealand. October 2, 1990. "Clinical Utility of Molecular Diagnostics and Cytogenetics" 173. Symposium. Puerto Rican Society of Hematology, San Juan, Puerto Rico. October 12-13, 1990. "Clinical Significance of Chromosomes in Leukemia/Lymphoma" "Current Approach to CGL" 174. Keystone Symposia on Molecular and Cellular Biology. Curing Leukemia. Martha's Vineyard, MA.

November 26-28, 1990. "The Impact of Intensity of Treatment on Specific Cytogenetic Subgroups" 175. University of Louisville's Department of Medicine Segal Lecture. Louisville, KY. November 28, 1990.

"The Significance of Chromosomes in Acute Leukemia" 176. Symposium. Present and Future in AML Treatment. American Society of Hematology. Boston, MA.

November 30, 1990. "Cytogenetics and Leukemia" 177. American Society of Hematology Education Session on Acute Leukemia. Acute Leukemia: Recent

Advances in Management. Boston, MA. December 1-2, 1990. "Prognostic Factors for Selecting Curative Therapy for Adult AML" 178. Visiting Professor for the Massachusetts Chapter of the Leukemia Society of America at the

University of Massachusetts Medical Center and Brigham & Women's Hospital. Worcester and Boston, MA. May 30-31, 1991.

"Clinical Significance of Chromosome Studies in Adult Acute Leukemia" 179. Guest Speaker. Nebraska Lymphoma Study Group. University of Nebraska Medical Center.

Omaha, NE. September 12, 1991. "Cytogenetics of Lymphoma"


131

MAJOR INVITED TALKS (cont.) 180. Lecture. Memphis Oncology Journal Club. The University of Tennessee. Memphis, TN. November

21, 1991. "Clinical Utility of Chromosome Findings in Adult Acute Leukemia" 181. American Society of Hematology Education Session on Acute Leukemia: Recent Advances in

Management. Denver, CO. December 7-8, 1991. "The Clinical Significance of Biological Characteristics of the Cells in AML" 182. Lecture. 1991-1992 Hematology Research Seminar Series. The University of Rochester.

Rochester, NY. March 5, 1992. "The Clinical Significance of Cytogenetic Abnormalities in Acute Leukemia" 183. Keystone Symposium on CML: Biology and Therapy. Martha's Vineyard, MA. April 4-7, 1992. "Is Ph1 Chromosome Positive ALL Curable? "CALGB Trial of IFN in CML" 184. Invited Presentation. American Society of Clinical Oncology Pediatric Leukemia and Lymphoma

Slide Session. San Diego, CA. May 19, 1992. "Secondary Leukemia" 185. Grand Rounds. National Cancer Institute. Bethesda, Maryland. June 17, 1992. "The Clinical Significance of Cytogenetic Abnormalities in Adult Acute Leukemia" 186. Leukemia 1992: Second International Course, Recent Progress in Biology and Clinical Research in

Adult Leukemia. Genoa, Italy. July 5, 1992. "Treatment of Adult Acute Myeloid Leukemia: Prognostic Factors" 187. Invited Presentation: Workshop on New Developments Concerning the Molecular Background and

Treatment Strategies in Acute Myeloid Leukemia in Adults (Annual Meeting of the German Society of Hematology). Berlin, Germany. October 5, 1992.

"The Role of Cytogenetics in the Management of Acute AML" 188. Board Review Course. Hematology. George Washington University. Washington, D.C. October

16, 1992. "Chromosomal Abnormalities and Oncogenes in Hematologic Malignancies" "Acute Leukemias of Adults" 189. American Society of Clinical Oncology. Meet the Professor Session. New Orleans, LA. October 31,

1992. "Prognostic Factors for Selecting Treatment for Adult Acute Leukemia" 190. Invited Presentation: European Society of Hematology Study Session on Leukaemias: Risk Factors

and Treatment. Paris, France. November 9, 1992. "Cytogenetics of ALL" 191. American Society of Hematology Education Session on Acute Leukemia: Recent Advances in

Management. Anaheim, CA. December 5-6, 1992. "Dose Intensive Therapy to Cure AML" 192. Invited Presentation: Second International Conference on Leukemia. Houston, TX. March 24-27,

1993. "Cytogenetics in Acute Lymphocytic Leukemia" 193. Distinguished Lecturer: Alpha Omega Alpha of Nebraska Spring Convocation. University of

Nebraska Medical Center, Omaha, NE. March 31, 1993. "Curing Adult Leukemia--The Rewards of Academic Medicine"


132

MAJOR INVITED TALKS (cont.) 194. American Society of Clinical Oncology Education Session: Acute Myeloblastic Leukemia: Recent

Advances in Management, Orlando, FL. May 16, 1993. "Management of Adult Acute Myeloid Leukemia" 195. Seminar: Hematology/Oncology Research Seminar. New York University, New York, NY. September

10, 1993. "Curing Adult Acute Myelogenous Leukemia" 196. Invited Presentation: Hyogo College of Medicine, Hyogo, Japan. September 22, 1993. "Recent Advances in the Management of Adult Acute Myeloid Leukemia" 197. Symposium: Malnati Symposium: Biology of Hematologic Malignancies. Northwestern University

Medical School, Chicago, IL. September 30, 1993. "The Role of Cytogenetics in the Management of Acute Leukemia" 198. Board Review Course. Hematology. George Washington University. Washington, D.C. October

11, 1993. "Acute Myelocytic Leukemia" 199. Second Vivian Saykaly Visiting Professorship in Oncology. McGill University. Montreal, Canada.

October 21-22, 1993. "The Clinical Significance of Cytogenetic Abnormalities in Adult Acute Leukemia" (Montreal General

Hospital) "Curing Adult Acute Myeloid Leukemia" (Royal Victoria Hospital) "The Clinical Significance of Cytogenetic Abnormalities in Adult Acute Leukemia" (Hospital

Maisonneuve Rosemont) 200. Invited Presentations: XIV National Congress of the Brazilian College of Hematology. Curitiba,

Brazil. October 31-November 2, 1993. "Controversies on the Treatment of Acute Leukemias" "Clinical Importance of the Biological Features of Acute Myeloblastic Leukemia Cells" "Minimal Residual Disease: Potential and Feasibility in Acute Myeloblastic Leukemia" 201. Medical Grand Rounds. Dana-Farber Cancer Institute. Boston, MA. November 18, 1993. "Curing Adult AML" 202. American Society of Hematology Meet-The-Professor Session. St. Louis, MO. December 5, 1993. "Management of Adult Leukemia" 203. Hematology Grand Rounds. Mt. Sinai Medical Center. New York, NY. March 17, 1994. "The Clinical Significance of Cytogenetics in Adult Acute Leukemia" 204. Lecture. Clinical Investigations Meeting. M.D. Anderson Cancer Center. Houston, TX. March 31,

1994. "The Clinical Significance of Cytogenetics in Adult Leukemia" 205. Controversy Session. American Association for Cancer Research. San Francisco, CA. April 12,

1994. “Is Bone Marrow Transplantation Indicated for Adult Acute Leukemia in First Remission?" 206. Symposium. Methods of Classification of the Acute Leukemias. XXV Congress of the International

Society of Hematology. Cancun, Mexico. April 18, 1994. "Cytogenetics/Molecular Genetics in the Classification of Acute Leukemia"


133

MAJOR INVITED TALKS (cont.) 207. Invited Presentation. XXV Congress of the International Society of Hematology. Cancun, Mexico.

April 20, 1994. "Clinical Significance of Cytogenetic Studies in Acute Myeloblastic Leukemia" 208. Invited Presentation. 10th Nagoya International Symposium on Cancer Treatment. Cancer

Chemotherapy--Challenges for Today and New Targets for Tomorrow. Nagoya, Japan. September 16, 1994.

"Recent Advances in Curing Adult AML" 209. Invited Presentation. XXI Brazilian Hematology and Hemotherapy Congress. Sao Paulo, Brazil.

October 10, 1994. "Cytogenetics in Leukemia" "Chemotherapy for AML" 210. Board Review Course. Hematology. George Washington University. Washington, D.C. October

14, 1994. "Cytogenetics and Oncogenes in Leukemia" "Acute Myeloid Leukemia" 211. Invited Presentation. Hematologic Malignancies, New Strategies and Targets. Atlanta, Georgia.

October 27, 1994. "AML - Promising New Approaches" 212. Invited speaker at the Evan and Marion Helfaer Cancer Center Seminar. Medical College of

Wisconsin. Milwaukee, Wisconsin. November 16, 1994. "Recent Advances in Curing Adult Acute Myeloid Leukemia" 213. Invited Presentation. American Association for Cancer Research Conference on Translational

Research in Cancer: New Opportunities for Progress. Asheville, North Carolina. December 1, 1994. "Opportunities for Improving Cure in AML Based on Genetic Characteristics of the Leukemic Cell." 214. Plenary Session. American Society of Hematology. Nashville, Tennessee. December 4, 1994. "Curative Impact of Intensification with High-dose Cytarabine (HiDAC) in Acute Myeloid Leukemia

(AML) Varies by Cytogenetic Group" 215. Visiting Professor. Johns Hopkins Oncology Center. Baltimore, Maryland. December 15-16, 1994 "Recent Advances in the Management of Adult Acute Myeloid Leukemia". (Multidisciplinary Clinical

Conference) "The Clinical Significance of Cytogenetics in Acute Leukemia" (Oncology Grand Rounds) 216. Hematologic Oncology Grand Rounds. Memorial Sloan-Kettering Cancer Center. New York, New

York. March 14, 1995. "Clinical Importance of Cytogenetics in Adult Acute Leukemia" 217. Hematopathology Workshop. New York University Medical School. New York, New York. May 16,

1995. "Recent Advances in the Management of Adult Non-Hodgkin's Lymphoma" "Recent Advances in the Management of Adult Leukemias" 218. Invited Presentation. 19th International Congress of Chemotherapy. Montreal, Quebec, Canada.

July 19, 1995. "North American Approaches to the Treatment of Adult Acute Myelogenous Leukemia" 219. Invited Speaker and Moderator at Pharmacia Symposium on Future Directions in the Treatment of

Hematologic Malignancies. Hilton Head, South Carolina. September 22, 1995. "Cytogenetic Influence in AML Induction"


134

MAJOR INVITED TALKS (cont.) 220. Invited Speaker. University of Chicago Symposium in Honor of Janet Rowley. "Chromosome

Translocations Identified in Chicago: Impact on Cancer Biology." Chicago, Illinois. October 23, 1995.

"Clinical Implications of Chromosome Abnormalities in Leukemia" 221. Fifth Annual Mark E. Nesbit Lectureship in Pediatric Oncology. University of Minnesota,

Minneapolis, MN. October 27, 1995. "Clinical and Biologic Significance of Cytogenetics in Acute Leukemia" 222. American Society of Hematology 37th Annual Meeting. Meet the Professor Session. Seattle,

Washington. December 3, 1995 "Management of Adult Acute Leukemia" 223. Invited Speaker. University of Helsinki Departments of Medicine Grand Rounds. Helsinki, Finland.

December 14, 1995. "Adult Acute Myeloid Leukemia Today" 224. Second Annual Hematopathology Workshop. NYU Medical Center. New York, New York. May 9,

1996. "Recent Advances in the Management of Adult Non-Hodgkin's Lymphomas" "Recent Advanced in the Management of Adult Leukemias" 225. American Society of Clinical Oncology 32nd Annual Meeting. Meet the Professor Session.

Philadelphia, PA. May 18 and 19, 1996. "Adult Acute Leukemia: Recent Advances in Biology and Treatment" 226. Second Meeting of the European Haematology Association. Educational Session on Acute

Leukaemia. Paris, France. May 30, 1996. "AML: An Update" 227. Invited Speaker. 26th Congress of the International Society of Haematology. Education Programme

on Acute Leukaemia. Singapore. August 26, 1996. "AML Cytogenetics: Clinical and Biologic Significance" 228. Satellite Symposium of the 38th Annual Meeting of the American Society of Hematology. Leukemia

Long-Term Survival: Collaborative Task Force Review and Analysis. Orlando, Florida. December 5, 1996.

"Long-Term Survival in Acute Myeloid Leukemia: Updated Results from Three Trials" 229. Satellite Symposium of the 38th Annual Meeting of the American Society of Hematology. New

Curative Approaches to Leukemia and Lymphoma. Orlando, Florida. December 6, 1996. "Clinical, Molecular and Therapeutic Advances in Acute Myeloid Leukemia" 230. American Society of Hematology 38th Annual Meeting. Meet the Professor Session. Orlando,

Florida. December 8, 1996. "Acute Myeloid Leukemia: Recent Advances in Biology and Treatment" 231. Chair, Symposium on Acute Myeloid Leukemia. American Association for Cancer Research 88th

Annual Meeting. San Diego, CA. April 13, 1997. "Clinical Significance of Genetic Changes in AML" 232. Presidential Address. Scandinavian Society for Hematology. Helsinki, Finland. May 23, 1997. “Recent Advances in the Management of Adult Acute Myeloid Leukemia" 233. Invited Speaker. First Meeting on Acute Leukemias with Structurally Altered Core Binding Factor

Subunits [t(8;21), inv(16) and t(12;21)]. Rotterdam, The Netherlands. June 28, 1997. "Clinical Outcome of Acute Myeloid Leukemia (AML) Involving CBF"


135

MAJOR INVITED TALKS (cont.) 234. Guest Speaker. UK Cancer Cytogenetics Group Symposium on Chromosomes in Haematological

Malignancy. London, England. June 30, 1997. "Cytogenetics of Adult AML" 235. Invited Speaker. XIX Symposium of the International Association for Comparative Research on

Leukemia and Related Diseases. Mannheim, Germany. July 17, 1997. "Cytogenetic Risk Stratification in the Treatment of AML" 236. Invited Speaker. International Symposium on Minimal Residual Disease. From methodological

problems to clinical goals. Salamanca, Spain. October 31 – November 1, 1997. “What is MRD and what should we expect from studying MRD” 237. Invited Speaker. World Health Organization Clinical Advisory Committee Meeting: Classification of

Neoplastic Diseases of the Hematopoietic and Lymphoid Systems. Warrenton, Virginia. November 3-5, 1997.

“Role of Clinical advisory Committee & Goals of meeting” “Clinical Requirements for a classification” “What are the relative roles of morphology and cyto- or molecular genetics in defining disease

entities?” 238. Invited Speaker. American Association for Cancer Research Philadelphia Cancer Research

Association Symposium. Philadelphia, PA. November 10-11, 1997. “The Clinical Significance of Genetic Abnormalities in Adult AML” 239. Invited Speaker. Oncology Grand Rounds. University of Toronto. Toronto, Canada. November 14,

1997. “Clinical Significance Of Genetic Abnormalities In Adult Acute Myeloblastic Leukemia” 240. Organizer and Invited Speaker. American Society of Clinical Oncology Thirty-Fourth Annual

Meeting. Los Angeles, CA. Education Session, May 17, 1998. Adult Acute Myeloid Leukemia” 241. Invited Speaker. First International Forum on AML. Siguenza, Spain. May 22, 1998. “Cytogenetics of AML” 242. Invited Speaker. 23rd E.T. Bell Fall Pathology Symposium. Update in Bone Marrow Pathology.

Minneapolis, MN. November 13, 1998. “Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia” 243. Invited Speaker. Acute Leukemias VIII Prognostic Factors and Treatment Strategies. International

Symposium., Munster, Germany. March 2, 1999. “Patients with t(8;21) have a Superior Outcome after Repetitive Cycles of HDAC” 244. Invited Speaker. Ireland Cancer Center Blood Club Seminar, Case Western Reserve University,

Cleveland, Ohio. April 23, 1999. “Clinical Significance of Genetic Abnormalities in Adult AML” 245. American Society of Clinical Oncology Thirty-Fifth Annual Meeting. Atlanta GA. Meet the Professor,

May 15, 1999. “Cytogenetic Abnormalities in AML”


136

MAJOR INVITED TALKS (cont.) 246. Invited Speaker. The Second International Acute Leukaemia Forum. Toronto, Canada. August 27-

28, 1999. “Molecular and Cytogenetic Insights in ALL” “Biology of Cytogenetic Subgroups in AML” 247. Invited Speaker. The Barrett Cancer Center Distinguished Lecture Series. Cincinnati OH.

September 9, 1999. “Clinical Significance of Genetic Changes in Adult Acute Myeloid Leukemia” 248. Invited Speaker. The University of Illinois at Chicago, Chicago, IL. November 4, 1999. “Significance of Genetic Findings in Adult Acute Myeloid Leukemia” 249. Invited Speaker. Haartman Institute, University of Helsinki and Helsinki Biomedical Graduate

School, Helsinki, Finland. May 18, 2000. “Leukemias and Lymphomas” 250. Invited Speaker / Web Presentation. American Society of Clinical Oncology. ASCO Online Grand

Rounds. October 2000. http://www.conference-cast.com/asco/grandrounds/lectures.htm “Clinical importance of genetic abnormalities in adult acute myeloid leukemia” 251. Chairperson and Organizer: Corporate Friday Symposium, American Society of Hematology 42nd

Annual Meeting, San Francisco, CA, December 1, 2000. "Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic

Malignancies" 252. Invited Speaker: Corporate Friday Symposium, American Society of Hematology 42nd Annual

Meeting, San Francisco, CA, December 1, 2000. “Clinical Issues and Current Management of Acute Promyelocytic Leukemia” 253. Invited Speaker. Ohio State University Winter College 2001. Naples, Florida. January 26-28, 2001. “The Contribution of Genetics to the Detection, Prevention and Treatment of Cancer” 254. Invited Speaker. Acute Leukemias Symposium IX. Munich, Germany. February 24 – March 1,

2001. “Cytogenetics for Treatment Stratification in Adult Acute Leukemia”

255. Invited Speaker. AML Workshop. Madrid Spain. March 23-25, 2001. “Reporting Standards: Duration of Follow-up in Adult AML” “The Role of Cytogenetics/Molecular Genetics in Prognosis in Adult de novo AML” “The Role of Cytogenetics in Response Assessment in Adult AML” 256. Invited Speaker. University of Witwatersrand, Johannesburg, South Africa. June 28, 2001. “Clinical Importance of Genetic Findings in Acute Myeloid Leukaemia” 257. Invited Speaker. The University of the Free State of Bloemfontein, Bloemfontein, South Africa, June 29, 2001. “Clinical Importance of Genetic Findings in Acute Myeloid Leukemia” 258. Invited Speaker. 2001 Congress of the Federation of the Pathology Societies of South Africa. Cape

Town, South Africa. July 1-3, 2001. “Recent Advances in the Management of AML” “Recent Advances in the Classification of Acute Leukaemias and the Myelodysplastic Syndromes” “Clinical Significance of Genetics in Adult AML” 259. Invited Speaker: National Cancer Center, Seoul, South Korea, September 10, 2001. "Clinical Significance of Genetics in Acute Myeloid Leukemia"


137

MAJOR INVITED TALKS (cont.) 260. Invited Speaker: National Cancer Advisory Board Meeting, National Institutes of Health, Bethesda,

MD, December 4, 2001. "Leukemia, Lymphoma and Myeloma PRG Report" 261. Chairperson and Organizer: Corporate Friday Symposium, American Society of Hematology 43rd

Annual Meeting and Exposition, Orlando, Florida, December 6, 2001. "Nontraditional Cytotoxic Approaches to the Treatment of Advanced Hematologic Malignancies" 262. Invited Speaker: Corporate Friday Symposium, American Society of Hematology 43rd Annual

Meeting and Exposition, Orlando, Florida, December 6, 2001. "Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia"

263. Invited Speaker: American Society of Hematology 43rd Annual Meeting and Exposition, Orlando, FL,

December 9, 2001. "NCI Initiative: Report of the Program Review Group on Leukemia, Lymphoma, and Multiple Myeloma”

264. Invited Discussion Speaker: 38th Annual Meeting of the American Society of Clinical Oncology,

Orlando, FL, May 19, 2002. “Maintenance Therapy in AML Revisited” 265. Invited Speaker: The 29th World Congress of the International Society of Hematology, Seoul, Korea,

August 25, 2002. “Clinical Importance of Genetic Findings in Adult AML” 266. Invited Speaker. Meet the Expert: The 29th World Congress of the International Society of

Hematology, Seoul, Korea, August 26, 2002. “Recent Advances in the Classification of Acute Leukemias and the Myelodysplastic Syndromes” 267. Invited Speaker. Global Organization Against Leukemia (GOAL). Leukemia 2002, Miami, FL,

September 19, 2002. “Cytogenetics to genomics to proteomics?” 268. Invited Speaker / Web Presentation. American Society of Clinical Oncology. ASCO Online Grand

Rounds 2002. http://www.asco.org/ac/1,1003,_12-002322,00.asp “Acute Myeloid Leukemia: Recent Advances in Classification” 269. Plenary Speaker. Annual Symposium of the German Competence Network “Acute and Chronic

Leukemias”. Heidelberg , Germany. February 4, 2003. “Clinical Significance of Genetic Findings in Adult AML” 270. Invited Speaker. Hematology Grand Rounds. M.D. Anderson Cancer Center. Houston, TX. March 5,

2003. “Clinical Significance of Genetic Findings in Adult AML” 271. Invited Speaker. Dana-Farber/Partners Cancer Care Grand Rounds, Boston, MA, March 18, 2003.

“Clinical Importance of Genetic Findings in Adult Adult AML” 272. Invited Speaker. First Annual Conference: Targeted Therapies for the Treatment of Hematological

Malignancies, Kona, Hawaii, July 17, 2003. “Potential Therapeutic Targets in AML with Normal Cytogenetics” 273. Invited Plenary Speaker. Start Symposium of the European Leukemia Net Symposium, Heidelberg,

Germany, January 28, 2004. “Core Binding Factor (CBF) in AML: Results from CALGB”


138

MAJOR INVITED TALKS (cont.) 274. Invited Speaker. Annual Symposium of the Kimmel Cancer Center’s Scientific & Clinical Update on

Hematologic Malignancies, Philadelphia, PA, February 20, 2004. “Acute Lymphoid Leukemia & Acute Myeloid Leukemia (ALL/ AML)” 275. Invited Speaker. Acute Leukemias X International Symposium, Munich, Germany, February 23,

2004. “Core Binding Factor Acute Myeloid Leukemia. Cancer & Leukemia Group B (CALGB) Study 8461”

276. Award Speaker. 9th AACR- Joseph H. Burchenal Clinical Cancer Research Award Lecture. 95th

Annual American Association for Cancer Research Meeting, Orlando, FL, March 30, 2004. “Curing Acute Leukemia in Adults” 277. Invited Speaker. Barbara Ann Karmanos Cancer Institute Grand Rounds, Wayne State University,

Detroit, MI, May 27, 2004. “Curing Acute Leukemia in Adults” 278. Invited Speaker. Second Annual Conference: Therapeutic Advances in the Treatment of

Hematological Malignancies, Kauai, Hawaii, August 9, 2004. “New Molecular Biomarkers for Prognostic Stratification and Novel Therapeutic Interventions in AML with Normal Cytogenetics”

279. Invited Speaker: Leukemia 2004 – towards the cure, Houston, TX, October 7-10, 2004. “Has understanding the biology of AML helped?” 280. Invited Speaker: Special Lecture III. 4th Benjamin Franklin Stem Cell Workshop, Berlin, Germany,

October 21, 2004. “Cytogenetics Predicting Prognosis in Leukemia” 281. Invited Panel Discussant. 2005 WICR Networking Caucus Panel Discussion. American Association

for Cancer Research 96th Annual Meeting, Anaheim, Orange County, CA. April 18, 2005. 282. Invited Speaker. Symposium on New Concepts in Organ Site Research: AML. American Association

for Cancer Research 96th Annual Meeting, Anaheim, Orange County, CA. April 20, 2005. “Clinical Significance of Molecular Markers in AML” 283. Invited Discussant. Plenary Session II. American Society of Clinical Oncology 41st Annual Meeting,

Orlando, FL. May 15, 2005. “Genetic Markers for Predicting Response and Selecting Therapy” 284. Invited Discussant. Leukemia/Myeloma, including Transplantation Poster Discussion. American

Society of Clinical Oncology 41st Annual Meeting, Orlando, FL. May 16, 2005. “Clinical Significance of Cytogenetic and Molecular Markers in Myeloid Malignancies” 285. Invited Speaker. Satellite symposium: Chromosomal Abnormalities and Treatment Outcomes: New

Insights from Hematologic Malignancies. American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL. May 17, 2005.

“Prognostic Significance of Cytogenetics in Myeloid Leukemias” 286. Invited Speaker. Education Session: Acute Myeloid Leukemia. European Hematology Association

10th Congress. Stockholm, Sweden. June 3, 2005. “AML Prognostic Factors: From Cytogenetics to Chip” 287. Invited Speaker. 1. Marburger CCC-Symposium: Comprehensive Cancer Center. Der Philipps-

Universitat Marburg, Marburg, Germany. June 25, 2005. “What U.S. Comprehensive Cancer Centers are Intended to Do”


139

MAJOR INVITED TALKS (cont.) 288. Charlotte Friend Memorial Lecture, XXII Symposium of the International Association for Comparative

Research on Leukemia and Related Diseases (IACRLRD), Heidelberg, Germany. July 4, 2005. “Progress in curing adult acute leukemias” 289. Invited Speaker. Third Annual Conference: Therapeutic Advances in the Treatment of

Hematological Malignancies. Santa Monica, CA. August 4, 2005. “Clinical Significance of Molecular Markers in AML”

290. Invited Speaker. Piedmont Oncology Association 26th Annual Symposium. Myrtle Beach , SC,

September 30, 2005. “Progress in Curing Adult Acute Leukemia” 291. Invited Speaker. Chromosomes and Cancer: From Translocations to Targeted Therapies. Chicago,

IL. November 7, 2005. “The Changing Clinical Significance of Translocations in Adult Acute Leukemia” 292. Invited Speaker. Hematologic Malignancies. World Oncology Congress. New York, NY. November

17, 2005. “Is 3+ 7 Still Standard for AML?” 293. Invited Speaker. Cytogenetics Committee. CALGB Fall Group Meeting. Amelia Island, FL.

November 19, 2005. “Prognostic Molecular Markers in Adult AML with Normal Cytogenetics”

“Overexpression of the ETS Transcription Factor ERG Predicts a Worse Outcome in Acute Myeloid Leukemia with Normal Karyotype: A Cancer and Leukemia Group B Study”

294. Invited Speaker. Spotlight Session. American Society of Hematology Annual Meeting. Atlanta, GA.

December 12, 2005. “Cytogenetics, FISH and PCR Analysis for Diagnosis, Prognosis and MRD” 295. Invited Speaker. International Symposium . Acute Leukemias XI Prognostic Factors and Treatment

Strategies, Munich, Germany, February 20, 2006. Main Session IV – Genetic and Molecular Characterization of AML – Clinical Relevance.

“Molecular Heterogeneity and it’s Prognostic Significance” 296. Invited Speaker. Campus Benjamin Franklin. Berlin, Germany, March 23, 2006. “Molecular heterogeneity and its prognostic significance in AML.” 297. Invited Plenary Speaker. Deutscher Krebskongress, Berlin, Germany. March 25, 2006. “Comprehensive Cancer Centers – Experience in the USA”. 298. Invited Speaker. Medical Grand Rounds. The University of Chicago. May 2, 2006. “Progress in curing Adult Acute Leukemia” 299. Invited Speaker. GM Research Awards. Washington, DC. June 13, 2006. “Clinical Significance of Chromosomal Rearrangements in Leukemia” 300. Invited Speaker. CALGB Summer Group Meeting. Chicago, IL. June 16 – 18, 2006. “Leading the Way to Cure Through Genetic Dissection of Acute Leukemia” 301. Invited Speaker. NIH/NCI Workshop, “Celebrating 50 Years of Human Chromosomes”, Bethesda,

MD. July 20 – 21, 2006. "Clinical Significance of Cytogenetics in Acute Leukemia" 302. Invited Speaker. Brigid G. Leventhal Memorial Lecture, John Hopkins University, Baltimore, MD.

September 8, 2006. “Clinical Use of Molecular Abnormalities in Curing Acute Leukemia”


140

MAJOR INVITED TALKS (cont.) 303. Invited Speaker. NCI Workshop. “Mechanisms and Consequences of Chromosomal Translocation”,

Airlie Conference Center, Warrenton, VA. October 24, 2006. “Clinical Significance of Chromosomal Translocations in Adult Acute Leukemia” 304. Invited Speaker. ASH 48th Annual Meeting. Orange County Convention Center, Orlando, FL.

December 9 -12, 2006. “Gene Expression and Mutation and Prognosis in AML”. 305. Key note Speaker. 1st Annual Dr. Emil Frei, III Symposium, Las Vegas, NV. March 2 – 3, 2007. “Clinical Use of Molecular Findings in Curing Adult Acute Leukemia”. 306. Invited Speaker. Chemogenomics Workshop. Mathematical Biosciences Institute, The Ohio State

University, Columbus, OH. May 8, 2007. “Current Use of Molecular Abnormalities for Selecting Treatment in Adult Acute Leukemia” 307. Invited Speaker. EHA 12th Congress, Vienna Austria. June 7 – 10, 2007. “Clinical Use of Molecular Markers in Adult Acute Myeloid Leukemia” 308. Kent Kiekow Annual Memorial Leukemia Lecture, Medical Grand Rounds, Northwestern University,

Chicago, Il, September 4, 2007. “Progress in Curing Adult Acute Leukemia”. 309. Invited Speaker, International Association for Comparative Research on Leukemia and Related

Diseases (IACRLRD) , Freiburg Germany, September 7 – 12, 2007. “From FAB classification and chromosomal translocations to RTK mutations and beyond: 30 years of

evolving AML subclassification and prognosis”. 310. Invited Speaker, M.D. Anderson: Leukemia and Lymphoma - East and West Together, Dubrovnik

Croatia, September 14 – 20, 2007. “Biology, Cytogenetics and molecular studies in AML” 311. Inaugural Keynote Speaker, 1st Annual Cancer Therapeutics Track Mini-Retreat, Department of

Pharmacology, Case Western University, Cleveland, Ohio, November 1, 2007. “Clinical Use of Molecular Findings in Curing Adult Acute Leukemia” 312. Keynote Speaker, American Society of Hematology Clinical Research Training Institute Annual

Dinner Reunion. Atlanta, GA. December 8, 2007. “Curing Adult Acute Leukemia Through 40 Years of Clinical Research-Could we do it Today?” 313. Scientific Symposium Speaker, 5th Annual Symposium of the European LeukemiaNet. Heidelberg,

Germany. January 30, 2008 “The New WHO Classification for AML” 314. Invited Seminar Speaker, Department of Medicine, Johann Wolfgang Goethe University. Frankfurt

Am Main, Germany. January 30, 2008 “Clinical Use of Molecular Markers in Adult Acute Myeloid Leukemia” 315. Invited Speaker. Main Session II. Genetic and Molecular Characterization of AML-Clinical

Relevance. Acute Leukemias XII. Biology and Treatment Strategies. Munich, Germany. February 18, 2008

“The New WHO Classification” 316. Invited Speaker. Workshop on Molecular Prognostic Markers in Acute Myeloid Leukemia Mandelieu,

France. October 3-5, 2008. “Prognostic Significance of Cytogenetic Markers Used for AML Classification in the 2008 WHO

Classification of Tumours of the Haematopoietic and Lymphoid Tissues.” “Considerations for the use of molecular markers to guide therapy in cytogenetically normal (CN)

AML in adults under 60 years”


141

MAJOR INVITED TALKS (cont.) 317. Invited Speaker. OSU Personalized Health Care National Conference. Columbus, OH. October 16,

2008. “Considerations for the use of molecular markers to guide therapy in cytogenetically normal (CN)

AML in adults under 60 years” 318. Invited Speaker. AACR Centennial Symposium at Roswell Park Cancer Institute. Buffalo, NY.

October 27, 2008. “Clinical Use of Molecular Markers in Curing Acute Myeloid Leukemia” 319. Invited Speaker. ASH 50th Annual Conference at Moscone Center. San Francisco, CA. December 6-

9, 2008. “Importance of FLT3 Mutations and Other Genetic Abnormalities in Normal Karyotype AML”

320. Invited Speaker. 4th Reisensburg Symposium of the AML Intergroup. Reisensburg, Germany.

February 6, 2009. “Advanced classification and strategies in AML”

321. Invited Speaker. Meet-the-Professor Session. Division of Hematology and Oncology, Department of

Medicine, University of California at San Diego. La Jolla, CA. February 27, 2009. “Clinical Use of Molecular Markers in Curing Acute Myeloid Leukemia”

322. Invited Speaker. 5th Annual Moores UCSD Cancer Center Industry/Academia Translational

Oncology Symposium. La Jolla, CA. February 27, 2009. “Clinical Use of Molecular Markers in Curing Acute Myeloid Leukemia”

323. Invited Speaker. 40th Anniversary Nordic Hematology Spring. Tampere, Finland. May 7-8, 2009. “Recent Advances in Classification of Acute Myeloid Leukemia and Therapeutic Implications” 324. 2009 David A Karnofsky Memorial Award and Lecture. American Society of Clinical Oncology Annual

Meeting, Orlando, FL. May 29-June 2, 2009. “Importance of Genetic Heterogeneity in Curing Adult Acute Leukemia” 325. Wiederman Lecture. Annual Meeting of Czech Society of Hematology: Olomouc Hematology Days.

Olomouc Czech Republic. June 24-26, 2009. “Recent Advances in Classification of Acute Myeloid Leukemia and Therapeutic Implications”

326. Meet the Expert. American Society of Hematology. New Orleans, LA. December 5-8, 2009.

“Prognostic Factors in Acute Myeloid Leukemia” 327. The Richard T. Silver, M.D. Distinguished Visiting Professor in Hematology-Medical Oncology.

Medicine Grand Rounds. Weill Cornell Medical College, New York, NY. January 12, 2010. “Progress in Curing Adult Acute Leukemia” 328. The Director’s Seminar. Roswell Park Cancer Institute, Buffalo, NY. February 10, 2010. “Clinical Use of Molecular Markers in Curing Acute Myeloid Leukemia” 329. Mentoring Session on Gender-Equality. Helmholtz Zentrum München, Technische Universität

München, Faculty of Medicine, Munich, Germany. March 30, 2010. 330. Invited Speaker. Helmholtz Zentrum München, Technische Universität München, Faculty of

Medicine, Munich, Germany. March 30, 2010. "Importance of Genetic Heterogeneity in Curing Adult Acute Leukemia". 331. Warren Medical Humanities Lecture Panel. Local Legends Panelists. Medical Heritage Center, The

Ohio State University. April 7, 2010. “Female Physicians in Academic Medicine. “1960s-present”


142

MAJOR INVITED TALKS (cont.) 332. Invited Speaker. National Cancer Institute Center for Cancer Research Grand Rounds. National

Institutes of Health, Bethesda, MD. October 12, 2010. “Clinical Significance of Molecular Findings in Acute Leukemia” 333. Invited Speaker. ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer. Hollywood,

Florida. October 19, 2010 “The Role of Molecular Markers in the Classification of Leukemias: Diagnostic and Therapeutic Implications”

334. Invited Grand Rounds Speaker. Massachusetts General Hospital Cancer Center. November 4, 2010. “Clinical Use of Molecular Markers in curing Acute Myeloid Leukemia” 335. CALGB Fall Group Meeting, Cytogenetics Workshop. Miami, FL. November 12, 2010. “New recommended standardized reporting for correlation of cytogenetic and molecular genetic data

with clinical data in acute myeloid leukemia” 336. Invited Speaker. Acute Leukemias XIII. Munich, Germany. March 1, 2011. “Molecular Markers in Cytogenetically Normal Elderly Acute Myeloid Leukemia” 337. Invited Speaker. Helmholtz Zentrum München, Technische Universität München, Faculty of

Medicine, Munich, Germany. March 2, 2011. “Increasing the Numbers of Women in Senior Roles in Academia” 338. Invited Keynote Speaker. Taiwan Hematology Society Annual Meeting. Taipei, Taiwan. April 16,

2011. “Clinical Use of Molecular Markers in Curing Acute Myeloid Leukemia” 339. Invited Speaker. National Taiwan University Hospital (NTUH). Taipei, Taiwan. April 18, 2011. “ELN Clinical Practice Guidelines: New Recommended Standardized Reporting for Correlation of

Cytogenetic & Molecular Data with Clinical Data in AML” 340. Invited Speaker. 20th International Leukemia-Workshop. Mannheim, Germany. July 2, 2011. “From basics to clinical application – 40 years Wilsede and IACRLRD Leukemia-meetings” 341. Invited Keynote Speaker. 20th International Leukemia-Workshop. Mannheim, Germany. July 3, 2011. “Prognostic impact of karyotype in AML” 342. Invited Speaker. Mildred Scheel Cancer Conference. Bonn, Germany. July 14, 2011. “Clinical Significance of Molecular Findings in AML” 343. Invited Speaker. Special Lecture for the 50th Jubilee. XXV IACRLRD Symposium. Tokyo, Japan.

September 15, 2011. “Clinical Use of Molecular Markers in Curing Acute Myeloid Leukemia” 344. Invited Speaker. ESH EHA Scientific Workshop on Acute Myeloid Leukemia “Molecular”. Mandelieu,

France. October 15, 2011. “Clinical Utility of the European LeukemiaNet Standardized System for Reporting Genetic

Abnormalities in Acute Myeloid Leukemia” 345. NCI Leukemia SPORE’s Meeting. MD Anderson Cancer Center, Houston, TX. October 27, 2011.

“OSU Molecular Characteristics and Risk Stratification of Acute Myeloid Leukemia” 346. Invited Keynote Speaker. International Symposium on “New Frontiers in Hematological

Malignancies”. Pamplona, Spain. November 17, 2011. “New Prognostic Factors in Acute Myeloid Leukemia”


143

MAJOR INVITED TALKS (cont.) 347. Invited Keynote Speaker. Molecular and Translational Breakthroughs in Leukemia Research.

Chicago, IL. April 13, 2012. “Clinical Use of Molecular Markers in Curing Acute Myeloid Leukemia” 348. Invited Speaker. 10th Advanced Hematology Seminar. Tokyo, Japan. June 9, 2012. "Prognostic markers and treatment strategy of AML” 349. Invited Speaker. Okayama, Japan. June 11, 2012. “Biologic and Clinical Significance of New Molecular Markers in Acute Myeloid Leukemia” 350. Taped remarks. Bertha A. Bouroncle Awards Banquet. The Ohio State University, Hematology &

Medical Oncology Divisions. June 14, 2012. “The Legacy of Bertha A. Bouroncle, MD”

351. Award Lecture. 2012 Richard L. Schilsky Cancer and Leukemia Group B Achievement Award.

Alliance for Clinical Trials in Oncology Group Meeting. June 30, 2012. “CALGB Leukemia Correlative Sciences: 30 years of progress with a focus on the genetics of acute leukemia”

352. Invited Speaker. Bone Marrow Transplant Tandem Meetings. Salt Lake City, Utah. February 16,

2013. “Clinical Implications of Mutations in AML: Who Would Be Considered Candidates for Transplant?"

353. Invited Speaker. Acute Leukemias XIII. Munich, Germany. February 25, 2013.

“Genetic Markers in Older Cytogenetically Normal Acute Myeloid Leukemia Patients” 354. Invited Speaker. Minimal Residual Disease (MRD) as a Surrogate Endpoint in Acute Myeloid

Leukemia (AML) Workshop. Silver Springs, Maryland. March 4, 2013. “Biologic Heterogeneity of AML: Implications for Prognosis and Treatment”

355. Award Lecture. Second Annual Giants in Oncology. University of Arkansas for Medical Sciences. Little Rock, Arkansas. March 11, 2013. “Biologic Heterogeneity of AML: Implications for Prognosis and Treatment”

356. Invited Speaker. Semi-annual Meeting of the School of Molecular Medicine, University of Warsaw. Warsaw, Poland. June 17, 2013. "Clinical Use of Molecular Markers in Curing Acute Myeloid Leukemia"

357. Invited Speaker. Oncocytogenetics Workshop. Polish Society of Human Genetics. Gdansk, Poland.

June 20, 2013. “Biologic Heterogeneity of AML: Implications for Prognosis and Treatment”

358. Invited Speaker. Leipzig, Germany. July 6, 2013.

“Biologic Heterogeneity of AML: Implications for Prognosis and Treatment” 359. Award Lecture. Kenneth McCredie Memorial Lecture XXVI IACRLRD Symposium. Turin, Italy.

September 11, 2013. “Clinical Significance of prognostic molecular markers in adult AML”

360. Invited Speaker. Joint International Journal of Cancer –Klaus Tschira Foundation Lectureship 2013.

at Deutsches Krebsforschungszentrum (DKFZ). Heidelberg, Germany. November 14, 2013. “Biologic Heterogeneity of AML: Implications for Prognosis and Treatment”


144

MAJOR INVITED TALKS (cont.) 361. Invited Speaker. University of Rochester Wilmot Cancer Center Monthly Colloquium: John and Carol

Bennett Annual Invited Lectureship. Rochester, New York. September 5, 2014. “Biologic Heterogeneity of AML: Implications for Prognosis and Treatment”

362. Invited Speaker. American Association for Cancer Research (AACR) Hematologic Malignancies:

Translating Discoveries to Novel Therapies. Philadelphia, Pennsylvania. September 20, 2014. “Clinical Significance of Molecular Findings in AML” 363. Invited Speaker. Eminent OSU Scholars Seminar Series of the Central Ohio Chapter of Association

for Women in Science (AWISCO). Columbus, Ohio. October 16, 2014. “Part I: Curing Adult Acute Leukemia, Part II: Female Physicians in Academic Medicine: 1960s – Present”

364. Invited Speaker. The Ohio State University, College of Medicine, Medical Scientist Training Program

Monthly Roundtable. Columbus, Ohio. October 23, 2014. 365. Invited Speaker. 30th Nagoya International Cancer Treatment Symposium. Nagoya, Japan. February

14, 2015. “Biologic Heterogeneity of AML: Implications for Prognosis and Treatment”

366. Invited Speaker. Acute Leukemias XV. Munich, Germany. February 23, 2015.

“New Molecular Diagnostic Characterization of AML in the 2015 WHO Classification” 367. Invited Speaker. 5th Annual Meeting of the Society for Translational Oncology; Perspectives on

Progress: Using Genomics to Guide Clinical Therapy. Columbus, Ohio. April 10, 2015. “Biologic Heterogeneity of AML: Implications for Prognosis and Treatment” 368. Alliance for Clinical Trials in Oncology Spring Group Meeting. Chicago, IL. May 15, 2015

“New Molecular Diagnostic Characterization of AML in the 2015 WHO Classification” 369. Invited Speaker. 20th Congress of the European Hematology Association. Vienna, Austria. June 13,

2015. “What's new in the WHO classification?”

370. Invited Speaker. Meet the Expert Session. European School of Hematology International Conference

on Acute Myeloid Leukemia “Molecular and Translational”: Advances in Biology and Treatment. Budapest, Hungary. September 11, 2015.

“Update on diagnostic and prognostic factors (WHO 2015)” 371. Award Lecture. Howard Temin Memorial Lecture XXVII IACRLRD Symposium. Paris, France.

September 23, 2015. “New WHO Classification of AML”

372. Webinar Introduction. Introduction to the Science of Cancer, Putting it All Together: Discovery to Clinical Trials. Available on Coursera, Youtube, iTunes U. October, 12, 2015.

373. Invited Lecture. Annual Symposium of the European LeukemiaNet. Mannheim, Germany. February

3, 2016. “ELN-Management recommendations for AML 2016: state of consensus and open questions”

374. 8th Annual Margaret L. Kripke Award Lecure. Houston, TX. March 24, 2016.

“AML: 2016 World Health Organization (WHO) and European LeukemiaNet (ELN) Guideline Updates”


145

MAJOR INVITED TALKS (cont.) 375. Invited Speaker. University of Louisville memorial symposium to honor Dr. Geoff Herzig. Louisville,

KY. April 8, 2016. “Cytogenetic and molecular risk stratification for AML: 2016 WHO and ELN Guideline Updates”

376. Invited Speaker. ASCI Dinner Keynote Address. Chicago, IL. April 15, 2016. “Advances in Acute Leukemia: Believe what you see, not what they say” 377. Invited Speaker.. Finnish Association of Hematology. Turku, Finland. April 22, 2016.

“AML: 2016 World Health Organization (WHO) and European LeukemiaNet (ELN) Guideline Updates”

378. Invited Speaker. Hematological Malignancies Professional Committee of Shanghai Anticancer

Association. Shanghai, China. September 24, 2016. “2016 New World Health Organization and European LeukemiaNet AML Classifications”

379. Invited Speaker. Summit of Hematological Malignancies. Tianjin, China. September 25, 2016.

“Biologic Heterogeneity of AML: Implications for Prognosis and Treatment”

380. Webinar Moderator. National Marrow Donor Program. September 29, 2016. “AML risk stratification: Influence of emerging cytogenetics and molecular markers on treatment decisions”

381. NCTN ITSC Grantees Meeting at the NCI. Rockville, MD. October 31, 2016.

“OSU update for U10CA180861. Integrated Translational Science Center (ITSC) for Leukemia: Novel Molecular Strategies for National Clinical Trials Network (NCTN) Individualized Therapies”

382. Invited Speaker. 7th Annual Masonic Cancer Center Research Symposium. Minneapolis, MN.

November 3, 2016. “2016 New World Health Organization and European LeukemiaNet AML Classifications”

383. Alliance for Clinical Trials November 2016 Group Meeting, Leukemia/ Leukemia Correlative

Sciences Committee Meeting. Chicago, IL. November 5, 2016. “Update: NCTN Integrated Translational Science Center for Leukemia”

384. Invited Speaker. Acute Leukemias XVI. Munich, Germany. February 21, 2017 "ELN guidelines: Important changes"

385. Invited Speaker. OSUCCC Grand Rounds. Columbus, OH. March 3, 2017

“New World Health Organization and European LeukemiaNet AML Classifications” 386. Invited Speaker. 25th International Leukemia Workshop. Mannheim, Germany. July 15, 2017

“AML – from therapeutic nihilism to the ELN recommendations 2017” 387. Award Lecture. Robert A. Kyle Award for Outstanding Clinician Scientist, Mayo Clinic Division of

Hematology. Rochester, MN. September 20, 2017 “Advances in Acute Leukemia: Believe what you see, not what they say”

388. Invited Speaker. Mayo Clinic Division of Hematology. Rochester, MN. September 21, 2017

“Biologic Heterogeneity of AML: Implications for Prognosis and Treatment” 389. Award Lecture. XXVIII IACRLRD Symposium: Frank Rauscher Memorial Lecture. Houston, Texas.

November 1, 2017. “European LeukemiaNet: Relevant Clinical Updates in Acute Myeloid Leukemia”


146

MAJOR INVITED TALKS (cont.) 390. Invited Speaker. Novel Approaches in Medicine – Where Are We in the 21st Century? Hong Kong,

Hong Kong. November 19, 2017. “Biologic Heterogeneity of AML: Implications for Prognosis and Treatment”

Clara D. Bloomfield, M.D. NAME: ADDRESS: EDUCATION:...

Documents

Transcript of Clara D. Bloomfield, M.D. NAME: ADDRESS: EDUCATION:...